Ryerson University

Digital Commons @ Ryerson
Theses and dissertations

1-1-2011

Functional Comparison Of Immunoglobulin G Versus Oxidized Low-Density Lipoprotien Phagocytic Receptors In Human U937 Macrophages
David T. Vance
Ryerson University

Follow this and additional works at: http://digitalcommons.ryerson.ca/dissertations Part of the Molecular Biology Commons Recommended Citation
Vance, David T., "Functional Comparison Of Immunoglobulin G Versus Oxidized Low-Density Lipoprotien Phagocytic Receptors In Human U937 Macrophages" (2011). Theses and dissertations. Paper 1647.

This Thesis is brought to you for free and open access by Digital Commons @ Ryerson. It has been accepted for inclusion in Theses and dissertations by an authorized administrator of Digital Commons @ Ryerson. For more information, please contact bcameron@ryerson.ca.

FUNCTIONAL COMPARISON OF IMMUNOGLOBULIN G VERSUS OXIDIZED LOW-DENSITY LIPOPROTEIN PHAGOCYTIC RECEPTORS IN HUMAN U937 MACROPHAGES

by

David Thomson Vance B.Sc., University of Guelph, 2008

A thesis presented to Ryerson University in partial fulfillment of the requirements for the degree of Master of Science in the program of Molecular Science

Toronto, Ontario, Canada, 2011 © David T. Vance, 2011

ii

Author's Declaration
I hereby declare that I am the sole author of this thesis. I authorize Ryerson University to lend this thesis to other institutions or individuals for the purposes of scholarly research.

____________________________________________

I further authorize Ryerson University to reproduce this thesis by photocopying or by other means, in total, or in part, at the request of other institutions or individuals for the purpose of scholarly research.

_____________________________________________

iii

FUNCTIONAL COMPARISON OF IMMUNOGLOBULIN G VERSUS OXIDIZED LOW-DENSITY LIPOPROTEIN PHAGOCYTIC RECEPTORS IN HUMAN U937 MACROPHAGES David Thomson Vance Master of Science, Molecular Science, Ryerson University, 2011

ABSTRACT

Phagocytic macrophages bind to solid oxidized low-density lipoprotein (oxLDL) deposited on the arterial intima, differentiate into foam cells and cause atherosclerosis --the largest cause of mortality in Canada. The mechanism of oxLDL internalization was examined in vitro using differentiated U937 cells exposed to latex microbeads coated with oxLDL or Immunoglobulin G (IgG). Bead internalization was quantified using immunofluorescent staining and laser confocal assays. IgG-mediated engulfment was more rapid than oxLDL-mediated engulfment indicating a qualitatively different internalization pathway. The filamentous actin inhibitors Cytochalasin D (10µM) and Latrunculin B (5µM) completely inhibited phagocytosis of both oxLDL-coated and IgG-coated beads. The Src and Spleen tyrosine kinase inhibitor 3,4-methylenedioxy-betanitrostyrene (20 µM), the phospholipase C inhibitor U73122 (5 µM), and the Janus kinase inhibitor AG 490 (25 µM) displayed significant inhibitory effects on the phagocytosis of both IgG and oxLDL microbeads. The specific isoforms of oxLDL and IgG receptor associated enzymes were determined by nano LC-ESI-MS/MS with an LTQ ion trap.

iv

ACKNOWLEDGEMENTS
I would like to extend my thanks to my supervisor John Marshall for his thorough involvement and guidance throughout every aspect of this project. I consider myself fortunate to have had this opportunity. I would like to acknowledge the significant contributions of Angelique Florentinus, Peter Bowden and Monika Tucholska and thank them for their adroit assistance. I would also like to thank my supervisory committee members Roberto Botelho and Marie Killeen for their insight and suggestions, Narendra Tandon for his -CD36 antibody, the Sergio Grinstein laboratory and Andy Jankowski for his preliminary oxLDL internalization work. Finally, I would also like to thank my family and friends for their support and understanding.

v

TABLE OF CONTENTS
AUTHOR'S DECLARATION...................................................................................................III ABSTRACT.................................................................................................................................IV ACKNOWLEDGEMENTS.........................................................................................................V INDEX OF TABLES.................................................................................................................VII INDEX OF FIGURES.................................................................................................................IX INDEX OF APPENDICES...........................................................................................................X LIST OF SELECTED ABBREVIATIONS..............................................................................XI INTRODUCTION.........................................................................................................................1 The Beginnings of Atherosclerosis.......................................................................................1 Oxidized Low-Density Lipoprotein......................................................................................2 Macrophage Scavenger Receptors......................................................................................5 The Role of CD36 in Atherosclerosis...................................................................................6 CD36 Structure....................................................................................................................8 CD36 Signalling................................................................................................................10 The Fc Gamma Receptor...................................................................................................15 RATIONALE...............................................................................................................................19 CENTRAL HYPOTHESIS.........................................................................................................21 MATERIALS AND METHODS................................................................................................23 Antibodies..........................................................................................................................23 Pharmacological Inhibitors and Reagents........................................................................23 Cell Culture........................................................................................................................24 Bead Internalization Assay................................................................................................24 Western Blotting.................................................................................................................26 CD36 Immunofluorescent Staining....................................................................................27 Pharmacological Inihibition Assay....................................................................................28 Live-cell affinity receptor chromatography......................................................29 RESULTS.....................................................................................................................................33 CD36 Western Blot............................................................................................................33 CD36 Immunofluorescent Staining...................................................................................34 Bead Internalization Assay in Isotonic Experimental Medium.........................................34 Bead Internalization Assay in RPMI with 10% FBS.........................................................39

vi

Bead Internalization Assay in RPMI with 10% FBS After a 30 Minute On Ice Incubation..........................................................................................................................39 Bead Internalization Assay in the Presence of Pharmacological Inhibitors.....................42 Live-cell Affinity Chromatography of oxLDL and IgG Phagocytic Receptor Complex.............................................................................................................................42 DISCUSSION...............................................................................................................................47 Src and Syk...........................................................................................47 Actin...................................................................................................48 FAK...................................................................................................49 PI3K...................................................................................................50 PLC...................................................................................................50 Jak.....................................................................................................51 PKC...................................................................................................51 PLD ...................................................................................................52 PAP...................................................................................................53 HMGCR...................................................................................................54 LARC Determination of oxLDL/CD36 Receptor Complex Binding Partners..................54 CONCLUSION............................................................................................................................56 FUTURE OBJECTIVES.............................................................................................................57 REFERENCES...........................................................................................................................111

vii

INDEX OF TABLES
Table 1: List of antibodies used, their respective isotypes, clone designation, source, immunogen and species of production..........................................................................................28 Table 2: Pharmacological Inhibitors used and their respective final concentrations...................31

viii

INDEX OF FIGURES
Figure 1: Low-density lipoprotein schematic.................................................................................2 Figure 2: Outline of selected foam cell-related proatherogenic positive feedback loop mechanisms.....................................................................................................................................4 Figure 3: CD36 membrane protein schematic...............................................................................9 Figure 4: CD36 Immunoblot of PMA-differentiated U937 lysate...............................................33 Figure 5: Immunofluorescent staining of PMA-differentiated U937 cells with an -CD36 antibody with or without a 30 minute 0.1% Triton X-100 permeabilizing step............................35 Figure 6: Intracellular and extracellular immunofluorescent bead staining of IgG-coated and oxLDL-coated beads internalized by U937...................................................................................36 Figure 7: Internalization of IgG-coated and oxLDL-coated Beads by U937 in Saline Experimental Medium over 4 hours..............................................................................................37 Figure 8: Number of IgG-coated and oxLDL-coated beads internalized by U937 in Saline Experimental Medium over 4 hours..............................................................................................38 Figure 9: Number of IgG-coated and oxLDL-coated Beads internalized by U937 in RPMI with 10% fetal bovine serum over 4 hours....................................................................................40 Figure 10: Number of IgG-coated and oxLDL-coated beads internalized by U937 after a limited 30 minute bead incubation in RPMI with 10% fetal bovine serum over 4 hours..............41 Figure 11: Effect of Cytochalasin D on the internalization of oxLDL-coated and IgG-coated beads. Cells were differentiated for 3 days with 100 nM PMA then incubated with 10 µM Cytochalasin D or a 0.1% DMSO vehicle control for 1 hour........................................................44 Figure 12: Pharmacological inhibition of oxLDL-coated and IgG-coated bead internalization................................................................................................................................45 Figure 13: Live-cell affinity receptor chromatography oxLDL and IgG receptor complex 500 mM NaCl elution base peak mass spectrometric traces.................................................................46

ix

INDEX OF APPENDICES
APPENDIX A ­ BEADS INTERNALIZED IN RPMI WITH 10% FETAL BOVINE SERUM..........................................................................................................................................59 APPENDIX B ­ BEADS INTERNALIZED AFTER LIMITED BEAD PREINCUBATION... 60 APPENDIX C ­ UNCOATED BEADS INTERNALIZED IN SALINE EXPERIMENTAL MEDIUM ......................................................................................................................................62 APPENDIX D ­ INTERNALIZATION OF UNCOATED, IGG-COATED AND OXLDL-COATED BEADS IN SALINE EXPERIMENTAL MEDIUM OVER 4 HOURS......63 APPENDIX E ­ STATISTICAL ANALYSIS OF BEAD INTERNALIZATION IN SALINE EXPERIMENTAL MEDIUM ASSAY.........................................................................................64 APPENDIX F ­ PHARMACOLOGICAL INHIBITION OF PHAGOCYTOSIS ......................66 APPENDIX G ­ POOLED IGG AND OXLDL ONE-WAY ANOVA OF PHARMACOLOGICAL INHIBITION ASSAY..........................................................................70 APPENDIX H ­ TWO-WAY ANOVA OF PHARMACOLOGICAL INHIBITION ASSAY...72 APPENDIX I ­ ONE-WAY ANOVA OF NORMALIZED IGG-BEAD INTERNALIZATION DURING PHARMACOLOGICAL INHIBITION ASSAY....................75 APPENDIX J ­ ONE-WAY ANOVA OF NORMALIZED OXLDL-BEAD INTERNALIZATION DURING PHARMACOLOGICAL INHIBITION ASSAY....................80 APPENDIX K ­ LARC BASE PEAK TRACES........................................................................85 APPENDIX L ­ OXLDL, IGG, CD36 IGG AND CD36 IGA LARC MASS SPECTRA .........89

x

LIST OF SELECTED ABBREVIATIONS
acLDL ACN ATF2 CD36 CDC42 CLA-1 Cy DIC DMSO dSR-CI EDTA Erk FAK FBS FcR HEPES HMGCR IgG ITAM Jak Jnk LOX-1 Lyn MAPK MARCO MEKK2 NADPH NF-B nLDL oxLDL p130Cas PAP1 PBS PI3K PKC PLC PLD PMA Pyk Rho GEF ROS RPMI SDS-PAGE SH2 SHP-1 acetylated low-density lipoprotein acetonitrile activating transcription factor 2 cluster of differentiation 36 cell division control protein 42 homolog CD36 and LIMPII analogous-1 cyanine differential interference contrast dimethyl sulfoxide Drosophila macrophage scavenger receptor class C type I ethylenediaminetetraacetic acid extracellular signal-related protein kinase focal adhesion kinase fetal bovine serum fragment crystallizable  receptor N-2-Hydroxyethylpiperazine-N'-2-ethanesulfronic Acid 3-hydroxy-3-methyl-glutaryl-CoA reductase immunoglobulin G immunoreceptor tyrosine-based activation motif janus kinases c-Jun N-terminal protein kinase lectin-type oxidized low-density lipoprotein receptor 1 V-yes-1 Yamaguchi sarcoma viral related oncogene homolog mitogen activated protein kinase macrophage receptor with collagenous structure MAPK/ERK kinase kinase 2 nicotinamide adenine dinucleotide phosphate nuclear factor kappa-light-chain-enhancer of activated B cells native LDL oxidized low-density lipoprotein Crk-associated substrate p130 phosphatidate phosphatase phosphate buffered saline phosphoinositide 3-kinase protein kinase C phospholipase C phospholipase D phorbol 12-myristate 13-acetate proline-rich tyrosine kinase rho guanine nucleotide exchange factor reactive oxygen species roswell park memorial institute sodium dodecyl sulphate polyacrylamide electrophoresis Src Homology 2 src homology 1-containing phosphotyrosine phosphatase
xi

LIST OF SELECTED ABBREVIATIONS (CONTINUED)
SRA STAT Syk Th1 Th2 TIC TLR scavenger receptor A signal transducer and activator of transcription spleen tyrosine kinase T helper cell 1 T helper cell 2 total ion current toll-like receptor

xii

INTRODUCTION
The Beginnings of Atherosclerosis Atherosclerosis is an inflammatory disease of great epidemiological significance. Cholesterol and triglycerides are transported to peripheral tissues from the liver through the blood in phospholipid protein complexes called low-density lipoprotein (LDL). These complexes are manufactured in the liver from lipids obtained from the intestine via chylomycrons. LDL is approximatey 22 nm in diameter, 3 MDa in mass and composed of triglyceride, esterified and unesterified cholesterol, phosphlipid and apolipoprotein B-100 (ApoB-100) (Figure 1) (Segrest et al., 2001; Mohty et al., 2008). A variety of tissues possess LDL receptors which participate in the normal internalization and use of LDL (Srivastava et al., 1995). Atherosclerosis is believed to be a result of large amounts of plasma LDL overwhelming the native LDL receptors' ability to internalize it. This is consistent with evidence that high LDL levels constitute a significantly increased risk for cardiovascular disease and the knockout of murine LDL receptors results in lowered LDL uptake and increased levels of LDL and atherosclerosis in response to a high fat diet (Glass and Witztum, 2001; Ishibashi et al., 1993). Additionally, humans with mutations in the LDL receptor or its putative adaptor protein also display hypercholesterolemia (Varret et al., 2008; Garcia et al., 2001). Excess LDL is capable of crossing the arterial intima and becoming trapped in the subendothelial space--primarily in the large vessels (Glass and Witztum, 2001; Febbraio et al., 2001). Here they can become modified by proteoglycans, lipases or by glycosylating enzymes (Aviram, 1993). Modified LDL is initially bound to the arterial intima in part by proteoglycans. However once this atherosclerotic fatty streak is established the role of LDL attachment is

1

shifted to macrophage secreted lipoprotein lipase (Pentikainen et al., 2002). The binding of modified LDL to the arterial intima represents the first step in the onset of atherosclerosis.

Figure 1: Low-density lipoprotein schematic. Adapted from Milioti et al., 2008.

Oxidized Low-Density Lipoprotein Of particular interest to the formation of an atherosclerotic lesion is the oxidation of LDL, a process that can be mediated by nitric oxide, myeloperoxide or 7-lipooxygenase (Podrez et al., 2000). Once LDL becomes oxidized it is no longer recognized by the native LDL receptor and gains an affinity for the Class B scavenger receptor CD36 leading to its accumulation in CD36-expressing macrophages (Glass and Witztum, 2001).

2

It is well established that the internalization of oxLDL by monocyte-derived macrophages is a key event in the progression of atherosclerosis (Glass and Witztum, 2001) (Bobryshev, 2006). In particular, the role of macrophages is also supported by evidence that disrupting the macrophage colony-stimulating factor gene of pro-atherogenic ApoE mice significantly decreases the size and incidence of atherosclerotic lesions while increasing serum cholesterol levels (Smith et al., 1995; Qiao et al., 1997). Additionally, in pig arteries, progressing atherosclerotic lesions sequester monocyte-derived cells whereas they emigrate from improving lesions (Daoud et al., 1981; Llodrá et al., 2004). Lipids from oxLDL accumulate inside CD36-expressing macrophages but are not adequately metabolized (Glass and Witztum, 2001). This precipitates the cell's differentiation into a foam cell, the characteristic cell type of atherosclerosis, typified by a large vacuolated appearance, low mobility and the release of pro-inflammatory cytokines and reactive oxygen species (ROS) (Bobryshev, 2006). Unable to deal with this lipid-induced stress, foam cells eventually die by necrosis or apoptosis leading to the release of more cytokines and the unprocessed oxLDL. The release of ROS oxidizes additional LDL and cytokine release attracts other leukocytes such as Th1 and Th2 which secrete additional cytokines that exacerbate inflammation. Cytokine release also attracts monocytes which differentiate into macrophages (Glass and Witztum, 2001). These macrophages attempt to internalize the apoptotic bodies and free lipid and eventually succumb to the same fate as their predecessors thus participating in an inflammatory feedback loop (Figure 2) (Bobryshev, 2006).

3

Figure 2: Outline of selected foam cell-related proatherogenic positive feedback loop mechanisms Complicating proatherogenic mediators include lysophosphatidic acid and platelet activating factor both of which decreased the mobility of monocytes (Llodrá et al., 2004). oxLDL uptake is also enhanced in vitro and in vivo in rat macrophages by C-reactive protein concomitant with increased intracellular accumulation of cholesterol ester and matrix metalloproteinase secretion (Singh et al., 2008). Additionally, there is evidence to suggest that chronic intracellular infection by chlamidia pneumonia may exacerbate this inflammation and the ability of cells to degrade LDL (de Kruif et al., 2005). Monocytes, macrophages, foam cells, necrotic and apoptotic cell debris and deposited lipid form an atheromatous plaque in the subendothelial space which is eventually covered by a cytokine-induced smooth muscle cell sheath. Inflammatory cytokines spur smooth muscle cells to infiltrate the medial portion of the arterial lumen and secrete extracellular matrix components giving rise to the fibrous plaque (Glass and Witztum, 2001). As the level of inflammation grows by feedback so does the size of the plaque (Ross, 1999).

4

Narrowing of the arterial lumen caused by the encroachment of atherosclerotic plaque can cause ischemic events, however thrombosis and infarction from plaque rupture is much more common. This plaque rupture, caused by macrophage-secreted matrix metalloproteinases and neovascularisation-induced destabilization, exposes previously internal plaque tissue factors and lipid leading to platelet recruitment, clotting and the formation of a thrombus which can cause infarction (Glass and Witztum, 2001). This method of pathogenesis has caused heart disease to be recognized as the leading cause of death in the world (Mathers et al., 2009).

Macrophage Scavenger Receptors oxLDL is recognized by scavenger receptors present on leukocytes. Scavenger receptors, like N-formyl methionine mannose receptors and Toll-like receptors (TLR), are inherited nonself surface receptor components of the innate immune system. They are expressed on professional phagocytes but they are also expressed on aortic smooth muscle cells, neuronal cells, keratinocytes, endothelial cells, dendritic cells and Kupfer cells in varying amounts (Zingg et al., 2000). Scavenger receptors are divided into 6 major classes: classes A-F. Class A consists of MARCO and SR-AI/II, Class B encompasses CD36 and SR-B1/CLA-1, Class C as of yet only encompasses the Drosophila protein dSR-CI. Class D contains Macrosialin (gene product of CD68) Class E contains LOX-1 and Class F contains SREC (Zingg et al., 2000).

5

The Role of CD36 in Atherosclerosis oxLDL and other modified lipoproteins are known to interact with multiple scavenger receptors. oxLDL can be internalized by scavenger receptor A (SRA) I/II and CD36 but it can also enter the cell via opsonisation with IgG or IgM anti-oxLDL autoantibodies (Kunjathoor et al., 2002; Tsimikas et al., 2007). However, levels of IgG, IgM or apolipoprotein B immune complexes--while possessing univariate divergent correlations with coronary artery disease-- were not independently predictive of coronary artery disease among a group of coronary angiography patients (Tsimikas et al., 2007). Macrophage CD36 has been identified as the primary pro-atherogenic surface receptor of oxLDL (Collot-Teixeira et al., 2007; Silverstein and Febbraio, 2000; Podrez et al., 2000). Three to eleven percent of Japanese blood donors lack a functional CD36 allele compared to 0.2% among American donors and monocyte-derived macrophages from CD36-deficient (aka Nak deficient) humans show a significant decrease in oxLDL internalization (Yamamoto et al., 1990; Tandon et al., 1989; Nozaki et al., 1995; Janabi et al., 2001). Additionally, CD36-deficient patients exposed to oxLDL displayed significantly less activation of NF-Kappa B and other proinflammatory genes (Janabi et al., 2000). Also, macrophages from CD36-deficient humans show marked resistance to foam cell formation in vitro however the anti-atherogenic effect may be mitigated by a higher prevalence of metabolic syndrome that also accompanies this mutation (Hirano et al., 2003). While knockout of either CD36 or SR A I/II results in the mitigation of atherosclerotic lesions in mice and dual knockout CD36-/-/SRA I/II-/- mice show a 75%-90% decrease in acLDL and oxLDL uptake and degradation and do not display modified lipoprotein cholesterol accumulation, knockout of both SRA I/II and CD36 results in no better protection from murine
6

atherosclerotic lesion development than CD36 alone (Suzuki et al., 1997; Febbraio et al., 2000; Kunjathoor et al., 2002; Kuchibhotla et al., 2008). Transfection of CD36 into Human Embryonic Kidney 293 cells leads to strong specific binding to oxLDL followed by uptake. Expression of CD36 in CHO hamster cells elicits susceptibility to oxLDL stress (Endemann et al., 1993)(Rusiñol et al., 2000). Also, lightly oxidized LDL (oxidized for only 4 hours) is readily recognized by CD36 transfected murine 293 cells whereas cells transfected with other scavenger receptors known to bind oxLDL (FcRII-B2 and the acetylated LDL receptor) require significantly more oxidation (Endemann et al., 1993). Samples of human atherosclerotic aorta obtained from autopsies reveal that CD36 is expressed more strongly on macrophages at the centre of the atheromatous lipid core. Additionally, multiple ex-vivo models demonstrate that foam cell formation appears to be 6090% dependent on CD36 (Nakata et al., 1999; Febbraio et al., 2001; Silverstein and Febbraio, 2000). Cross linking of CD36 with a monoclonal antibody elicits release of H2O2--a burst that is also observed when macrophages are exposed to a surface coated with oxLDL (Aiken et al., 1990; Maxeiner et al., 1998). -CD36 antibody treatment also blocks half of oxLDL binding to human THP macrophages and nearly abrogates foam cell formation in human CD34+ progenitor cells (Endemann et al., 1993; Seizer et al., 2010). Thus it can be concluded that CD36 is the most significant transporter of oxLDL with regards to atherosclerosis.

7

CD36 Structure Encoded on band 11.2 of chromosome 7 the class B scavenger receptor, CD36 consists of 472 amino acids. It is a member of the CD36 family of proteins along with LIMP II, SRBI/CLA-1, and Emp and is expressed by multiple cells lines such as U937, HEL, THP-1 and C32 (Tao et al., 1996; Tandon et al., 1989) Largely hydrophilic, CD36 contains two hydrophobic domains believed to span the plasma membrane (Figure 3). Both the N- and C- termini are intracellular with the relatively short sequences GCDRNC and SYCACRSKTIK, respectively. Each tail contains two cysteine residues that are sites of palmitoylation. This is thought to target CD36 to lipid rafts or caveolae (Tao et al., 1996). However, CD36 does not seem to associate with caveolin-1 in Chinese hamster ovary cells or C32 cells while at rest or while internalizing fluid-phase oxLDL. It does, however, reside in lipid rafts and relatively homogenously throughout the membrane in these cells (Zeng et al., 2003a). At 88 KDa CD36 is highly N-glycosylated compared to 53 KDa unglycosylated (Serghides et al., 2003; Hoosdally et al., 2009). This glycosylation might mediate association with lectins. CD36 has a high affinity for a conserved group of oxidized choline glycerophospholipids that allow it to bind to oxLDL (Podrez et al., 2002). This binding site is located at 155-183 aa. This region also binds apoptotic neutrophils, the synthetic growth hormone-releasing peptide heraxelin, advanced glycation endproducts and monoclonal antibodies (Collot-Teixeira et al., 2007).

8

Figure 3: CD36 membrane protein schematic. N-linked glycosylation sites predicted from sequence. Adapted from Collot-Teixeira et al. 2007.

CD36 also binds erythrocytes infected with plasmodium falciparum, collagen, native LDL, vLDL and HDL, -amyloid fibrils and apoptotic cells (Yamada et al., 1998; Calvo et al., 1998; Coraci et al., 2002). It acts as a fatty acid translocase involved in plasmalemmal fatty acid transport (such as long-chain fatty uptake acids from lipoprotein) as well as a mediator of platelet-platelet binding (van der Vusse et al., 2002; Zingg et al., 2000; Yamada et al., 1998; Tandon et al., 1989). Amino acids 93-120 (CD36 LIMP-II Emp sequence homology binding site) bind thrombospondin 1 and 2 along with a.a. 146-164 or 145-171 which also bind Plasmodium falciparum (Collot-Teixeira et al., 2007).

9

CD36 Signalling Significant data has been published concerning the signalling mechanisms of CD36. Additionally, CD36 seems to recruit different kinases depending on the cell type in which it is expressed (Rahaman et al., 2006). Several foam cell-forming oxLDL internalization methods have been proposed including phagoctosis (Chou et al., 2009), endocytosis (Zeng et al., 2003b) and macropinocytosis (Kruth et al., 2005; Jones and Willingham, 1999; Jones et al., 2000). However macropinocytosis and conventional endocytosis theories are contradicted by reports of insensitivity to PI3K or Na/H exchange inhibitors and dominant-negative dynamin transfections, respectively (Collins et al., 2009). CD36 might regulate binding and activate migration internalization and degradation pathways through spatial association with integrins Rho GEFs and Pyk/Fak kinases and use these molecules to signal (Prieto et al., 1994). It has been demonstrated that members of the Vav family of guanine nucleotide exchange factors become phosphorylated upon exposure to oxLDL in a CD36 dependent manner and deletion of Vav can decrease oxLDL uptake and foam cell formation in murine peritoneal macrophages (Rahaman et al., 2011). CD36 associates with the tetraspannin CD151 and 31 and 61 integrins in C32 melanoma cells via the extracellular domain (Thorne et al., 2007; Thorne et al., 2000). It also associates with the tetraspannin CD9 and IIb3 and 61 integrins on human platelets (Miao et al., 2001). While membrane bound CD36 usually exists in a monomeric state, it has been found to dimerize upon exposure to thrombospondin (Daviet et al., 1997). It has also been shown to
10

associate with other co-receptors such as TLR2 in the binding of Mycobacterium tuberculosis and Staphylococcus and is necessary for the binding and proper immune recognition of Staphylococcal diacylglycerides via the TLR2/6 heterodimer in murine macrophages (Drage et al., 2009; Hoebe et al., 2005). CD36 has also been found to participate in the heterodimerization of Toll-like receptors 4 and 6 in response to oxLDL and -amyloid resulting in sterile inflammation (Stewart et al., 2010). However, CD36 mediated foam cell formation in response to oxLDL does not seem to require TLR2 and deletion of TLR2 or SRA in hyperlipidemic mice had no effect on foam-cell formation (Rahaman et al., 2006). CD36 expression is regulated by peroxisome proliferator-activated receptor , additionally CD36 activates PPAR- (Lee et al., 2004; Munteanu et al., 2006). Expression of PPAR- and CD36 is highly increased in monocytes by exposure to oxLDL (Kavanagh et al., 2003).

It is hypothesized that the c-terminus is involved in signalling due to homology with several other signalling domains such as those present on CD4 and CD8 (Rahaman et al., 2006). There is evidence of a direct physical association between the carboxy-terminal cytoplasmic tail of CD36 and lyn and MEKK2 within a signalling complex (Rahaman et al., 2006). Additionally, the c-terminus of CD36 is required for oxLDL-mediated tumor necrosis factor-alpha modulation of NF-kappa B (Lipsky et al., 1997). CD36 from platelets, endothelial and monocytic cell lysate co-precipitates with Fyn Lyn and Yes (Huang et al., 1991; Medeiros et al., 2004; Bull et al., 1994). Lyn's involvement is also consistent with evidence that a lower rate of atherosclerosis is observed in Lyn-deficient mice
11

and Fyn is activated by thrombospodin-1 via CD36 in microvascular endothelial cells, along with caspase-3 and p38 MAP kinase, leading to a proapoptotic antiangiogenic effect (Miki et al., 2001; Jimenez et al., 2000). Furthermore, oxLDL initiates a platelet activation signalling pathway via CD36 that phophorylates and activates Fyn and Lyn and results in their direct or indirect attachment to CD36 (Chen et al., 2008). Additionally, both (JNK)2 and MKK4 were also phosphorylated in response to oxLDL. Src inhibition reversed this oxLDL-mediated phosphorylation of JNK and both Src and JNK inhibition blocked platelet activation (Chen et al., 2008). Interestingly, Apyrase and RGDS peptide treatment suggested outside-in integrin signals were not required for JNK phosphorylation in these platelets (Chen et al., 2008). Another study reported CD36-mediated phosphorylation of JNK1 and 2 and their downstream effectors c-Jun and ATF2 in murine macrophages upon exposure to oxLDL but not native LDL (nLDL) and that inhibition of JNK or Src blocked oxLDL uptake and foam cell formation. This study also found no correlation between foam-cell formation and the following: Erk1/2, U0126, Jak, PI3K and PKC (Rahaman et al., 2006). Furthermore, JNK activity is significantly upregulated in atheromas and JNK deletion mitigates atherosclerosis in murine models (Ricci et al., 2004; Metzler et al., 2000).

It has been demonstrated that internalization of oxLDL from the fluid phase by CD36 requires src kinases, c-Jun N-terminal kinases and Rac and/or CDC42 but not PI3K (Collins et al., 2009). Fluid-phase oxLDL, but not nLDL, uptake by macrophages also caused membrane ruffling and the formation of large vacuoles containing relatively small amounts of CD36 compared with smaller vesicles (Jones and Willingham, 1999; Collins et al., 2009).

12

Macrophage exposure to fluid-phase oxLDL activates FAK in a CD36-dependent manner (Park et al., 2009). CD36 is thought to initiate NADPH oxidase ROS production in response to oxLDL leading to oxidative SHP-1 inactivation and thus sustained FAK activation which in turn leads to actin polymerization and spreading. This is thought to contribute to the trapping of macrophages in the arterial intima leading to foam cell formtion (Park et al., 2009). There is also evidence that CD36 signals to the cytoskeleton and initiates actin polymerization using the scaffold protein p130Cas, Pyk2, paxillin and Fyn via a phosphorylation cascade (Stuart et al., 2007). Correspondingly CD36-mediated fluid phase oxLDL uptake in macrophages was inhibited by Cytochalasin D and Latrunculin B (Collins et al., 2009).

CD36 is also known to associate with Syk in human umbilical vein endothelial cells and microglial CD36 forms a receptor complex with 61-integrin and integrin-associated protein (CD47) when binding fibrillar amyloid- which subsequently activates Syk and NADPH oxidase (Kazerounian et al., 2011; Wilkinson et al., 2006; Bamberger et al., 2003).

There is little evidence forming a direct link between PLC and CD36, however, they are both localized in platelet lipid rafts and PLC becomes activated with the tyrosine kinase phosphorylation associated with platelet activation (Gousset et al., 2004). There is no direct evidence for interaction between CD36 and PLD, however, PLD activation is strongly associated with monocyte-derived macrophage-mediated phagocytosis of Mycobacterium tuberculosis, which is in part regulated by CD36 (Kusner et al., 1996). There is no direct link between phosphatidate phosphatase (PAP) and CD36 however both participate in phopholipid recruitment, and propranolol, an inhibitior of PAP-1, has been used to successfully treat diseases related to atherosclerosis (Engelmann and Wiedmann, 2010; Olakowska and Olakowski, 2006).

13

Lovastatin decreases circulating LDL levels by inhibiting the rate-limiting enzyme 3-hydroxy-3methyl-glutaryl-CoA reductase (HMGCR) needed for LDL biosynthesis (Endo, 1979). It has also been shown to upregulate the expression of CD36 in some cases (Ruiz-Velasco et al., 2004). However, it is not known whether CD36 affects HMGCR levels or activity.

There is little data on the signalling pathways that regulate CD36 mediated adhesion to solid oxLDL deposited on surfaces. Potential oxLDL internalization signalling pathways were tested using a selection of pharmacological inhibitors targeted to a variety of proteins.

14

The Fc Gamma Receptor

The Fc Gamma receptor is a well studied leukocytic surface protein that binds to the Fragment, crystallisable (Fc) portion of Immunoglobulin G and initiates phagocytosis of the antibody and the infected cell or pathogen to which it is bound. The activated Fc receptor complex has been isolated from the surface of live cells and its binding partners have been successfully identified (Jankowski et al., 2008). It will serve as a control receptor in this study. The Fc receptor is a member of the immunoglobulin superfamily and signals to the cytoplasm mainly via phosphorylation using phosphoinositides, PKC and Rho-family GTPases in distinct phases (Swanson and Hoppe, 2004). Binding of ligand allows Src family kinases to phosphorylate tyrosine pairs on immunoreceptor tyrosine-based activation motifs (ITAMs) allowing the binding of the SH2 domains of Syk (Underhill and Goodridge, 2007). Subsequent phophorylation events regulate actin polymerization, myosin activation, membrane fusion and ROS production allowing the formation of a functioning phagosome (Aderem and Underhill, 1999; Etienne-Manneville and Hall, 2002). PLD is required for certain functions at the cell membrane such as membrane ruffling and cell migration (O'Luanaigh et al., 2002; Santy and Casanova, 2001). In addition, the PLD product phosphatidic acid localizes to the inner leaflet of the plasma membrane in response to FcR ligation (Groves et al., 2008). Furthermore, inactivation of PLD isoforms 1 and 2 has been reported to partially impair phagocytosis of IgG-opsonized 3 µm latex beads in RAW264.7 murine macrophages (Corrotte et al., 2006). PI3K and PLC are both involved in the depletion of the actin assembly and remodelling molecule PI(4,5)P2 at the phagosome (Scott et al., 2005). Inhibition of PI3K and PLC blocks
15

actin depolymerization around the nascent phagosome (Scott et al., 2005). PI3K was also shown to regulate the pseudopod extender protein Myosin X and the phagocytosis-regulating small gproteins ADP-ribosylation factor 1 and 6 (Groves et al., 2008). Interestingly phagocytosis of IgG-coated beads smaller than 3 µm was not affected by PI3K inhibition by either Wortmannin or LY294002 (Groves et al., 2008). In murine RAW 264.7 macrophages PKC-,  and  localize to the plasma membrane during phagocytosis but not necissaily PKC- or  (Larsen et al., 2000). Also, the rate of FcRmediated phagocytosis in RAW 264.7 macrophages is significantly increased upon PKC- overexpression (Larsen et al., 2002). One study found that the PKC inhibitors H7, staurosporine and calphostin C inhibited IgG-coated 3µm bead internalization by human monocytes (Zheleznyak and Brown, 1992). However another study found that the same PKC inhibitors had no effect on the phagocytosis of IgG-opsonized red-blood cells by murine macrophages (Greenberg et al., 1993). Finally, a later study found the phagocytosis of IgG-opsonized erythrocytes by RAW 264.7 was inhibited by staurosporine and calphostin C (general PKC inhibitors) but not by Gö6976 and CGP 41251 (classic/selective inhibitors) (Larsen et al., 2000). One study found that cross-linking of Fc receptors on human macrophages precipitates the rapid yet transient phosphorylation of Fak (Pan et al., 1999). However, another reported no increased tyrosine phosphorylation of p125Fak during FcR-mediated phagocytosis in murine macrophages (Greenberg et al., 1994). Previous studies have found partial inhibition of human monocyte phagocytosis of IgGopsonized sheep red blood cells using lovastatin (Loike et al., 2004). Fluvastatin, a related
16

inhibitor of HMGCR, inhibited FcR signal transduction tyrosine kinase activation, although this was hypothesized to be due to disruption of lipid rafts in monocytes (Hillyard et al., 2004). There has been no study establishing the requirement of Phosphatidate phosphatase in IgG-mediated phagocytosis. However, PAP may play a part in diacylgycerol production and activation of the NADPH oxidase catalyzed ROS production that is concomitant with phagocytosis (Lennartz, 1999). There has been some evidence of cross-regulation between ITAM motifs and the cytokine receptor Jak-Signal Transducer and Activator of Transcription (STAT) pathway via Proline-rich tyrosine kinase (Pyk2) (Ivashkiv, 2009; Hu et al., 2007). The Jak/Stat pathway is inhibited by binding of immune complexes to FcR leading to the suppression of interferon gamma activation, however this does not imply a requirement for phagocytosis (Boekhoudt et al., 2007; Feldman et al., 1995).

17

18

RATIONALE
The majority of studies examining the internalization of oxLDL use oxLDL in the fluid phase. However, incubation of macrophages with liquid oxLDL induces a slow (48 hr.) differentiation into foam cell morphology (Shen et al., 2008). As oxLDL deposits on the artery wall it would seem more physiologically relevant to examine the uptake of oxLDL from the solid phase. This distinction is emphasized by evidence that macrophages incubated on oxLDL-coated surfaces release three to four times more H2O2 than macrophages incubated on acLDL or nLDL coated surfaces in contrast no H2O2 was released upon exposure to fluid-phase oxLDL, nLDL or acLDL (Maxeiner et al., 1998). Polystyrene microbeads can be coated with various types of ligand and added to in vitro macrophage cultures and easily visualized via microscopic examination. Usefully, protein-coated microbeads that are exterior to the cell can be selectively immunofluorescently stained to determine the extent of bead internalization. Recent data (Jankowski & Marshall, unpublished) has suggested that RAW 264.7 macrophages presented with oxLDL coated on the surface of a polystyrene microbead rapidly differentiate into foam cells within hours, much faster than when presented with fluid phase oxLDL. Also, it has been established that U937 cells can easily be differentiated into foam cells using oxLDL (Yu et al., 2003). Intact phagocytic receptor complexes can be isolated from live cells by coating polystyrene microbeads with receptor ligand, allowing cell-bead binding, lysing the resulting mixture and extracting the resultant protein-bound microbeads (Jankowski et al., 2008).

19

These membrane receptors are key targets for disease treatment and might come together in different combinations to form functionally distinct signalling complexes (Davis, 2007). It is already known that CD36 stably associates with kinases tetraspannins and integrins (Huang et al., 1991; Bamberger et al., 2003; Koenigsknecht and Landreth, 2004; Miao et al., 2001) It is hypothesized that CD36 will co-segregate in membrane sub-domains with its signalling partners as mass spectrometric evidence demonstrates that phagocytic receptors associate with a large group of membrane-bound receptors upon activation (Jankowski et al., 2008; Marshall et al., 2001). The resulting bead binding partners may be analyzed by nano LCESI-MS/MS with an LTQ ion trap to identify possible signalling partners including their various splice variants and isoforms (Jankowski et al., 2008).

20

Central Hypothesis The central hypothesis of this research is that oxLDL internalization by macrophages can be quantified and differentiated from other types of phagocytosis using bead based assays and that the identities of specific types of enzymes differentially involved in oxLDL internalization such as SRC, SYK, Janus and PLC can be determined via nano LC-ESI-MS/MS.

21

22

Materials and Methods
Antibodies Monoclonal mouse anti-human CD36 immunoglobulin G (IgG) (clone FA6-152) was purchased from Beckman Coulter (Brea, CA, USA). Monoclonal mouse anti-human CD36 immunoglobulin M (IgM) (clone CB38 [NL07]) was purchased from BD Pharmingen (Franklin Lakes, NJ, USA). Monoclonal mouse anti-mouse CD36 immunoglobulin A (IgA) (clone 63) was purchased from Cascade BioScience (Winchester, MA, USA). Monoclonal mouse anti-human IgG (clone 131.2) was generously provided by Narendra N. Tandon. Polyclonal rabbit anti-Cu2+oxidized human lipoprotein antibody was purchased from Calbiochem (La Jolla, CA, USA). All secondary antibodies were purchased from Jackson ImmunoResearch (West Grove, PA, USA).

Pharmacological Inhibitors and Reagents Genestein, Cytochalasin D, LY 294 002, Wortmannin, AG 490, Latrunculin B, AG 1879, 3,4-Methylenedioxy-b-nitrostyrene (MNS), PF 573228, Go6983, propranolol, and human IgG were purchased from Sigma Aldrich (St. Louis, MO, USA). U73122, Lovastatin, BAY 61-3606 and Phorbol 12-myristate 13-acetate (PMA) were purchased from Calbiochem. Ethanol was purchased from Caledon Laboratories (Georgetown, ON). All microspheres were purchased from Bangs Laboratories (Fishers, IN, USA). Oxidized low-density lipoprotein (oxLDL) was prepared by the ultracentrifugation of EDTA-treated human plasma, adjusted to a density of 1.30 g/mL with KBr and overlayed with a 1.006 g/mL NaCl solution, in a TLA110 rotor (Beckman Coulter) at 100 000 rpm at 4°C for one hour. The low-density lipoprotein (LDL) band was extracted and extensively dialyzed against PBS containing 0.5 mM EDTA. Oxidation was performed by

23

incubating LDL with 5 µM CuSO4 for 16 hours in the dark at 37°C (Shen et al., 2008). Oxidized and unoxidized samples were analyzed for purity blot by western blot.

Cell Culture Human leukemic U937 cells obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA), were cultured at 37°C at 5% CO2 in RPMI 1640 medium with L-glutamine (Mediatech, Manassas, VA, USA) supplemented with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, USA).

Bead Internalization Assay In order to quantify the extent of internalization of particles of oxLDL, PMA-treated U937 cells were exposed to 2 µm oxLDL-coated or IgG-coated microspheres and examined via fluorescent microscopy. Cells were seeded onto (2.5 cm diameter) sterile microscope cover slips deposited in (3.5 cm diameter) 6-well plates (2 mL of ~25% confluent cell culture per well). PMA was added to each well to a final concentration of 100 nM and plates were incubated for 72 hours. Polystyrene microspheres were opsonized with either oxLDL or human IgG for 30 min. Coverslips were either washed 5-times with PBS and placed in isotonic experimental medium (140 mM NaCl, 1mM CaCl2, 1mM MgCl2, buffered to pH 7.4 with 20 mM HEPES) or left in their original or the media prior to the addition of 1 µL of opsonized 2 µm microspheres (2.091 × 107 beads) per well. Alternatively, in a third group, media was replaced and plates were placed on ice and incubated for 30 min with beads then washed gently three times with PBS to remove unbound beads followed by the addition of fresh media. All three groups were then incubated at 37°C for 15, 30, 60, 120, 180 and 240 min. Control groups consisting of cells with no beads

24

added, cells with uncoated beads added and cells incubated with beads on ice for 30 min or 270 min were also used. Cells were subsequently washed 3 times in ice-cold PBS and fixed in PBS with 4% paraformaldehyde for 20 min. Fixing was terminated by the addition of PBS with 5% Glycine. Blocking was performed with PBS with 5% skim milk powder and, in the case of IgGcoated beads, 1% donkey serum. Cover slips that were exposed to oxLDL-coated microspheres were incubated in primary rabbit anti-Cu2+-oxidized human lipoprotein antibody (1:25) for 30 min followed by secondary Cy3-conjugated donkey anti-rabbit antibody (1:10 000) for 30 min in the dark. This was followed by a second 30 minute permeabilizing blocking step with 5% skim milk powder and 0.1% Triton X-100 and another round of primary rabbit anti-Cu2+-oxidized human lipoprotein antibody (1:25) followed by secondary Cy5-conjugated donkey anti-rabbit antibody (1:10 000). Cover slips that were exposed to human IgG-coated microspheres were incubated in PBS for 30 min followed by Cy3-conjugated donkey anti-human antibody (1:20 000) for 30 min in the dark. This was followed by a second 30 minute permeabilizing blocking step with 5% skim milk powder, 1% donkey serum and 0.1% Triton X-100 and incubation in Cy5-conjugated donkey anti-human antibody (1:20 000). All antibody incubations were done at room temperature. Wells were washed three times with PBS followed by two five minute washes before removing the cover slips and affixing them to microscope slides with fluorescence mounting medium (Dako, Carpinteria, CA, USA). Additionally the internalization of non-opsonized microspheres was assessed in the presence of four different buffers to ascertain the degree of background binding. Cells were grown in PMA-treated RPMI as above. After 72 hours the growth medium was either left untouched or removed by washing 5 times with PBS and replaced with RPMI without FBS, PBS with 1 mM CaCl2 and 1 mM MgCl2, or isotonic experimental medium (140 mM NaCl, 1mM

25

CaCl2, 1mM MgCl2, buffered to pH 7.4 with 20 mM HEPES). 1 µL of 2µm microspheres was added to each well on ice and incubated for 30 min. Wells were then washed gently three times with PBS to remove unbound beads and fresh media was added. Plates were then incubated at 37°C for 60, 120, 180 and 240 min. Cover slips were washed, fixed and mounted as above. Slides were examined using a Zeiss LSM 510 laser scanning confocal microscope in conjunction with Zeiss LSM Image Browser. Three to five images per treatment, containing an average of 15 cells per frame, were taken using a 63× water immersion objective lens using the excitation wavelengths 488 and 633 nm for statistical analysis. Several fluorescence and differential interference contrast micrographs per slide were also taken using a 100 × oil immersion objective lens. Internalized 2µm microspheres were quantified by manually counting the total number of microspheres per frame and subtracting any microspheres that were deemed extracellular by the presence of Cy3 fluorescence, indicating the presence of extracellular oxLDL or IgG and dividing by the number of cells. Treatments were replicated at least three times for statistical analysis.

Western Blotting U937 cells were grown in four 70 cm2 culture flasks in RPMI supplemented with 10% FBS with 100 nM PMA for 72 hours. Cells were scraped, pelleted, washed three times in PBS, treated with 0.1 mM diisopropyl fluorophosphate (Toronto Research Chemicals, Toronto, ON, Canada), pelleted, resuspended in 200 µL 2 × sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer and heated at 95°C for 5 min. Protein content was determined using the method described by Ghosh et al. (Ghosh et al., 1988). Samples were resolved via tricine SDS-PAGE using 500 µg of protein per well, transferred onto a

26

polyvinylidene fluoride membrane (Millipore, Billerica, MA, USA), stained with 0.05% Coomassie brilliant blue R-250 in 50% methanol, partially destained with 50% methanol, marked with a pencil to record the position of the molecular weight marker, completely destained with 100% methanol and blocked with PBS containing 0.1% tween, 5% skim milk and 1% goat serum for 30 min. Membranes were probed with mouse anti-human CD36 clone FA6152 (Beckman Coulter, Brea, CA, USA), mouse anti-human CD36 clone CB38 [NL07] (BD Pharmingen, Franklin Lakes, NJ, USA), mouse anti-mouse CD36 clone 63 (Cascade BioScience Winchester, MA, USA) or mouse anti-human CD36 antibody clone 131.2 (N. Tandon) at a dilution of 1:1000, followed by peroxidase conjugated goat anti-mouse secondary antibody at a dilution 1:10 000. Protein was detected by the enhanced chemiluminescece technique using a solution containing 0.1 M Tris/HCl pH 8.8, 0.125 mM luminol, 2 mM 4-iodopheylboronic acid, and 7.7 mM H2O2 on HyBlot CLTM autoradiography film (Denville, Metuchen, NJ, USA).

CD36 Immunofluorescent Staining Permeabilized and non-permeabilized U937 cells were stained with anti-CD36 antibodies to confirm the localization of CD36. Cells were seeded onto cover slips and grown in PMA treated media as above. Cover slips were subsequently washed 3 times in PBS and fixed in PBS with 4% paraformaldehyde for 20 min. Fixing was terminated by the addition of PBS with 5% Glycine. Blocking was performed with PBS with 5% skim milk powder and 1% goat serum with or without 0.1% Triton X-100. Cover slips were incubated in primary monoclonal anti-CD36 antibody (clones: 63, CB38 [NL07], and FA6-152) (Table 1) at 1:25 concentration and in secondary Cy3-conjugated goat anti-mouse IgG or goat anti-mouse IgM antibody (1:10 000) at room temperature in the dark for 30 min each. Wells were washed 3 times with PBS followed by
27

two five minute washes before removing the cover slips and affixing them to microscope slides with mounting medium. Slides were examined using a Zeiss LSM 510 laser scanning confocal microscope with an excitation wavelength of 543 nm in conjunction with Zeiss LSM Image Browser.

Table 1: List of antibodies used, their respective immunogen, isotype, species of production, clone designation and source Immunogen Human CD36 Human CD36 Human CD36 Human CD36 Human oxLDL Mouse IgG/IgA Mouse IgG/IgA Mouse IgM Rabbit IgG Isotype IgG IgG IgM IgA pAb IgG IgG IgG IgG Species Mouse Mouse Mouse Mouse Rabbit Donkey Goat Goat Donkey Clone FA6-152 131.2 CB38 [NL07] clone 63 pAb Secondary Secondary Secondary Secondary Source Beckman Coulter N. Tandon BD Phamingen Cascade Bioscience Calbiochem Jackson ImmunoResearch Jackson ImmunoResearch Jackson ImmunoResearch Jackson ImmunoResearch

Pharmacological Inhibition Assay To test the possibility that 2 µm oxLDL-coated microsphere internalization utilizes a biochemical pathway distinct from that of IgG-coated microsphere internalization cells were exposed to a variety of pharmacological inhibitors prior to and during microsphere internalization. Cells were grown on cover slips and treated with PMA as above. Cells were pretreated with pharmacological inhibitors or DMSO vehicle alone at the indicated concentrations (Table 2) for one hour (except in the case of lovastatin which was applied for 72 hours) coverslips were washed 5 times with PBS and placed in isotonic experimental medium followed by the addition of either IgG-coated or oxLDL-coated 2µm microspheres and incubated for four hours at 37°C. Cells were stained and analyzed as above.
28

Live-cell affinity receptor chromatography To determine the interacting members of the oxLDL/CD36 receptor complex, beads were coated with oxLDL or IgG as above. Macrophages were washed in PBS three times and incubated with beads on ice for 30 min in isotonic experimental medium to allow bead binding. Excess beads were washed off and cells were incubated at 37°C for 0 min, 30 min, 1 hr, 2 hr or 4 hr. Cells were then washed three times with PBS and scraped in Homogenization buffer (20 mM Tris-HCl pH 7.4, with 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride, phenylmethanesulfonylfluoride, DNAse I and II and protease inhibitor cocktail (Sigma Aldrich, St. Louis, MO, USA)). All 5 time points were pooled and homogenized in a French pressure cell press. Additionally a cell lysate control was created by preparing cells as above without adding beads until just prior to homogenization. Beads were pelleted resuspended in PBS and layered on top of a 40% sucrose gradient created in a 4 mL Beckman Coulter OptiSeal polyallomer centrifuge tube using a Beckman Coulter Optima Max Ultracentrifuge with a TLA110 fixed angle rotor at 45 000 rpm for 20 min. Beads were centrifuged at 45 000 rpm at 4°C for 10 min, aspirated with a syringe, and washed once with PBS via pelleting in a microcentrifuge. Bead binding partners were then sequentially extracted with a series of NaCl washes of increasing concentration (50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 and 1000 mM NaCl) followed by 70% Acetonitrile. Beads and extracts were trypsinized overnight followed by an additional 1 hr trypsinization. Beads were pelleted, resuspended in chloroform and trypsonized once more. Samples were analyzed by nano LC-ESI-MS/MS with an LTQ ion trap.

29

Table 2: Pharmacological Inhibitors used and their respective final concentrations Inhibitor Cytochalasin D Target Filamentous actin Concentration 10 µM Reference (Sulahian et al., 2008) (Nikkhah et al., 2009) (Cuschieri et al., 2009) (Huang et al., 2008) (Sun et al., 2009) (Epstein et al., 1999) (Segal et al., 2001) (Tatara et al., 2009) (Cho et al., 2009) (Li et al., 2009) (Kim et al., 2009) (Chan et al., 2009) (Zu et al.) (Tripathi and Sodhi, 2008) (Pang et al.) (Huang et al., 2008) (Jing Chen-Roetling et al., 2008) (Ha et al., 2008) (Chiou et al.) (Akifusa et al., 2010) (Han et al., 2010) (Tripathi and Sodhi, 2008) (Tripathi and Sodhi, 2008) (Yang et al., 2008) (Bhatt et al., 2010) (Miksa et al., 2007) (Maa et al., 2008) (Yang et al., 2008) (Georgakopoulos et al.) (Xue et al., 2010) (Cammer et al., 2009)

Latrunculin B

Filamentous actin

5 µM

LY 294 002

Phosphoinositide 3-kinase

25 µM

Wortmannin

Phosphoinositide 3-kinase

0.5 µM

AG 490

Janus kinases

25 µM

Genestein

Protein tyrosine kinases

35 µM

AG 1879 (PP2)

Src tyrosine kinases

10 µM

continued on next page

30

continued from previous page BAY 61 3606 Spleen tyrosine kinases (Syk) Src and Syk Focal adhesion kinases 1 µM (Sanderson et al., 2010) (Stadanlick et al., 2008) (Yang et al., 2008) (Wang et al., 2006) (Wendt and Schiemann, 2009) (Jones et al., 2009) (Hatta et al., 2009) (Lafrenaye and Fuss, 2010) (Sulahian et al., 2008) (Fulton et al., 2008) (Mogami et al., 1997) (Roy and Rai, 2008) (Kusner et al., 1996a) (Slomiany et al., 2002) (Imagawa et al.) (Grkovich et al., 2009) (Laitinen et al.) (Mallants et al., 2009) (Mandal et al.) (Dalvai and Bystricky, 2010) (Gralczyk et al., 2009)

MNS PF 573228

20 µM 1 µM

Go6983 U73122

Protein kinase C Phospholipase C

10 µM 5 µM

Ethanol

Phospholipase D

200 mM (1.2% v/v) 100 µM

Propranolol

Phosphatidate Phosphatase-1 3-hydroxy-3methylglutarylCoA reductase

lovastatin, sodium salt

10 µM

31

32

RESULTS
CD36 Western Blot

Four antibodies specific for CD36 were used in the detection of CD36 in PMAdifferentiated U937 lysates (Table 1) via immunoblot. Clones FA6-152, 131.2, CB38 [NL07] and 63 of isotypes IgG, IgG, IgM and IgA respectively produced differing banding patterns (Figure 4). Antibody 131.2 from Narendra Tandon produced only one band. All displayed a visible band at CD36's recorded molecular mass of 88 kDa. This band was not visible when membranes were stained with the secondary antibody alone.

2 only

IgM

IgA

IgG

2 only

Tandon

250
.

250
.

150

150 100 75

88 kDa

100 75

50 37

50 37

Figure 4: CD36 Immunoblot of PMA-differentiated U937 cells. Cells were incubated in 100 nM PMA for 3 days and lysed in a French pressure cell press. Lysate was separated via PAGE, blotted onto polyvinyl membrane, in 3 5% skim milk Figure _: CD36 Immunoblot of PMA-differentiated U937 cells.difluoride Cells were incubated in 100 blocked nM PMA for days and lysed in a French pressure cell press. Lysate was separated via PAGE, blotted onto polyvinyl difluoride membrane, blocked in 5% with 1% goat serum and treated with mouse IgG, IgM or IgA -CD36 antibody and peroxidiseskim milk with 1% goat serum and treated with mouse IgG, IgM or IgA -CD36 antibody and peroxidise-conjugated -IgG conjugated -IgG or  -IgM secondary antibody. Membranes were developed via enhanced or -IgM secondary antibody. Membranes were developed via enhanced chemiluminescence. chemiluminescence. Technical assistance: Angelique Florentinus

33

CD36 Immunofluorescent Staining Three antibodies specific for CD36 were used in the immunofluorescent staining of CD36 in permeabilized and non permeabilized PMA-differentiated U937 cells (Table 1). Clones FA6-152, CB38 [NL07] and 63 of isotypes IgG, IgM and IgA respectively all produced a bright distinct ring around the membrane of the cell when imaged using a confocal laser scanning microcope (Figure 5). This pattern was not observed when cells were stained with the secondary antibody alone.

Bead Internalization Assay in Isotonic Experimental Medium To determine the efficacy of the staining procedure polystyrene beads were coated with oxLDL or IgG and incubated with macrophages for 4 hours. The cells were fixed and beads were stained with Cy3 conjugated antibodies, cells were permeabilized and beads were stained a second time (Figure 6). Internalization was ascertained by the presence of Cy5 fluorescence and absence of Cy3 fluorescence. Once the preliminary assay was completed, a 4 hour internalization time course was performed to examine the progression of internalization. Macrophages were washed 5 times with PBS and incubated in isotonic experimental medium to lower bead contamination from complex medium components with oxLDL or IgG beads for varying times (15 min, 30 min, 1 hr, 2 hr, 3 hr, and 4 hr) and external beads were stained (Figure 7). The average number of internalized beads per cell was quantified with at least three replicates (Figure 8). IgG beads were internalized more quickly and to a greater extent. Over 4 hours an average of approximately 5 IgG beads and 1 oxLDL bead were internalized per cell. Results were analyzed by JMP statistical analysis software (Appendix E).
34

A

B

C

D

E

F

Figure 5: Immunofluorescent staining of PMA-differentiated U937 cells with an -CD36 Figure 1 : Immunofluorescent staining of PMA-differentiated U937 cells with an -CD36 antibody with or without a 30 antibody with or without a 30 minute 0.1% Triton X-100 permeabilizing step. in 5% skim minute 0.1% Triton X-100 permeabilizing step to determine presence and distribution. All cells were blocked
milk with 1% goat serum and stained with an IgG, IgM or IgA -CD36 antibody followed by a goat Cy3-conjugated IgG/IgA or - presence IgM secondary (A) all IgG cells antibody withblocked permeabilization. IgG antibody To determine and antibody. distribution were in 5% (B) skim milk withwithout 1% goat permeabilization. (C) IgM antibody with permeabilization. (D) IgM antibody without permeabilization. (E) IgA serum and with (F) an IgA IgG, IgM or IgA -CD36 antibody followed by a goat Cy3antibody with stained permeabilization. antibody without permeabilization. conjugated - IgG/IgA or - IgM secondary antibody. (A) IgG antibody with permeabilization. (B) IgG antibody without permeabilization. (C) IgM antibody with permeabilization. (D) IgM antibody without permeabilization. (E) IgA antibody with permeabilization. (F) IgA antibody without permeabilization. Technical assistance: Angelique Florentinus

DIC -CD36 2 alone DIC

35

A

B

C

D

E

F

Figure 6: Intracelular and extracellular immunofluorescent bead staining of IgG-coated and oxLDL-coated beads internalized by U937. Cells were differentiated for 3 days with 100 nM PMA and incubated with oxLDL-coated or IgG-coated beads in isotonic experimental medium. Cells were fixed in a 5% paraformaldehye solution and blocked with 5% skim milk for oxLDLcoated beads and 5% skim milk with 1% donkey serum for IgG coated beads. Beads were subsequently stained with Cy3-conjugated anti-IgG antibody or rabbit polyclonal anti-oxLDL antibody follwed by Cy3-conjugated donkey anti-rabbit antibody to visualize non-internalized beads. All beads were subsequently stained by permeabilizing with a 0.1% Triton X-100 blocking solution followed by Cy5-conjugated antiIgG antibody or rabbit polyclonal antioxLDL antibody followed by Cy5-conjugated donkey anti-rabbit antibody. (A) External and internal IgG-coated bead Cy5 staining. (B) External IgGcoated bead Cy3 staining. (C) IgG-coated bead DIC. (D) External and internal oxLDL-coated bead Cy5 staining (E) External oxLDL-coated bead Cy3 staining (F) oxLDL-coated bead DIC.

36

IgG beads

oxLDL beads 0h . 15 min .
.

30 min
.

.1h
.

2h
.

3h
.

4h

Figure Number of IgG-coated oxLDL-coated and beads oxLDL-coated internalized by U937 in Saline Experimental over Figure 7: 4: Internalization ofand IgG-coated Beads by U937 Medium in Saline 4 hours. Cells were differentiated for 3 days with 100 nM PMA, washed 5-times with PBS and incubated with oxLDLExperimental Medium 4 hours coated or IgG-coated beadsover in isotonic experimental medium. Cells were fixed in a 5% paraformaldehye solution at 15 min, 30 min, 1h, 2h, 3h or 4h. Beads were subsequently stained with Cy3-conjugated anti-IgG antibody or rabbit anti-oxLDL antibody by Cy3-conjugated donkey anti-rabbit antibody to visualize non-internalized Cellspolyclonal were differentiated forfollowed 3 days with 100 nM PMA, washed 5-times with PBS and beads. Confocal laser scanning images. incubated with oxLDL-coated or IgG-coated beads in isotonic experimental medium. Cells were fixed in a 5% paraformaldehye solution at 15 min, 30 min, 1h, 2h, 3h or 4h. Beads were subsequently stained with Cy3-conjugated anti-IgG antibody or rabbit polyclonal anti-oxLDL antibody followed by Cy3-conjugated donkey anti-rabbit antibody to visualize non-internalized beads. Confocal laser scanning images.

37

Figure 8: Number of IgG-coated and oxLDL-coated beads internalized by U937 in Saline Experimental Medium over 4 hours.

Cells were differentiated for 3 days with 100 nM PMA, washed 5-times with PBS and incubated with oxLDL-coated or IgG-coated beads in isotonic experimental medium. Cells fixed a 5% paraformaldehye solution at 15 min, 30 min, 1h, 2h, or 4h. Beads Figure 4:were Number ofin IgG-coated and oxLDL-coated beads internalized by U937 in3h Saline Experimental Medium ov were subsequently stained with Cy3-conjugated anti-IgG antibody or rabbit polyclonal anti4 hours. Cells were differentiated for 3 days with 100 nM PMA, washed 5-times with PBS and incubated with oxLDL antibody followed by experimental Cy3-conjugated donkeyCells anti-rabbit antibody visualize noncoated or oxLDL IgG-coated beads in isotonic medium. were fixed in a to 5% paraformaldehye solution at 1 internalized Quantification ofsubsequently bead internalization at Cy3-conjugated least 3 replicatesanti-IgG with an antibody or rabb min, 30 min, 1h, 2h, beads. 3h or 4h. Beads were stained of with average of 3 images perfollowed treatmentby and 15 cells per image +/- standard error. polyclonal anti-oxLDL antibody Cy3-conjugated donkey anti-rabbit antibody to visualize non-internalize beads. Quantification of bead internalization of at least 3 repetitions +/- standard error.

38

Bead Internalization Assay in RPMI with 10% FBS oxLDL or IgG beads were incubated with macrophages as above. Cells were not washed beforehand and bead incubation took place in RPMI with 10% fetal bovine serum to be more physiologically relevant to the arterial conditions experienced by macrophages in vivo. The average number of internalized beads per cell was quantified with at least three replicates (Figure 9). IgG beads were internalized more quickly initially, but engulfment plateaued while oxLDL engulfment continued. Over 4 hours an average of approximately 7 IgG beads and 9 oxLDL bead were internalized per cell.

Bead Internalization Assay in RPMI with 10% FBS After a 30 Minute On Ice Incubation Macrophages were exposed to beads for a 30 minute on ice preincubation period in RPMI with FBS to allow beads to bind without internalization. This was done to remove the element of bead settling time. Excess beads were washed off and cells were then heated to 37° C in RPMI with FBS bead internalization was assayed as above (Figure 10). IgG beads were internalized more quickly initially but engulfment plateaued while oxLDL engulfment continued. Over 4 hours an average of approximately 0.5 IgG beads and 1 oxLDL bead were internalized per cell.

39

Figure 9: Number of IgG-coated and oxLDL-coated Beads internalized by U937 in RPMI with 10% fetal bovine serum over 4 hours.

Figure 5: Number of IgG-coated and oxLDL-coated Beads internalized by U937 in RPMI with 10% fetal calf serum over 4 hours. Cells were differentiated for 3 days with 100 nM PMA and incubated with oxLDLCells were differentiated for 3 days with 100 nM PMA and incubated with oxLDL-coated or coated or IgG-coated beads. Cells were fixed in a 5% paraformaldehye solution at 15 min, 30 min, 1h, 2h, IgG-coated beads. Cells were fixed in a 5% paraformaldehye solution min, 30 min, 1h, 3h or 4h. Beads were subsequently stained with Cy3-conjugated anti-IgG antibodyat or 15 rabbit polyclonal antioxLDL antibody followed by Cy3-conjugated donkey anti-rabbit antibody to visualize non-internalized 2h, 3h or 4h. Beads were subsequently stained with Cy3-conjugated anti-IgG antibody or beads.

rabbit polyclonal anti-oxLDL antibody followed by Cy3-conjugated donkey anti-rabbit antibody to visualize non-internalized beads. Quantification of bead internalization of at least 3 replicates with an average of 3 images per treatment and 15 cells per image +/- standard error.

40

Figure 10: Number of IgG-coated and oxLDL-coated beads internalized by U937 after a limited 30 minute bead incubation in RPMI with 10% fetal bovine serum over 4 hours Figure 6: Number of IgG-coated and oxLDL-coated beads internalized by U937 after a limited 30 minute
bead incubation in RPMI with 10% fetal calf serum over 4 hours. Cells were differentiated for 3 days with Cells differentiated for PBS 3 days with 100with nM PMA washed 3 times with and 100 nM were PMA washed 3 times with and incubated oxLDL-coated or IgG-coated beadsPBS for 30 min. incubated with oxLDL-coated or IgG-coated beads for 30 min. Excess Excess beads were washed off and replaced with fresh medium and cells beads were were fixed washed in a 5% paraformaldehye solution 15 min, 30 min, 1h, 2h, 3h or 4h. Beads were stainedsolution with Cy3off and replaced with at fresh medium and cells were fixed in a 5% subsequently paraformaldehye conjugated anti-IgG antibody or rabbit polyclonal anti-oxLDL antibody followed by Cy3-conjugated donkey at 15 min, 30 min, 1h, 2h, 3h or 4h. Beads were subsequently stained with Cy3-conjugated anti-rabbit antibody to visualize non-internalized beads.

anti-IgG antibody or rabbit polyclonal anti-oxLDL antibody followed by Cy3-conjugated donkey anti-rabbit antibody to visualize non-internalized beads. Quantification of bead internalization of at least 3 replicates with an average of 3 images per treatment and 15 cells per image +/- standard error.
41

Bead Internalization Assay in the Presence of Pharmacological Inhibitors Macrophages were incubated with oxLDL or IgG beads in isotonic experimental medium for 4 hours as above. Cells were incubated with a variety of pharmacological inhibitors (Table 2) for one hour prior to bead incubation and during bead incubation. The effect of the actin polymerization inhibitor Cytochalasin D is shown (Figure 11). Bead internalization for all inhibitors was assessed as above and quantified over 3 replicates (Figure 12). The actin polymerization inhibitors Cytochalasin D and Latrunculin B completely prevented bead internalization. Inhibition of Src and Syk by 3,4-methylenedioxy-betanitrostyrene prevent 99% of IgG and 94% of oxLDL bead internalization. Inhibition of Phospholipase C by U73122 prevented 90% of IgG and 75% of oxLDL bead internalization. Inhibition of Janus kinase by AG 490 prevented 84% of IgG and 77% of oxLDL bead internalization. Finally, General protein tyrosine kinase inhibiton by Genistein prevented 60% of IgG and 76% of oxLDL bead internalization. Wortmannin (PI3K), PP2 (Src tyrosine kinases), ethanol (PLD), LY 294 002 (PI3K), BAY 61 3606 (Syk tyrosine kinases), PF 573228 (FAK), Go6983 (PKC), propranolol (PAP-1) and lovastatin (HMGCR) had little effect on bead internalization. Results were analyzed by JMP statistical analysis software (Appendices G-J).

Live-cell Affinity Chromatography of oxLDL and IgG Phagocytic Receptor Complex U937 cells were incubated on ice for 30 min with IgG-coated or oxLDL coated beads. Excess beads were then washed off and cells were incubated at 37°C to allow for bead internalization for 0 min, 30 min, 1h, 2h or 4h. Cells were then scraped and all time points were pooled and lysed. A control sample was created by adding beads just prior to lysis. Beads were

42

isolated via sucrose density gradient centrifugation and associated proteins were sequentially dissociated by a series of NaCl concentrations. Elutes were analyzed by nano LC-ESI-MS/MS. The base peak trace results of the 500 mM NaCl LARC elution (Figure 13) were selected arbitrarily to ascertain the ability of the IgG/oxLDL-bead LARC system to distinguish IgG/FcR receptor complex associated proteins from oxLDL/CD36 receptor complex associated proteins. Qualitative differences between the patterns were observed. AG490, U73122, MNS, Latrunculin B and Cytochalain D inhibited bead phagocytosis. Accordingly, the mass spectra of various isoforms of the Src-family, Syk-family, JAK, PLC, and actin protein groups detected via LC-ESI-MS/MS in IgG, oxLDL, anti-CD36 IgA and anti-CD36 IgG coated bead LARC treatments were compiled (Appendix I). The mass spectra of additional proteins investigated in this study are also shown.

43

A

B

C

D

E

F

G

H

Figure 11: Effect of Cytochalasin D on the internalization of oxLDL-coated and IgGcoated beads. Cells were differentiated for 3 days with 100 nM PMA then incubated with 10 µM Cytochalasin D or a 0.1% DMSO vehicle control for 1 hour. Cells were subsequently washed 5 times with PBS and incubated for 4 hours with oxLDLcoated or IgG-coated beads in isotonic experimental medium with or without 10 µM Cytochalasin D. Beads were stained with Cy3-conjugated anti-IgG antibody or rabbit polyclonal anti-oxLDL antibody followed by Cy3-conjugated donkey anti-rabbit antibody to visualize non-internalized beads. (A) oxLDL beads without Cytochalasin D DIC. (B) Staining of external oxLDL beads without Cytochalasin D. (C) oxLDL beads with Cytochalasin D DIC. (D) Staining of external oxLDL beads with Cytochalasin D. (E) IgG beads without Cytochalasin D DIC. (F) Staining of external IgG beads without Cytochalasin D. (G) IgG beads with Cytochalasin D DIC. (H) Staining of external IgG beads with Cytochalasin D. (Scale bar: 5 µm)

44

Figure 9: Pharmacological inhibition of oxLDL-coated and IgG-coated bead internalization. Cells were differentiated for Figure 12: Pharmacological inhibition of oxLDL-coated and IgG-coated bead 3 days with 100 nM PMA then incubated with one of 13 pharmacological inhibitors at indicated concentrations (Table 1) orinternalization. 0.1% DMSO for 1 hour. Cells were subsequently washed 5-times with PBS and incubated with oxLDL-coated or IgGcoated beads in isotonic experimental medium with their respective inhibitors. Cells were fixed in a 5% paraformaldehye solution external beads were subsequently stained with Cy3-conjugated anti-IgG antibody or rabbit polyclonal Cellsand were differentiated for 3 days with 100 nM PMA then incubated with one of anti13 oxLDL antibody followed by Cy3-conjugated donkey anti-rabbit antibody to visualize non-internalized beads. pharmacological inhibitors at indicated concentrations (Table 1) or 0.1% DMSO for 1 Abbreviations are as follows: N/D ­ No drug; DMSO ­ Dimethyl sulphoxide; CytD ­ Cytochalasin D; LatB ­ Latrunculin B;hour. Wort ­Cells Wortmannin; PP2 ­ AG 1879; MNS ­ 3,4-Methylenedioxy-beta-nitrostyrene; U7 ­ U73122; Eth ­ Ethanol; LY were subsequently washed 5-times with PBS and incubated with oxLDL-coated ­ LY 294 002; AG ­ AG 490; Gen ­ Genistein; BAY ­ BAY 61 3606; PF ­ PF 573228; Go ­ Gö6983; Prop ­ or IgG-coated beads in isotonicof experimental medium with their respective inhibitors. Cells Propranolol hydrochloride. Representative at least three repetitions. Error bars indicate standard error.

were fixed in a 5% paraformaldehye solution and external beads were subsequently stained with Cy3-conjugated anti-IgG antibody or rabbit polyclonal anti-oxLDL antibody followed by Cy3-conjugated donkey anti-rabbit antibody to visualize non-internalized beads. At least 3 replicates were conducted with an average of 3 images per treatment and 15 cells per image. Error bars indicate standard error. Abbreviations with drug target in parenthesis as follows: N/D ­ No drug; DMSO ­ Dimethyl sulphoxide; CytD ­ Cytochalasin D (actin); LatB ­ Latrunculin B (actin); Wort ­ Wortmannin (PI3K); PP2 ­ AG 1879 (Src); MNS ­ 3,4-Methylenedioxy-beta-nitrostyrene (Src and Syk); U7 ­ U73122 (PLC); Eth ­ Ethanol (PLD); LY ­ LY 294 002 (PI3K); AG ­ AG 490 (JAK); Gen ­ Genistein (protein tyrosine kinases); BAY ­ BAY 61 3606 (Syk); PF ­ PF 573228 (FAK); Go ­ Gö6983 (PKC); Prop ­ Propranolol hydrochloride (PAP-1).

45

RT: 0.00 - 100.06 100 90 80 70 18.92 60.60 NL: 1.35E7 Base Peak MS LARC_I gG_500m MNaCl_150umI D5 um300AMonMade SP006_STRANGE _Apr28

Relative Abundance

60 50 40 30 20 18.53 10 0.69 0 0 RT: 0.00 - 88.64 100 90 44.97 80 70 4.60 10 17.89 20.95 23.21 20 30 41.47 46.51 49.71 60 70 19.70 78.50 77.67 78.83 59.50 67.52

A
86.84 92.05

40

50 Time (min) 41.91 41.64

80

90

100 NL: 1.04E7 Base Peak MS LARC_I gG_CONTR OL_500mMNaCl_15 0umI D5um300AMon MadeSP006_STRA NGE_May11

Relative Abundance

60 50 40 63.20 30 20 10 0.38 0 0 10 20 8.65 20.12 20.82 22.85 30 40.16 39.24 40 50 Time (min) 60 70 53.60 48.63 57.77

B
72.72 66.88 81.83 82.94

80

RT: 0.00 - 100.01 100 90 80 70 54.85 NL: 1.36E7 Base Peak MS LARC3_oxLDL_5 00mMNaCl_ZOR BAX300A_C18_ 5u_STRANGE_J une21

Relative Abundance

C
62.54 53.62 63.72 53.20 57.45 64.99 52.13 65.75 78.26 70.91 43.81 50 Time (min) 60 70 80.08 80 83.84 90 98.97 1.82 34.71 3.55 10 14.15 20 26.01 30 40 39.61

60 50 40 30 20 10 0 0
RT: 0.00 - 100.03 100 90 80 70 44.53 50.46

100
NL: 2.12E6 Base Peak MS LARC3_oxLDL_C ONTROL_500mMN aCl_ZORBAX300A _C18_5u_STRANG E_July6

57.10

Relative Abundance

60 50 40 30 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 2.65 13.07 14.28 26.37 25.83 14.96 32.62 31.42 27.19

D
65.80 78.10 62.06 90 84.95 87.39 98.15

43.96

35.42 36.49

100

Figure 7: Live-cell affinity receptor chromatography oxLDL and IgG receptor complex base peak mass spectrometric traces. Figure 13: Live-cell affinity receptor chromatography of oxLDL and IgG receptor U937 cells were differentiated for 3 days in PMA washed three times with PBS and incubated on ice for 30 minutes with IgGcomplex 500 mM NaCl base peakoff mass spectrometric traces . U937 cells coated or oxLDL coated beads. Excesselution beads were then washed with three washes of PBS and cells were incubated at 37 were C to allow for bead internalization for 30 min, 1h, 2h or 4h. Cells were then scraped and all time points were pooled and lysed in a differentiated for 3 days in PMA washed three times with PBS and incubated on ice for 30 French pressure cell press. A control sample was created by adding beads just prior to lysis. Beads were isolated via sucrose density gradient centrifugation and associated proteins were sequentially dissociated by a series of NaCl minutes with IgG-coated or oxLDL coated beads. Excess beads were thenconcentrations. washed offElutes with were analyzed by nano LC-ESI-MS/MS with an LTQ ion trap. (A) 500 mM NaCl elution of IgG-coated bead associated proteins. (B) 500 mM NaCl elution of IgG-coated bead control. (C) 500 mM elution of oxLDL-coated bead associated proteins. (D) three washes of PBS and cells were incubated at NaCl 37°C to allow for bead internalization for 30 500 mM NaCl elution of IgG-coated bead control.

min, 1h, 2h or 4h. Cells were then scraped and all time points were pooled and lysed in a French pressure cell press. A control sample was created by adding beads just prior to lysis. Beads were isolated via sucrose density gradient centrifugation and associated proteins were sequentially dissociated by a series of NaCl concentrations. Elutes were analyzed by nano LC-ESI-MS/MS with an LTQ ion trap. (A) 500 mM NaCl elution of IgG-coated bead associated proteins. (B) 500 mM NaCl elution of IgG-coated bead control. (C) 500 mM NaCl elution of oxLDL-coated bead associated proteins. (D) 500 mM NaCl elution of IgG-coated bead control.
46

DISCUSSION
The successful Western blotting and immunofluorescent cell-staining of CD36 confirms the presence of the scavenger receptor for oxLDL at the plasmalemma (Figures 4 & 5). The differential immunofluorescent staining of intracellular and extracellular oxLDL and IgG beads demonstrates the ability of the experimental system to quantify bead internalization. Moreover, only extracellular 2µm beads need to be stained in order to be quantified. The differences between IgG and oxLDL bead internalization (figures 8, 9 and 10) imply that IgG and oxLDL mediated phagocytosis utilize different internalization pathways.

Src and Syk The dual selective Src/Syk inhibitor MNS significantly inhibited both IgG and oxLDL bead internalization. CD36 is known to associate with Src and Syk and the Src kinases Fyn Lyn and Yes coprecipitate with CD36 from monocytic cell lysate (Medeiros et al., 2004). Additionally, Fyn and Lyn are phosphorylated and activated by CD36-mediated oxLDL internalization in mouse peritoneal macrophages and the internalization of oxLDL from the fluid phase in macrophages has been shown to require Src kinases (Collins et al., 2009; Rahaman et al., 2006). Correspondingly previous studies have found that pharmacological inhibition of Src blocks foam-cell formation in vitro and in vivo (Rahaman et al., 2006). Furthermore, Lyn-deficient mice display a lower rate of atherosclerosis than wildtype specimens (Miki et al., 2001). It should also be noted that the use of Src as a CD36 signalling molecule is not exclusive to macrophages. Fyn Lyn and Yes co-precipitate with CD36 from platelets and endothelial cell
47

lysate (Huang et al., 1991; Bull et al., 1994). Upon interaction with thrombospodin-1, CD36 activates Fyn in microvascular endothelial cells leading to a proapoptotic antiangiogenic effect.(Jimenez et al., 2000) Src is also integral to oxLDL-mediated CD36 signalling in platelet avtivation (Chen et al., 2008). oxLDL/CD36 mediated platelet activation involves the activation and phosphorylation of Fyn and Lyn and is stopped by Src inhibition (Chen et al., 2008). Syk present in human umbilical vein endothelial cells is known to associate with CD36 (Kazerounian et al., 2011). Upon binding fibrillar amyloid-, CD36, 61-integrin and integrin-associated protein (CD47) form a receptor complex in microglial cells that activates Syk (Wilkinson et al., 2006; Bamberger et al., 2003). The FcR is also known to signal through Src and Syk. It has previously been established that binding of IgG to the FcR allows Src family kinases to phosphorylate tyrosine pairs on ITAMs thus allowing the binding of the SH2 domains of Syk which, in turn, activates downstream phagocytic signalling components (Underhill and Goodridge, 2007). However, the selective Src inhibitor PP2 and the highly selective Syk inhibitor BAY 61 3606 on their own did not produce a large effect.

Actin There is considerable evidence that actin is required for phagocytosis (Aderem and Underhill, 1999; Etienne-Manneville and Hall, 2002). A phosphorylation chain following Src and Syk FcR-ITAM-mediated phosphorylation precipitates the polymerization of actin, in addition to other events required for phagosome formation such as myosin activation, membrane

48

fusion and ROS production (Aderem and Underhill, 1999; Etienne-Manneville and Hall, 2002; Underhill and Goodridge, 2007). Fluid phase CD36-mediated oxLDL uptake in macrophages also requires actin (Collins et al., 2009). There is some evidence that CD36 initiates this actin polymerization using the scaffold protein p130Cas, Pyk2, paxillin and Fyn via a phosphorylation cascade (Stuart et al., 2007) Accordingly, inhibition of actin by Cytochalasin D or Latrunculin B completely inhibited bead phagocytosis.

FAK Inhibition of FAK by PF 573228 did not produce a large effect on oxLDL or IgG bead phagocytosis. Previous research postulated that fluid-phase oxLDL induced CD36 activation initiated NADPH oxidase ROS production leading to oxidative SHP-1 inactivation which would, in turn, constitutively activate FAK, leading to actin polymerization and that this reforming of the cytoskeleton would cause macrophages to become trapped in the arterial intima leading to foam cell formation (Park et al., 2009). When examining Fc signalling, one study found that by cross-linking Fc receptors they could precipitate a rapid transient Fak phosphorylation in human macrophages (Pan et al., 1999). However, another study found no increased tyrosine phosphorylation of p125Fak during mAb-

49

mediated FcII & III receptor aggregation in murine macrophages (Greenberg et al., 1994). The lack of IgG bead internalization inhibiton under Fak inhibition seems to support the latter.

PI3K PI3K has previously been shown to be involved in several key IgG-mediated phagocytic processes such as the depletion of PI(4,5)P2, an actin assembly and remodelling molecule present at the phagosome (Scott et al., 2005), the regulation of the small g-proteins ADP-ribosylation factor 1 and 6 and pseudopod extension via Myosin X (Groves et al., 2008). The present study found that inhibition of PI3K by LY 294 002 or Wortmannin did not produce a large reduction in oxLDL or IgG bead internalization. This is consistent with previous findings that phagocytosis of IgG-coated beads smaller than 3µm were not affected by PI3K inhibition by either Wortmannin or LY294002 (Groves et al., 2008). It is also consistent with earlier research that found no correlation between PI3K and CD36-mediated fluid phase oxLDL internalization or foam-cell formation (Rahaman et al., 2006; Collins et al., 2009).

PLC

There is little prior evidence directly linking PLC and CD36 however CD36-mediated platelet activation tyrosine kinase phosphorylation is associated with PLC activation and both PLC and CD36 are localized to platelet lipid rafts (Gousset et al., 2004).

50

With regards to the FcR, PLC was implicated in both the depletion of the actin assembly and remodelling molecule PI(4,5)P2 at the phagosome and the depolymerization of actin around the nascent phagosome (Scott et al., 2005). Accordingly, inhibition of PLC by U73122 significantly inhibits IgG bead internalization by approximately 90% (Figure 12). The internalization of oxLDL beads was also significantly reduced suggesting that PLC may play a more general role in phagocytosis.

Jak Inhibition of Jak by AG 490 significantly inhibited both oxLDL and IgG bead internalization. Earlier research found no correlation between foam-cell formation and Jak when murine macrophages were exposed to fluid-phase oxLDL (Rahaman et al., 2006). There has been some evidence of cross-regulation between ITAM motifs and the cytokine receptor Jak-STAT pathway (Ivashkiv, 2009; Hu et al., 2007). The Jak/Stat pathway is inhibited by the binding of immune complexes to the FcR leading to the suppression of Interferon-gamma activation while this does not imply a requirement for phagocytosis it does establish a signalling association (Boekhoudt et al., 2007; Feldman et al., 1995).

PKC Inhibition of PKC by Gö6983 did not produce a large effect on oxLDL or IgG bead internalization.
51

Earlier research found no correlation between foam-cell formation and PKC when macrophages were exposed to fluid-phase oxLDL (Rahaman et al., 2006). However, the overexpression of PKC- (which is not inhibited by Gö 6983) increases the rate of FcR-mediated phagocytosis in RAW 264.7 macrophages (Larsen et al., 2002). During phagoytosis PKC-,  and , but not necissaily PKC- or , localize to the plasma membrane in murine RAW 264.7 macrophages (Larsen et al., 2000). A study by Zheleznyak et. al. found that IgG-coated 3µm bead internalization by human monocytes was inhibited by the PKC inhibitors H7, staurosporine and calphostin C (Zheleznyak and Brown, 1992). While another study found that IgG-opsonized red-blood cell phagocytosis by murine macrophages was insensitive to the same PKC inhibitors (Greenberg et al., 1993). Furthermore, a later study found staurosporine and calphostin C (general PKC inhibitors) but not Gö6976 and CGP 41251(classic/selective inhibitors) inhibit the phagocytosis of IgG-opsonized erythrocytes by RAW 264.7 (Larsen et al., 2000). Accordingly, it is possible that an isoform of PKC not effectively inhibited by Gö 6983 is required for IgG-coated and/or oxLDL-coated bead phagocytosis.

PLD

Ethanol, a phospholipase D inhibitor, did not have a large effect on oxLDL or IgG bead internalization.

There has been no prior direct evidence for interaction between CD36 and PLD however a strong association was found between PLD activation and the phagocytosis of Mycobacterium

52

tuberculosis in monocyte-derived macrophages, a process that has been shown to involve CD36 (Kusner et al., 1996).

3 µm IgG-coated latex bead uptake has been reported to have been impaired upon the inactivation of PLD isoforms 1 and 2 in murine macrophages (Corrotte et al., 2006). Also, in response to FcR ligation phosphatidic acid, a product of PLD, localizes to the inner leaflet of the plasma membrane (Groves et al., 2008). Additionally, mechanical cell membrane processes such as membrane ruffling and cell migration have been shown to require PLD (O'Luanaigh et al., 2002; Santy and Casanova, 2001).

PAP The PAP-1 inhibitor Propranolol did not have a large effect on oxLDL or IgG bead internalization. Propranolol has been successfully used to treat atherosclerosis-related conditions (Olakowska and Olakowski, 2006). Additionally, PAP and CD36 both participate in phospholipid recruitment (Engelmann and Wiedmann, 2010). However, there has been no direct evidence of PAP activity regulation by CD36. To date, phosphatidate phosphatase has not been directly implicated in IgG-mediated phagocytosis either. However, some speculate that the NADPH oxidase catalyzed ROS production concomitant with phagocytosis is reliant, in part, on PAP-mediated production of diacylglycerol (Lennartz, 1999). Thus it remains possible that PAP-1 still plays an important role in the response to oxLDL.

53

HMGCR A significant reduction in IgG or oxLDL bead phagocytosis was not observed in response to HMGCR inhibition by Lovastatin (Appendix F). Excess serum LDL can be controlled by inhibiting the rate-limiting LDL biosynthesis enzyme HMGCR via Lovastatin and CD36 expression has been shown to be upregulated in some cases by Lovastatin (Endo, 1979; Ruiz-Velasco et al., 2004). It is not known, however whether CD36 has a direct effect on HMGCR levels or activity. Partial inhibition of the phagocytosis of IgG-opsonized sheep red blood cells by human monocytes has been reported in response to 10 µM lovastatin (Loike et al., 2004). Additionally, Fc signal transduction tyrosine kinase activation was inhibited by Fluvastatin, a related inhibitor of HMGCR, although this was hypothesized to be due to disruption of lipid rafts in monocytes (Hillyard et al., 2004).

LARC Determination of oxLDL/CD36 Receptor Complex Binding Partners The selectivity of the base peak trace patterns of the 500 mM NaCl IgG, oxLDL and control elutions (Figure 13) demonstrate the ability of the aforementioned LARC system to distinguish IgG/FcR receptor complex associated proteins from oxLDL/CD36 receptor complex associated proteins. A variety of Src-family, Syk-family, JAK, PLC, actin, FAK, PI3K, PLD, PKC, HMGCR and phosphatidate phosphatase isoforms were identified in IgG, oxLDL, anti-CD36 IgA and antiCD36 IgG coated bead LARC thus supporting the validity of the central hypothesis. Many of

54

these protein groups were also identified in control treatments therefore further analysis must be conducted to eliminate irrelevant isoforms.

55

CONCLUSION
Pharmacological inhibition assays confirmed the validity of the system for quantifying phagocytic rates and demonstrated that actin, Janus kinase, PLC, Src and Syk are involved in oxLDL and IgG phagocytosis. Bead assays did not demonstrate a relationship between PI3K, HMGCR, Phosphatidate phosphatase, PKC, Fak, or PLD and oxLDL or IgG phagocytosis. Differential inhibition of oxLDL phagocytosis over IgG phagocytosis was not observed with the selected inhibitors under the tested conditions. However, further pharmacological testing may yet reveal an inhibitor that differentially inhibits oxLDL uptake thus elucidating the biochemical pathway involved in oxLDL phagocytosis and presenting a target for potential atherosclerosis treatment. Bead internalization assays were successful in accurately assaying the number of beads internalized per cell and establishing statistically distinct uptake results. It seems that oxLDLmediated phagocytosis can be quantified and differentiated from other types of phagocytosis using bead based assays and that the presence of specific types of enzymes potentially involved in oxLDL internalization such as SRC, SYK, Janus and PLC can be determined via nano LCESI-MS/MS. LC-ESI-MS/MS of the U937 cell may be used to reveal the isoforms of the drug target proteins expressed in human macrophages.

56

FUTURE OBJECTIVES
Live-cell affinity receptor chromatography appears to be a useful technique in understanding the workings of oxLDL phagocytic signalling. Now that a group of potential oxLDL receptor complex proteins has been identified via mass spectrometry, isoforms that are associated with the complex to a statistically relevant degree can be identified and the task of confirming their complicity in the pathogenic signalling pathways of oxLDL phagocytosis that lead to foam cell formation can be approached using dominant-negative transfection or siRNA. Additionally their presence at the site of internalization could be confirmed by GFP-fusion constructs or immunofluorescent staining.

57

58

APPENDIX A-BEADS INTERNALIZED IN RPMI WITH 10% FETAL BOVINE SERUM
DIC and Cy3 fluorescent images of IgG and oxLDL-coated beads internalized by U937 in RPMI with 10% fetal bovine serum for different periods of time. IgG-coated beads incubated for 15 min (A,B), 1h (C,D), 2h (E,F), 3h (G,H), 4(I,J). OxLDL-coated beads incubated for 15 min (K,L), 1h (M,N), 3h (O,P), 4h (Q,R). 3 replicates with an average of 3 images per treatment and 15 cells per image were collected.

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

DIC and Cy3 fluorescent images of IgG and oxLDL-coated beads internalized by U937 in RPMI with 10% fetal calf serum for 59 different periods of time. IgG-coated beads incubated for 15 min (A,B), 1h (C,D), 2h (E,F), 3h (G,H), 4(I,J). OxLDL-coated beads incubated for 15 min (K,L), 1h (M,N), 3h (O,P), 4h (Q,R).

APPENDIX B - BEADS INTERNALIZED AFTER LIMITED BEAD PREINCUBATION
DIC and Cy3 fluorescent images of IgG-coated beads internalized by U937 after a limited 30 minute bead incubation in RPMI with 10% fetal bovine serum for different periods of time. 0h on ice (A,B), 15 min (C,D), 30min (E,F), 1h (G,H), 2h (I,J), 3h (K,L), 4h (M,N), 4h on ice (O,P), no bead (Q,R). 3 replicates with an average of 3 images per treatment and 15 cells per image were collected.

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

DIC and Cy3 fluorescent images of IgG-coated beads internalized by U937 after a limited 30 minute bead incubation in RPMI 60 with 10% fetal calf serum for different periods of time. 0h on ice (A,B), 15 min (C,D), 30min (E,F), 1h (G,H), 2h (I,J), 3h (K,L), 4h (M,N), 4h on ice (O,P), no bead (Q,R).

DIC and Cy3 fluorescent images of oxLDL-coated beads internalized by U937 after a limited 30 minute bead incubation in RPMI with 10% fetal bovine serum for different periods of time. 0h on ice (A,B), 15 min (C,D), 30min (E,F), 1h (G,H), 2h (I,J), 3h (K,L), 4h (M,N), 4h on ice (O,P), 2° antibody alone (Q,R). 3 replicates with an average of 3 images per treatment and 15 cells per image were collected.

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

DIC and Cy3 fluorescent images of oxLDL-coated beads internalized by U937 after a limited 30 minute bead incubation in RPMI with 10% fetal calf serum for different periods of time. 0h on ice (A,B), 15 min (C,D), 30min (E,F), 1h (G,H), 2h (I,J), 3h (K,L), 61 4h (M,N), 4h on ice (O,P), no bead (Q,R).

APPENDIX C ­ UNCOATED BEADS INTERNALIZED IN SALINE EXPERIMENTAL MEDIUM DIC images of uncoated polystyrene bead internalization by U937 in Saline Experimental Medium at different time points. Cells were differentiated for 3 days with 100 nM PMA, washed 5-times with PBS and incubated with uncoated beads in isotonic experimental medium. Cells were fixed in a 5% paraformaldehye solution at 15min (A), 30min (B), 1h (C), 2h (D), 3h (E), 4h (F).

A

B

C

D

E

F

DIC images of uncoated polystyrene bead internalization by U937 in Saline Experimental Medium at different time points. Cells were differentiated for 3 days with 100 nM PMA, washed 5-times with PBS and incubated with uncoated beads in isotonic experimental medium. Cells were fixed 62 in a 5% paraformaldehye solution at 15min (A), 30min (B), 1h (C), 2h (D), 3h (E), 4h (F).

APPENDIX D ­ INTERNALIZATION OF UNCOATED, IGG-COATED AND OXLDL-COATED BEADS IN SALINE EXPERIMENTAL MEDIUM OVER 4 HOURS Number of IgG-coated, oxLDL-coated and uncoated beads internalized by U937 in Saline Experimental Medium over 4 hours. Cells were differentiated for 3 days with 100 nM PMA, washed 5-times with PBS and incubated with oxLDL-coated or IgG-coated beads in isotonic experimental medium. Cells were fixed in a 5% paraformaldehye solution at 15 min, 30 min, 1h, 2h, 3h or 4h. Beads were subsequently stained with Cy3-conjugated anti-IgG antibody or rabbit polyclonal anti-oxLDL antibody followed by Cy3-conjugated donkey anti-rabbit antibody to visualize non-internalized beads. Quantification of bead internalization of at least 3 replicates +/standard error.

7

6 Beads Internalized Per Cell

5

4

3

2

1

0 0 1 2 Time (Hours) 3 4

63

APPENDIX E: STATISTICAL ANALYSIS OF BEAD INTERNALIZATION IN SALINE EXPERIMENTAL MEDIUM ASSAY The following model compares the average number of internalized beads per cell for oxLDLcoated IgG-coated and uncoated treatments at different time points. Significant differences between treatments and time points were observed.
Response in Whole Model Actual by Predicted Plot

Summary of Fit
RSquare RSquare Adj Root Mean Square Error Mean of Response Observations (or Sum Wgts) 0.765307 0.738096 0.839874 1.235984 78

Analysis of Variance
Source Model Error C. Total DF 8 69 77 Sum of Squares 158.71342 48.67182 207.38524 Mean Square 19.8392 0.7054 F Ratio 28.1252 Prob > F <.0001*

Lack Of Fit
Source Lack Of Fit Pure Error Total Error DF 12 57 69 Sum of Squares 34.502011 14.169813 48.671825 Mean Square 2.87517 0.24859 F Ratio 11.5658 Prob > F <.0001* Max RSq 0.9317

Effect Tests
Source treatment time Nparm 2 6 DF 2 6 Sum of Squares 29.52328 129.40448 F Ratio 20.9270 30.5752 Prob > F <.0001* <.0001*

64

Residual by Predicted Plot

65

APPENDIX F ­ PHARMACOLOGICAL INHIBITION OF PHAGOCYTOSIS
DIC and Cy3 fluorescent images of IgG-coated bead internalization over 4 hours with pharmacological inhibitors. No drug (A, B), DMSO (C, D), BAY 61 3606 (E, F), Cytochalasin D (G, H), Latrunculin B (I, J), MNS (K, L), Wortmannin (M, N), Ethanol (O, P), PP2 (Q, R), U73122 (S, T).

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

DIC and Cy3 fluorescent images of IgG-coated bead internalization over 4 hours when exposed to various pharmacological inhibitors. No drug (A, B), DMSO (C, D), BAY 61 3606 (E, F),66 Cytochalasin D (G, H), Latrunculin B (I, J), MNS (K, L), Wortmannin (M, N), Ethanol (O, P), PP2 (Q, R), U73122 (S, T).

DIC and Cy3 fluorescent images of IgG-coated bead internalization over 4 hours when exposed to various pharmacological inhibitors. AG490 (A, B), Genistein (C, D), Go6983 (E, F), LY 294 002 (G, H), PF 573228 (I, J), Propranolol (K, L), Lovastatin (M, N). 3 replicates with an average of 3 images per treatment and 15 cells per image were collected.

A

B

C

D

E

F

G

H

I

J

K

L

M

N

DIC and Cy3 fluorescent images of IgG-coated bead internalization over 4 hours when exposed to various pharmacological inhibitors. AG490 (A, B), Genistein (C, D), Go6983 (E, F), LY 294 002 (G, H), PF 573228 (I, J), Propranolol (K, L), Lovastatin (M, N).

Q

R

67

DIC and Cy3 fluorescent images of oxLDL-coated bead internalization over 4 hours when exposed to various pharmacological inhibitors. No drug (A, B), DMSO (C, D), BAY 61 3606 (E, F), Cytochalasin D (G, H), Latrunculin B (I, J), MNS (K, L), Wortmannin (M, N), Ethanol (O, P), PP2 (Q, R), U73122 (S, T).

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

DIC and Cy3 fluorescent images of oxLDL-coated bead internalization over 4 hours when exposed to various pharmacological inhibitors. No drug (A, B), DMSO (C, D), BAY 61 3606 (E, F), Cytochalasin D (G, H), Latrunculin B (I, J), MNS (K, L), Wortmannin (M, N), Ethanol (O, P), PP2 (Q, R), U73122 (S, T).

68

DIC and Cy3 fluorescent images of oxLDL-coated bead internalization over 4 hours when exposed to various pharmacological inhibitors. AG490 (A, B), Genistein (C, D), Go6983 (E, F), LY 294 002 (G, H), PF 573228 (I, J), Propranolol (K, L), Lovastatin (M, N). 3 replicates with an average of 3 images per treatment and 15 cells per image were collected.

A

B

C

D

E

F

G

H

I

J

K

L

M

N

DIC and Cy3 fluorescent images of oxLDL-coated bead internalization over 4 hours when exposed to various pharmacological inhibitors. AG490 (A, B), Genistein (C, D), Go6983 (E, F), LY 294 002 (G, H), PF 573228 (I, J), Propranolol (K, L), Lovastatin (M, N).

Q

R

69

APPENDIX G: POOLED IGG AND OXLDL ONE-WAY ANOVA OF PHARMACOLOGICAL INHIBITION ASSAY The following analysis compares the average number of internalized beads per cell for oxLDLcoated and IgG-coated bead treatments for different pharmacological inhibitors. Analysis by Tukey-Cramer HSD reveals significant bead internalization inhibition under AG 490, U73122, MNS, Cytochalasin D and Latrunculin B treatments.
Oneway Analysis of in By drug

Missing Rows 35

Oneway Anova Summary of Fit
Rsquare Adj Rsquare Root Mean Square Error Mean of Response Observations (or Sum Wgts) 0.509734 0.430659 1.215823 1.925164 109

Analysis of Variance
Source drug Error C. Total DF 15 93 108 Sum of Squares 142.93425 137.47498 280.40923 Mean Square 9.52895 1.47823 F Ratio 6.4462 Prob > F <.0001*

Means for Oneway Anova
Level AG 490 BAY 61 3606 Cytochalasin D DMSO Ethanol Genistein Number 6 7 6 12 6 6 Mean 0.54205 2.86090 0.00000 2.93935 2.46321 1.03862 Std Error 0.49636 0.45954 0.49636 0.35098 0.49636 0.49636 Lower 95% -0.444 1.948 -0.986 2.242 1.478 0.053 Upper 95% 1.5277 3.7734 0.9857 3.6363 3.4489 2.0243

70

Level Go 6983 Latrunculin B LY 294 002 MNS No Drug PF 573 228 PP2 Propranolol U73122 Wortmannin

Number 6 6 6 6 12 6 6 6 6 6

Mean 2.22586 0.00000 2.88587 0.07667 2.87422 2.79447 2.55202 2.68771 0.43123 2.31125

Std Error 0.49636 0.49636 0.49636 0.49636 0.35098 0.49636 0.49636 0.49636 0.49636 0.49636

Lower 95% 1.240 -0.986 1.900 -0.909 2.177 1.809 1.566 1.702 -0.554 1.326

Upper 95% 3.2115 0.9857 3.8715 1.0623 3.5712 3.7801 3.5377 3.6734 1.4169 3.2969

Std Error uses a pooled estimate of error variance

Means and Std Deviations
Level AG 490 BAY 61 3606 Cytochalasin D DMSO Ethanol Genistein Go 6983 Latrunculin B LY 294 002 MNS No Drug PF 573 228 PP2 Propranolol U73122 Wortmannin Number 6 7 6 12 6 6 6 6 6 6 12 6 6 6 6 6 Mean 0.54205 2.86090 0.00000 2.93935 2.46321 1.03862 2.22586 0.00000 2.88587 0.07667 2.87422 2.79447 2.55202 2.68771 0.43123 2.31125 Std Dev 0.46572 2.12851 0.00000 1.40979 1.24168 1.11479 1.48060 0.00000 1.13302 0.08472 1.17225 2.03025 0.91621 0.98937 0.39593 1.44263 Std Err Mean 0.19013 0.80450 0.00000 0.40697 0.50691 0.45511 0.60445 0.00000 0.46255 0.03459 0.33840 0.82885 0.37404 0.40391 0.16164 0.58895 Lower 95% 0.053 0.892 0.000 2.044 1.160 -0.131 0.672 0.000 1.697 -0.012 2.129 0.664 1.591 1.649 0.016 0.797 Upper 95% 1.0308 4.8294 0.0000 3.8351 3.7663 2.2085 3.7797 0.0000 4.0749 0.1656 3.6190 4.9251 3.5135 3.7260 0.8467 3.8252

Means Comparisons Comparisons for all pairs using Tukey-Kramer HSD

Level DMSO LY 294 002 No Drug BAY 61 3606 PF 573 228 Propranolol PP2 Ethanol Wortmannin Go 6983 Genistein AG 490 U73122 MNS Cytochalasin D Latrunculin B

A A A A A A A A A A A

B B B B B B B B B B

C

C C C C C C C C C

D D D D D D D D D

Mean 2.9393535 2.8858696 2.8742167 2.8608962 2.7944682 2.6877135 2.5520207 2.4632132 2.3112475 2.2258598 1.0386202 0.5420536 0.4312350 0.0766667 0.0000000 0.0000000

Levels not connected by same letter are significantly different.

71

APPENDIX H: TWO-WAY ANOVA OF PHARMACOLOGICAL INHIBITION ASSAY The following analyzes the average number of internalized oxLDL-coated beads, IgG-coated beads and the effect of different pharmacological inhibitors.
Response normal in Whole Model Actual by Predicted Plot

Summary of Fit
RSquare RSquare Adj Root Mean Square Error Mean of Response Observations (or Sum Wgts) 0.800895 0.720736 0.528454 -3.7e-16 109

Analysis of Variance
Source Model Error C. Total DF 31 77 108 Sum of Squares 86.49667 21.50333 108.00000 Mean Square 2.79022 0.27926 F Ratio 9.9913 Prob > F <.0001*

Parameter Estimates
Term Intercept treatment[IgG] drug[AG 490] drug[BAY 61 3606] drug[Cytochalasin D] drug[DMSO] drug[Ethanol] drug[Genistein] drug[Go 6983] drug[Latrunculin B] drug[LY 294 002] drug[MNS] drug[No Drug] drug[PF 573 228] drug[PP2] drug[Propranolol] drug[U73122] Estimate -0.089672 0.4062062 -0.768694 0.5508209 -1.105096 0.7190838 0.4235885 -0.460522 0.2762856 -1.105096 0.6858914 -1.057516 0.6786595 0.6291672 0.4787029 0.5629146 -0.837469 Std Error 0.052004 0.052004 0.2084 0.195805 0.2084 0.15188 0.2084 0.2084 0.2084 0.2084 0.2084 0.2084 0.15188 0.2084 0.2084 0.2084 0.2084 t Ratio -1.72 7.81 -3.69 2.81 -5.30 4.73 2.03 -2.21 1.33 -5.30 3.29 -5.07 4.47 3.02 2.30 2.70 -4.02 Prob>|t| 0.0887 <.0001* 0.0004* 0.0062* <.0001* <.0001* 0.0455* 0.0301* 0.1888 <.0001* 0.0015* <.0001* <.0001* 0.0034* 0.0243* 0.0085* 0.0001*

72

Term treatment[IgG]*drug[AG 490] treatment[IgG]*drug[BAY 61 3606] treatment[IgG]*drug[Cytochalasin D] treatment[IgG]*drug[DMSO] treatment[IgG]*drug[Ethanol] treatment[IgG]*drug[Genistein] treatment[IgG]*drug[Go 6983] treatment[IgG]*drug[Latrunculin B] treatment[IgG]*drug[LY 294 002] treatment[IgG]*drug[MNS] treatment[IgG]*drug[No Drug] treatment[IgG]*drug[PF 573 228] treatment[IgG]*drug[PP2] treatment[IgG]*drug[Propranolol] treatment[IgG]*drug[U73122]

Estimate -0.321811 0.430797 -0.406206 0.3376171 0.2733703 -0.020131 0.0344156 -0.406206 0.0472874 -0.420687 0.1470031 0.5890716 -0.107233 -0.080322 -0.410076

Std Error 0.2084 0.195805 0.2084 0.15188 0.2084 0.2084 0.2084 0.2084 0.2084 0.2084 0.15188 0.2084 0.2084 0.2084 0.2084

t Ratio -1.54 2.20 -1.95 2.22 1.31 -0.10 0.17 -1.95 0.23 -2.02 0.97 2.83 -0.51 -0.39 -1.97

Prob>|t| 0.1266 0.0308* 0.0549 0.0292* 0.1935 0.9233 0.8693 0.0549 0.8211 0.0470* 0.3361 0.0060* 0.6083 0.7010 0.0527

Effect Tests
Source treatment drug treatment*drug Nparm 1 15 15 DF 1 15 15 Sum of Squares 17.038341 54.141406 10.722640 F Ratio 61.0116 12.9248 2.5597 Prob > F <.0001* <.0001* 0.0038*

Residual by Predicted Plot

treatment Leverage Plot

73

Least Squares Means Table
Level IgG oxLDL Least Sq Mean 0.3165339 -0.4958785 Std Error 0.07323571 0.07385374 Mean 0.43706 -0.44515

drug Leverage Plot

treatment*drug Leverage Plot

74

APPENDIX I: ONE-WAY ANOVA OF NORMALIZED IGG-BEAD INTERNALIZATION DURING PHARMACOLOGICAL INHIBITION ASSAY

The following analysis compares the average number of internalized beads per cell for IgGcoated bead treatments for different pharmacological inhibitors. Analysis by Tukey-Cramer HSD reveals significant bead internalization inhibition under Genistein, AG 490, U73122, MNS, Cytochalasin D and Latrunculin B treatments.

Oneway Analysis of normal in By drug

Missing Rows 17

Oneway Anova Summary of Fit
Rsquare Adj Rsquare Root Mean Square Error Mean of Response Observations (or Sum Wgts) 0.769876 0.681367 0.564476 -7.7e-17 55

Analysis of Variance
Source drug Error C. Total DF 15 39 54 Sum of Squares 41.573311 12.426689 54.000000 Mean Square 2.77155 0.31863 F Ratio 8.6983 Prob > F <.0001*

Means for Oneway Anova
Level AG 490 BAY 61 3606 Cytochalasin D Number 3 4 3 Mean -1.0706 0.7612 -1.4426 Std Error 0.32590 0.28224 0.32590 Lower 95% -1.730 0.190 -2.102 Upper 95% -0.411 1.332 -0.783

75

Level DMSO Ethanol Genistein Go 6983 Latrunculin B LY 294 002 MNS No Drug PF 573 228 PP2 Propranolol U73122 Wortmannin

Number 6 3 3 3 3 3 3 6 3 3 3 3 3

Mean 0.8276 0.5096 -0.5315 0.1681 -1.4426 0.5416 -1.4133 0.6234 0.9704 0.2218 0.3201 -1.2094 0.4613

Std Error 0.23045 0.32590 0.32590 0.32590 0.32590 0.32590 0.32590 0.23045 0.32590 0.32590 0.32590 0.32590 0.32590

Lower 95% 0.361 -0.150 -1.191 -0.491 -2.102 -0.118 -2.073 0.157 0.311 -0.437 -0.339 -1.869 -0.198

Upper 95% 1.294 1.169 0.128 0.827 -0.783 1.201 -0.754 1.089 1.630 0.881 0.979 -0.550 1.121

Std Error uses a pooled estimate of error variance

Means and Std Deviations
Level AG 490 BAY 61 3606 Cytochalasin D DMSO Ethanol Genistein Go 6983 Latrunculin B LY 294 002 MNS No Drug PF 573 228 PP2 Propranolol U73122 Wortmannin Number 3 4 3 6 3 3 3 3 3 3 6 3 3 3 3 3 Mean -1.0706 0.7612 -1.4426 0.8276 0.5096 -0.5315 0.1681 -1.4426 0.5416 -1.4133 0.6234 0.9704 0.2218 0.3201 -1.2094 0.4613 Std Dev 0.34687 1.13503 0.00000 0.37448 0.14288 0.75513 0.96606 0.00000 0.59346 0.05068 0.34602 0.70875 0.64274 0.55797 0.24802 0.58630 Std Err Mean 0.20026 0.56751 0.00000 0.15288 0.08249 0.43597 0.55776 0.00000 0.34263 0.02926 0.14126 0.40919 0.37108 0.32214 0.14320 0.33850 Lower 95% -1.932 -1.045 -1.443 0.435 0.155 -2.407 -2.232 -1.443 -0.933 -1.539 0.260 -0.790 -1.375 -1.066 -1.826 -0.995 Upper 95% -0.209 2.567 -1.443 1.221 0.865 1.344 2.568 -1.443 2.016 -1.287 0.986 2.731 1.818 1.706 -0.593 1.918

Means Comparisons Comparisons for all pairs using Tukey-Kramer HSD
q* 3.65655
Abs(Dif) -HSD PF DMSO BAY N/D LY Eth. Wort Prop. PP2 Gö Gen. AG U7. MNS Cyto. D Lat. B PF -1.6853 -1.3167 -1.3673 -1.1124 -1.2565 -1.2245 -1.1762 -1.0349 -0.9367 -0.8830 -0.1834 0.3557 0.4945 0.6984 0.7277 0.7277 DMSO -1.3167 -1.1917 -1.2660 -0.9874 -1.1735 -1.1415 -1.0932 -0.9520 -0.8537 -0.8000 -0.1004 0.4387 0.5775 0.7814 0.8107 0.8107

Alpha 0.05
BAY -1.3673 -1.2660 -1.4595 -1.1945 -1.3568 -1.3248 -1.2765 -1.1353 -1.0370 -0.9833 -0.2838 0.2554 0.3942 0.5981 0.6274 0.6274 N/D -1.1124 -0.9874 -1.1945 -1.1917 -1.3777 -1.3457 -1.2975 -1.1562 -1.0580 -1.0043 -0.3047 0.2344 0.3733 0.5772 0.6064 0.6064 LY -1.2565 -1.1735 -1.3568 -1.3777 -1.6853 -1.6533 -1.6050 -1.4638 -1.3655 -1.3118 -0.6122 -0.0731 0.0657 0.2696 0.2989 0.2989 Eth. -1.2245 -1.1415 -1.3248 -1.3457 -1.6533 -1.6853 -1.6370 -1.4958 -1.3975 -1.3438 -0.6442 -0.1051 0.0337 0.2376 0.2669 0.2669 Wort. -1.1762 -1.0932 -1.2765 -1.2975 -1.6050 -1.6370 -1.6853 -1.5440 -1.4458 -1.3921 -0.6925 -0.1534 -0.0145 0.1894 0.2186 0.2186 Prop. -1.0349 -0.9520 -1.1353 -1.1562 -1.4638 -1.4958 -1.5440 -1.6853 -1.5870 -1.5333 -0.8337 -0.2946 -0.1558 0.0481 0.0774 0.0774 PP2 -0.9367 -0.8537 -1.0370 -1.0580 -1.3655 -1.3975 -1.4458 -1.5870 -1.6853 -1.6316 -0.9320 -0.3929 -0.2540 -0.0501 -0.0209 -0.0209 Go -0.8830 -0.8000 -0.9833 -1.0043 -1.3118 -1.3438 -1.3921 -1.5333 -1.6316 -1.6853 -0.9857 -0.4466 -0.3078 -0.1038 -0.0746 -0.0746 Gen. -0.1834 -0.1004 -0.2838 -0.3047 -0.6122 -0.6442 -0.6925 -0.8337 -0.9320 -0.9857 -1.6853 -1.1462 -1.0073 -0.8034 -0.7742 -0.7742 AG 0.3557 0.4387 0.2554 0.2344 -0.0731 -0.1051 -0.1534 -0.2946 -0.3929 -0.4466 -1.1462 -1.6853 -1.5465 -1.3425 -1.3133 -1.3133 U7. 0.4945 0.5775 0.3942 0.3733 0.0657 0.0337 -0.0145 -0.1558 -0.2540 -0.3078 -1.0073 -1.5465 -1.6853 -1.4814 -1.4521 -1.4521 MNS Cyto. D 0.6984 0.7814 0.5981 0.5772 0.2696 0.2376 0.1894 0.0481 -0.0501 -0.1038 -0.8034 -1.3425 -1.4814 -1.6853 -1.6560 -1.6560 0.7277 0.8107 0.6274 0.6064 0.2989 0.2669 0.2186 0.0774 -0.0209 -0.0746 -0.7742 -1.3133 -1.4521 -1.6560 -1.6853 -1.6853 Lat. B 0.7277 0.8107 0.6274 0.6064 0.2989 0.2669 0.2186 0.0774 -0.0209 -0.0746 -0.7742 -1.3133 -1.4521 -1.6560 -1.6853 -1.6853

Positive values show pairs of means that are significantly different.

76

Level PF 573 228 DMSO BAY 61 3606 No Drug LY 294 002 Ethanol Wortmannin Propranolol PP2 Go 6983 Genistein AG 490 U73122 MNS Cytochalasin D Latrunculin B

A A A A A A A A A A A

B B B B B B B B

C C C C C C C

D D D D D D D D

Mean 0.970406 0.827603 0.761228 0.623360 0.541602 0.509583 0.461341 0.320079 0.221844 0.168123 -0.531452 -1.070575 -1.209401 -1.413309 -1.442569 -1.442569

Levels not connected by same letter are significantly different. Level PF 573 228 PF 573 228 PF 573 228 DMSO DMSO DMSO BAY 61 3606 BAY 61 3606 PF 573 228 BAY 61 3606 No Drug No Drug PF 573 228 DMSO No Drug LY 294 002 LY 294 002 BAY 61 3606 LY 294 002 Ethanol Ethanol Ethanol Wortmannin Wortmannin DMSO Wortmannin No Drug BAY 61 3606 Propranolol Propranolol LY 294 002 Propranolol Ethanol No Drug Wortmannin PP2 PP2 PP2 LY 294 002 Go 6983 - Level Cytochalasin D Latrunculin B MNS Cytochalasin D Latrunculin B MNS Cytochalasin D Latrunculin B U73122 MNS Cytochalasin D Latrunculin B AG 490 U73122 MNS Cytochalasin D Latrunculin B U73122 MNS Cytochalasin D Latrunculin B MNS Cytochalasin D Latrunculin B AG 490 MNS U73122 AG 490 Cytochalasin D Latrunculin B U73122 MNS U73122 AG 490 U73122 Cytochalasin D Latrunculin B MNS AG 490 Cytochalasin D Difference 2.412975 2.412975 2.383715 2.270172 2.270172 2.240912 2.203797 2.203797 2.179808 2.174537 2.065929 2.065929 2.040981 2.037004 2.036669 1.984171 1.984171 1.970629 1.954911 1.952152 1.952152 1.922892 1.903909 1.903909 1.898178 1.874649 1.832762 1.831803 1.762648 1.762648 1.751004 1.733387 1.718984 1.693935 1.670742 1.664412 1.664412 1.635152 1.612177 1.610692 Std Err Dif 0.4608927 0.4608927 0.4608927 0.3991447 0.3991447 0.3991447 0.4311256 0.4311256 0.4608927 0.4311256 0.3991447 0.3991447 0.4608927 0.3991447 0.3991447 0.4608927 0.4608927 0.4311256 0.4608927 0.4608927 0.4608927 0.4608927 0.4608927 0.4608927 0.3991447 0.4608927 0.3991447 0.4311256 0.4608927 0.4608927 0.4608927 0.4608927 0.4608927 0.3991447 0.4608927 0.4608927 0.4608927 0.4608927 0.4608927 0.4608927 Lower CL 0.72770 0.72770 0.69844 0.81068 0.81068 0.78142 0.62736 0.62736 0.49453 0.59810 0.60644 0.60644 0.35570 0.57751 0.57718 0.29889 0.29889 0.39420 0.26963 0.26687 0.26687 0.23761 0.21863 0.21863 0.43869 0.18937 0.37327 0.25537 0.07737 0.07737 0.06573 0.04811 0.03371 0.23444 -0.01454 -0.02086 -0.02086 -0.05013 -0.07310 -0.07459 Upper CL 4.098252 4.098252 4.068992 3.729665 3.729665 3.700405 3.780229 3.780229 3.865085 3.750969 3.525422 3.525422 3.726258 3.496497 3.496162 3.669448 3.669448 3.547062 3.640188 3.637429 3.637429 3.608169 3.589187 3.589187 3.357671 3.559927 3.292254 3.408236 3.447925 3.447925 3.436281 3.418665 3.404262 3.153428 3.356019 3.349690 3.349690 3.320429 3.297455 3.295969 p-Value Difference 0.0006* 0.0006* 0.0007* 0.0001* 0.0001* 0.0002* 0.0008* 0.0008* 0.0026* 0.0010* 0.0007* 0.0007* 0.0063* 0.0009* 0.0009* 0.0089* 0.0089* 0.0042* 0.0107* 0.0108* 0.0108* 0.0129* 0.0145* 0.0145* 0.0024* 0.0172* 0.0039* 0.0104* 0.0327* 0.0327* 0.0349* 0.0385* 0.0416* 0.0106* 0.0540 0.0559 0.0559 0.0652 0.0734 0.0740

77

Level Go 6983 Go 6983 Ethanol Wortmannin Propranolol PF 573 228 PP2 Propranolol Go 6983 DMSO BAY 61 3606 PP2 Go 6983 No Drug LY 294 002 Ethanol Wortmannin Genistein Genistein Genistein Propranolol PF 573 228 PP2 PF 573 228 Go 6983 Genistein DMSO PF 573 228 DMSO BAY 61 3606 BAY 61 3606 Genistein PF 573 228 DMSO PF 573 228 No Drug BAY 61 3606 PF 573 228 No Drug LY 294 002 AG 490 AG 490 DMSO PF 573 228 AG 490 Ethanol LY 294 002 DMSO No Drug BAY 61 3606 Wortmannin Ethanol DMSO BAY 61 3606 Wortmannin U73122 U73122 LY 294 002 BAY 61 3606 PF 573 228 DMSO

- Level Latrunculin B MNS AG 490 AG 490 U73122 Genistein U73122 AG 490 U73122 Genistein Genistein AG 490 AG 490 Genistein Genistein Genistein Genistein Cytochalasin D Latrunculin B MNS Genistein Go 6983 Genistein PP2 Genistein U73122 Go 6983 Propranolol PP2 Go 6983 PP2 AG 490 Wortmannin Propranolol Ethanol Go 6983 Propranolol LY 294 002 PP2 Go 6983 Cytochalasin D Latrunculin B Wortmannin No Drug MNS Go 6983 PP2 Ethanol Propranolol Wortmannin Go 6983 PP2 LY 294 002 Ethanol PP2 Cytochalasin D Latrunculin B Propranolol LY 294 002 BAY 61 3606 No Drug

Difference 1.610692 1.581431 1.580158 1.531916 1.529480 1.501859 1.431245 1.390654 1.377524 1.359055 1.292680 1.292418 1.238698 1.154812 1.073055 1.041035 0.992793 0.911117 0.911117 0.881856 0.851531 0.802284 0.753296 0.748563 0.699575 0.677949 0.659480 0.650328 0.605760 0.593105 0.539385 0.539123 0.509066 0.507524 0.460823 0.455237 0.441149 0.428804 0.401517 0.373480 0.371994 0.371994 0.366262 0.347046 0.342734 0.341460 0.319759 0.318020 0.303281 0.299887 0.293218 0.287740 0.286001 0.251645 0.239497 0.233167 0.233167 0.221524 0.219626 0.209178 0.204243

Std Err Dif 0.4608927 0.4608927 0.4608927 0.4608927 0.4608927 0.4608927 0.4608927 0.4608927 0.4608927 0.3991447 0.4311256 0.4608927 0.4608927 0.3991447 0.4608927 0.4608927 0.4608927 0.4608927 0.4608927 0.4608927 0.4608927 0.4608927 0.4608927 0.4608927 0.4608927 0.4608927 0.3991447 0.4608927 0.3991447 0.4311256 0.4311256 0.4608927 0.4608927 0.3991447 0.4608927 0.3991447 0.4311256 0.4608927 0.3991447 0.4608927 0.4608927 0.4608927 0.3991447 0.3991447 0.4608927 0.4608927 0.4608927 0.3991447 0.3991447 0.4311256 0.4608927 0.4608927 0.3991447 0.4311256 0.4608927 0.4608927 0.4608927 0.4608927 0.4311256 0.4311256 0.3259003

Lower CL -0.07459 -0.10385 -0.10512 -0.15336 -0.15580 -0.18342 -0.25403 -0.29462 -0.30775 -0.10044 -0.28375 -0.39286 -0.44658 -0.30468 -0.61222 -0.64424 -0.69248 -0.77416 -0.77416 -0.80342 -0.83375 -0.88299 -0.93198 -0.93671 -0.98570 -1.00733 -0.80001 -1.03495 -0.85373 -0.98333 -1.03705 -1.14615 -1.17621 -0.95197 -1.22445 -1.00426 -1.13528 -1.25647 -1.05798 -1.31180 -1.31328 -1.31328 -1.09323 -1.11245 -1.34254 -1.34382 -1.36552 -1.14147 -1.15621 -1.27655 -1.39206 -1.39754 -1.17349 -1.32479 -1.44578 -1.45211 -1.45211 -1.46375 -1.35681 -1.36725 -0.98743

Upper CL 3.295969 3.266709 3.265435 3.217193 3.214757 3.187136 3.116522 3.075931 3.062801 2.818548 2.869113 2.977696 2.923975 2.614305 2.758332 2.726313 2.678070 2.596394 2.596394 2.567134 2.536808 2.487561 2.438573 2.433840 2.384852 2.363226 2.118973 2.335605 2.065253 2.169538 2.115817 2.224400 2.194343 1.967017 2.146100 1.914730 2.017582 2.114081 1.861010 2.058757 2.057271 2.057271 1.825755 1.806539 2.028011 2.026738 2.005036 1.777513 1.762774 1.876320 1.978495 1.973017 1.745494 1.828078 1.924774 1.918445 1.918445 1.906801 1.796058 1.785611 1.395914

p-Value Difference 0.0740 0.0858 0.0864 0.1096 0.1109 0.1266 0.1748 0.2083 0.2201 0.0912 0.2161 0.3082 0.3735 0.2632 0.6069 0.6534 0.7210 0.8230 0.8230 0.8543 0.8832 0.9222 0.9513 0.9537 0.9733 0.9797 0.9471 0.9860 0.9734 0.9889 0.9956 0.9978 0.9988 0.9948 0.9996 0.9983 0.9995 0.9998 0.9996 1.0000 1.0000 1.0000 0.9999 0.9999 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000

78

Level U73122 Ethanol No Drug Propranolol PF 573 228 Wortmannin AG 490 BAY 61 3606 No Drug Propranolol No Drug LY 294 002 DMSO PP2 Ethanol LY 294 002 MNS MNS Latrunculin B

- Level MNS Propranolol Wortmannin Go 6983 DMSO Propranolol U73122 No Drug Ethanol PP2 LY 294 002 Wortmannin BAY 61 3606 Go 6983 Wortmannin Ethanol Cytochalasin D Latrunculin B Cytochalasin D

Difference 0.203907 0.189504 0.162019 0.151956 0.142803 0.141262 0.138826 0.137868 0.113777 0.098235 0.081758 0.080262 0.066375 0.053721 0.048242 0.032019 0.029260 0.029260 0.000000

Std Err Dif 0.4608927 0.4608927 0.3991447 0.4608927 0.3991447 0.4608927 0.4608927 0.3643676 0.3991447 0.4608927 0.3991447 0.4608927 0.3643676 0.4608927 0.4608927 0.4608927 0.4608927 0.4608927 0.4608927

Lower CL -1.48137 -1.49577 -1.29747 -1.53332 -1.31669 -1.54402 -1.54645 -1.19446 -1.34572 -1.58704 -1.37774 -1.60502 -1.26595 -1.63156 -1.63703 -1.65326 -1.65602 -1.65602 -1.68528

Upper CL 1.889184 1.874782 1.621512 1.837233 1.602296 1.826539 1.824104 1.470197 1.573270 1.783512 1.541251 1.765539 1.398704 1.738998 1.733520 1.717297 1.714537 1.714537 1.685277

p-Value Difference 1.0000 1.0000 1.0000 1.0000 1.0000 . . 1.0000 . . . . . . . . . . 1.0000

79

APPENDIX J: ONE-WAY ANOVA OF NORMALIZED OXLDL-BEAD INTERNALIZATION DURING PHARMACOLOGICAL INHIBITION ASSAY

The following analysis compares the average number of internalized beads per cell for oxLDLcoated bead treatments for different pharmacological inhibitors. Analysis by Tukey-Cramer HSD reveals significant bead internalization inhibition under MNS, Cytochalasin D and Latrunculin B treatments.

Oneway Analysis of normal in By drug

Missing Rows 18

Oneway Anova Summary of Fit
Rsquare Adj Rsquare Root Mean Square Error Mean of Response Observations (or Sum Wgts) 0.683408 0.558437 0.664502 -3.1e-16 54

Analysis of Variance
Source drug Error C. Total DF 15 38 53 Sum of Squares 36.220618 16.779382 53.000000 Mean Square 2.41471 0.44156 F Ratio 5.4686 Prob > F <.0001*

Means for Oneway Anova
Level AG 490 BAY 61 3606 Cytochalasin D Number 3 3 3 Mean -0.8612 0.1199 -1.2973 Std Error 0.38365 0.38365 0.38365 Lower 95% -1.638 -0.657 -2.074 Upper 95% -0.085 0.897 -0.521

80

Level DMSO Ethanol Genistein Go 6983 Latrunculin B LY 294 002 MNS No Drug PF 573 228 PP2 Propranolol U73122 Wortmannin

Number 6 3 3 3 3 3 3 6 3 3 3 3 3

Mean 0.5724 0.1722 -0.8500 0.3308 -1.2973 1.0174 -1.1899 0.8323 -0.0184 0.9263 1.0254 -0.8275 -0.0598

Std Error 0.27128 0.38365 0.38365 0.38365 0.38365 0.38365 0.38365 0.27128 0.38365 0.38365 0.38365 0.38365 0.38365

Lower 95% 0.023 -0.604 -1.627 -0.446 -2.074 0.241 -1.967 0.283 -0.795 0.150 0.249 -1.604 -0.836

Upper 95% 1.122 0.949 -0.073 1.107 -0.521 1.794 -0.413 1.381 0.758 1.703 1.802 -0.051 0.717

Std Error uses a pooled estimate of error variance

Means and Std Deviations
Level AG 490 BAY 61 3606 Cytochalasin D DMSO Ethanol Genistein Go 6983 Latrunculin B LY 294 002 MNS No Drug PF 573 228 PP2 Propranolol U73122 Wortmannin Number 3 3 3 6 3 3 3 3 3 3 6 3 3 3 3 3 Mean -0.8612 0.1199 -1.2973 0.5724 0.1722 -0.8500 0.3308 -1.2973 1.0174 -1.1899 0.8323 -0.0184 0.9263 1.0254 -0.8275 -0.0598 Std Dev 0.31685 1.03861 0.00000 0.72764 0.46740 0.24359 1.00041 0.00000 0.71031 0.09472 0.91033 1.03029 0.18562 0.82189 0.46497 0.18819 Std Err Mean 0.18293 0.59964 0.00000 0.29706 0.26985 0.14064 0.57759 0.00000 0.41010 0.05469 0.37164 0.59484 0.10717 0.47452 0.26845 0.10865 Lower 95% -1.648 -2.460 -1.297 -0.191 -0.989 -1.455 -2.154 -1.297 -0.747 -1.425 -0.123 -2.578 0.465 -1.016 -1.983 -0.527 Upper 95% -0.074 2.700 -1.297 1.336 1.333 -0.245 2.816 -1.297 2.782 -0.955 1.788 2.541 1.387 3.067 0.328 0.408

Means Comparisons Comparisons for all pairs using Tukey-Kramer HSD
q* 3.66273
Abs(Dif) -HSD Prop. LY PP2 N/D DMSO Gö Ethanol BAY PF Wort. U7. Gen. AG MNS Cyto. D Lat. B Prop. -1.9873 -1.9792 -1.8881 -1.5279 -1.2680 -1.2926 -1.1340 -1.0818 -0.9434 -0.9020 -0.1344 -0.1119 -0.1006 0.2281 0.3355 0.3355 LY -1.9792 -1.9873 -1.8961 -1.5359 -1.2760 -1.3007 -1.1420 -1.0898 -0.9515 -0.9100 -0.1424 -0.1199 -0.1087 0.2201 0.3275 0.3275

Alpha 0.05
PP2 -1.8881 -1.8961 -1.9873 -1.6271 -1.3672 -1.3918 -1.2332 -1.1809 -1.0426 -1.0012 -0.2335 -0.2110 -0.1998 0.1289 0.2363 0.2363 N/D -1.5279 -1.5359 -1.6271 -1.4052 -1.1453 -1.2195 -1.0609 -1.0086 -0.8703 -0.8289 -0.0612 -0.0387 -0.0275 0.3012 0.4086 0.4086 DMSO -1.2680 -1.2760 -1.3672 -1.1453 -1.4052 -1.4794 -1.3208 -1.2686 -1.1302 -1.0888 -0.3212 -0.2987 -0.2874 0.0413 0.1487 0.1487 Gö -1.2926 -1.3007 -1.3918 -1.2195 -1.4794 -1.9873 -1.8286 -1.7764 -1.6381 -1.5967 -0.8290 -0.8065 -0.7953 -0.4665 -0.3591 -0.3591 Eth. -1.1340 -1.1420 -1.2332 -1.0609 -1.3208 -1.8286 -1.9873 -1.9350 -1.7967 -1.7553 -0.9876 -0.9651 -0.9539 -0.6252 -0.5178 -0.5178 BAY -1.0818 -1.0898 -1.1809 -1.0086 -1.2686 -1.7764 -1.9350 -1.9873 -1.8489 -1.8075 -1.0399 -1.0174 -1.0061 -0.6774 -0.5700 -0.5700 PF -0.9434 -0.9515 -1.0426 -0.8703 -1.1302 -1.6381 -1.7967 -1.8489 -1.9873 -1.9459 -1.1782 -1.1557 -1.1445 -0.8157 -0.7083 -0.7083 Wort. -0.9020 -0.9100 -1.0012 -0.8289 -1.0888 -1.5967 -1.7553 -1.8075 -1.9459 -1.9873 -1.2196 -1.1971 -1.1859 -0.8572 -0.7497 -0.7497 U7. -0.1344 -0.1424 -0.2335 -0.0612 -0.3212 -0.8290 -0.9876 -1.0399 -1.1782 -1.2196 -1.9873 -1.9648 -1.9535 -1.6248 -1.5174 -1.5174 Gen. -0.1119 -0.1199 -0.2110 -0.0387 -0.2987 -0.8065 -0.9651 -1.0174 -1.1557 -1.1971 -1.9648 -1.9873 -1.9760 -1.6473 -1.5399 -1.5399 AG -0.1006 -0.1087 -0.1998 -0.0275 -0.2874 -0.7953 -0.9539 -1.0061 -1.1445 -1.1859 -1.9535 -1.9760 -1.9873 -1.6585 -1.5511 -1.5511 MNS Cyto. D 0.2281 0.2201 0.1289 0.3012 0.0413 -0.4665 -0.6252 -0.6774 -0.8157 -0.8572 -1.6248 -1.6473 -1.6585 -1.9873 -1.8799 -1.8799 0.3355 0.3275 0.2363 0.4086 0.1487 -0.3591 -0.5178 -0.5700 -0.7083 -0.7497 -1.5174 -1.5399 -1.5511 -1.8799 -1.9873 -1.9873 Lat. B 0.3355 0.3275 0.2363 0.4086 0.1487 -0.3591 -0.5178 -0.5700 -0.7083 -0.7497 -1.5174 -1.5399 -1.5511 -1.8799 -1.9873 -1.9873

Positive values show pairs of means that are significantly different.

81

Level Propranolol LY 294 002 PP2 No Drug DMSO Go 6983 Ethanol BAY 61 3606 PF 573 228 Wortmannin U73122 Genistein AG 490 MNS Cytochalasin D Latrunculin B

A A A A A A A A A A A A A

B B B B B B B B B B B

Mean 1.025425 1.017408 0.926257 0.832318 0.572392 0.330799 0.172181 0.119925 -0.018403 -0.059813 -0.827464 -0.849958 -0.861194 -1.189924 -1.297329 -1.297329

Levels not connected by same letter are significantly different. Level Propranolol Propranolol LY 294 002 LY 294 002 PP2 PP2 Propranolol LY 294 002 No Drug No Drug PP2 No Drug Propranolol LY 294 002 Propranolol DMSO DMSO LY 294 002 Propranolol LY 294 002 PP2 PP2 DMSO PP2 No Drug No Drug No Drug Go 6983 Go 6983 Go 6983 Ethanol Ethanol DMSO DMSO BAY 61 3606 BAY 61 3606 DMSO Ethanol BAY 61 3606 PF 573 228 - Level Cytochalasin D Latrunculin B Cytochalasin D Latrunculin B Cytochalasin D Latrunculin B MNS MNS Cytochalasin D Latrunculin B MNS MNS AG 490 AG 490 Genistein Cytochalasin D Latrunculin B Genistein U73122 U73122 AG 490 Genistein MNS U73122 AG 490 Genistein U73122 Cytochalasin D Latrunculin B MNS Cytochalasin D Latrunculin B AG 490 Genistein Cytochalasin D Latrunculin B U73122 MNS MNS Cytochalasin D Difference 2.322754 2.322754 2.314737 2.314737 2.223587 2.223587 2.215349 2.207332 2.129648 2.129648 2.116181 2.022243 1.886619 1.878602 1.875383 1.869722 1.869722 1.867366 1.852888 1.844871 1.787452 1.776216 1.762316 1.753721 1.693513 1.682277 1.659782 1.628128 1.628128 1.520723 1.469510 1.469510 1.433586 1.422350 1.417255 1.417255 1.399856 1.362105 1.309849 1.278927 Std Err Dif 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.4698738 0.4698738 0.5425635 0.4698738 0.5425635 0.5425635 0.5425635 0.4698738 0.4698738 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.4698738 0.5425635 0.4698738 0.4698738 0.4698738 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.4698738 0.4698738 0.5425635 0.5425635 0.4698738 0.5425635 0.5425635 0.5425635 Lower CL 0.33549 0.33549 0.32747 0.32747 0.23632 0.23632 0.22809 0.22007 0.40863 0.40863 0.12892 0.30122 -0.10064 -0.10866 -0.11188 0.14870 0.14870 -0.11990 -0.13437 -0.14239 -0.19981 -0.21105 0.04130 -0.23354 -0.02751 -0.03874 -0.06124 -0.35913 -0.35913 -0.46654 -0.51775 -0.51775 -0.28743 -0.29867 -0.57001 -0.57001 -0.32116 -0.62516 -0.67741 -0.70834 Upper CL p-Value Difference 4.310017 0.0098* 4.310017 0.0098* 4.302000 0.0102* 4.302000 0.0102* 4.210849 0.0162* 4.210849 0.0162* 4.202611 0.0169* 4.194594 0.0176* 3.850668 0.0048* 3.850668 0.0048* 4.103444 0.0274* 3.743262 0.0092* 3.873882 0.0780 3.865865 0.0808 3.862646 0.0819 3.590742 0.0223* 3.590742 0.0223* 3.854629 0.0847 3.840151 0.0901 3.832134 0.0932 3.774714 0.1180 3.763478 0.1235 3.483336 0.0402* 3.740984 0.1350 3.414533 0.0577 3.403297 0.0611 3.380802 0.0685 3.615391 0.2162 3.615391 0.2162 3.507985 0.3098 3.456773 0.3621 3.456773 0.3621 3.154606 0.1961 3.143370 0.2055 3.404517 0.4201 3.404517 0.4201 3.120876 0.2253 3.349368 0.4851 3.297112 0.5491 3.266189 0.5875

82

Level PF 573 228 Wortmannin Wortmannin Go 6983 Go 6983 PF 573 228 Go 6983 Wortmannin Propranolol LY 294 002 Propranolol LY 294 002 Ethanol Ethanol Ethanol PP2 BAY 61 3606 BAY 61 3606 BAY 61 3606 PP2 Propranolol LY 294 002 No Drug Propranolol No Drug LY 294 002 PF 573 228 PF 573 228 PF 573 228 PP2 Wortmannin Wortmannin Wortmannin PP2 No Drug Propranolol LY 294 002 No Drug DMSO PP2 DMSO No Drug U73122 U73122 Propranolol DMSO Genistein Genistein LY 294 002 AG 490 AG 490 DMSO Go 6983 U73122 PP2 Go 6983 Genistein AG 490 No Drug DMSO Ethanol

- Level Latrunculin B Cytochalasin D Latrunculin B AG 490 Genistein MNS U73122 MNS Wortmannin Wortmannin PF 573 228 PF 573 228 AG 490 Genistein U73122 Wortmannin AG 490 Genistein U73122 PF 573 228 BAY 61 3606 BAY 61 3606 Wortmannin Ethanol PF 573 228 Ethanol AG 490 Genistein U73122 BAY 61 3606 AG 490 Genistein U73122 Ethanol BAY 61 3606 Go 6983 Go 6983 Ethanol Wortmannin Go 6983 PF 573 228 Go 6983 Cytochalasin D Latrunculin B DMSO BAY 61 3606 Cytochalasin D Latrunculin B DMSO Cytochalasin D Latrunculin B Ethanol Wortmannin MNS DMSO PF 573 228 MNS MNS DMSO Go 6983 Wortmannin

Difference 1.278927 1.237516 1.237516 1.191993 1.180757 1.171521 1.158262 1.130111 1.085238 1.077221 1.043827 1.035810 1.033375 1.022139 0.999645 0.986070 0.981120 0.969884 0.947389 0.944660 0.905499 0.897482 0.892132 0.853244 0.850721 0.845227 0.842791 0.831555 0.809061 0.806332 0.801381 0.790145 0.767650 0.754076 0.712393 0.694626 0.686609 0.660137 0.632205 0.595459 0.590795 0.501520 0.469866 0.469866 0.453032 0.452467 0.447371 0.447371 0.445015 0.436135 0.436135 0.400211 0.390612 0.362461 0.353865 0.349201 0.339966 0.328730 0.259926 0.241594 0.231994

Std Err Dif 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.4698738 0.5425635 0.4698738 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.4698738 0.5425635 0.5425635 0.4698738 0.4698738 0.5425635 0.4698738 0.4698738 0.5425635 0.5425635 0.4698738 0.4698738 0.5425635 0.5425635 0.4698738 0.5425635 0.5425635 0.4698738 0.5425635 0.5425635 0.4698738 0.5425635 0.5425635 0.5425635 0.3836503 0.4698738 0.5425635

Lower CL -0.70834 -0.74975 -0.74975 -0.79527 -0.80651 -0.81574 -0.82900 -0.85715 -0.90202 -0.91004 -0.94344 -0.95145 -0.95389 -0.96512 -0.98762 -1.00119 -1.00614 -1.01738 -1.03987 -1.04260 -1.08176 -1.08978 -0.82889 -1.13402 -0.87030 -1.14204 -1.14447 -1.15571 -1.17820 -1.18093 -1.18588 -1.19712 -1.21961 -1.23319 -1.00863 -1.29264 -1.30065 -1.06088 -1.08881 -1.39180 -1.13022 -1.21950 -1.51740 -1.51740 -1.26799 -1.26855 -1.53989 -1.53989 -1.27600 -1.55113 -1.55113 -1.32081 -1.59665 -1.62480 -1.36715 -1.63806 -1.64730 -1.65853 -1.14528 -1.47943 -1.75527

Upper CL p-Value Difference 3.266189 0.5875 3.224779 0.6387 3.224779 0.6387 3.179256 0.6936 3.168020 0.7068 3.158784 0.7176 3.145525 0.7328 3.117374 0.7640 3.072500 0.8104 3.064483 0.8182 3.031090 0.8489 3.023073 0.8559 3.020638 0.8579 3.009402 0.8673 2.986907 0.8849 2.973333 0.8948 2.968382 0.8983 2.957146 0.9059 2.934652 0.9201 2.931923 0.9217 2.892762 0.9426 2.884745 0.9463 2.613152 0.8607 2.840506 0.9640 2.571741 0.8974 2.832489 0.9666 2.830054 0.9674 2.818818 0.9709 2.796323 0.9769 2.793595 0.9776 2.788644 0.9788 2.777408 0.9812 2.754913 0.9855 2.741339 0.9877 2.433413 0.9734 2.681889 0.9944 2.673872 0.9950 2.381157 0.9864 2.353225 0.9909 2.582721 0.9989 2.311815 0.9953 2.222540 0.9992 2.457129 0.9999 2.457129 0.9999 2.174052 0.9997 2.173487 0.9998 2.434634 1.0000 2.434634 1.0000 2.166035 0.9998 2.423398 1.0000 2.423398 1.0000 2.121231 0.9999 2.377874 1.0000 2.349723 1.0000 2.074885 1.0000 2.336464 1.0000 2.327228 1.0000 2.315993 1.0000 1.665133 1.0000 1.962614 1.0000 2.219257 1.0000

83

Level Go 6983 Propranolol Ethanol LY 294 002 BAY 61 3606 Go 6983 BAY 61 3606 MNS MNS Propranolol PP2 LY 294 002 Ethanol PF 573 228 U73122 U73122 Genistein Propranolol Latrunculin B

- Level BAY 61 3606 No Drug PF 573 228 No Drug Wortmannin Ethanol PF 573 228 Cytochalasin D Latrunculin B PP2 No Drug PP2 BAY 61 3606 Wortmannin AG 490 Genistein AG 490 LY 294 002 Cytochalasin D

Difference 0.210873 0.193106 0.190584 0.185089 0.179739 0.158618 0.138328 0.107405 0.107405 0.099167 0.093939 0.091150 0.052256 0.041410 0.033731 0.022495 0.011236 0.008017 0.000000

Std Err Dif 0.5425635 0.4698738 0.5425635 0.4698738 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.4698738 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635 0.5425635

Lower CL -1.77639 -1.52791 -1.79668 -1.53593 -1.80752 -1.82865 -1.84893 -1.87986 -1.87986 -1.88810 -1.62708 -1.89611 -1.93501 -1.94585 -1.95353 -1.96477 -1.97603 -1.97925 -1.98726

Upper CL p-Value Difference 2.198136 1.0000 1.914126 1.0000 2.177847 1.0000 1.906109 1.0000 2.167001 1.0000 2.145880 . 2.125591 . 2.094668 . 2.094668 . 2.086430 . 1.814959 . 2.078413 . 2.039518 . 2.028673 . 2.020993 . 2.009757 . 1.998499 . 1.995280 . 1.987263 1.0000

84

APPENDIX K - LARC BASE PEAK TRACES
G

IgG Bead LARC Base Peak Traces of the following bead elutions NaCl concentrations in mM: (A) 50; (B) 100; (C) 150; (D) 200; (E) 250; (F) 300; (G) 350; (H) 400; (I) 450; (J) 500; (K) 550; (L) 600; (M) 700; (N) 800; (O) 900; (P) 1000. The following additional elution conditions: (Q) Acetonitrile; (R) Trypsin; (S) Chloroform; (T) PBS; (U) First Wash
RT: 0.00 - 100.01 100 90 57.56 80 70 61.34 NL: 1.96E6 Base Peak MS LARC_IgG_50mM NaCl_150umID5u m300AMonMadeS P006_STRANGE_ Apr23 RT: 0.00 - 88.34 100 90 80 70 60 50 40 46.91 30 69.27 20 10 10.47 11.55 0 0 10 20 30 40 50 Time (min) 60 70 80 90 100 21.77 31.24 37.60 45.22 70.58 43.56 80.91 86.42 93.08 96.51 7.54 0 0 10 20 30 40 50 Time (min) 60 70 80 9.13 12.29 13.52 20 42.96 10 28.73 31.99 70.26 59.53 60.54 73.19 83.03 82.70
10 0 0 7.46 11.63 22.70 10 20 35.79 27.62 35.20 30 40 50 Time (min) 60 70 80 90 20

39.72

A
Relative Abundance
64.51 76.87

B
52.72 56.79

NL: 1.60E7 Base Peak MS LARC_IgG_100mM NaCl_150umID5um 300AMonMadeSP0 06_STRANGE_Apr 26_2

RT: 0.00 - 96.77 100 90 80 70 43.94 54.90 NL: 1.11E7 Base Peak MS LARC_IgG_150m MNaCl_150umID5 um300AMonMade SP006_STRANGE _Apr26

C

Relative Abundance

Relative Abundance

60 50 52.18 40 30

60 43.50 50 40 30 42.75 39.93 60.57 64.58 82.34 82.67 81.67 89.94 91.59 36.21 58.18 59.08 44.10 50.01

71.72

RT: 0.00 - 100.07 100 90 80 70 49.26 57.03 46.09

NL: 8.53E6 Base Peak MS LARC_IgG_200m MNaCl_150umID5 um300AMonMade SP006_STRANGE _Apr27

.

RT: 0.00 - 93.11 100 90 80 70 60 50 40 30 58.60 62.35 54.73 75.21 46.59 49.56

.

RT: 0.00 - 96.86

53.17

Relative Abundance

60 60.50 50 40 30 42.25 20 13.20 10 15.50 8.97 10.52 0 0 10 20 30 40 50 Time (min) 60 70 80 90 100 23.16 31.50 39.18 40.43 65.62 70.52 83.64 83.38 77.71 90.74 92.23 93.22 73.36

Relative Abundance

Relative Abundance

D

E
43.45 67.69 85.12 84.78 39.28 70.49 10.82 12.84 22.20 25.87 20 30 38.70 80.40 85.45 91.79 0 10 40 50 Time (min) 60 70 80 90

NL: 9.99E6 Base Peak MS LARC_IgG_250m MNaCl_150umID5 um300AMonMade SP006_STRANGE _Apr27

100 90 80 70

21.45

25.80

60.03

NL: 8.60E6 Base Peak MS LARC_IgG_300m MNaCl_150umID5 um300AMonMade SP006_STRANGE _Apr27

.

65.53 60 50 40 30 20 20.62 10 0.24 0 0 20.38 3.88 8.94 10 20 26.45 30 39.32 40 50 Time (min) 60 70 80 90 68.94 45.81 48.76 21.01 91.71 53.87 83.32 78.60 84.08 84.34 72.87

F

58.64

84.07

20 10 0

RT: 0.00 - 93.62 100 90 80 70 59.60 NL: 1.79E7 Base Peak MS LARC_IgG_350m MNaCl_150umID5 um300AMonMade SP006_STRANGE _Apr27

RT: 0.00 - 99.97 100 90 80 70 60 50 40 30 44.60 20 44.26 10
41.76 43.58 40 50.60 60 70 75.72 80 86.15

RT: 0.00 - 85.19

49.05

G
Relative Abundance

NL: 1.56E7 Base Peak MS LARC_IgG_400m MNaCl_150umID5 um300AMonMade SP006_STRANGE _Apr28

100 90 80 70

18.06

H

80.22

NL: 1.41E6 Base Peak MS 84.52 LARC_IgG_450m MNaCl_150umID5 um300AMonMade SP006_STRANGE _Apr28

I

Relative Abundance

Relative Abundance

66.63 65.80 56.43

60 50 40

57.29 61.56 64.48 71.48 72.39 80.72 90.48 19.53 19.29 0.31 10.22 16.82 20.82 28.12 0 10 20 30

60 50 40

77.75 77.33

55.29

62.97

52.32 30 20 10 0

65.94

76.00 30 74.61 16.30 20 1.86 20.37 2.19 15.29 3.40 11.80 26.50 32.25 41.31 53.93 53.68 53.28 63.06 60.51

68.97 62.12 85.79 77.79 91.15

10.86 0
90

16.02 14.84 17.45 10 20

10 0

29.18 30

40.35 40 50 Time (min) 60 70 80

50 Time (min)

0

90

0

10

20

30

40 Time (min)

50

60

70

80

RT: 0.00 - 100.06 100 90 80 70 18.92 60.60

.

RT: 0.00 - 97.55
NL: 1.35E7 Base Peak MS LARC_IgG_500m MNaCl_150umID5 um300AMonMade SP006_STRANGE _Apr28

100 90 80 70

49.25

.
56.23

RT: 0.00 - 94.86

J
59.50 67.52 18.53 19.70 20.95 23.21 20 30 78.50 77.67 49.71 41.47 46.51 40 50 Time (min) 60 70 0.69 78.83 86.84 92.05 4.60 17.89 10

K
64.11 71.88 77.66 82.95 67.87 90.54

NL: 3.01E7 Base Peak MS LARC_IgG_550m MNaCl_150umID5 um300AMonMade SP006_STRANGE _Apr28

100 90 80 70

49.31

42.64 48.26

64.51

NL: 1.82E7 Base Peak MS LARC_IgG_600m MNaCl_150umID5 um300AMonMade SP006_STRANGE _Apr29

.

L

Relative Abundance

Relative Abundance

Relative Abundance

60 50 40 30 20 10 0 0

60 50 40 63.02 30 20 10 0 2.20 0 9.31 20.37 10 21.89 22.54 20 30 44.03

60 50 40 30 58.99 20 10 8.45 9.64 0 0 10 40.34 39.83 22.61 20 35.01 38.42 30 40 50 Time (min) 60 70 80 71.54 76.42 81.68 89.04 90 51.78

63.68

41.74 40.71 40 50 Time (min) 60

14.44

80

90

100

70

80

90

RT: 0.00 - 89.63 100 90 80 70 60.11

.

RT: 0.00 - 100.00
NL: 1.38E7 Base Peak MS LARC_IgG_700m MNaCl_150umID5 um300AMonMade SP006_STRANGE _Apr29

100 90 80

23.42

.
63.82

Relative Abundance

Relative Abundance

60 14.59 50 40 30 15.55 20 10 5.08 0 0 10 13.90 16.17 17.40 20.03 20 30.19 29.71 30.88 30 41.72 49.40 60 70 80 58.17 58.00 14.30 68.90 67.96 61.48 64.54 74.68 79.55 84.56 87.58

60 50 21.73 40 30 20 47.40 10 1.10 0 0 4.54 10 20.30 20 24.12 30 41.28 58.51 43.32 21.20 49.53 54.12 55.26 66.16 71.47 77.39 82.33 63.07 64.56

Relative Abundance

M
40 50 Time (min)

70

N
87.67 90.05 90 70 80

NL: 3.42E7 Base Peak MS LARC_IgG_800m MNaCl_150umID5 um300AMonMade SP006_STRANGE _Apr29

RT: 0.00 - 92.45 100 90 80 70 60 64.74 50 40 30 20 43.36 10 39.39 41.80 0 0 1.78 5.57 9.98 19.79 20 31.64 30 40 50 Time (min) 60 70 80 90 10 52.83 63.91 57.15 71.63 77.30 82.54 88.42 44.98 49.96

.

51.11

O

NL: 3.02E7 Base Peak MS LARC_IgG_900m MNaCl_150umID5 um300AMonMade SP006_STRANGE _Apr29

40

50 Time (min)

60

RT: 0.00 - 92.63 100 90 70.70 80 70 74.41 64.20 77.15

NL: 1.76E7 Base Peak MS LARC_IgG_1000m MNaCl_150umID5u m300AMonMadeS P006_STRANGE_ Apr30

.

RT: 0.00 - 99.98 100 90 80 70 60 50 40 30 20 84.33

.

RT: 0.00 - 99.99

P
Relative Abundance

Q
84.08 92.00 0.40 2.02 78.51 10.30 10 17.53 18.31 20.80 20 30 40.87 39.46 40 43.12 50 Time (min) 61.04 63.94 60 70 79.55 89.00 93.73 75.61

NL: 2.78E6 Base Peak MS LARC_IgG_ACN _150umID5um30 0AMonMadeSP0 06_STRANGE_A pr30

100 90 80 38.39 70 60 50 40 30 20 10 0.53 0 8.78 10 16.53 20 32.22 35.04

44.77 47.24

.
49.42

R
61.59 73.51 72.02 67.68 73.93 82.99 84.37 90 92.87

NL: 9.46E6 Base Peak MS LARC_IgG_BEA DS_150umID5um 300AMonMadeS P006_STRANGE _May3

53.48

Relative Abundance

60 50 40 30 20 10 0 0 4.36 10 13.45 17.28 20 28.59 33.93 30 42.85 40 62.08 60.31 59.90 53.62 58.26 60 70 80 87.66 77.32 83.04

Relative Abundance

59.14

38.24

10 0

50 Time (min)

90

0

80

90

0

30

40

50 Time (min)

60

70

80

RT: 0.00 - 92.98 100 90 80 70 66.21

.

RT: 0.00 - 92.26 100 19.45 90 80 70 60 50 40 30 20.51 20 18.56 67.28 80.87 71.73 53.70 50.90 50.17 38.23 19.64 70.88 54.10 54.86 64.11

S
58.47 66.56 75.70 65.61 58.81 58.13 68.54 57.78 73.32 6.51 7.19 8.28 15.67 10 35.76 33.77 28.51 29.44 20 30 40 50 Time (min) 60 70 45.55 48.16 55.08 76.12 76.54 82.57

NL: 7.44E6 Base Peak MS LARC_IgG_CHLO ROFORM_150umI D5um300AMonMa deSP006_STRAN GE_May3

NL: 4.92E6 Base Peak MS LARC_IgG_PBS 90.29 _150umID5um30 0AMonMadeSP0 06_STRANGE_A pr30

.

RT: 0.00 - 90.73 100 90 80 55.22 70 70.41

T

NL: 3.52E6 Base Peak MS LARC_IgG_Wash _150umID5um30 0AMonMadeSP0 06_STRANGE_A pr30

.

U

Relative Abundance

Relative Abundance

Relative Abundance

60 50 40 30 20 10 0 0

87.12

60 50 40 30

57.86 80.49 81.43 59.73 81.69 89.47

81.74

20 10 0 8.53 8.93 0.32 38.60 20.90 21.64 22.20 26.02 20 30 37.87 47.88

50.69 63.07 76.59 69.74

21.49 10 0.32 2.29 0 80 90 0 10 20 30 40 17.91 8.43

22.66 31.14 32.13

39.24 40.53 40 50 Time (min) 60

50 Time (min)

60

70

80

90

0

10

70

80

90

85

IgG Bead Control LARC Base Peak Traces of the following bead elutions NaCl concentrations in mM: (A) 50; (B) 100; (C) 150; (D) 200; (E) 250; (F) 300; (G) 350; (H) 400; (I) 450; (J) 500; (K) 550; (L) 600; (M) 700; (N) 800; (O) 900; (P) 1000. The following additional elution conditions: (Q) Acetonitrile; (R) Trypsin; (S) Chloroform; (T) PBS; (U) First Wash
RT: 0.00 - 93.97 100 90 80 70 55.64 83.09 54.33 NL: 4.26E6 Base Peak MS LARC_IgG_CONTR OL_50mMNaCl_150 umID5um300AMon MadeSP006_STRA NGE_May7 RT: 0.00 - 99.98 100 90 80 70 60 45.33 50 40 30 77.51 18.67 10 3.70 0 0 10 20 30 40 50 Time (min) 60 70 80 90 9.62 19.09 23.51 0 0 10 36.92 38.85 62.35 74.03 80.54 88.29 20 10 1.17 7.90 17.42 20 18.95 80.78 79.97 74.63 88.38 89.93 91.47 90 43.05 51.50 70.83 52.68 59.06 55.36 83.81 NL: 1.00E7 Base Peak MS LARC_IgG_CONTR OL_100mMNaCl_15 0umID5um300AMon MadeSP006_STRA NGE_May7 RT: 0.00 - 96.25 100 90 80 55.50 70 45.22 NL: 8.73E6 Base Peak MS LARC_IgG_CONTR OL_150mMNaCl_15 0umID5um300AMon MadeSP006_STRA NGE_May10 53.03

Relative Abundance

Relative Abundance

Relative Abundance

60 50 40

45.48

58.72 70.24

A

B

60 50 40 30 36.31 44.62

53.89

59.11

C

45.68 67.74 80.18 51.11

47.41 30 20

20 41.24 10 0 2.70 2.95 19.78 20.82 22.34

62.61 76.23 71.28 86.04

20.39

23.96 26.87 30

42.24 38.08 40 50 Time (min)

61.33

94.39

60

70

80

0

10

20

30

40

50 Time (min)

60

70

80

90

RT: 0.00 - 94.40 100 90 80 70 43.70 53.81 82.80 NL: 5.63E6 Base Peak MS LARC_IgG_CONTR OL_200mMNaCl_15 0umID5um300AMon MadeSP006_STRA NGE_May10

RT: 0.00 - 90.96

RT: 0.00 - 91.43 54.18 44.05 NL: 6.92E6 Base Peak MS LARC_IgG_CONTR OL_250mMNaCl_15 0umID5um300AMon MadeSP006_STRA NGE_May10

52.74 55.68 59.76

.

100 90 80 70

53.09

.

100 90 80 70 19.65

51.71

NL: 6.82E6 Base Peak MS LARC_IgG_CONTR OL_300mMNaCl_15 0umID5um300AMon MadeSP006_STRA NGE_May10

.

Relative Abundance

Relative Abundance

Relative Abundance

60 49.60 50 40 30 20 10 10.24 12.00 22.25 24.17 0 0 10 20 30 40 50 Time (min) 60 38.06

69.69

D
79.67 88.76 78.78 80 90

86.57 60.98

60 55.98 50 40 30 66.17 20 10 1.17 10.05 0 84.03 83.38 42.90 48.59 73.15

E
90

60 50 40 30 20 0.31 10 0 0.62 2.77 0 10 18.61 18.04 20 41.51 40 48.30 44.30 50 Time (min) 60 73.55 83.12 85.49 19.32 25.82 49.46

F
55.48 77.58 60.13 64.89 74.79 36.93 30 70 80 90

42.96

63.89

41.82

73.41

23.28 24.46 19.87 20 30

38.49 40 50 Time (min) 60

70.86 70

83.05

70

0

10

80

RT: 0.00 - 92.03 100 90 42.78 80 70 47.05 42.22 NL: 1.03E7 Base Peak MS LARC_IgG_CONTR OL_350mMNaCl_15 0umID5um300AMon MadeSP006_STRA NGE_May11

RT: 0.00 - 90.60 100 90 80 70 60 50 40 30 20 37.85 40.73 73.74 69.72 40 50 Time (min) 60 70 77.02 10 82.24 80 90.41 0 90 0 5.00 7.57 16.48 10 18.47 20 41.08 19.23 34.92 30 40 50 Time (min) 60 51.64 74.28 75.43 78.05 83.02 80 90 61.41 45.27 NL: 1.61E7 Base Peak MS LARC_IgG_CONTR OL_400mMNaCl_15 0umID5um300AMon MadeSP006_STRA NGE_May11

RT: 0.00 - 94.64 100 90 80 22.65 70 49.81 55.28 NL: 1.02E7 Base Peak MS LARC_IgG_CONTR OL_450mMNaCl_15 0umID5um300AMon MadeSP006_STRA NGE_May11

G
Relative Abundance

41.53

H

65.50

I

Relative Abundance

60 50 57.89 40 30 20 10 0.38 0 0 10 20 30 10.17 20.27 24.10 52.71 66.46

Relative Abundance

61.46

49.84

60 22.79 50 40 30 60.57 72.64

56.57

61.58 20 21.55 10 0 70 0 5.05 10.12 10 20.63 20 48.03 46.95 31.92 42.74 30 40 50 Time (min) 60 70 82.18 76.76 83.11 86.11

36.90

69.66

80

90

RT: 0.00 - 88.64 100 90 44.97 80 70 41.91 41.64

NL: 1.04E7 Base Peak MS LARC_IgG_CONTR OL_500mMNaCl_15 0umID5um300AMon MadeSP006_STRA NGE_May11

.

RT: 0.00 - 100.01 100 90 80 70 65.82 60 50 40 87.30 30 73.41 66.94 61.04 65.15

J

59.93

NL: 1.20E7 Base Peak MS LARC_IgG_CONTR OL_550mMNaCl_15 0umID5um300AMon MadeSP006_STRA NGE_May12

.

RT: 0.00 - 93.45 100 90 80 70 43.61 51.31

K

NL: 1.34E7 Base Peak MS LARC_IgG_CONTR OL_600mMNaCl_15 0umID5um300AMon MadeSP006_STRA NGE_May12

.

L

Relative Abundance

60 50 40 63.20 30 20 10 0.38 0 0 10 8.65 20.12 20.82 22.85 20 30 40.16 39.24 40 50 Time (min) 60 70 80 53.60 48.63 57.77

Relative Abundance

Relative Abundance

60 50 44.30 40 30 20 54.79 56.42 60.24

52.36

69.80

20 72.72 81.83 66.88 82.94 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 100 51.34 56.93 44.64 36.64 43.66 88.06 88.29

77.89 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 3.44 3.65 12.24 4.94 36.33 69.12 66.41 74.28 78.44 93.18

2.87

12.02 20.76 26.68

81.96

23.44 27.54

RT: 0.00 - 93.66 100 90 80 70 48.95

41.27 41.45

NL: 1.37E7 Base Peak MS LARC_IgG_CONTR OL_700mMNaCl_15 0umID5um300AMon MadeSP006_STRA NGE_May12

.

RT: 0.00 - 93.66 100 90 80 70 41.77 60 50 40 30 48.95

M
Relative Abundance

41.27 41.45

NL: 1.37E7 Base Peak MS LARC_IgG_CONTR OL_700mMNaCl_15 0umID5um300AMon MadeSP006_STRA NGE_May12

.

RT: 0.00 - 95.01 100 90 80 70 50.23

N

NL: 2.20E7 Base Peak MS LARC_IgG_CONTR OL_900mMNaCl_15 0umID5um300AMon MadeSP006_STRA NGE_May13

.

40.30 50.72 49.96

O

Relative Abundance

Relative Abundance

41.77 60 50 40 30 49.98 20 10 0.86 6.55 0 0 10 16.58 21.74 20 39.40 60.09 56.51 69.46 77.95 33.12 31.16 30 40 50 Time (min) 60 68.35 63.21 70 73.52 78.65 80.96 80 88.73

60 50 40 30 48.13 56.46 43.02 60.34 68.26

37.10

48.61

57.10

48.61

57.10

49.98 20 10 0.86 6.55 0 90 0 10 16.58 21.74 20 39.40 60.09 56.51 69.46 77.95 33.12 31.16 30 40 50 Time (min) 60 68.35 63.21 70 73.52 78.65 80.96 80 88.73 90

20 10 4.17 0 0 10 36.74 10.29 17.77 20 28.78 30 40 50 Time (min) 60 66.75 77.08 72.25 70 77.95 80 92.21 90

RT: 0.00 - 91.52 100 90 80 70 49.28

.
NL: 2.12E7 Base Peak MS LARC_IgG_CONTRO L_1000mMNaCl_150 umID5um300AMonM adeSP006_STRANG E_May13

RT: 0.00 - 92.27 100 90 80 70 77.88 50.63

.
NL: 2.04E6 Base Peak MS LARC_IgG_CONT ROL_ACN_150umI D5um300AMonMa deSP006_STRAN GE_May14

RT: 0.00 - 100.00 100 90 80 70 48.00

.
NL: 1.92E7 Base Peak MS LARC_IgG_CONTR OL_TRPbeads_150 umID5um300AMonM adeSP006_STRAN GE_May14

P

Q

R

Relative Abundance

Relative Abundance

Relative Abundance

60 50 40 39.21 40.10 30 20 10 37.84 4.34 0 0 10.80 15.20 10 20 31.73 30 40 50 Time (min) 60

60 50 40 30 20 36.30 37.60 45.45 30.16 22.72 35.39 45.06 42.61 20 30 40 50 Time (min) 71.97 52.12 53.17 56.70 71.11 64.85 60 70 80

60 50

37.59 43.49

48.91

55.81 40 30 20 10 0 4.30 9.51 0 10 21.93 22.62 20 33.61 30.95 30 40 50 Time (min) 36.27 57.59 66.34 59.19 75.13 75.91 70.35 80.79 70 80

77.65

38.34 47.27 41.27

49.85 57.47 67.36 65.49 77.04 77.75 72.52 80.83 91.49 70 80 90

10 0 0

4.61 10.36

20.66

85.64

90.84 90 100

10

90

60

RT: 0.00 - 94.86 100 90 80 62.87 70 61.93 58.85 69.17 50 40 30 47.00 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 3.70 7.75 22.13 28.71 46.12 53.50 80.82 73.37 71.25

NL: 8.26E6 Base Peak MS LARC_IgG_CONTRO L_CHLOROFORM_1 50umID5um300AMon MadeSP006_STRAN GE_May17

.

RT: 0.00 - 91.20 100 90 80 70 60 50 40 48.70 30 36.75 20 10 45.33 57.72 61.46 72.88 1.21 4.25 0 0 10 20 30 40 50 Time (min) 60 70 80 90 14.35 63.42 15.11 28.77 82.73 77.81 69.05 77.18 51.79 52.59

S

NL: 9.66E6 Base Peak MS LARC_IgG_CONT ROL_PBS_150umI D5um300AMonMa deSP006_STRAN GE_May14

.

RT: 0.00 - 95.06 100 90 80 70 44.63 66.96

T

NL: 1.25E7 Base Peak MS LARC_IgG_CONTR OL_WASH_150umI D5um300AMonMad eSP006_STRANG E_May13

.

U

Relative Abundance

Relative Abundance

Relative Abundance

60

40.58 50.26 41.17

60 50 40 30 41.37 20 55.41 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 8.97 10.44 12.17 16.19 34.65 30.85 40.09 55.71 71.25 76.23 76.78 79.64 91.82

56.95

51.80 49.43 54.98

78.37

36.06 37.07 33.86

82.49 92.55

86

oxLDL Bead LARC Base Peak Traces of the following bead elutions NaCl concentrations in mM: (A) 50; (B) 100; (C) 150; (D) 200; (E) 250; (F) 300; (G) 350; (H) 400; (I) 450; (J) 500; (K) 550; (L) 600; (M) 700; (N) 800; (O) 900; (P) 1000. The following additional elution conditions: (Q) Acetonitrile; (R) Trypsin; (S) Chloroform; (T) PBS; (U) First Wash
RT: 0.00 - 96.71 RT: 0.00 - 100.02 100 90 80 70 72.03 NL: 1.17E7 Base Peak MS LARC3_oxLDL_ 50mMNaCl_ZOR BAX300A_C18_ 5u_STRANGE_J une16 100 90 80 70 60 71.25 50 40 30 63.78 68.79 20 84.09 10 5.74 9.61 0 0 10 20 30 40 50 Time (min) 60 70 80 90 100 20.35 30.24 33.19 50.70 52.96 68.18 48.09 59.56 43.11 93.35 10 0 0 6.20 10.65 11.23 19.61 10 20 30 51.26 34.22 41.94 48.84 40 82.48 52.70 61.84 82.90 20 88.46 87.04 79.95 88.60 90.00 10 0 60 70 80 90 0 3.85 6.76 10 16.58 21.36 20 39.82 29.36 34.40 30 40 50 Time (min) 60 70 80 90 41.64 49.30 73.53 74.08 NL: 1.81E7 Base Peak MS LARC3_oxLDL_1 00mMNaCl_ZOR BAX300A_C18_ 5u_STRANGE_J une17 RT: 0.00 - 90.20 100 90 80 70 60 50 58.64 40 30 20 57.23 49.79 55.99 68.89 69.09 70.32 73.15 59.92 NL: 1.85E7 Base Peak MS LARC3_oxLDL_1 50mMNaCl_ZOR BAX300A_C18_ 5u_STRANGE_J une17

Relative Abundance

Relative Abundance

A
69.78 77.65 98.65 98.04

B
79.09 70.05 50 Time (min)

C

Relative Abundance

63.81

60 50 40 30

84.86

RT: 0.00 - 99.25 100 90 80 70 60.17 NL: 2.26E7 Base Peak MS LARC3_oxLDL_2 00mMNaCl_ZOR BAX300A_C18_ 5u_STRANGE_J une17

RT: 0.00 - 96.67

.

100 90

63.94

.
72.82

67.91 80 70 60 50 63.51 40 90.26 30 73.91 77.11 83.90 91.11

Relative Abundance

Relative Abundance

60 50 40 58.16 30 20 10 3.96 0 0 10 20 53.54 24.86 30 39.13 42.48 38.14 40 50 Time (min) 60 55.17

64.54

Relative Abundance

D

E
61.30 42.47 57.32 40.58 44.71 54.78 39.12 45.09 38.66 33.73 37.35 30 40 50 Time (min) 60 70 2.39 5.34 10.14 21.82 20 0 10 80 90

NL: 1.09E7 Base Peak MS LARC3_oxLDL_2 50mMNaCl_ZOR BAX300A_C18_ 5u_STRANGE_J une17

RT: 0.00 - 92.40 100 90 68.51 80 70 60 50 62.68 40 30 44.14 20 43.70 10 4.69 0 0 10 20 30 40 50 Time (min) 60 70 80 90 16.81 18.25 19.68 42.79 33.86 40.98 49.02 74.57 56.78 77.98 78.21 82.23 86.90 46.39 62.25 58.67 73.16 64.27

NL: 8.06E6 Base Peak MS LARC3_oxLDL_3 00mMNaCl_ZOR BAX300A_C18_ 5u_STRANGE_J une18

.

F

59.27

66.11 67.15 68.56 71.44 74.68 80

20
85.69 91.44 90

10.91 11.12

10 0

70

RT: 0.00 - 95.65 100 90 80 70 70.42 NL: 1.43E7 Base Peak MS LARC3_oxLDL_3 50mMNaCl_ZOR BAX300A_C18_ 5u_STRANGE_J une18

RT: 0.00 - 90.12 100 90 80 70 60 50 63.09 40 30 20 42.79 68.52 51.30 45.07 77.00 77.66 87.01 93.94 10 5.80 0 60 70 80 90 0 6.02 14.25 10 20 55.76 54.73 84.76 67.28 59.40 NL: 9.91E6 Base Peak MS LARC3_oxLDL_4 00mMNaCl_ZOR BAX300A_C18_ 5u_STRANGE_J une18

RT: 0.00 - 97.23 100 90 80 70 60 50 40 30 62.01 20 13.39 10 0.40 5.02 0 30 40 50 Time (min) 60 70 80 90 0 10 20 30 40 50 Time (min) 60 70 80 90 17.06 26.94 35.24 41.01 42.89 44.48 58.90 71.71 77.22 70.55 85.39 86.26 63.69 69.58 NL: 1.84E7 Base Peak MS LARC3_oxLDL_4 50mMNaCl_ZOR BAX300A_C18_ 5u_STRANGE_J une18

57.67

G
Relative Abundance

H
Relative Abundance

I

Relative Abundance

69.45 60 50 54.37 40 30 52.95 20 10 0 0 10 20 30 40 50 Time (min) 71.61 14.21 14.97 3.61 5.31 20.72 34.63 37.35 30.36 79.26 47.51 62.25 64.95 82.11

42.48 24.76 32.45 38.78

RT: 0.00 - 100.01 100 90 80 70 54.85

NL: 1.36E7 Base Peak MS LARC3_oxLDL_5 00mMNaCl_ZOR BAX300A_C18_ 5u_STRANGE_J une21

.

RT: 0.00 - 100.06 100 90 80 70 60 50 52.93 40 64.66 30 49.96 56.01 61.76

.

RT: 0.00 - 82.35 100 90 80 70 60 50 40 30 20 60.72 57.21 62.50 63.68 61.28

J

K
Relative Abundance
48.91 12.03 12.63 14.66 32.80 33.40 37.04 40 50 Time (min) 60 70 69.02 69.43 77.75 83.00 80 85.97

NL: 2.15E7 Base Peak MS LARC3_oxLDL_5 50mMNaCl_ZOR BAX300A_C18_ 5u_STRANGE_J une21

NL: 4.01E7 Base Peak MS LARC3_oxLDL_6 00mMNaCl_ZOR BAX300A_C18_ 5u_STRANGE_J une21

.

L

Relative Abundance

60 50 40 30 20 52.13 10 1.82 0 0 10 20 30 40 50 Time (min) 3.55 14.15 26.01 34.71 39.61

62.54

53.62 63.72 53.20 57.45 64.99 65.75 78.26 70.91 43.81 60 70 80.08 83.84 80 90 98.97

Relative Abundance

64.28

20 10 0 100 0 10 20 30 90 100

54.15

65.27 68.99 76.28 77.06 60 70 80

10 0 0 3.87 8.12 12.69 16.11 10 20 24.61 33.78 35.65 43.94 31.44 30 40 Time (min) 51.85 50

RT: 0.00 - 92.84 100 90 80 70 48.94 54.22

NL: 7.40E6 Base Peak MS LARC3_oxLDL_7 00mMNaCl_ZOR BAX300A_C18_ 5u_STRANGE_J une21

.

RT: 0.00 - 91.95 100 90 80 70 60 50 40 30 55.68 20 52.01 59.99 63.62

.

RT: 0.00 - 90.78 100 90 80 70 60 50 40 30 20 58.98 50.15 10 10.49 6.87 11.60 0 22.07 20 29.12 30 38.29 40 48.41 50 Time (min) 60 66.52 72.70 73.33 80.90 83.46 80 90 52.68 61.52 59.26

M
Relative Abundance

N
72.84 66.79 73.40 82.08 77.77 86.57 80 90

NL: 1.65E7 Base Peak MS LARC3_oxLDL_8 00mMNaCl_ZOR BAX300A_C18_ 5u_STRANGE_J une22

NL: 2.07E7 Base Peak MS LARC3_oxLDL_9 00mMNaCl_ZOR BAX300A_C18_ 5u_STRANGE_J une22

.

O

Relative Abundance

60 56.37 50 40 30 20 48.22 10 4.68 7.76 0 0 10 20 30 40 50 Time (min) 60 70 80 90 26.69 30.09 10.73 18.81 22.45 43.47 41.09 67.66 58.12 67.11 83.56 87.01 57.03

10.42

33.53 10 3.19 0 0 10 20 30 40 10.70 11.39 33.07 27.48 32.40 35.19 41.54

50.25 49.36

Relative Abundance

70.47

50 Time (min)

60

70

0

10

70

RT: 0.00 - 91.84 100 90 80 70 61.74 56.87

56.07

NL: 1.44E7 Base Peak MS LARC3_oxLDL_1 000mMNaCl_ZO RBAX300A_C18 _5u_STRANGE_J une22

.

RT: 0.00 - 88.49 100 90 80 70 60 50 40 30 48.95 20 10 6.55 0 11.72 13.17 10 20 25.23 30 40 50 Time (min) 32.04 65.31 61.89 60 67.07 49.76

. NL: 1.21E7

RT: 0.00 - 93.61 100 90 80 70 53.99 60 50 40 63.93 30 35.05 36.78 38.98 33.55 29.92 30 40.59 48.44 60 69.81 79.28 83.13 90 55.12

P
Relative Abundance

52.10

Q
Relative Abundance
57.61 72.40 80.38 77.16 80.70

Base Peak MS LARC3_oxLDL _ACN_ZORBA X300A_C18_5u _STRANGE_Ju ne23

62.74 58.14

NL: 8.09E6 Base Peak MS LARC3_oxLDL_B EAD_DIGEST_Z ORBAX300A_C1 8_5u_STRANGE_ June25

.

R

Relative Abundance

60 50 40 30 20 53.57 10 6.82 0 0 10 20 30 40 50 Time (min) 60 70 80 90 11.57 13.39 25.98 31.65 33.99 45.30 50.35 64.36

53.08

63.56 75.69 76.32

55.44

74.21 74.84 70.16 85.58 91.43

20 10 5.83 0 14.85 10 21.51 20

34.31

47.53

0

70

80

0

40

50 Time (min)

70

80

RT: 0.00 - 94.31 100 90 80 70 73.99 74.62

NL: 2.86E6 Base Peak MS LARC3_oxLDL_C HLOROFORM_Z ORBAX300A_C1 8_5u_STRANGE _June25

.

RT: 0.00 - 90.16 100 90 80 70 60 77.96 50 33.60 40 30 20 7.30 7.55 17.33 20.90 16.50 32.55 48.56 46.58 33.30 60.12 57.79 37.51 65.52 65.94 82.68 48.94 72.92 35.79 51.01 80.99 60.69

.

RT: 0.00 - 97.66 100 90 80 70 60 50 40 11.27 45.10 30 11.84 20 12.62 10 0 14.46 25.84 36.89 44.08 81.80 85.86 91.49 48.54 7.77 9.96 10.55 66.19 33.18 73.48 77.99 81.49 54.31 58.17 64.60 72.86 61.06

S
Relative Abundance

T

NL: 3.37E6 Base Peak MS LARC3_oxLDL _PBS_ZORBA X300A_C18_5u _STRANGE_Ju ne23

NL: 2.53E6 Base Peak MS LARC3_oxLDL_ WASH_ZORBA X300A_C18_5u _STRANGE_Ju ne22

.

U

Relative Abundance

60 50 40 30 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 9.63 32.38 31.99 33.97 10.20 26.09 30.86 42.03 56.08 68.27 50.26 56.99 61.55 86.79 89.46

68.67

80.66

81.28

84.80

4.93

9.13

10 0 0 10

20

30

40

50 Time (min)

60

70

80

90

Relative Abundance

0

10

20

30

40

50 Time (min)

60

70

80

90

87

oxLDL Bead Control LARC Base Peak Traces of the following bead elutions NaCl concentrations in mM: (A) 50; (B) 100; (C) 150; (D) 200; (E) 250; (F) 300; (G) 350; (H) 400; (I) 450; (J) 500; (K) 550; (L) 600; (M) 700; (N) 800; (O) 900; (P) 1000. The following additional elution conditions: (Q) Acetonitrile; (R) Trypsin; (S) Chloroform; (T) PBS; (U) First Wash
RT: 0.00 - 89.97 100 90 80 70 63.37 NL: 6.36E6 Base Peak MS LARC3_oxLDL_C ONTROL_50mMNa Cl_ZORBAX300A_ C18_5u_STRANG E_June29 RT: 0.00 - 92.05 100 90 61.40 80 70 60 79.44 50 56.16 40 18.37 30 49.30 55.38 20 10 4.69 0 0 10 11.68 12.45 13.81 17.38 20 80.31 36.55 37.08 40 50 Time (min) 60 70 74.46 10 3.89 0 30 80 0 10 20 30 40 50 Time (min) 60 70 80 90 7.51 13.73 37.05 19.73 25.30 40.23 0 0 10 20 30 40 50 Time (min) 60 70 80 90 20 66.73 74.39 80.08 86.64 10 51.43 20 2.63 2.78 6.25 11.68 62.13 57.83 NL: 4.78E6 Base Peak MS LARC3_oxLDL_CO NTROL_100mMNa Cl_ZORBAX300A_ C18_5u_STRANGE _June29 RT: 0.00 - 94.42 100 90 80 70 60 44.15 50 40 46.32 30 40.85 40.17 39.43 37.92 23.18 35.81 54.56 55.53 57.59 48.40 70.71 71.00 75.83 79.75 69.11 69.78 88.19 63.26 64.72 NL: 4.74E6 Base Peak MS LARC3_oxLDL_C ONTROL_150mMN aCl_ZORBAX300A _C18_5u_STRANG E_JuLY5

Relative Abundance

Relative Abundance

60 50 40 56.09 58.19 30 67.61

79.75

35.57

RT: 0.00 - 94.99 100 90 80 70 67.80 72.24 65.24

Relative Abundance

A

B

C

RT: 0.00 - 93.08

RT: 0.00 - 97.37 72.19 NL: 4.46E6 Base Peak MS LARC3_oxLDL_C ONTROL_250mMN aCl_ZORBAX300A _C18_5u_STRANG E_JuLY5

.

NL: 8.71E6 Base Peak MS LARC3_oxLDL_C ONTROL_200mMN aCl_ZORBAX300A _C18_5u_STRANG E_JuLY5

100 90 80 70

.

100 90 80 70 60 50 40 30

66.65

Relative Abundance

60 50 40 30 20 10 6.63 0 0 10 20 30 40 50 Time (min) 13.42 14.26 30.18 35.41 47.35 49.60 51.87

72.84 64.73

Relative Abundance

60 50 76.51 40 30 20 10 0.16 4.65 43.54 42.33 41.36 49.78 49.25 54.44 55.41 65.51 77.64 79.77 83.42

Relative Abundance

D
91.52 86.38 80 90

70.69

NL: 8.81E6 Base Peak MS LARC3_oxLDL_C ONTROL_300mMN aCl_ZORBAX300A _C18_5u_STRANG E_JuLY5

.

69.88

E
91.96 84.84 80 90

66.30

F
67.26 68.10 76.94 85.48 86.10 80 90 73.45 70

61.85

75.88

66.00

20 10 0

1.31 1.78 9.08 9.39 14.45 20

57.66

76.88

9.32 15.64 20

30.72

37.14

52.65 56.86 57.47 51.89 64.18 49.94 36.77 41.78 46.92 30 40 50 Time (min) 60

0 60 70 0 10 30 40 50 Time (min) 60 70

0

10

RT: 0.00 - 100.02 100 90 80 70 59.71

RT: 0.00 - 100.06

RT: 0.00 - 80.93 66.14 NL: 1.10E7 Base Peak MS LARC3_oxLDL_C ONTROL_400mMN aCl_ZORBAX300A _C18_5u_STRANG E_July6 100 90 29.37 80 12.34 70 11.96 12.87 30.58 44.19

G
Relative Abundance
38.36 39.93 37.75 40.07 37.45 58.26 57.63 65.58 81.30 42.64 82.00 75.73 2.57 10.21 18.24 19.76 27.96 33.27 46.12 54.98 54.02 68.61 91.46 99.89

NL: 4.08E6 Base Peak MS LARC3_oxLDL_C ONTROL_350mMN aCl_ZORBAX300A _C18_5u_STRANG E_July6

100 90 80 70 60 50 40 30 20 10 3.04 2.74 0 0 10 44.29 42.12 22.65 29.31 30.30 37.13 20 30 40 46.49 48.53 51.86

H
Relative Abundance

25.80 25.95

NL: 7.76E5 Base Peak MS LARC3_oxLDL_C ONTROL_450mMN aCl_ZORBAX300A _C18_5u_STRANG E_July6

I

Relative Abundance

60 50 40 30 20 10 0 0 10 20 30

60 50

10.81 8.38 5.79 16.45

25.34 22.39

47.60

65.61 67.91 76.15 90.95

54.78 51.86

40 30 20

4.36 65.73 66.19 34.60

72.09

76.45

90.48 86.44

10 91.78 0 100 0 10 20 30

34.98 43.55

62.01 61.63 67.87 76.74

40

50 Time (min)

60

70

80

90

100

50 Time (min)

60

70

80

90

40 Time (min)

50

60

70

80

RT: 0.00 - 100.03 100 90 80 70 44.53 50.46 57.10

.

RT: 0.00 - 89.97 100 90 80 70 56.23

.
NL: 2.17E6 Base Peak MS LARC3_oxLDL_C ONTROL_550mMN aCl_ZORBAX300A _C18_5u_STRANG E_July7

RT: 0.00 - 100.03 100 90 80 70 12.83

.
NL: 1.46E7 Base Peak MS LARC3_oxLDL_C ONTROL_600mMN aCl_ZORBAX300A _C18_5u_STRANG E_July7

J
Relative Abundance
65.80 78.10 84.95 62.06 87.39 98.15

NL: 2.12E6 Base Peak MS LARC3_oxLDL_C ONTROL_500mMN aCl_ZORBAX300A _C18_5u_STRANG E_July6

K
Relative Abundance

12.23 11.99 11.26

L

Relative Abundance

60 50 40 30 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 100 2.65 13.07 26.37 25.83 14.28 14.96 32.62 31.42 27.19

60 47.54 50 40 32.51 30 34.40 20 2.96 16.23 10.40 46.38 51.22 22.68 31.15 34.86 38.22 78.02 75.70 78.57 87.28 80.67 58.61 67.83

60 13.21 50 40 17.65 30 20 10.84 18.66 10.24 4.98 0 10 22.24 20 23.00 29.85 30 40 59.95 50.44 56.13 50 Time (min) 60 70

43.96

35.42 36.49

10 0 0

67.43 61.90 60

10 0

67.00 68.02 79.40 83.26 87.06 80 90 100

10

20

30

40 50 Time (min)

70

80

RT: 0.00 - 100.04 100 90 29.35 80 70 46.86 28.83

.
38.92

RT: 0.00 - 95.15 100 90 80 30.95 70 60 50 40 30.56 46.73 38.67 60.57 30 20 49.97 10 53.21 58.07 31.44

M
Relative Abundance
60.73 60.25 55.78 72.62 62.28 77.24 70 80 86.26 90 95.29

NL: 3.91E6 Base Peak MS LARC3_oxLDL_C ONTROL_700mMN aCl_ZORBAX300A _C18_5u_STRANG E_July8

NL: 4.15E6 Base Peak MS LARC3_oxLDL_C ONTROL_800mMN aCl_ZORBAX300A _C18_5u_STRANG E_July8

.

RT: 0.00 - 100.05 100 90 80 70 60 50 40 39.97 30 20 10 4.65 6.31 39.18 49.70 11.33 27.79 29.31 42.66 32.67 40 52.59 62.56 89.25 69.00 70 73.73 79.82 90 97.87 100 63.12 72.57

N
Relative Abundance

NL: 4.62E6 Base Peak MS LARC3_oxLDL_C ONTROL_900mMN aCl_ZORBAX300A _C18_5u_STRANG E_July9

.

O

Relative Abundance

60 49.79 50 40 30 41.28 20 10 3.64 0 0 10 20 30 40 50 Time (min) 60 100 12.57 26.28 25.90 25.45 26.90

37.12

3.71 7.72 11.26 17.47 23.00 0 0 10 20 30 40 50 Time (min)

72.48 77.18 70.12 70 80

85.86 93.84 0 90 0 10

60

20

30

50 Time (min)

60

80

RT: 0.00 - 97.59 100 90 80 70 34.34 42.34

.
NL: 5.19E6 Base Peak MS LARC3_oxLDL_CO NTROL_1000mMN aCl_ZORBAX300A _C18_5u_STRANG E_July9

RT: 0.00 - 100.05 100 90 80 70 29.45

.
NL: 1.48E7 Base Peak MS LARC3_oxLDL_C ONTROL_ACN_Z ORBAX300A_C1 8_5u_STRANGE_ July12

RT: 0.00 - 100.05 100 90 37.45 80 70 41.26 28.43 30.17

.
NL: 2.35E7 Base Peak MS LARC3_oxLDL_CO NTROL_BEADdige st_ZORBAX300A_ C18_5u_STRANGE _July12

P
Relative Abundance

Q
Relative Abundance

R

41.81

30.91

Relative Abundance

60 50 33.84 40 30 31.63 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 3.71 12.97 13.75 7.33 55.24 65.37 63.51 69.70 75.59 91.68 78.04 82.64 40.24 52.03 34.88 47.63 65.85

60 50 40 30 37.19 20 26.89 10 3.95 15.64 0 0 10 20 30 40 50 Time (min) 60 17.07 36.64 40.55 44.45 45.69 60.71 60.17

60 50 40 27.01 30 20 10 49.13 42.08 49.61 51.03 4.83 7.86 0 0 10 25.85 16.47 20 30 40 61.76 58.71 50 Time (min) 60 62.35 70 73.89 87.47 88.20 80 90 95.02 100

31.25

69.51 72.81 70

86.48 87.12 80 90

99.46 100

RT: 0.00 - 100.01 100 90 42.80 80 70 48.06 48.73 49.66 60 50 40 30 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 32.79 31.78 31.01 15.85 16.98 30.00 10.76 18.95 39.94 35.30 65.44 41.52 71.26 81.26 67.67 72.22 82.06 55.85

.
NL: 1.76E6 Base Peak MS LARC3_oxLDL_CO NTROL_CHLOROF ORM_ZORBAX300 A_C18_5u_STRAN GE_July12

RT: 0.00 - 100.06 100 90 80 70 36.57 60.87 29.18 60 30.68 50 40 30 20 10 28.20 43.15 51.11 50.28 26.10 8.14 15.35 15.88 5.96 10.56 25.28 18.37 86.56 87.20 87.36 38.75

.
NL: 1.67E6 Base Peak MS LARC3_oxLDL_C ONTROL_PBS_Z ORBAX300A_C1 8_5u_STRANGE _July9

RT: 0.00 - 94.16 100 90 80 70 51.08

.
NL: 5.91E6 Base Peak MS LARC3_oxLDL_C ONTROL_WASH_ ZORBAX300A_C 18_5u_STRANGE _July9

S
Relative Abundance

T

U

Relative Abundance

Relative Abundance

60 50 40 30 37.37 20 9.64 10.68 8.84 12.31 13.18 15.41 0 36.57 28.41 27.37 30.35 38.89 43.33 50.13 60.35 64.62 30 40 50 Time (min) 60 87.14 70.45 70 76.93 77.72 80 88.46 90 60.82

29.45

60.32 53.54 70.67 70.43 73.13

80.17 73.55

84.85 91.08 0 100 0 10 20 30 40 50 Time (min) 60

77.66

95.37

10

70

80

90

100

0

10

20

88

APPENDIX L ­ OXLDL, IGG, CD36 IGG AND CD36 IGA LARC MASS SPECTRA The following spectra were collected from IgG, oxLDL, CD36 IgG and CD36 IgA-coated beads incubated with U937 for 0 min, 30 min, 1h, 2h or 4h (pooled) and subjected to two PBS washes, a series of increasing NaCl concentrations, Acetonitrile, direct bead trypsinization, detergent, and chloroform. Two mass spectrometers were used. Corresponding total ion current (TIC) and base peak chromatograms are also shown.

Actin
TIC
RT: 0.00 - 100.06 100 90 80 70 60 50 40 30 59.50 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 100 1.59 17.89 10.75 4.06 22.79 23.21 24.91 39.43 45.95 57.97 55.86 67.52 19.46 22.62 60.60 60.77 18.38
Relative Abundance

Base Peak
RT: 0.00 - 100.06
NL: 1.28E8 TIC MS LARC_IgG_500 mMNaCl_150umI D5um300AMonM adeSP006_STR ANGE_Apr28

Spectrum
NL: 1.35E7 Base Peak MS LARC_IgG_500m MNaCl_150umID5 um300AMonMade SP006_STRANGE _Apr28

18.92

100 90 80 70 18.92 60 50 40 30 20

60.60

Extracted from: C:\data_STRANGE\APRIL_2010_STRANGE\LARC_IgG_STRANGE\LARC_IgG_500mMNaCl_150umID5um300AMonMadeSP006_STRANGE_Apr28.RAW #78 RT: 0.99 ITMS, CID, z=+3, Mono m/z=654.30219 Da, MH+=1960.89200 Da, Match Tol.=0.8 Da 1200 1000
Intens ity [counts ]

323.2706

Actin Alpha 2
Relative Abundance

800 600 400 200 397.2122
2+ y 1+ y 15 6 823.2965 899.3632 2+ y 14 851.1130

59.50

67.52

y 1+ 5 637.2539 594.3831

y 1+ 8 1038.3016

67.86 78.50 83.39 90.18 69.05

18.53 10 0.69 0 0 4.60 17.89 10

19.70 20.95 23.21 20 30

78.50 49.71 41.47 46.51 40 50 Time (min) 60 70 77.67 78.83 86.84 92.05

0 200
100

51.41

400

600 m/z

800

1000

1200

80

90

RT: 0.00 - 89.31 100 90 80 70 60 50 40 30 20 10 3.83 11.11 0 0 10 20 30 40 50 Time (min) 60 70 80 19.02 19.60 18.43 31.49 17.92 29.41 32.39 NL: 2.53E8 TIC MS LARC_IgG_PB S_150umID5um 300AMonMade SP006_CHAR MED_Apr30

RT: 0.00 - 89.31 100 90 80 32.39 38.33 70
Relative Abundance

35.40

33.00

NL: 1.64E7 Base Peak MS LARC_IgG_PBS _150umID5um30 0AMonMadeSP0 06_CHARMED_ Apr30

Extracted from: C:\data_CHARMED\CHARMED_April2010\LARC_IgG CHARMED\LARC_IgG_PBS_150umID5um300AMonMadeSP006_CHARMED_Apr30.RAW #2978 RT: 38.90 ITMS, CID, z=+3, Mono m/z=407.52313 Da, MH+=1220.55484 Da, Match Tol.=0.8 Da

200
Intens ity [counts ]

449.7882

Actin Alpha 2
Relative Abundance

33.55 33.86 35.40 43.04 44.22 45.50 48.00 51.37 52.51 55.72 56.71 57.47 58.84 59.77 61.33 66.94 73.68 77.83

49.27 60 43.04 50 40 30 31.88 20 19.60 10 18.85 6.59 0 0 10 20 30 40 50 Time (min) 60 70 80 17.18 21.21 22.12 23.47 51.45 56.38 58.41 72.32 78.77 81.78 66.85 73.68 77.83 55.72

150

2+ y7 378.8037

100

322.2825 280.6071 479.3891
2+ b3 183.1531

560.2927

b1+ 6 659.9833 784.2561

50

0 100 200 300 400 m/z 500 600 700 800

79.10

RT: 0.00 - 91.19 100 90 51.39 80 70
Relative Abundance

RT: 0.00 - 91.19
63.49 NL: 3.54E7 TIC MS LARC2_CD36_Ig A_U937LIVEcells _1000mMNaCl_Z ORBAX_CHARM ED_Dec3

100 90 80 70

46.84

51.89 59.94 63.49

75.86

62.52 52.20

NL: 4.42E6 Base Peak MS LARC2_CD36_IgA _U937LIVEcells_1 000mMNaCl_ZOR BAX_CHARMED_ Dec3

Extracted from: C:\data_CHARMED\CHARMED_DECEMBER2010\LARC2_CD36_IgA_U937LIVEcell_CHARMED\LARC2_CD36_IgA_U937LIVEcells_1000mMNaCl_ZORBAX_CHARMED_Dec3.RAW #4854 RT: 61.89 ITMS, CID, z=+2, Mono m/z=1108.52771 Da, MH+=2216.04814 Da, Match Tol.=0.5 Da

400
53.03
Intens ity [counts ]

y 1+ 6 628.3405

Beta Actin

49.12 47.07

52.88
Relative Abundance

60 50

60.25 58.02

63.97 65.19 75.86

y 1+ 7 791.3782
1+ b15 1587.5061

60 50 76.17 40 30 56.50 68.03 85.57 84.73

300 b1+ 14 1+ y 12 1424.4708 1089.8296 1238.5381 y 1+ 8 922.3638

84.65 40 45.26 30 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 4.72 5.97 9.09 9.96 19.15 25.29 39.68 38.38 37.77 41.57 40.90 68.27 71.09 67.03

200

100
40.44 43.88

79.42

20 69.77 10 0
90

76.80

6.83 7.78 9.34

24.16 25.52 28.10 39.14 20 30 40 50 Time (min) 60 70 80 90

0 400 600 800 1000 1200 m/z 1400 1600 1800 2000

0

10

RT: 0.00 - 90.20 100 90 80 70
Relative Abundance

RT: 0.00 - 90.20
19.34 NL: 1.84E8 TIC MS LARC2_CD36_I gA_U937LIVEcel l_150mMNaCl_Z orbax_STRANG E_Nov17

100 90 80 70

19.28

NL: 1.03E7 Base Peak MS LARC2_CD36_Ig A_U937LIVEcell_1 50mMNaCl_Zorba x_STRANGE_Nov 17

Extracted from: C:\data_STRANGE\STRANGE_NOVEMBER_2010\LARC2_CD36_IgA_U937LIVEcell_STRANGE\LARC2_CD36_IgA_U937LIVEcell_150mMNaCl_Zorbax_STRANGE_Nov17.RAW #3132 RT: 40.73 ITMS, CID, z=+2, Mono m/z=1107.88391 Da, MH+=2214.76055 Da, Match Tol.=0.5 Da 4000 y 1+ 6 628.3602
Intens ity [counts ]

1+ b15 1587.3018

Beta Actin

3000

y 1+ 7 791.3908

60 50 40 30 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 2.34 2.81 12.05 47.81 49.56 46.86 50.05 44.85 52.30 43.27 40.50 36.66

Relative Abundance

60 50 40 30 51.96 61.37 19.03 19.88 47.81 63.03

2000 y 1+ 8 922.4136 1000

1+ y 12 1238.4216

b1+ 14 1424.2581
1+ b18 1854.5712

1+ y 1+ y 13 9 1089.9916 1325.4896 1023.3823

22.05 22.37 23.01

62.96 67.14 73.43

20 18.79
82.00

10
83.01

25.16 18.48 9.34 15.06 0 10 20 26.16 30

36.66

55.99 45.48 45.16

70.72 75.53 67.61 60 70

81.84 84.48

0 400
90

600

800

1000

1200 m/z

1400

1600

1800

2000

0
90

40 50 Time (min)

80

RT: 0.00 - 100.02 100 90 80 70
Relative Abundance

RT: 0.00 - 100.02
21.52 21.99 21.15 NL: 1.22E8 TIC MS LARC2_CD36_I gA_U937LIVEcel l_250mMNaCl_Z orbax_STRANG E_Nov17

100 90 80 70

21.45 52.95 57.72

2.97

NL: 4.48E6 Base Peak MS LARC2_CD36_Ig A_U937LIVEcell_2 50mMNaCl_Zorba x_STRANGE_Nov 17

Extracted from: C:\data_STRANGE\STRANGE_NOVEMBER_2010\LARC2_CD36_IgA_U937LIVEcell_STRANGE\LARC2_CD36_IgA_U937LIVEcell_250mMNaCl_Zorbax_STRANGE_Nov17.RAW #1619 RT: 21.68 ITMS, CID, z=+2, Mono m/z=1172.20776 Da, MH+=2343.40825 Da, Match Tol.=0.5 Da

1000 y 1+ 6 628.3658
Intens ity [counts ]

b1+ 16 1715.5134 y 1+ 14 1+ 1438.5585 1154.5647 y 13 1325.4241 y 1+ 7 791.3596 b1+ 9 1018.3735
1+ b15 1552.5461 1+ y 17 1752.5017

Beta Actin

800

60 50 28.22 40 30 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 4.03 10.89 20.00 33.66 28.77 50.87 48.88 48.17 45.99 43.98 41.60 53.62 57.25 61.79 62.12 67.25 52.95

Relative Abundance

60 50 40 30 20 10 0 8.72 12.03 44.48 44.98 44.15 51.02 41.68 39.68 40 50 Time (min) 60 70 80 62.83

600 400 200

68.83 67.25

23.08

81.34 76.23 71.03 89.17 90.79 90 100 88.16

73.20 81.89 84.62 88.09 91.18 100

0 400 600 800 1000 1200 m/z 1400 1600 1800 2000

23.40 29.08 20 30

0

10

89

SRC-Family Kinases
TIC
RT: 0.00 - 87.50 100 95 90 85 80 75 70 17.24 NL: 1.82E8 TIC MS LARC2_CD36_IgA _U937LIVEcell_10 0mMNaCl_Zorbax _STRANGE_Nov1 7

Base Peak
RT: 0.00 - 87.50 100 95 90 85 80 75 70 65 17.24
Intens ity [counts ]

Spectrum
NL: 1.56E7 Base Peak MS LARC2_CD36_IgA_ U937LIVEcell_100m MNaCl_Zorbax_STR ANGE_Nov17

18.00

Extracted from: C:\data_STRANGE\STRANGE_NOVEMBER_2010\LARC2_CD36_IgA_U937LIVEcell_STRANGE\LARC2_CD36_IgA_U937LIVEcell_100mMNaCl_Zorbax_STRANGE_Nov17.RAW #1473 RT: 19.26 ITMS, CID, z=+2, Mono m/z=951.15771 Da, MH+=1901.30815 Da, Match Tol.=0.5 Da 5000 885.9445 829.3271 933.1941
1+ b10 1158.4176

41.42

4000
40.76

Relative Abundance

60 55 50 45 40 35 30 25 20 15 10 5 0 0 10 20 30 40 50 Time (min) 60 70 80 16.11 6.22 9.16 20.21 38.99 37.53 47.82 50.91 61.50 54.75 69.36 71.69 43.01 41.42 40.76 43.98 40.11

Relative Abundance

Src

65

60 55 50 45 40 35 30 25 20 15 10 5 0 0 10 20 30 40 50 Time (min) 60 70 80 11.45 14.19 18.55 30.63 35.28 54.75 73.70 78.11 38.30 69.36 40.11 50.91 59.80 46.92 61.50

3000

2000 706.5436 1000

1059.3622

1+ b11 1286.5515

1543.5774

0 400 600 800 1000 m/z 1200 1400 1600 1800

RT: 0.00 - 100.00 100 90 80 70
Relative Abundance

RT: 0.00 - 100.00
24.75 NL: 1.78E8 TIC MS LARC_CD36_IgA_U 937livecell_900mMN aCl__Zorbax_STRA NGE_Oct26_10102 6154800

100 90 80

25.09

NL: 9.89E6 Base Peak MS LARC_CD36_IgA_U9 37livecell_900mMNaC l__Zorbax_STRANGE _Oct26_1010261548 00 48.15

Extracted from: Y:\CD36\Larc_WorkingCopy\ExcellProtMGFRawFiles\1_LARC_antiCD36_IgA\LARC_CD36_IgA_U937livecell_900mMNaCl__Zorbax_STRANGE_Oct26_101026154800.raw #2320 RT: 28.70 ITMS, CID, z=+3, Mono m/z=994.17944 Da, MH+=2980.52378 Da, Match Tol.=0.8 Da 10000 9000 8000
Intens ity [counts ]

1131.5778

70 25.70
Relative Abundance

7000 6000 5000 4000 3000 2000 1000 y 3+ 23 670.4713 837.3750 855.3905 1244.6382 1316.5846

Src

60 50 40 30 20 10 0.76 0 0 10 20 30 40 50 Time (min) 60 70 80 90 14.39 23.47 22.95

60 50 40 23.47 30

26.91 34.13

25.70

37.97 46.11 30.54

26.25 26.65 28.07 48.15 37.97 47.59 56.15 64.73 73.79 85.64 88.59

20 22.71 10 0.76 0
100

1544.7904

41.20 17.34 10 21.27 20 30 40 50 Time (min)

73.87 60.22 64.73 72.54 60 70 74.97 82.45 85.34 86.17 80 90 100

0 400 600 800 1000 m/z 1200 1400 1600 1800 2000

0

RT: 0.00 - 96.51 100 95 90 85 80 75 70 65 64.95 63.90 63.56 60.78 58.29 56.71 55.24 28.63 77.06 76.26 72.36 71.95 77.62 90.94 85.40 NL: 1.94E8 TIC MS LARC_oxLDL_200 mMNaCl_NSI_150 umMonManeColu mn_STRANGE_M arch22

RT: 0.00 - 96.51 100 95 90 85 80 75 70 65 65.95 65.10 65.45 NL: 9.70E6 Base Peak MS LARC_oxLDL_200m MNaCl_NSI_150um MonManeColumn_S TRANGE_March22

Extracted from: C:\data_STRANGE\STRANGE_MArch_2010\LARC_STRANGE\LARC_oxLDL_200mMNaCl_NSI_150umMonManeColumn_STRANGE_March22.RAW #3981 RT: 53.72 ITMS, CID, z=+3, Mono m/z=715.72858 Da, MH+=2145.17118 Da, Match Tol.=0.8 Da 300 250
Intens ity [counts ]

705.7694

830.4508

Relative Abundance

Src

60 55 50 45 40 35 30 25 20 15 10 5 0 0 10 20 30 40 50 Time (min) 1.54 26.87 21.68 26.38 34.98 50.11 48.83 46.14

Relative Abundance

60 55 50 45 40 35 30 25 20 15 10 5 0 7.00 13.64 62.54 16.28 37.73 39.05 39.55 40.70 57.09 67.24 94.72 78.47 86.12

200 150 100 50 0 200 400 600 800 m/z 1000 1200 1400
2+ b1+ y 15 7 655.3537 774.9182

910.0296 843.7286

60

70

80

90

0

10

20

30

40

50 Time (min)

60

70

80

90

RT: 0.00 - 99.25 100 90 59.72 80 59.27 70
Relative Abundance

RT: 0.00 - 99.25
60.17 64.54 NL: 1.61E8 TIC MS LARC3_oxLDL _200mMNaCl_Z ORBAX300A_C 18_5u_STRAN GE_June17

100 90 80 70

60.17

65.27 65.91 66.11 66.76 67.68 67.95 68.43

NL: 2.26E7 Base Peak MS LARC3_oxLDL_2 00mMNaCl_ZOR BAX300A_C18_ 5u_STRANGE_J une17

Extracted from: C:\data_STRANGE\STRANNGE_JUNE2010\LARC3_oxLDL STRANGE\LARC3_oxLDL_200mMNaCl_ZORBAX300A_C18_5u_STRANGE_June17.RAW #4371 RT: 56.21 ITMS, CID, z=+3, Mono m/z=1035.50183 Da, MH+=3104.49094 Da, Match Tol.=0.8 Da

4000
Intens ity [counts ]

743.9200

Relative Abundance

Src

58.10 60 50 40 30 54.90 20 4.60 10.91 10 0 0 10 20 30 40 50 Time (min) 60 11.73 16.37 30.37 54.01 52.66 41.94 47.72 56.64

60 50 40 58.16 30 55.17

64.54

3000 1326.4865 2000 b 2+ 20 1074.6448 931.0111 1139.6323 1016.5350

68.91 56.13 55.17 69.41 69.71 71.08 72.71 75.16 76.70 85.69

59.27

1000
66.11 67.15 68.56 71.44 74.68 80

20 10 3.96 0 53.54 24.86 20 30 39.13 42.48 38.14 40 50 Time (min) 60

85.69 91.44 90

12.76

86.48 70 80 90

98.93

10.91 11.12 10

0 400 600 800 1000 1200 m/z 1400 1600 1800 2000

0

70

RT: 0.00 - 96.51 100 90 80 77.06 76.62 72.36 64.95 71.95 64.36 63.56 60.78 58.88 57.09 56.41 55.24 28.63 51.00 49.30 46.14 34.98 41.32 77.62 85.40 82.98 90.94 NL: 1.94E8 TIC MS LARC_oxLDL_2 00mMNaCl_NSI_ 150umMonMane Column_STRAN GE_March22

RT: 0.00 - 96.51 100 90 80 70 65.95
Relative Abundance

65.10 65.45

NL: 9.70E6 Base Peak MS LARC_oxLDL_200 mMNaCl_NSI_150 umMonManeColum n_STRANGE_Mar ch22

Extracted from: C:\data_STRANGE\STRANGE_MArch_2010\LARC_STRANGE\LARC_oxLDL_200mMNaCl_NSI_150umMonManeColumn_STRANGE_March22.RAW #3981 RT: 53.72 ITMS, CID, z=+3, Mono m/z=715.72858 Da, MH+=2145.17118 Da, Match Tol.=0.8 Da 300 250
Intens ity [counts ]

Fyn, Isoform A
Relative Abundance

705.7694

830.4508

70 60 50 40 30 20 10 0 0 10 20 30 40 50 Time (min) 1.54 5.84

200 150 100 50 0 200 400 600 800 m/z 1000 1200 1400
2+ b1+ y 15 7 655.3537 774.9182

60 50 40 30 3.71 20 10 0 62.54 16.28 21.04 39.05 57.09 62.32 30.42 38.23 40.30 28.63 48.83 67.24 69.82 72.15 78.47

86.12 94.72

7.00

13.64

910.0296 843.7286

85.60

26.87 21.68 26.38

60

70

80

90

0

10

20

30

40

50 Time (min)

60

70

80

90

RT: 0.00 - 94.37 100 90 80 70
Relative Abundance

RT: 0.00 - 94.37
33.35 NL: 8.17E7 TIC MS LARC2_oxLDL_1 50mMNaCl_150u mID5um300AMon MadeSP006_CH ARMED_May20 73.85
Relative Abundance

100 33.41 90 80 70 60 50 40 30 16.18 29.88 30.79

41.17

32.36 42.43 31.69 30.79 41.17 47.93

42.50 73.85

NL: 1.03E7 Base Peak MS LARC2_oxLDL_15 0mMNaCl_150umI D5um300AMonMad eSP006_CHARME D_May20

Extracted from: C:\data_CHARMED\CHARMED_MAY2010\LARC2_oxLDL_CHARMED\LARC2_oxLDL_150mMNaCl_150umID5um300AMonMadeSP006_CHARMED_May20.RAW #3837 RT: 45.28 ITMS, CID, z=+3, Mono m/z=891.47839 Da, MH+=2672.42063 Da, Match Tol.=0.8 Da

20000 879.4788
Intens ity [counts ]

38.28

44.44 48.94 51.09

38.92

15000

Yes-1

60 30.45 50 40 30 16.82 20 10 0 0 10 20 30 40 5.15 16.18 18.90

10000
2+ b17 973.4830 1049.7761

51.90 52.95 56.96 57.73

47.93 52.54 70.68 70.44 68.74 77.69 90.65 91.45

5000
2+ 629.3572 b13

1131.6585

1224.7553 1267.8420

61.11 70.52

75.45 76.76 80.84 92.94

20 56.96 10 8.71 0 10.15 10 20 16.54 59.51 22.47 30 40 50 Time (min) 60

727.6519 800 1000 m/z 1200 1400 1600

13.85

0 400 600

50 Time (min)

60

70

80

90

0

70

80

90

90

SRC-Family Kinases
TIC
RT: 0.00 - 100.00 100 90 50.20 80 70 46.09 60 50 40 71.23 30 20 10 5.37 6.91 0 0 10 20 30 40 50 Time (min) 60 70 80 90 20.70 74.69 75.02 75.66 76.05 78.68 85.85 36.69 40.50 34.82 86.47 89.48 96.99 55.82 NL: 2.54E8 TIC MS LARC2_oxLD L_PBS_ZOR BAX300A_C1 8_5u_STRAN GE_May26

Base Peak
RT: 0.00 - 100.00 100 90 80 70
Relative Abundance
Intens ity [counts ]

Spectrum
NL: 1.37E7 Base Peak MS LARC2_oxLDL _PBS_ZORBA X300A_C18_5 u_STRANGE_ May26

54.34

Extracted from: C:\data_STRANGE\STRANGE_MAY2010\LARC2_oxLDL STRANGE\LARC2_oxLDL_PBS_ZORBAX300A_C18_5u_STRANGE_May26.RAW #6254 RT: 74.00 ITMS, CID, z=+3, Mono m/z=938.83826 Da, MH+=2814.50022 Da, Match Tol.=0.8 Da

55.22 50.84

56.31 56.68 63.27 62.76

53.79 56.18

49.92

150

2+ b18 920.3982

Lyn Isoform A
Relative Abundance

50.48 60 50 57.54 40 62.00 30 20 10 2.02 0 0 10 20 30 40 50 Time (min) 60 70 80 90 9.69 19.10 27.15 36.39 37.12 45.07 49.81 45.58 74.47 86.64 92.08 69.69

100

2+ b25 1334.2074 1133.3499 1284.8192

67.53 69.90

1007.0913 50

0 400 600 800 1000 m/z 1200 1400 1600 1800

RT: 0.00 - 87.55 100 90 80 70
Relative Abundance

RT: 0.00 - 87.55
31.08 NL: 1.50E8 TIC MS LARC2_oxLDL_5 50mMNaCl_150u mID5um300AMon MadeSP006_CH ARMED_May25

100 90 80

31.15

35.44

NL: 3.56E7 Base Peak MS LARC2_oxLDL_55 0mMNaCl_150umI D5um300AMonMad eSP006_CHARME D_May25

Extracted from: C:\data_CHARMED\CHARMED_MAY2010\LARC2_oxLDL_CHARMED\LARC2_oxLDL_550mMNaCl_150umID5um300AMonMadeSP006_CHARMED_May25.RAW #3782 RT: 44.95 ITMS, CID, z=+2, Mono m/z=842.47400 Da, MH+=1683.94072 Da, Match Tol.=0.8 Da

15000
Intens ity [counts ]

b1+ 9 1083.7874

37.13 70
Relative Abundance

Lyn

60 50 40 30 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 29.94 42.44 45.86 29.50 29.08 52.87 55.74 0.38 3.64 15.27 27.25 69.38 67.92 51.51 37.13 43.68

60 50 40 30 20 27.97 51.90 53.45 54.24 43.76

10000 970.6820 742.6119 828.5655 y 1+ 10 1182.8706 1310.8276 1439.9741

29.94 42.44 45.86 51.51

5000

y 1+ 5 600.4444

72.85 74.15

10
81.62

0
58.51 60 69.70 72.77 74.23 70 80 83.63

3.64 0 0

13.38 10

15.50 16.02 25.72 20 30 40 50 Time (min)

400

600

800

1000 m/z

1200

1400

1600

RT: 0.00 - 94.79 100 90 34.25 80 70
Relative Abundance

RT: 0.00 - 94.79
61.83 59.09 71.80 68.32 53.69 30.70 38.56 39.04
Relative Abundance

NL: 4.57E7 TIC MS LARC_IgG_CHL OROFORM_150 umID5um300AM onMadeSP006_ CHARMED_May 3

100 90

59.09 68.32

71.72 80 70 61.83

NL: 7.76E6 Base Peak MS LARC_IgG_CHLO ROFORM_150umI D5um300AMonMa deSP006_CHARM ED_May3

Extracted from: C:\data_CHARMED\CHARMED_April2010\LARC_IgG CHARMED\LARC_IgG_CHLOROFORM_150umID5um300AMonMadeSP006_CHARMED_May3.RAW #3007 RT: 40.44 ITMS, CID, z=+3, Mono m/z=708.73975 Da, MH+=2124.20469 Da, Match Tol.=0.8 Da 120 100 698.6638

29.41 60 29.18 50 28.79 40 30 20 10 0 0 10 20 30 40

Lyn

48.57 40.60

49.69

49.69 57.33 60 50 40 30 30.79 29.41 37.94 37.21 42.09 48.48 40.35 62.53

Intens ity [counts ]

80 60 40 20
2+ b7 321.1583

62.53

1016.5283 963.5996 b1+ 448.3829 561.5622 7 641.0223 1129.6946 864.2844

28.33 73.22 74.94 78.07 1.31 9.27 16.27 16.88 80.14 81.63 50 Time (min) 60 70 80 94.36

20 10 1.31 8.41 0
90

28.72 28.48 19.10 24.03 20 30 40 50 Time (min) 60 70

76.50 77.09 79.56 80

0
94.19 90

200

400

600

800 m/z

1000

1200

1400

0

10

RT: 0.00 - 106.17 100 90 44.56 80 43.10 70
Relative Abundance
Relative Abundance

RT: 0.00 - 106.17
48.26 45.33 NL: 2.80E8 TIC MS LARC_OXLDL_l Beads_NSI_150 umMonMadeCol umn_STRANGE _March17

100 90 80

54.04

50.77 54.04 54.45 56.61 58.44 60.91 61.97 72.75 73.30 74.70 71.52

49.93 70 45.08 54.45 60 50 40 30 44.36 59.19 39.74 61.05 61.66 62.13 62.53 69.38 10 0 21.42 28.13 8.09 16.80 0 10 20 30 34.20 58.89 71.52

NL: 1.86E7 Base Peak MS LARC_OXLDL_lB eads_NSI_150um MonMadeColumn _STRANGE_Marc h17

Extracted from: C:\data_STRANGE\STRANGE_MArch_2010\LARC\LARC_OXLDL_lBeads_NSI_150umMonMadeColumn_STRANGE_March17.RAW #3348 RT: 44.02 ITMS, CID, z=+2, Mono m/z=812.45117 Da, MH+=1623.89507 Da, Match Tol.=0.8 Da

400 794.2993
Intens ity [counts ]

Lck

42.34 60 41.48 50 40 30 37.87 20 10 0 0 10 20 30 40 3.30 14.53 16.56 37.09 35.25 19.57 40.91 39.74

300

200 780.3160 628.5226 711.4868

100
78.07 79.15 79.72 80.15

78.56 82.94 85.74

893.3969

1022.4246

20
97.30

1+ b12 1223.4924

1494.5890

0
89.63 91.13

400

600

800 m/z

1000

1200

1400

1600

50 60 Time (min)

70

80

90

100

40

50 60 Time (min)

70

80

90

100

RT: 0.00 - 99.99 100 90 58.91 80 70
Relative Abundance

RT: 0.00 - 99.99
59.36 NL: 5.11E7 TIC MS LARC4_oxLDL_C ONTROL_1000mM NaCl_ZORBAX5u m_300Acolumn_C HARMED_Aug13

100 90 80 70 49.44

59.51

66.60 48.73

NL: 1.88E7 Base Peak MS LARC4_oxLDL_CO NTROL_1000mMNa Cl_ZORBAX5um_30 0Acolumn_CHARM ED_Aug13

Extracted from: C:\data_CHARMED\CHARMED_Aug2010\LARC4_oxLDL_CONTROL_CHARMED\LARC4_oxLDL_CONTROL_1000mMNaCl_ZORBAX5um_300Acolumn_CHARMED_Aug13.RAW #5375 RT: 66.98 ITMS, CID, z=+3, Mono m/z=391.56039 Da, MH+=1172.66663 Da, Match Tol.=0.8 Da 500 y 2363.5213 331.1055 373.1957 149.0317 200 y 2+ 4 279.1805 100 166.9319 0 426.0504 485.2545
1+

400
54.27 94.50 70.32 50 40 87.07 30 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 42.35 5.60 8.09 9.30 44.79 80.31 75.98 87.69
Relative Abundance

66.60 60 50 40 30 20 75.98 44.79 87.69 85.83 2.27 6.58 0 0 10 20 30 40 50 Time (min) 60 70 80 90 22.57 27.63 37.47 38.91 94.72 48.73 50.37 54.14

Lck

60

Intens ity [counts ]

300

11.00

23.70 30.13

38.84

10

100

200

300

400 m/z

500

600

700

RT: 0.00 - 86.42 100 95 90 85 80 75 70 65 37.54 57.20 51.98 43.24 47.25 38.47 42.52 NL: 1.10E8 TIC MS LARC2_oxLDL_6 00mMNaCl_ZOR BAX300A_C18_5 u_STRANGE_Ma y21

RT: 0.00 - 86.42 100 95 90 85 80 75 70 65 46.97 38.59 44.85 NL: 3.36E7 Base Peak MS LARC2_oxLDL_60 0mMNaCl_ZORBA X300A_C18_5u_S TRANGE_May21

Extracted from: C:\data_STRANGE\STRANGE_MAY2010\LARC2_oxLDL STRANGE\LARC2_oxLDL_600mMNaCl_ZORBAX300A_C18_5u_STRANGE_May21.RAW #4634 RT: 56.04 ITMS, CID, z=+3, Mono m/z=474.87668 Da, MH+=1422.61548 Da, Match Tol.=0.8 Da

25000 20000 15000 10000 379.9159 5000 303.4251 0

y 1+ 5 569.1466

60 55 50 45 40 35 30 25 20 15 10 5 0 0 10 20 30 40 50 Time (min) 6.15 9.12 11.80 15.28 30.82 35.29 35.88 36.39

Hck

59.54

60 55 50 45 40 35 60.20 61.91 30.82 62.77 68.78 78.28 4.09 0 10 16.11 20.27 20 30 40 50 Time (min) 60 70 80 36.39 53.82 59.54

60.20 62.77

Intens ity [counts ]

Relative Abundance

Relative Abundance

y 2+ 486.7500 9 525.3927 617.0688 y 1+ 6 724.5533 700 800 y 1+ 8 893.4489

63.57 68.21 68.78 72.04 30.21 60 70 80 82.22

30 25 20 15 10 5 0

200

300

400

500 m/z

600

900

91

SRC-Family Kinases
TIC
RT: 0.00 - 100.04 100 90 44.31 80 70
Relative Abundance
Relative Abundance

Base Peak
RT: 0.00 - 100.04
NL: 8.66E7 TIC MS LARC_IgG_400 mMNaCl_150umI D5um300AMonM adeSP006_CHA RMED_Apr28

Spectrum
Base Peak MS LARC_IgG_400m MNaCl_150umID5 um300AMonMade SP006_CHARME D_Apr28

33.20 36.83

100 90 80 70

36.83

73.25 :TR 1493# WAR.82rpA_DEMRAHC_600PSedaMnoMA003 mu5DI mu051_lCaNM m004_GgI_CRAL\DEMRAHC GgI_CRAL\0102lirpA_DEMRAHC\DEMRAHC_atad\:C : morf detcartxE NL: 2.43E7 aD 8.0=.loT hctaM ,aD 40914.7882=+HM ,aD 35441.369=z/ m onoM ,3+=z ,DIC ,SMTI

42.67 47.56 32.78

1442.3421
33.33 60 44.23 50 40 30 51.93

051
] st n u oc[ yt i s n et nI

Blk

60 50 40 30 20 10 0 0 10 20 30 40 31.12 30.79

50.92 51.93 52.25 59.69

3197.668 9482.9921 5907.7611
47.72 59.69 31.12

5942.539

001

7094.3401 05

60.12 60.62 61.65

70.58

20 30.96
71.41

70.58 52.41

11.75 14.39 16.08

76.80 81.30 80 90

10
95.58

0
69.31 80.72 82.65 95.33

0
50 Time (min) 60 70 100

16.39 8.69 12.54 0 10 20

30.71 29.41 30 40

55.60 50 Time (min) 60

0081
90 100

0061

0041

0021 z/ m

0001

008

006

004

70

80

RT: 0.00 - 88.70 100 90 80 70 48.41
Relative Abundance

RT: 0.00 - 88.70
40.10 NL: 1.99E8 TIC MS LARC2_oxLDL _700mMNaCl_ ZORBAX300A_ C18_5u_STRA NGE_May25

100 90 80 70

40.04

NL: 6.83E7 Base Peak MS LARC2_oxLDL_ 700mMNaCl_ZO RBAX300A_C18 _5u_STRANGE_ May25

Extracted from: C:\data_STRANGE\STRANGE_MAY2010\LARC2_oxLDL STRANGE\LARC2_oxLDL_700mMNaCl_ZORBAX300A_C18_5u_STRANGE_May25.RAW #3033 RT: 38.06 ITMS, CID, z=+3, Mono m/z=506.62802 Da, MH+=1517.86951 Da, Match Tol.=0.8 Da

8000 7000
Intens ity [counts ]

494.8858
2+ y 11 646.5060

6000 5000 4000 3000 2000 1000 427.5995 517.4330 379.0570 404.3172

Csk

60 50 49.63 40 30 20 10 9.83 0 0 10 20 30 40 50 Time (min) 60 70 80 11.89 12.96 37.98 63.80 31.04 30.56 28.01 64.31 64.96 66.42 69.75 45.60 53.10 63.42 59.92

Relative Abundance

60 50 40 30 39.63 20 10 0 0 5.09 12.27 10 20.05 20 37.98 31.04 30.56 36.93 28.01 30 40 50 Time (min) 60 41.91 49.63 53.17 62.92 63.80 65.05 70 69.75 78.82 82.05 80 63.42 48.48

663.1794 613.4558 726.4335

0 200 300 400 500 600 m/z 700 800 900 1000

78.04 82.05

RT: 0.00 - 80.47 100 90 80 70
Relative Abundance

RT: 0.00 - 80.47
60.79 NL: 2.00E7 TIC MS LARC_oxLDL_ ACN_NSI_150 umMonMadeC olumn_CHARM ED_April5

100 90 80 70

60.62

NL: 5.27E6 Base Peak MS LARC_oxLDL_A CN_NSI_150um MonMadeColum n_CHARMED_A pril5

Extracted from: C:\data_CHARMED\CHARMED_March2010\LARC_CHARMED\LARC_oxLDL_ACN_NSI_150umMonMadeColumn_CHARMED_April5.RAW #4386 RT: 59.60 ITMS, CID, z=+3, Mono m/z=846.13806 Da, MH+=2536.39963 Da, Match Tol.=0.8 Da 200 1040.4872
Intens ity [counts ]

150 933.3655 100 y 1+ 6 769.2194 y 1+ 7 1089.9002

60 50 40 30 20 10 0 0 10 20 30 40 Time (min) 50 60 70 0.69 46.52 46.85 43.85 53.47 21.96 22.46 23.64 40.11 42.92 59.02

Relative Abundance

Fgr

60 50 40 30 20 10 0
80

2.78 3.38 4.92 5.39 12.17

62.26 65.17

73.79

676.5471 50

804.5479

12.62

46.35 54.03 21.72 22.79 28.09 5.15 9.08 17.23 20.33 0 10 20 30 43.76 42.75 48.85 73.79 62.59 74.27 73.40

0 400
80

600

800

1000 m/z

1200

1400

1600

40 Time (min)

50

60

70

RT: 0.00 - 103.10 100 90 80 70
Relative Abundance

RT: 0.00 - 103.10
61.73 60.86 NL: 2.07E8 TIC MS LARC_oxLDL_2 00mMNaCl_NSI _150umMonMad eColumn_CHAR MED_Mar23

100 90 80 70

40.36 40.59

60.03 59.82

43.72 50.07 52.63 57.56

NL: 4.92E6 Base Peak MS LARC_oxLDL_20 0mMNaCl_NSI_15 0umMonMadeColu mn_CHARMED_ Mar23

Extracted from: C:\data_CHARMED\CHARMED_March2010\LARC_CHARMED\LARC_oxLDL_200mMNaCl_NSI_150umMonMadeColumn_CHARMED_Mar23.RAW #4505 RT: 61.20 ITMS, CID, z=+3, Mono m/z=830.42761 Da, MH+=2489.26828 Da, Match Tol.=0.8 Da

800 700
Intens ity [counts ]

y 1+ 8 829.4572

60 50 40 30 20 10 0 0 10 20 30 40 50 Time (min) 60 0.97 2.50 12.77

Relative Abundance

Frk

64.92 66.37 68.00 69.72 71.38

60 50 40 30 20 10 0

2.41 3.09 28.87 9.02 21.63 25.80

29.50 30.58 36.86

600 500 400 300 200 100 y 1+ 7 785.4269 715.5983

81.75

58.74

80.77

59.75 60.86 66.09 67.48 79.57 75.74 81.90 86.06

82.76 91.83 93.15 94.56

y 9 1035.6432 943.6705 1227.5139

1+

99.53

0 400 600 800 m/z 1000 1200 1400 1600

28.48 29.58

40.59

50.41

70

80

90

100

0

10

20

30

40

50 Time (min)

60

70

80

90

100

92

Syk Family Kinases
TIC
RT: 0.00 - 110.03 100 90 80 70 60 50 40 30 20 0.16 10 0 0 10 20 30 40 50 60 Time (min) 70 80 90 100 110 51.33 54.36 54.68 55.72 63.13 32.08 29.42 28.49 27.57 24.40 23.58 12.31 21.82 91.62 64.35 65.64 70.13 90.41 92.45 71.77 87.86 94.98 73.14 81.89 98.44
Relative Abundance

Base Peak
RT: 0.00 - 110.03
NL: 4.38E7 TIC MS LARC_oxLDL_1 000mMNaCl_NSI _150umMonMad eColumn_CHAR MED_April5

Spectrum
NL: 1.59E7 Base Peak MS LARC_oxLDL_100 0mMNaCl_NSI_15 0umMonMadeColu mn_CHARMED_A pril5

40.63 40.47 33.04 33.34 41.60 48.74

100 90 80 70

33.04

Extracted from: C:\data_CHARMED\CHARMED_March2010\LARC_CHARMED\LARC_oxLDL_1000mMNaCl_NSI_150umMonMadeColumn_CHARMED_April5.RAW #4542 RT: 61.48 ITMS, CID, z=+3, Mono m/z=866.12756 Da, MH+=2596.36814 Da, Match Tol.=0.8 Da

32.79

120 848.1463 100

ZAP-70 Isoform 1
Relative Abundance

48.82 60 50 40 30 20 10 0.16 0 0 10 20 30 40 50 60 Time (min) 70 80 90 100 110 19.49 40.22 49.07 51.02

Intens ity [counts ]

80 60 775.3492 40 20 692.9736 1061.4994 1002.4663 1192.1040

41.60 52.23 54.52 63.13 59.54 25.42 29.58

70.54

0
72.01 73.55 90.49 92.61 100.84

400

600

800

1000 m/z

1200

1400

1600

RT: 0.00 - 92.00 100 90 80 70 60 50 40 30 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 33.21 33.94 32.46 29.74 29.37 34.57 37.69 NL: 7.77E7 TIC MS LARC_oxLDL_3 50mMNaCl_NSI _150umMonMad eColumn_CHAR MED_Mar26

RT: 0.00 - 92.00 100 90 80 70
Relative Abundance

33.21

45.31 46.36 46.66 47.70 49.81 50.77 58.29 54.65 60.68 61.75 62.52 63.18 64.73 69.71 70.12 72.01 74.80 76.61

NL: 8.93E6 Base Peak MS LARC_oxLDL_35 0mMNaCl_NSI_15 0umMonMadeColu mn_CHARMED_ Mar26

Extracted from: C:\data_CHARMED\CHARMED_March2010\LARC_CHARMED\LARC_oxLDL_350mMNaCl_NSI_150umMonMadeColumn_CHARMED_Mar26.RAW #4352 RT: 58.29 ITMS, CID, z=+3, Mono m/z=789.73730 Da, MH+=2367.19736 Da, Match Tol.=0.8 Da

400

43.79

y 1+ 7 780.3058

ZAP-70 Isoform 1
Relative Abundance

32.08 60 50 26.42 40

33.94 34.33

28.53 27.64

Intens ity [counts ]

300 909.6295 200 760.0502
2+ y 18 976.2244

26.59

34.88 30

46.04 46.43 45.71 46.66

61.01 60.68 58.29

100
62.26

87.88 86.72

1046.4082 1255.6943

20 3.99 10 6.44 0 0 10 20 30 40 20.41 24.27

48.03 50.93 66.30 68.89 71.69

1.15 3.99

0
75.30 80 89.55 90

8.24

24.27

77.92

400

600

800 m/z

1000

1200

1400

50 Time (min)

60

70

RT: 0.00 - 98.16 100 90 80 70
Relative Abundance

RT: 0.00 - 98.16
50.60 49.95 48.99 48.71 48.09 51.42 56.87 57.09 57.46 61.71 62.39 63.28 63.79 47.01 65.87 68.51 68.74 69.43 69.66 70.70 79.65
Relative Abundance

NL: 2.26E8 TIC MS LARC_OXLDL _PBS_NSI_150 umMonManeCo lumn_STRANG E_March18

100 90 80 48.71 70 60 50 40 30 54.39 54.73 18.78 18.37 10.32 17.90 10.83 5.65 17.02 19.37 26.54 29.81 31.03 39.73 34.36 43.56 57.02

79.49 79.73

NL: 6.11E6 Base Peak MS LARC_OXLDL_ PBS_NSI_150um MonManeColumn _STRANGE_Mar ch18

Extracted from: C:\data_STRANGE\STRANGE_MArch_2010\LARC\LARC_OXLDL_PBS_NSI_150umMonManeColumn_STRANGE_March18.RAW #4444 RT: 57.89 ITMS, CID, z=+3, Mono m/z=726.41687 Da, MH+=2177.23606 Da, Match Tol.=0.8 Da

3000 716.6402
Intens ity [counts ]

2500 2000 1500 1000 661.0366 500 605.1635
2+ b16 896.8051 851.5095

Syk

60 50

68.51 63.64 72.12 74.66

46.29 40 30 20 10 0 0 10 20 30 40 50 Time (min) 60 15.68 16.39 24.93 44.34 43.71 42.68 41.58 8.69 10.74 39.56 37.87 35.33

81.82 86.19 90.33 91.89

989.5127

20 2.31 10 0

86.27

97.06 96.46

0 200 400 600 800 m/z 1000 1200 1400

70

80

90

0

10

20

30

40

50 Time (min)

60

70

80

90

RT: 0.00 - 98.16 100 90 80 70
Relative Abundance

RT: 0.00 - 98.16
50.60 49.95 48.99 48.71 48.09 51.42 56.87 57.09 57.46 61.71 62.39 63.28 63.79 47.01 65.87 68.51 68.74 69.43 69.66 70.70 79.65
Relative Abundance

NL: 2.26E8 TIC MS LARC_OXLDL _PBS_NSI_150 umMonManeCo lumn_STRANG E_March18

100 90 80 48.71 70 60 50 40 30 54.39 54.73 18.78 18.37 10.32 17.90 10.83 5.65 17.02 19.37 26.54 29.81 31.03 39.73 34.36 43.56 57.02

79.49 79.73

NL: 6.11E6 Base Peak MS LARC_OXLDL_ PBS_NSI_150um MonManeColumn _STRANGE_Mar ch18

Extracted from: C:\data_STRANGE\STRANGE_MArch_2010\LARC\LARC_OXLDL_PBS_NSI_150umMonManeColumn_STRANGE_March18.RAW #6796 RT: 88.91 ITMS, CID, z=+2, Mono m/z=617.26318 Da, MH+=1233.51909 Da, Match Tol.=0.8 Da 350 300
Intens ity [counts ]

599.2716

250 200 150 100 291.1864 50 816.8095 616.2783
2+ b10 481.2692 559.0435

Syk

60 50

68.51 63.64 72.12 74.66

46.29 40 30 20 10 0 0 10 20 30 40 50 Time (min) 60 15.68 16.39 24.93 44.34 43.71 42.68 41.58 8.69 10.74 39.56 37.87 35.33

81.82 86.19 90.33 91.89

20 2.31 10 0

86.27

97.06 96.46

0 200 400 600 m/z 800 1000 1200

70

80

90

0

10

20

30

40

50 Time (min)

60

70

80

90

93

Focal Adhesion Kinases
TIC
RT: 0.00 - 99.04 100 90 80 31.62 5.98 8.48 8.82 10.23 11.46 30.88 40 11.78 30 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 27.08 12.41 26.62 13.68 50.82 57.31 81.42 82.13 90.88 27.80 53.78 46.06 63.70 39.13 NL: 5.16E7 TIC MS LARC_CD36_Ig G_U937cellextrac t_450mMNaCl_Z orbax_STRANGE _Nov2

Base Peak
RT: 0.00 - 99.04 100 90 80 70
Relative Abundance

Spectrum
NL: 1.16E7 Base Peak MS LARC_CD36_IgG _U937cellextract_4 50mMNaCl_Zorba x_STRANGE_Nov 2

39.68 45.60 31.62

Extracted from: C:\data_STRANGE\STRANGE_OCTOBER_2010\LARC_CD36_IgG_U937cellextract_STRANGE\LARC_CD36_IgG_U937cellextract_450mMNaCl_Zorbax_STRANGE_Nov2.RAW #2741 RT: 34.90 ITMS, CID, z=+2, Mono m/z=579.57318 Da, MH+=1158.13909 Da, Match Tol.=0.5 Da

42.38 45.60 64.34 32.33 37.40

32.19 39.06 64.34

PTK2 Isoform B
Relative Abundance

15000
Intens ity [counts ]

488.3366

70 60 50

60 50 35.14 40 53.78 30 30.94 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 15.78 17.13 24.26 7.40 57.31 82.05 76.74 81.18 90.88 50.82 63.70 62.30

570.3887 10000 669.2144 651.1723 5000 y 1+ 2 246.2131 467.0963 813.2796 928.2611 1010.2197

74.56

83.45 92.12

0 200
98.63

83.21

300

400

500

600 m/z

700

800

900

1000

1100

RT: 0.00 - 100.06 100 90 80 NL: 3.46E7 TIC MS LARC3_CD36_Ig A_U937cellExtrac t_800mMNaCl_Z ORBAX_CHARM ED_Dec8

RT: 0.00 - 100.06 100 90 80 70
Relative Abundance

53.57

42.13

NL: 3.90E6 Base Peak MS LARC3_CD36_IgA _U937cellExtract_8 00mMNaCl_ZORB AX_CHARMED_D ec8

Extracted from: C:\data_CHARMED\CHARMED_DECEMBER2010\LARC3_CD36_IgA_U937cellExtract_CHARMED\LARC3_CD36_IgA_U937cellExtract_800mMNaCl_ZORBAX_CHARMED_Dec8.RAW #4384 RT: 56.04 ITMS, CID, z=+3, Mono m/z=585.64685 Da, MH+=1754.92600 Da, Match Tol.=0.5 Da

PTK2 Isoform B
Relative Abundance

52.35 56.83 60.32
Intens ity [counts ]

y 1+ 9 943.4811 3000

70 60 50 40 30 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 100 2.17 2.70 41.65 3.86 11.84 13.00 17.62 24.30 26.50 33.52 82.36 83.89 94.16 1.27 53.57 52.35 62.16 42.13 43.05 51.56 72.81 66.38 76.21 78.30 80.53 73.90

60 50 40 30 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 100 51.56 48.34 63.86

2000

y 1+ 8 830.4072 b1+ 2 227.0555
2+ y 517.3134 9 472.4508

1000
71.97 73.90 41.65 7.24 14.84 19.38 31.48 32.61 34.27

759.3987 630.4005

b1+ 10 1023.4439

71.06 79.99 98.86 80.68 95.83

0 200 300 400 500 600 m/z 700 800 900 1000 1100

RT: 0.00 - 90.52 100 90 80 60.79 60.61 61.89 62.14 63.05 14.42 63.24 64.11 70 60 50 57.58 40 56.74 30 81.23 75.24 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 2.07 3.66 8.68 55.82 16.53 22.80 32.22 36.56 51.30 54.59 46.07 81.62 73.34 59.93 58.41 69.59 70.20 68.25 68.80
Relative Abundance

RT: 0.00 - 90.52
NL: 1.55E8 TIC MS LARC_CD36_Ig A_U937cellExtra ct_TRPbeads_Z ORBAX_CHARM ED_Oct29

100 90 80 70

61.46 61.89

14.65

NL: 1.74E7 Base Peak MS LARC_CD36_IgA_ U937cellExtract_T RPbeads_ZORBA X_CHARMED_Oct 29

Extracted from: C:\data_CHARMED\CHARMED_OCTOBER2010\LARC_CD36_IgA_U937cellextract_CHARMED\LARC_CD36_IgA_U937cellExtract_TRPbeads_ZORBAX_CHARMED_Oct29.RAW #4437 RT: 56.28 ITMS, CID, z=+2, Mono m/z=544.18384 Da, MH+=1087.36040 Da, Match Tol.=0.5 Da 4000 534.2919

PTK2 Isoform B
Relative Abundance

58.35 60 62.91 50 40 65.53 30 68.45 20 57.90 15.07 10 1.92 0 0 10 20 30 40 50 Time (min) 60 70 80 90 13.95 15.54 23.03 25.76 36.56 56.74 50.77 51.30 76.38 88.55 80.21 64.24

Intens ity [counts ]

3000 y 1+ 8 859.3926

2000 y 1+ 5 560.4866 y 1+ 6 631.3598

73.34 81.07

y 1+ 7 746.3510

1000

1+ b2 228.1111

b1+ 3 341.2291

y 1+ 4 461.1726

0 200 300 400 500 600 m/z 700 800 900 1000 1100

RT: 0.00 - 92.24 100 90 80 62.95 NL: 1.30E8 TIC MS LARC2_oxLD L_WASH_ZO RBAX300A_C 18_5u_STRA NGE_May26

RT: 0.00 - 92.24 100 90 80 70
46.37 52.13 56.46
Relative Abundance

62.95

PTK2 Isoform B
Relative Abundance

NL: 1.59E7 Base Peak MS LARC2_oxLDL _WASH_ZORB AX300A_C18_ 5u_STRANGE_ May26

Extracted from: C:\data_STRANGE\STRANGE_MAY2010\LARC2_oxLDL STRANGE\LARC2_oxLDL_WASH_ZORBAX300A_C18_5u_STRANGE_May26.RAW #6032 RT: 74.54 ITMS, CID, z=+3, Mono m/z=1091.57983 Da, MH+=3272.72495 Da, Match Tol.=0.8 Da 2500 1024.1221 1225.6528

2000
70 60 50 67.37 40 30 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 5.60 10.73 13.92 41.66 18.96 23.16 36.46 38.41
Intens ity [counts ]

60 50 40 30 20 46.02 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 5.60 10.00 19.76 42.78 20.46 36.39 38.72 51.94 51.32 68.16 74.62 79.97 85.19 57.80

1500 1535.3604 1397.0709 y 1+ 9 995.5364 1072.6831

70.28 72.21 73.23 73.55 74.30 76.21 77.70 80.36 85.19 89.57

1000

500

0
90.12

400

600

800

1000

1200 m/z

1400

1600

1800

2000

RT: 0.00 - 90.20 100 90 80 63.81 63.18 64.27 61.76 61.50 64.78 66.50 59.92 60 50 40 56.56 30 55.19 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 58.98 57.03
Relative Abundance

RT: 0.00 - 90.20
NL: 1.79E8 TIC MS LARC3_oxLDL _150mMNaCl_Z ORBAX300A_C 18_5u_STRAN GE_June17

100 90 80 70 60 50

59.92

PTK2 Isoform B
Relative Abundance

NL: 1.85E7 Base Peak MS LARC3_oxLDL_1 50mMNaCl_ZOR BAX300A_C18_ 5u_STRANGE_J une17

Extracted from: C:\data_STRANGE\STRANNGE_JUNE2010\LARC3_oxLDL STRANGE\LARC3_oxLDL_150mMNaCl_ZORBAX300A_C18_5u_STRANGE_June17.RAW #4228 RT: 54.30 ITMS, CID, z=+3, Mono m/z=585.99341 Da, MH+=1755.96567 Da, Match Tol.=0.8 Da 10000 9000 8000
Intens ity [counts ]

y 1+ 6 646.3433

70

67.58 69.37 70.32 70.75 72.18 72.99 73.60 73.92

7000 6000 5000 4000 3000 2000
2+ b11 555.3405

63.81

58.64 40 30 20 10 0 0 3.85 6.76 10 16.58 21.36 20 41.64 49.30 40 50 Time (min) 60 70 73.53 57.23 49.79 55.99 68.89 69.09 70.32 73.15

488.3404 759.4416 996.3758

74.94 77.23 79.87

84.86

1000 0 200 300 400 500 600 m/z 700 800 900 1000 1100

8.21

9.16

10.90 16.65

32.87 39.52

41.64

48.62

39.82 29.36 34.40 30

80

90

RT: 0.00 - 90.78 100 90 80 59.26 NL: 6.92E7 TIC MS LARC3_oxLDL _900mMNaCl_Z ORBAX300A_C 18_5u_STRAN GE_June22

RT: 0.00 - 90.78 100 90 80 70
Relative Abundance

59.26

PTK2 Isoform B
Relative Abundance

52.68 70 60 50 40 30 20 11.14 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 11.98 21.46 38.29 29.12 40.33 10.02 10.25 10.56 48.41 10.90 48.10 73.33 76.47 66.60 52.19 50.22 72.70 7.96 6.71 6.21 8.30 8.71 9.53

NL: 2.07E7 Base Peak MS LARC3_oxLDL_9 00mMNaCl_ZOR BAX300A_C18_ 5u_STRANGE_J une22

Extracted from: C:\data_STRANGE\STRANNGE_JUNE2010\LARC3_oxLDL STRANGE\LARC3_oxLDL_900mMNaCl_ZORBAX300A_C18_5u_STRANGE_June22.RAW #4760 RT: 61.30 ITMS, CID, z=+3, Mono m/z=1091.57446 Da, MH+=3272.70884 Da, Match Tol.=0.8 Da

1500
Intens ity [counts ]

1024.2334

57.32

61.52

60 50 40 30 20 50.15 10 10.49 6.87 11.60 0 0 10 20 30 40 50 Time (min) 60 70 80 90 22.07 29.12 38.29 48.41 58.98 66.52 72.70 70.47 73.33 52.68 61.52

1000 1225.4605

500 y 1+ 9 995.4043 0
80.90 83.46

1074.6809

1397.1715

1535.3993

77.69 83.08

400

600

800

1000

1200 m/z

1400

1600

1800

2000

94

Focal Adhesion Kinases
TIC
RT: 0.00 - 91.58 100 90 80 70 60 4.94 50 40 30 38.39 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 13.62 13.99 15.60 35.95 33.98 28.56 64.36 64.98 10.70 9.43 11.16 11.87 13.01 13.32 41.30 38.94 53.24 53.73 58.54 81.31 77.82 82.04 83.42 43.18 41.54
Relative Abundance

Base Peak
RT: 0.00 - 91.58
NL: 3.86E7 TIC MS LARC3_oxLDL _800mMNaCl_ Zorbax300A_5 u_CHARMED_ June22

Spectrum
NL: 1.04E7 Base Peak MS LARC3_oxLDL_ 800mMNaCl_Zo rbax300A_5u_C HARMED_June 22

49.56

100 90 80 70

49.56

Extracted from: C:\data_CHARMED\CHARMED_JUNE2010\LARC3_oxLDL_CHARMED\LARC3_oxLDL_800mMNaCl_Zorbax300A_5u_CHARMED_June22.RAW #3075 RT: 39.35 ITMS, CID, z=+3, Mono m/z=574.64014 Da, MH+=1721.90586 Da, Match Tol.=0.8 Da

2000
Intens ity [counts ]

812.6538

PTK2 Isoform B
Relative Abundance

52.68

60 52.68 50 40 13.01 30 13.32 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 12.86 5.09 10.15 13.62 22.89 27.73 39.02 53.24 37.05 41.54 48.86 43.18 64.36 77.90 81.31 82.50 70.37 73.71

1500 562.4934 1000 516.1474 603.4901 500 254.2457 369.2221 0 200 300 400 500 600 m/z 700 800 900 1000 1100
3+ b10

682.4616 764.2332 1005.5127

y 2+ 7 447.6730

70.30 75.54

95

Phospholipase C
TIC
RT: 0.00 - 87.04 100 90 60.08 80 70
Relative Abundance

Base Peak
RT: 0.00 - 87.04
60.23 60.96 NL: 3.58E7 TIC MS LARC_CD36_Ig G_U937cellExtr act_ACN_ZOR BAX_CHARME D_Nov11

Spectrum
NL: 2.91E6 Base Peak MS LARC_CD36_Ig G_U937cellExtrac t_ACN_ZORBAX _CHARMED_Nov 11

100 90 80 70

53.91

Extracted from: C:\data_CHARMED\CHARMED_NOVEMBER2010\LARC_CD36_IgG_U937cellExtract_CHARMED\LARC_CD36_IgG_U937cellExtract_ACN_ZORBAX_CHARMED_Nov11.RAW #4109 RT: 52.51 ITMS, CID, z=+3, Mono m/z=458.95813 Da, MH+=1374.85984 Da, Match Tol.=0.5 Da 300 250
Intens ity [counts ]

61.19

449.5927

61.19 56.83 75.52

60 50 40 30 20 12.85 10 0 0 10 20 30 40 50 Time (min) 22.77 30.08 35.07 1.88 1.58

53.91 65.32 59.74

Relative Abundance

200 150 100 50 0 200 300 400 500 m/z 600 700 800 900 b 3+ 8 337.1818

60 50 40 0.97 30

PLCG2

69.99 13.52 17.21 22.77 13.22 12.24 23.37 27.89 29.55 34.47 53.51 77.98 49.68 61.58 38.24 41.27 82.90

7.37 11.06 11.39

53.51 53.22 53.00 47.91 45.30

66.01 66.17 66.51 75.52 80.98

440.3356
1+ 498.7452 y6 483.5005 531.0004 622.5093

1.13

20 10 0
60 70 80

1.58 12.01 11.77 2.27

0

10

20

30

40 50 Time (min)

60

70

80

RT: 0.00 - 93.61 100 90 53.93 80 70
Relative Abundance
Relative Abundance

RT: 0.00 - 93.61
55.12 54.79 59.68 NL: 8.28E7 TIC MS LARC3_oxLDL_ BEAD_DIGEST _ZORBAX300A _C18_5u_STRA NGE_June25

100 90 80 70

55.12

62.74 58.14

60.18 61.04

NL: 8.09E6 Base Peak MS LARC3_oxLDL_B EAD_DIGEST_Z ORBAX300A_C1 8_5u_STRANGE_ June25

Extracted from: C:\data_STRANGE\STRANNGE_JUNE2010\LARC3_oxLDL STRANGE\LARC3_oxLDL_BEAD_DIGEST_ZORBAX300A_C18_5u_STRANGE_June25.RAW #3594 RT: 46.00 ITMS, CID, z=+2, Mono m/z=769.94409 Da, MH+=1538.88091 Da, Match Tol.=0.8 Da

600 745.3853 500
Intens ity [counts ]

PLCB2

60 50 40 30 20 10 0 0 10 20 30 40 50 Time (min) 60

63.56 63.78

53.99 60 50 40 63.93 30 20 35.05 36.78 38.98 33.55 29.92 30 40.59 48.44 40 50 Time (min) 60 69.81 79.28 83.13 90

400 300 200 388.2588 100 668.5138

963.3301 574.3077 876.3214 b1+ 1091.3938 101206.3339 1132.3071 1391.2749

63.56 75.69 76.32

64.17 75.69 67.29 76.32 69.73 6.88 3.80 9.28 9.68 13.01 14.85 34.82 33.85 70 80 44.97 44.81 45.21 79.28 79.90

85.99

10 5.83 0 14.85 21.51 10 20

0 200 400 600 800 m/z 1000 1200 1400

90

0

70

80

RT: 0.00 - 86.57 100 90 54.01 80 70
Relative Abundance

RT: 0.00 - 86.57
54.19 NL: 1.91E8 TIC MS LARC2_oxLDL _50mMNaCl_Z ORBAX300A_ C18_5u_STRA NGE_May19

100 90 80 70

54.19

55.51 57.13

53.83

54.60

64.80

NL: 1.28E7 Base Peak MS LARC2_oxLDL_ 50mMNaCl_ZOR BAX300A_C18_ 5u_STRANGE_ May19

Extracted from: C:\data_STRANGE\STRANGE_MAY2010\LARC2_oxLDL STRANGE\LARC2_oxLDL_50mMNaCl_ZORBAX300A_C18_5u_STRANGE_May19.RAW #3753 RT: 45.78 ITMS, CID, z=+3, Mono m/z=501.27570 Da, MH+=1501.81253 Da, Match Tol.=0.8 Da

679.9027 15000
Intens ity [counts ]

63.85 55.33 57.84 42.57 46.80 42.11 41.88 41.30 65.83
Relative Abundance

PLCE1

60 50 40 30 20 10 3.93 12.28 12.95 13.80 0 0 10 20 30 40 50 Time (min) 25.89 33.00 38.14

60 50 40

46.91 47.74

2+ b8 514.8868

10000

66.34 66.82 68.42 71.04

57.84 64.10 30 42.74 53.65 58.29 71.83 79.65 10 4.01 0 19.77 23.70 32.93 38.07 9.78 18.49 10 20 30 40 50 Time (min) 60 70 80 68.42 75.54 85.48

5000 b 3+ 8 372.1119 343.8503 0 200 300 400

453.9204

571.4278 606.3781

75.54 76.11 84.70

20

42.11

500 m/z

600

700

800

900

1000

60

70

80

0

RT: 0.00 - 86.57 100 90 54.01 80 70
Relative Abundance

RT: 0.00 - 86.57
54.19 NL: 1.91E8 TIC MS LARC2_oxLDL _50mMNaCl_Z ORBAX300A_ C18_5u_STRA NGE_May19

100 90 80 70

54.19

55.51 57.13

53.83

54.60

64.80

NL: 1.28E7 Base Peak MS LARC2_oxLDL_ 50mMNaCl_ZOR BAX300A_C18_ 5u_STRANGE_ May19

Extracted from: C:\data_STRANGE\STRANGE_MAY2010\LARC2_oxLDL STRANGE\LARC2_oxLDL_50mMNaCl_ZORBAX300A_C18_5u_STRANGE_May19.RAW #5930 RT: 69.71 ITMS, CID, z=+3, Mono m/z=732.72467 Da, MH+=2196.15946 Da, Match Tol.=0.8 Da

600 976.0872 500
Intens ity [counts ]

63.85 55.33 57.84 42.57 46.80 42.11 41.88 41.30 65.83
Relative Abundance

PLCH1

60 50 40 30 20 10 3.93 12.28 12.95 13.80 0 0 10 20 30 40 50 Time (min) 25.89 33.00 38.14

60 50 40

46.91 47.74

400 300 200 100 0 200 400 600 800 m/z 1000 1200 1400 y1+ 3 357.3804 646.9244 890.7631 1087.5541 919.5159

66.34 66.82 68.42 71.04

57.84 64.10 30 42.74 53.65 58.29 71.83 79.65 10 4.01 0 19.77 23.70 32.93 38.07 9.78 18.49 10 20 30 40 50 Time (min) 60 70 80 68.42 75.54 85.48

714.3983

997.1508

75.54 76.11 84.70

20

42.11

60

70

80

0

RT: 0.00 - 86.57 100 90 54.01 80 70
Relative Abundance

54.19

53.83

54.60

64.80

RT: 0.00 - 86.57 NL: 100 1.91E8 TIC MS LARC2_oxLDL 90 _50mMNaCl_Z ORBAX300A_ C18_5u_STRA 80 NGE_May19 70

54.19

55.51 57.13

NL: 1.28E7 Base Peak MS LARC2_oxLDL_ 50mMNaCl_ZOR BAX300A_C18_ 5u_STRANGE_ May19

Extracted from: C:\data_STRANGE\STRANGE_MAY2010\LARC2_oxLDL STRANGE\LARC2_oxLDL_50mMNaCl_ZORBAX300A_C18_5u_STRANGE_May19.RAW #4695 RT: 55.40 ITMS, CID, z=+2, Mono m/z=980.99866 Da, MH+=1960.99004 Da, Match Tol.=0.8 Da

16000 14000
Intens ity [counts ]

1307.5424
2+ y 14 794.6320

63.85 55.33 57.84 42.57 46.80 42.11 41.88 41.30 65.83
Relative Abundance

12000 10000 8000 6000 4000

PLCZ1

60 50 40 30 20 10 3.93 12.28 12.95 13.80 0 0 10 20 30 40 50 Time (min) 25.89 33.00 38.14

60 50 40

46.91 47.74

66.34 66.82 68.42 71.04

923.5170 b1+ 8 899.7018 1137.4155 827.4717

1458.5096

57.84 64.10 30 42.74 53.65 58.29 71.83 79.65 10 4.01 0 19.77 23.70 32.93 38.07 9.78 18.49 10 20 30 40 50 Time (min) 60 70 80 68.42 75.54 85.48

75.54 76.11 84.70

20

42.11

2000 0 400 600 800 1000 m/z 1200 1400 1600 1800

60

70

80

0

RT: 0.00 - 86.57 100 90 54.01 80 70
Relative Abundance

54.19

53.83

54.60

64.80

RT: 0.00 - 86.57 NL: 100 1.91E8 TIC MS LARC2_oxLDL 90 _50mMNaCl_Z ORBAX300A_ C18_5u_STRA 80 NGE_May19 70

54.19

55.51 57.13

NL: 1.28E7 Base Peak MS LARC2_oxLDL_ 50mMNaCl_ZOR BAX300A_C18_ 5u_STRANGE_ May19

Extracted from: C:\data_STRANGE\STRANGE_MAY2010\LARC2_oxLDL STRANGE\LARC2_oxLDL_50mMNaCl_ZORBAX300A_C18_5u_STRANGE_May19.RAW #4595 RT: 54.40 ITMS, CID, z=+3, Mono m/z=530.29059 Da, MH+=1588.85721 Da, Match Tol.=0.8 Da

4000

y 2+ 8 481.1397

63.85 55.33 57.84 42.57 46.80 42.11 41.88 41.30 65.83
Relative Abundance

Intens ity [counts ]

PLCD3

60 50 40 30 20 10 3.93 12.28 12.95 13.80 0 0 10 20 30 40 50 Time (min) 25.89 33.00 38.14

60 50 40

46.91 47.74

3000

66.34 66.82 68.42 71.04

2000

57.84 64.10 30 42.74 53.65 58.29 71.83 79.65 10 4.01 0 19.77 23.70 32.93 38.07 9.78 18.49 10 20 30 40 50 Time (min) 60 70 80 68.42 75.54 85.48

1000 512.2525 0 200 300 400 500 600 m/z 652.5672

75.54 76.11 84.70

20

42.11

758.5596 734.5403 864.5017

960.3752 1000

700

800

900

60

70

80

0

96

Protein Kinase C
TIC
RT: 0.00 - 81.26 100 95 90 85 80 75 49.38 50.67 31.21 50.24 NL: 7.29E7 TIC MS LARC3_CD36_Ig A_U937LIVEcell_6 00mMNaCl_ZOR BAX_STRANGE_ Dec7

Base Peak
RT: 0.00 - 81.26 100 95 90 85 80 75 70
Intens ity [counts ]

Spectrum
NL: 1.10E7 Base Peak MS LARC3_CD36_IgA_ U937LIVEcell_600m MNaCl_ZORBAX_S TRANGE_Dec7

50.24

Extracted from: C:\data_STRANGE\STRANGE_DECEMBER_2010\LARC3_CD36_IgA_U937LIVEcell_STRANGE\LARC3_CD36_IgA_U937LIVEcell_600mMNaCl_ZORBAX_STRANGE_Dec7.RAW #5111 RT: 65.18 ITMS, CID, z=+3, Mono m/z=426.27966 Da, MH+=1276.82444 Da, Match Tol.=0.5 Da 600 500 400 300 200 100 0 b 2+ 5 251.1179 178.2352 223.0929 200 300 416.7585 361.4087 472.3781 400 500 m/z 600 713.4072 676.2275

49.38

408.2148

PKC Alpha

70 65 60 55 50 45 40 35 30 25 20 15 10 5 0 0 10 20 5.03 22.27 25.38 3.92 4.24

65

Relative Abundance

Relative Abundance

51.28 40.72 33.93 48.63 43.66

60 55 50 45 40 35 15.16 14.78 10.78 7.88 7.29 5.19 31.21 37.18 40.94 41.18 74.26 22.42 24.94

29.61

600.3786

51.28

74.26 52.01 53.13 65.82 53.93 59.93

30 25 20 15 10 5 0

73.23 53.13 60.00 65.82 10 20 30 40 Time (min) 50 60 70 80

700

800

30

40 Time (min)

50

60

70

80

0

RT: 0.00 - 92.32 100 95 90 85 80 75 31.00 42.63 30.17 44.50 46.20 74.74 31.61 33.08 41.78 32.66 NL: 8.94E7 TIC MS LARC2_oxLDL_200 mMNaCl_150umID 5um300AMonMade SP006_CHARMED _May20

RT: 0.00 - 92.32 100 95 90 85 80 75 70 65 32.66 41.78 40.49 NL: 1.19E7 Base Peak MS LARC2_oxLDL_200 mMNaCl_150umID5u m300AMonMadeSP0 06_CHARMED_May2 0

Extracted from: C:\data_CHARMED\CHARMED_MAY2010\LARC2_oxLDL_CHARMED\LARC2_oxLDL_200mMNaCl_150umID5um300AMonMadeSP006_CHARMED_May20.RAW #4976 RT: 59.70 ITMS, CID, z=+3, Mono m/z=808.45215 Da, MH+=2423.34189 Da, Match Tol.=0.8 Da

150
Intens ity [counts ]

1033.8787
2+ b12 792.3323

PKC Alpha

70 65 60 55 50 45 40 35 30 25 20 15 10 5 0 0 10 20 8.72 17.56 16.91 10.85

Relative Abundance

Relative Abundance

60 55 50 45 40 35 30 25 20 29.38 52.47 60.02 69.70 30.17 47.68 31.48

74.74

1081.5022 906.5266

100
2+ b10 670.3933

1213.3843

52.98 54.08 55.08 57.87 18.19 19.10 64.38 76.33 78.03

50

71.57

15 10 5 0

16.84 17.56 6.38 9.71 0 10 20 30

0
91.74

400

600

800 m/z

1000

1200

1400

1600

30

40 50 Time (min)

60

70

80

90

40 50 Time (min)

60

70

80

90

RT: 0.00 - 87.72 100 90 80 70
Relative Abundance
Relative Abundance

RT: 0.00 - 87.72
32.61 NL: 3.00E8 TIC MS LARC3_CD36_Ig A_U937cellextrac t_900mMNaCl_Z ORBAX_STRAN GE_Dec1

100 90 80 70

32.88

NL: 4.10E7 Base Peak MS LARC3_CD36_IgA _U937cellextract_9 00mMNaCl_ZORB AX_STRANGE_De c1

Extracted from: C:\data_STRANGE\STRANGE_NOVEMBER_2010\LARC3_CD36_IgA_U937cellextract_STRANGE\LARC3_CD36_IgA_U937cellextract_900mMNaCl_ZORBAX_STRANGE_Dec1.RAW #3665 RT: 46.76 ITMS, CID, z=+2, Mono m/z=882.59131 Da, MH+=1764.17534 Da, Match Tol.=0.5 Da

6000 451.2917 5000
Intens ity [counts ]

863.7759 793.4619 1040.4924
1+ b12 1389.5275 1242.5256

PKC Alpha

60 50 33.17 40 34.39 30 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 2.05 39.78 43.65 22.82 32.13 58.86 68.56 36.03

60 32.61 50 40 30 34.46

4000 3000 2000 1000

564.3906

771.7381

1128.4932

36.03

20 43.65
8.13 12.44 13.87 52.38 69.18

58.86 69.18 74.10 70 80 84.72

10
74.10 84.65

45.71 48.56 2.95 11.16 13.80 14.33 22.67 62.97 30 40 50 Time (min) 60

0 400 600 800 1000 m/z 1200 1400 1600

0 0 10 20

RT: 0.00 - 100.02 100 90 80 42.59 49.39 52.77 60.17 54.71 42.18 70
Relative Abundance

RT: 0.00 - 100.02
43.14 NL: 4.60E7 TIC MS LARC_CD36_IgA _U937cellExtract_ 1000mMNaCl_ZO RBAX_CHARME D_Oct28

100 90 80 70

43.14

NL: 1.55E7 Base Peak MS LARC_CD36_IgA_ U937cellExtract_10 00mMNaCl_ZORB AX_CHARMED_O ct28

Extracted from: C:\data_CHARMED\CHARMED_OCTOBER2010\LARC_CD36_IgA_U937cellextract_CHARMED\LARC_CD36_IgA_U937cellExtract_1000mMNaCl_ZORBAX_CHARMED_Oct28.RAW #2702 RT: 34.14 ITMS, CID, z=+2, Mono m/z=623.74341 Da, MH+=1246.47954 Da, Match Tol.=0.5 Da

2500 614.2929 2000 1500 1000 500 0 400.1936 y 1+ 4 499.2689 200 400 600 m/z 631.4031 845.4504 746.4691 1088.5200 y 1+ 8 960.4938 1070.4790 1000 1200

PKC Alpha

60 50 40 30 20 10 0 0 10 20 30 0.31 17.83 18.97

Relative Abundance

79.62

54.86 60 50 79.62 40 52.77 30 42.59 40.78 60.17 69.51 52.05 73.67 10 18.97 25.48 11.32 17.83 0 39.45 37.73 30 40 50 Time (min) 60 70 64.59 82.05 84.36 95.47 80 90 100 78.59

41.91 40.78

64.34

78.98 74.75 84.36

39.22 38.19 37.28 32.93 84.82

20
86.04 86.88 98.98

Intens ity [counts ]

800

40

50 Time (min)

60

70

80

90

100

0

10

20

RT: 0.00 - 97.23 100 90 64.85 80 70
Relative Abundance

RT: 0.00 - 97.23
66.06 65.26 66.32 66.94 NL: 1.35E8 TIC MS LARC3_oxLDL _450mMNaCl_Z ORBAX300A_C 18_5u_STRAN GE_June18

100 90 80 70

63.69 69.58

NL: 1.84E7 Base Peak MS LARC3_oxLDL_4 50mMNaCl_ZOR BAX300A_C18_ 5u_STRANGE_J une18

Extracted from: C:\data_STRANGE\STRANNGE_JUNE2010\LARC3_oxLDL STRANGE\LARC3_oxLDL_450mMNaCl_ZORBAX300A_C18_5u_STRANGE_June18.RAW #5343 RT: 68.33 ITMS, CID, z=+3, Mono m/z=1021.25391 Da, MH+=3061.74717 Da, Match Tol.=0.8 Da 2000 b 2+ 28 1457.9790

1322.6741 1500
Intens ity [counts ]

PKC Alpha

63.75
Relative Abundance

60 69.81 50 70.84 40 30 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 5.42 8.34 13.82 14.84 15.87 17.06 19.86 23.67 62.01 61.36 60.52 63.16 71.24 72.67 73.38 74.55 75.81 78.06

60 50 40 30 62.01 20 70.55 85.39 41.01 42.89 44.48 50 Time (min) 60 70 58.90 71.71 77.22 86.26 90

966.5205 1000 873.6102 500

1129.5862

85.39 86.26 92.87

13.39 10 0.40 5.02 0 0 10 20 30 40 80 17.06 26.94 35.24

0 400 600 800 1000 m/z 1200 1400 1600 1800 2000

41.08 42.89

55.66

RT: 0.00 - 92.07 100 95 90 85 80 75 32.01 31.09 46.81 45.00 44.60 48.19 48.86 49.35 50.77 34.19 NL: 6.87E7 TIC MS LARC_IgG_Was h_150umID5um3 00AMonMadeSP0 06_CHARMED_A pr30

RT: 0.00 - 92.07 100 95 90 85 80 75 70 65 34.19 NL: 1.59E7 Base Peak MS LARC_IgG_Wash_ 150umID5um300A MonMadeSP006_C HARMED_Apr30

Extracted from: C:\data_CHARMED\CHARMED_April2010\LARC_IgG CHARMED\LARC_IgG_Wash_150umID5um300AMonMadeSP006_CHARMED_Apr30.RAW #4236 RT: 57.38 ITMS, CID, z=+3, Mono m/z=904.16516 Da, MH+=2710.48093 Da, Match Tol.=0.8 Da 250 995.9195 885.3073 150 833.3497 100 1125.3192 1211.2473 1096.5107

200
Intens ity [counts ]

PKC Alpha

70 65 60 55 50 45 40 35 30 25 20 15 10 5 0 0 10 20 7.88 10.38 18.47 19.80

46.81

Relative Abundance

Relative Abundance

52.46 55.59 30.18 56.62 58.49

60 55 50 45 40 35 30 58.49 37.50 41.12

59.27 68.96

25 20 15 30.57 30.18 22.63 1.24 10.38 0 10 20 29.69

57.81 51.62 68.87 62.02 40 50 Time (min) 60 70 79.99 80

50

22.87 73.65 74.07 81.67 30 40 50 Time (min) 60 70 80 90

10 5 0

0 400
91.88 90

600

800

1000 m/z

1200

1400

1600

1800

30

97

Protein Kinase C
TIC
RT: 0.00 - 97.00 100 95 90 85 80 75 70 65 73.57 87.61 NL: 87.25 88.48 1.52E8 TIC MS 82.92 89.20 LARC_oxLDL_15 79.60 75.16 89.79 0mMNaCl_NSI_15 0umMonMadeCol umn_CHARMED_ 74.87 Mar22

Base Peak
RT: 0.00 - 97.00 100 95 90 85 80 75 70 65 73.57 75.99 63.96 67.41 76.34
Intens ity [counts ]

Spectrum
NL: 5.60E6 Base Peak MS LARC_oxLDL_150 88.92 mMNaCl_NSI_150u mMonMadeColumn _CHARMED_Mar22

88.55 88.33 87.61

Extracted from: C:\data_CHARMED\CHARMED_March2010\LARC_CHARMED\LARC_oxLDL_150mMNaCl_NSI_150umMonMadeColumn_CHARMED_Mar22.RAW #6846 RT: 89.55 ITMS, CID, z=+3, Mono m/z=922.13342 Da, MH+=2764.38572 Da, Match Tol.=0.8 Da

250 903.6719 200

75.58

Relative Abundance

PKC Beta

60 55 50 45 40 35 30 25 20 15 10 5 0 0 10 20 30 40 50 Time (min) 60 2.11 6.61 23.85 24.83 49.78 57.27 56.95 55.74 55.33 53.63 52.32

Relative Abundance

66.05 63.96 63.18 58.54

60 55 50 45 40 35 30 25 20 15 10 5 0 4.30 19.01 30.10 30.84 37.14 51.91 57.68 58.54

150

804.4136

1+ y 10 1022.41511150.4905

85.21 63.42

100 656.4096 50 1253.4451 1495.5569 y 1+ 15 1696.6409

0 400
60 70 80 90

600

800

1000 m/z

1200

1400

1600

1800

70

80

90

0

10

20

30

40

50 Time (min)

RT: 0.00 - 92.07 100 90 80 32.01 70 60 50 40 30 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 18.47 7.88 10.38 17.74 19.80 20.54 23.03 59.27 68.96 62.02 69.55 74.07 79.99 81.99 30.18 34.19 46.81 45.00 44.60 48.19 38.54 48.86 49.35 50.77 52.46 55.59 56.62
Relative Abundance

RT: 0.00 - 92.07
NL: 6.87E7 TIC MS LARC_IgG_Wa sh_150umID5u m300AMonMad eSP006_CHAR MED_Apr30

100 90 80 70 60 50 40 30 20 10 1.24 0 0 10 20 30 10.38 19.80 22.63

34.19

NL: 1.59E7 Base Peak MS LARC_IgG_Wash _150umID5um30 0AMonMadeSP0 06_CHARMED_ Apr30 46.81

Extracted from: C:\data_CHARMED\CHARMED_April2010\LARC_IgG CHARMED\LARC_IgG_Wash_150umID5um300AMonMadeSP006_CHARMED_Apr30.RAW #4236 RT: 57.38 ITMS, CID, z=+3, Mono m/z=904.16516 Da, MH+=2710.48093 Da, Match Tol.=0.8 Da 250 995.9195 885.3073 150 833.3497 100 1125.3192 1211.2473 1096.5107

200
Intens ity [counts ]

PKC Delta VIII
Relative Abundance

31.09 30.65

37.50 41.12

58.49

30.57 30.18 29.69

57.81 51.62 67.25 68.87 69.13 62.02 75.77 79.99 40 50 Time (min) 60 70 80

50

0
91.88 90

400

600

800

1000 m/z

1200

1400

1600

1800

RT: 0.00 - 99.99 100 90 80 70 60 50 60.49 40 30 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 3.77 38.24 60.84 62.18 37.69 36.60 27.37 32.69 16.38 17.25 20.06 62.44 64.15 64.66 66.22 73.43 82.99 84.37 90.17 42.32 41.73 38.39 44.77 52.43 42.91 53.48 NL: 1.17E8 TIC MS LARC_IgG_BE ADS_150umID5 um300AMonMa deSP006_STR ANGE_May3

RT: 0.00 - 99.99 100 90 80 38.39
57.37 59.06

44.77 47.24

49.42

NL: 9.46E6 Base Peak MS LARC_IgG_BEA DS_150umID5um 300AMonMadeS P006_STRANGE _May3

Extracted from: C:\data_STRANGE\APRIL_2010_STRANGE\LARC_IgG_STRANGE\LARC_IgG_BEADS_150umID5um300AMonMadeSP006_STRANGE_May3.RAW #2895 RT: 39.11 ITMS, CID, z=+3, Mono m/z=729.07007 Da, MH+=2185.19565 Da, Match Tol.=0.8 Da 5000 774.4006

4000
Intens ity [counts ]

PKC Epsilon
Relative Abundance

54.16
Relative Abundance

70 60 50 40 30 20 10 0.53 8.78 0 0 10 20 30 40 16.53 32.22 35.04

53.48

59.14

3000

678.1959

847.2888

2000
2+ b10 665.4305

61.59

1000
73.51

38.24 72.02 67.68

292.2131 0
82.99

y 1+ 3 403.1643 400

599.8039

870.5410

73.93 50 Time (min) 60 70 80

84.37 92.87 90

200

600

800 m/z

1000

1200

1400

RT: 0.00 - 89.31 100 90 80 70 60 50 40 30 20 10 4.22 8.41 13.99 0 0 10 20 30 40 50 Time (min) 60 70 80 15.42 28.00 33.93 56.58 62.44 38.99 50.22 38.65 38.35 55.36 55.63
Relative Abundance

RT: 0.00 - 89.31
44.07 52.50 39.15 52.37 52.87 NL: 1.77E8 TIC MS LARC2_oxLDL _400mMNaCl_ ZORBAX300A_ C18_5u_STRA NGE_May20

100 90 80 70

39.44 41.35

50.22

42.88

NL: 1.36E7 Base Peak MS LARC2_oxLDL_ 400mMNaCl_ZO RBAX300A_C18 _5u_STRANGE_ May20

Extracted from: C:\data_STRANGE\STRANGE_MAY2010\LARC2_oxLDL STRANGE\LARC2_oxLDL_400mMNaCl_ZORBAX300A_C18_5u_STRANGE_May20.RAW #4688 RT: 55.23 ITMS, CID, z=+3, Mono m/z=829.75415 Da, MH+=2487.24790 Da, Match Tol.=0.8 Da

1400 1200
Intens ity [counts ]

1065.8218

PKC Epsilon
Relative Abundance

1000 1122.9607 800 1000.0963 600 400 600.6428 357.2763 545.4570 797.9235
2+ y 15 914.9034

60 50 51.50 40 30 20 10 32.05 33.93 56.72 57.03 61.56 66.03 74.92 78.12 82.36 30 40 50 Time (min) 60 70 80 67.46 37.65

200 0

64.61 65.95 69.31

78.20 82.36

27.87 4.14 3.99 0 0 10 20 21.64

400

600

800 m/z

1000

1200

1400

1600

RT: 0.00 - 90.12 100 90 60.77 80 67.51 70 60 50 40 30 8.44 20 4.51 10 24.23 28.50 0 0 10 20 30 40 50 Time (min) 60 70 80 90 44.45 41.57 18.94 20.00 22.66 54.51 54.30 59.40
Relative Abundance

RT: 0.00 - 90.12
61.73 63.02 61.03 67.36 NL: 9.94E7 TIC MS LARC3_oxLDL _400mMNaCl_Z ORBAX300A_C 18_5u_STRAN GE_June18

100 90 80 70

59.40

67.28

NL: 9.91E6 Base Peak MS LARC3_oxLDL_4 00mMNaCl_ZOR BAX300A_C18_ 5u_STRANGE_J une18

Extracted from: C:\data_STRANGE\STRANNGE_JUNE2010\LARC3_oxLDL STRANGE\LARC3_oxLDL_400mMNaCl_ZORBAX300A_C18_5u_STRANGE_June18.RAW #5544 RT: 70.66 ITMS, CID, z=+3, Mono m/z=872.43848 Da, MH+=2615.30088 Da, Match Tol.=0.8 Da

140 120
Intens ity [counts ]

854.3654

PKC Epsilon
Relative Abundance

68.75 69.46 69.94 71.51 72.65 73.25 76.42 52.93 51.08 50.22 49.39

100 80 892.4346 60 40
2+ b13 743.0458

60 50 63.09 40 30 55.76 54.73 84.76

1039.5247 1126.4396

1371.5512

84.76

20 42.79 10 5.80 6.02 14.25 0 0 10 20 30 40 50 Time (min) 60 70 80 90 42.48 24.76 32.45 38.78 68.52 51.30 45.07 77.00 77.66

20 0 400 600 800 1000 m/z 1200 1400 1600

RT: 0.00 - 91.36 100 90 80 31.34 70 60 50 40 30 0.39 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 1.05 1.61 2.72 4.94 7.22 25.23 20.50 33.53 36.59 43.15 60.14 43.96 60.80 56.39 44.29 51.35 61.78 62.02 67.55
Relative Abundance

RT: 0.00 - 91.36
27.00 NL: 5.65E7 TIC MS LARC_oxLDL_7 00mMNaCl_NSI _150umMonMad eColumn_CHAR MED_Mar31

100 90 80 70

27.00

30.95

NL: 1.96E7 Base Peak MS LARC_oxLDL_70 0mMNaCl_NSI_15 0umMonMadeColu mn_CHARMED_ Mar31

Extracted from: C:\data_CHARMED\CHARMED_March2010\LARC_CHARMED\LARC_oxLDL_700mMNaCl_NSI_150umMonMadeColumn_CHARMED_Mar31.RAW #4208 RT: 56.90 ITMS, CID, z=+3, Mono m/z=639.03381 Da, MH+=1915.08689 Da, Match Tol.=0.8 Da 500

400
Intens ity [counts ]

582.2280

PKC Epsilon
Relative Abundance

60 30.55 33.29 50 40 30 20 10 0 0 3.96 6.50 10 20.10 19.60 15.60 20 30 40 50 Time (min) 60

300

200

36.59 36.84 41.61 44.12 60.47 60.05 60.80 61.29

2+ y 11 629.2922

779.3537 100 417.2668 0 544.3189 736.2387 600 m/z
80 90

827.8590

899.4683

68.52 68.77 86.18 86.91 79.60 84.72 77.22

51.67 56.39

62.66 67.63 70.17 70

85.04 85.60

200

400

800

1000

1200

98

Protein Kinase C
TIC
RT: 0.00 - 96.51 100 90 80 70 60 50 40 30 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 1.54 5.84 63.56 60.78 58.88 57.09 56.41 55.24 28.63 51.00 49.30 46.14 34.98 41.32 77.06 76.62 72.36 64.95 71.95 64.36 77.62 85.40 82.98 90.94 NL: 1.94E8 TIC MS LARC_oxLDL_2 00mMNaCl_NSI_ 150umMonMane Column_STRAN GE_March22

Base Peak
RT: 0.00 - 96.51 100 90 80 70 65.95
Relative Abundance

Spectrum
NL: 9.70E6 Base Peak MS LARC_oxLDL_200 mMNaCl_NSI_150 umMonManeColum n_STRANGE_Mar ch22

65.10 65.45

Extracted from: C:\data_STRANGE\STRANGE_MArch_2010\LARC_STRANGE\LARC_oxLDL_200mMNaCl_NSI_150umMonManeColumn_STRANGE_March22.RAW #5672 RT: 74.10 ITMS, CID, z=+3, Mono m/z=700.33459 Da, MH+=2098.98923 Da, Match Tol.=0.8 Da

800 700
Intens ity [counts ]

690.3132

PKC Zeta Isoform 1
Relative Abundance

600 500 400 300 200 100 0 200 400 600 800 m/z 1000 1200 1400 627.3812 568.8107 783.9996
2+ b15 911.8702

60 50 40 30 3.71 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 62.54 16.28 21.04 39.05 57.09 62.32 30.42 38.23 40.30 28.63 48.83 67.24 69.82 72.15 78.47

86.12 94.72

7.00

13.64

85.60

851.6572 927.6037

26.87 21.68 26.38

RT: 0.00 - 87.06 100 90 80 70 60 50 40 30 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 10.09 10.67 16.50 27.05 34.02 32.19 30.71 40.04 42.45 42.69 43.55 46.87 47.18 35.68 NL: 1.61E8 TIC MS LARC_oxLDL_7 00mMNaCl_NSI_ 150umMonMane Column_STRAN GE_March29

RT: 0.00 - 87.06 100 90 80 70
67.79 67.45 69.02 52.96 53.28 61.00 73.63 74.22 69.42 69.99
Relative Abundance

36.17 36.00

NL: 4.76E7 Base Peak MS LARC_oxLDL_700 mMNaCl_NSI_150 umMonManeColum n_STRANGE_Mar ch29

Extracted from: C:\data_STRANGE\STRANGE_MArch_2010\LARC_STRANGE\LARC_oxLDL_700mMNaCl_NSI_150umMonManeColumn_STRANGE_March29.RAW #3690 RT: 49.32 ITMS, CID, z=+3, Mono m/z=869.46204 Da, MH+=2606.37156 Da, Match Tol.=0.8 Da

700 600
Intens ity [counts ]

846.9589 859.8347 1085.6104 651.3904
1+ b13 1459.5519

PKC Zeta Isoform 1
Relative Abundance

60 43.39 50 40 30 20 55.47 10 5.29 0 0 10 20 30 40 50 Time (min) 60 70 80 11.34 17.04 31.13 33.46 55.72 61.40 74.05 74.63 75.28 80.32 42.99 44.03 44.19 52.63 54.42 55.14 68.29 68.86 67.79 69.42 69.83

500 400 300 200 100 0 400 600 800 586.2810 774.1674

77.53 80.57

947.4736 1000 m/z

b 2+ 21 1174.3381

1362.5682

1200

1400

1600

RT: 0.00 - 96.35 100 95 90 85 80 75 70 65 72.07 61.75 72.66 NL: 1.11E8 TIC MS LARC_IgG_DETE RGENT_150umID 5um300AMonMad eSP006_CHARME D_May3

RT: 0.00 - 96.35 100 95 90 85 80 75 70 65
58.86

72.57

72.15

NL: 2.51E7 Base Peak MS LARC_IgG_DETER GENT_150umID5u m300AMonMadeSP 006_CHARMED_Ma y3

Extracted from: C:\data_CHARMED\CHARMED_April2010\LARC_IgG CHARMED\LARC_IgG_DETERGENT_150umID5um300AMonMadeSP006_CHARMED_May3.RAW #2662 RT: 35.96 ITMS, CID, z=+3, Mono m/z=751.74036 Da, MH+=2253.20652 Da, Match Tol.=0.8 Da

400 782.5792
Intens ity [counts ]

300

Relative Abundance

60 55 50 45 40 35 30 25 20 15 10 5 0 0 10 20 30 40 34.24 8.29 15.72 18.65 38.18 45.17 47.28

Relative Abundance

60 55 50 45 40 35 30 58.86 58.17 66.58 49.18 53.96 73.68 61.83

y 1+ 5 687.4740
2+ b17 903.7095 1+ 953.7115b10 1017.27511052.7616 1117.3919

PKC Eta

200 y 1+ 4 574.3985 100 b1+ 3 346.3560 0 200 400 445.3820 b1+ 4 726.0569 839.1116

55.75 53.96 66.50

73.34 75.14 78.00 82.84

25 20 15 10 5 0 0 7.97 10 9.33 20 28.77 38.09 45.09

518.9723 600 800 m/z

75.14 81.17 82.84

1000

1200

1400

50 Time (min)

60

70

80

90

30

40

50 Time (min)

60

70

80

90

RT: 0.00 - 100.02 100 90 80 70
Relative Abundance

RT: 0.00 - 100.02
34.41 33.82 33.62 NL: 1.65E8 TIC MS LARC_IgG_200 mMNaCl_150umI D5um300AMonM adeSP006_CHA RMED_Apr27

100 90 80 70

34.41

35.58

41.53 46.64 64.67

NL: 1.44E7 Base Peak MS LARC_IgG_200m MNaCl_150umID5 um300AMonMade SP006_CHARME D_Apr27

Extracted from: C:\data_CHARMED\CHARMED_April2010\LARC_IgG CHARMED\LARC_IgG_200mMNaCl_150umID5um300AMonMadeSP006_CHARMED_Apr27.RAW #3780 RT: 49.70 ITMS, CID, z=+3, Mono m/z=875.77173 Da, MH+=2625.30063 Da, Match Tol.=0.8 Da

300 857.3810 250
Intens ity [counts ]

35.07
Relative Abundance

PKC Iota

60 50 40 30 20 10 10.75 0 0 10 20 30 40 50 Time (min) 60 70 80 90 13.26 16.41 32.46 35.94 38.15 46.64 47.51 50.07 51.22 53.06 54.14 57.04 64.67 69.61 72.82 73.94 79.80

60 50 40 33.82 30 20 10 33.62 48.39 56.45 73.94 15.68 3.84 12.63 0 10 20 25.20 30 40 50 Time (min) 60 70 79.80 80 80.38 92.43 90 100 69.61 58.74

200 150 802.4477 100 50 0 400 600 800 1000 m/z 1200 1400 1600 963.3143 1103.2783 1127.5759

988.8345

92.34 95.50

0
100

99

Phosphoinositide 3-kinase
TIC
RT: 0.00 - 100.02 100 90 80 70
Relative Abundance

Base Peak
RT: 0.00 - 100.02
NL: 1.22E8 TIC MS LARC2_CD36_I gA_U937LIVEcel l_250mMNaCl_Z orbax_STRANG E_Nov17

Spectrum
NL: 4.48E6 Base Peak MS LARC2_CD36_Ig A_U937LIVEcell_2 50mMNaCl_Zorba x_STRANGE_Nov 17

21.52 21.99 21.15

100 90 80 70

21.45 52.95 57.72

Extracted from: C:\data_STRANGE\STRANGE_NOVEMBER_2010\LARC2_CD36_IgA_U937LIVEcell_STRANGE\LARC2_CD36_IgA_U937LIVEcell_250mMNaCl_Zorbax_STRANGE_Nov17.RAW #2153 RT: 28.66 ITMS, CID, z=+2, Mono m/z=606.86108 Da, MH+=1212.71489 Da, Match Tol.=0.5 Da

70 60
Intens ity [counts ]

2.97

y 1+ 5 589.3494

PI3KCA

60 50 28.22 40 30 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 4.03 10.89 20.00 33.66 28.77 50.87 48.88 48.17 45.99 43.98 41.60 53.62 57.25 61.79 62.12 67.25 52.95

Relative Abundance

50 40 30 20 547.0300 507.4169 353.1451 424.2626 748.6154 808.6603 608.0487

60 50 40 30 20 10 0 8.72 12.03 44.48 44.98 44.15 51.02 41.68 39.68 40 50 Time (min) 60 70 80 62.83 81.34 76.23 71.03 89.17 90.79 90 100 88.16

68.83 67.25

23.08

10 0 200 400 600 m/z 800 1000 1200

73.20 81.89 84.62 88.09 91.18 100

23.40 29.08 20 30

0

10

RT: 0.00 - 95.12 100 90 80 70
Relative Abundance

RT: 0.00 - 95.12
32.32 NL: 2.12E8 TIC MS LARC2_CD36_Ig A_U937LIVEcell_ 450mMNaCl_Zor bax_STRANGE_ Nov18_2

100 90 80 70

34.05

NL: 1.33E7 Base Peak MS LARC2_CD36_IgA _U937LIVEcell_45 0mMNaCl_Zorbax_ STRANGE_Nov18 _2

Extracted from: C:\data_STRANGE\STRANGE_NOVEMBER_2010\LARC2_CD36_IgA_U937LIVEcell_STRANGE\LARC2_CD36_IgA_U937LIVEcell_450mMNaCl_Zorbax_STRANGE_Nov18_2.RAW #2993 RT: 38.60 ITMS, CID, z=+3, Mono m/z=718.01453 Da, MH+=2152.02903 Da, Match Tol.=0.5 Da 250

200
Intens ity [counts ]

700.3302

PIK3CB

60 50 33.29 40 30 20 2.02 4.46 11.91 10 14.33 0 0 10 20 30 40 50 Time (min) 60 70 80 90 31.70 29.94 37.48 39.20 47.59 43.63 50.16 57.44 57.99 67.32 73.10 75.55 80.81

Relative Abundance

60 50 40 30 20 10 0 0 1.94 6.92 10 15.40 27.55 31.55 20 30 40 50 Time (min) 33.16 32.32 46.69 37.71 43.63 47.25 50.24 66.24 60 69.70 55.15 33.73 33.35 57.44

150

100 b1+ 4 451.2351 602.4722 659.3944

50

717.3387

b1+ 7 865.3799

1011.2165

0
80.19 83.22 87.22 70 80 90

87.22

200

400

600

800 m/z

1000

1200

1400

RT: 0.00 - 89.49 100 90 80 70
Relative Abundance

RT: 0.00 - 89.49
31.92 NL: 3.96E8 TIC MS LARC_CD36_Ig A_U937livecell_1 50mMNaCl__Zor bax_STRANGE_ Oct21

100 90 80 70

33.99

NL: 1.98E7 Base Peak MS LARC_CD36_IgA _U937livecell_150 mMNaCl__Zorbax _STRANGE_Oct2 1

Extracted from: C:\data_STRANGE\STRANGE_OCTOBER_2010\LARC_CD36_IgA_U937LIVEcell_STRANGE\LARC_CD36_IgA_U937livecell_150mMNaCl__Zorbax_STRANGE_Oct21.RAW #971 RT: 12.73 ITMS, CID, z=+2, Mono m/z=401.07425 Da, MH+=801.14122 Da, Match Tol.=0.5 Da

8000 7000
Intens ity [counts ]

y 1+ 5 574.2720

PIK3CB

60 50 40 30 20 10 0 0 10 20 30 11.96 12.83 15.62

32.20

Relative Abundance

6000 5000 4000 3000 2000 227.0000
1+

60 50 40 31.92 30 20 10 0 31.32 45.01 52.60 12.83 12.21 30.29 13.26 25.57 0 10 20 30 38.61 50.33 40 50 Time (min) 62.68 60 63.24 63.55 70.97 79.90 74.23 70 32.55 37.90 54.69

32.49 33.38 33.99 35.14

9.98

31.40 28.92

38.04 38.96 40.47 45.01 54.69 50.16 55.20 63.24 65.07 79.90 81.24 82.25 40 50 Time (min) 60 70 80

b 1 199.1057 1000 129.0190 0
81.07 89.46 80

391.7685 332.1942 356.1026

y 1+ 4 445.1946

687.3105 672.3917

100

200

300

400 m/z

500

600

700

800

RT: 0.00 - 100.05 100 90 80 6.17 70
Relative Abundance

RT: 0.00 - 100.05
36.85 34.90 32.87 27.89 26.79 39.42 NL: 5.54E7 TIC MS LARC_CD36_Ig A_U937livecell_3 00mMNaCl__Zor bax_STRANGE_ Oct22

100 90 80 70

34.97

40.21 40.71
Relative Abundance

NL: 1.30E7 Base Peak MS LARC_CD36_IgA _U937livecell_300 mMNaCl__Zorbax _STRANGE_Oct2 2

Extracted from: C:\data_STRANGE\STRANGE_OCTOBER_2010\LARC_CD36_IgA_U937LIVEcell_STRANGE\LARC_CD36_IgA_U937livecell_300mMNaCl__Zorbax_STRANGE_Oct22.RAW #1227 RT: 16.25 ITMS, CID, z=+2, Mono m/z=387.74396 Da, MH+=774.48064 Da, Match Tol.=0.5 Da

160 140
Intens ity [counts ]

378.4755

PIK3CB

60 50 40 30 20 10 0 0

7.85 8.26 8.77 22.67

120 100 80 60 40 20 517.3646 472.0307 757.9701 y 2+ 6 304.2329 322.5882 429.0299

41.98 46.58

60 50 40 30

27.89 39.42 25.25

9.80

22.12

57.06 47.48 48.33 54.83

24.45 32.82 46.58 57.14

65.79 21.16 11.99

66.72 81.31

20
84.22 89.27 96.56

54.83 22.67 43.20 52.48 30 40 50 Time (min)

65.79 73.80 77.12 70 80 84.13 92.57 96.63 90 100

10 3.40 6.33 0 21.08 20

0 100 200 300 400 m/z 500 600 700

65.08 60

10

20

30

40

50 Time (min)

60

70

80

90

100

0

10

RT: 0.00 - 110.06 100 90 80 70
Relative Abundance

RT: 0.00 - 110.06
27.40 32.38 32.62 43.15 45.52 37.78 45.92 47.13
Relative Abundance

57.96

NL: 2.98E7 TIC MS LARC_oxLDL_5 50mMNaCl_NSI _150umMonMad eColumn_CHAR MED_Mar30

100 90 80 70

27.40 27.06 27.65

34.85

NL: 9.44E6 Base Peak MS LARC_oxLDL_55 0mMNaCl_NSI_15 0umMonMadeColu mn_CHARMED_ Mar30

Extracted from: C:\data_CHARMED\CHARMED_March2010\LARC_CHARMED\LARC_oxLDL_550mMNaCl_NSI_150umMonMadeColumn_CHARMED_Mar30.RAW #3567 RT: 48.37 ITMS, CID, z=+2, Mono m/z=846.95532 Da, MH+=1692.90337 Da, Match Tol.=0.8 Da

2000
35.08
Intens ity [counts ]

b1+ 7 774.1345

26.57

PIK3CB

60 50 40 24.51 30 20 0.54 5.80 10 0 0 10 20 30 40 22.74 21.51 20.50 15.16

62.85 63.67 63.91 64.15 64.48 65.61 66.18 87.07 88.20 88.86 90.41 92.47

60 45.43 50 40 30 20 24.89 10 0.54 3.04 0 49.74 22.74 20.73 20 30 40 50 60 Time (min) 65.61 72.40 70

1500 829.3947 1000
2+ y 13 717.0501

25.76

1061.5176 y 1+ 13 1432.6112

57.96 25.76 46.57

62.85 63.67 64.15 64.48 64.88

109.67

500

632.3514

1319.6464

66.83 68.23 72.23 83.00 50 60 Time (min) 70 80 90

87.23 87.96 88.78 86.26 98.55 80 90 100 110

0 400 600 800 1000 m/z 1200 1400 1600

100

110

0

10

RT: 0.00 - 95.12 100 90 80 70
Relative Abundance

RT: 0.00 - 95.12
32.32 NL: 2.12E8 TIC MS LARC2_CD36_Ig A_U937LIVEcell_ 450mMNaCl_Zor bax_STRANGE_ Nov18_2

100 90 80 70

34.05

NL: 1.33E7 Base Peak MS LARC2_CD36_IgA _U937LIVEcell_45 0mMNaCl_Zorbax_ STRANGE_Nov18 _2

Extracted from: C:\data_STRANGE\STRANGE_NOVEMBER_2010\LARC2_CD36_IgA_U937LIVEcell_STRANGE\LARC2_CD36_IgA_U937LIVEcell_450mMNaCl_Zorbax_STRANGE_Nov18_2.RAW #2993 RT: 38.60 ITMS, CID, z=+3, Mono m/z=718.01453 Da, MH+=2152.02903 Da, Match Tol.=0.5 Da 250

200
Intens ity [counts ]

700.3302

PIK3CB

60 50 33.29 40 30 20 2.02 4.46 11.91 10 14.33 0 0 10 20 30 40 50 Time (min) 60 70 80 90 31.70 29.94 37.48 39.20 47.59 43.63 50.16 57.44 57.99 67.32 73.10 75.55 80.81

Relative Abundance

60 50 40 30 20 10 0 0 1.94 6.92 10 15.40 27.55 31.55 20 30 40 50 Time (min) 33.16 32.32 46.69 37.71 43.63 47.25 50.24 66.24 60 69.70 55.15 33.73 33.35 57.44

150

100 b1+ 4 451.2351 602.4722 659.3944

50

717.3387

b1+ 7 865.3799

1011.2165

0
80.19 83.22 87.22 70 80 90

87.22

200

400

600

800 m/z

1000

1200

1400

100

Phosphoinositide 3-kinase
TIC
RT: 0.00 - 89.49 100 90 80 70
Relative Abundance

Base Peak
RT: 0.00 - 89.49
NL: 3.96E8 TIC MS LARC_CD36_Ig A_U937livecell_1 50mMNaCl__Zor bax_STRANGE_ Oct21

Spectrum
NL: 1.98E7 Base Peak MS LARC_CD36_IgA _U937livecell_150 mMNaCl__Zorbax _STRANGE_Oct2 1

31.92

100 90 80 70

33.99

Extracted from: C:\data_STRANGE\STRANGE_OCTOBER_2010\LARC_CD36_IgA_U937LIVEcell_STRANGE\LARC_CD36_IgA_U937livecell_150mMNaCl__Zorbax_STRANGE_Oct21.RAW #971 RT: 12.73 ITMS, CID, z=+2, Mono m/z=401.07425 Da, MH+=801.14122 Da, Match Tol.=0.5 Da

8000 7000
Intens ity [counts ]

y 1+ 5 574.2720

PIK3CB

60 50 40 30 20 10 0 0 10 20 30 11.96 12.83 15.62

32.20

Relative Abundance

6000 5000 4000 3000 2000 227.0000
1+

60 50 40 31.92 30 20 10 0 31.32 45.01 52.60 12.83 12.21 30.29 13.26 25.57 0 10 20 30 38.61 50.33 40 50 Time (min) 62.68 60 63.24 63.55 70.97 79.90 74.23 70 32.55 37.90 54.69

32.49 33.38 33.99 35.14

9.98

31.40 28.92

38.04 38.96 40.47 45.01 54.69 50.16 55.20 63.24 65.07 79.90 81.24 82.25 40 50 Time (min) 60 70 80

b 1 199.1057 1000 129.0190 0
81.07 89.46 80

391.7685 332.1942 356.1026

y 1+ 4 445.1946

687.3105 672.3917

100

200

300

400 m/z

500

600

700

800

RT: 0.00 - 100.05 100 90 80 6.17 70
Relative Abundance

RT: 0.00 - 100.05
36.85 34.90 32.87 27.89 26.79 39.42 NL: 5.54E7 TIC MS LARC_CD36_Ig A_U937livecell_3 00mMNaCl__Zor bax_STRANGE_ Oct22

100 90 80 70

34.97

40.21 40.71
Relative Abundance

NL: 1.30E7 Base Peak MS LARC_CD36_IgA _U937livecell_300 mMNaCl__Zorbax _STRANGE_Oct2 2

Extracted from: C:\data_STRANGE\STRANGE_OCTOBER_2010\LARC_CD36_IgA_U937LIVEcell_STRANGE\LARC_CD36_IgA_U937livecell_300mMNaCl__Zorbax_STRANGE_Oct22.RAW #1227 RT: 16.25 ITMS, CID, z=+2, Mono m/z=387.74396 Da, MH+=774.48064 Da, Match Tol.=0.5 Da

160 140
Intens ity [counts ]

378.4755

PIK3CB

60 50 40 30 20 10 0 0

7.85 8.26 8.77 22.67

120 100 80 60 40 20 517.3646 472.0307 757.9701
2+ y6 304.2329 322.5882

41.98 46.58

60 50 40 30

27.89 39.42 25.25

429.0299

9.80

22.12

57.06 47.48 48.33 54.83

24.45 32.82 46.58 57.14

65.79 21.16 11.99

66.72 81.31

20
84.22 89.27 96.56

54.83 22.67 43.20 52.48 30 40 50 Time (min)

65.79 73.80 77.12 70 80 84.13 92.57 96.63 90 100

10 3.40 6.33 0 21.08 20

0 100 200 300 400 m/z 500 600 700

65.08 60

10

20

30

40

50 Time (min)

60

70

80

90

100

0

10

RT: 0.00 - 91.52 100 90 80 70
Relative Abundance

RT: 0.00 - 91.52
27.18 NL: 2.18E8 TIC MS LARC_CD36_Ig A_U937livecell_3 50mMNaCl__Zor bax_STRANGE_ Oct22

100 90 80

27.98

34.77

NL: 1.30E7 Base Peak MS LARC_CD36_IgA _U937livecell_350 mMNaCl__Zorbax _STRANGE_Oct2 2

Extracted from: C:\data_STRANGE\STRANGE_OCTOBER_2010\LARC_CD36_IgA_U937LIVEcell_STRANGE\LARC_CD36_IgA_U937livecell_350mMNaCl__Zorbax_STRANGE_Oct22.RAW #2435 RT: 30.71 ITMS, CID, z=+3, Mono m/z=623.00354 Da, MH+=1866.99607 Da, Match Tol.=0.5 Da

16000 14000
Intens ity [counts ]

29.01 70 27.58

39.26

2+ y 10 605.3402

12000 10000 8000 6000 4000 y 1+ 6 784.3140 566.4471 311.2282 b1+ 7 769.2506 600 m/z 800 998.3917 y 1+ 7 897.2166 982.2875 1000 1200

PIK3CB

60 27.58 50 40 30 20 2.10 6.12 8.29 10 12.25 15.66 0 0 10 20 30 40 50 Time (min) 60 70 80 28.52 34.77 39.26 40.30 41.75 46.41 48.34 54.66 61.05 66.46 72.19 83.80 28.04

Relative Abundance

60 50 40 30 20 10 3.44 0 9.12 10.61 10 20 25.96 30 40 43.07 52.40 50 Time (min) 65.13 60 65.92 27.18 46.49 54.66 56.87 65.60 82.71 83.80 81.05 70 80 91.33 90

2000 0 200

400

90

0

RT: 0.00 - 90.37 100 90 80 70
Relative Abundance
Relative Abundance

RT: 0.00 - 90.37
31.86 NL: 2.38E8 TIC MS LARC_CD36_Ig A_U937livecell_8 00mMNaCl__Zor bax_STRANGE_ Oct26

100 90 80 70

32.03

NL: 1.38E7 Base Peak MS LARC_CD36_IgA _U937livecell_800 mMNaCl__Zorbax _STRANGE_Oct2 6

Extracted from: C:\data_STRANGE\STRANGE_OCTOBER_2010\LARC_CD36_IgA_U937LIVEcell_STRANGE\LARC_CD36_IgA_U937livecell_800mMNaCl__Zorbax_STRANGE_Oct26.RAW #1173 RT: 15.59 ITMS, CID, z=+2, Mono m/z=387.29196 Da, MH+=773.57665 Da, Match Tol.=0.5 Da

200
Intens ity [counts ]

377.9708

PIK3CB

60 50 40 32.39 30 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 6.48 9.45 10.03 11.17 11.64 32.89 33.82 34.40 30.80 15.42 39.59 43.26 47.01 50.36 57.24 58.69 66.65 69.26 82.93

60 50 40 33.75 30 20 10 31.17 0
90

150

32.64 57.24 42.55 46.92

100 y 1+ 2 326.9817 288.0624 243.0794 530.5717 487.4552 y 1+ 3 453.2802 403.3622

35.51 39.59

55.12

50

52.09 6.40 9.95 21.70 26.10 0 10 20 30 40 50 Time (min) 60

82.93 84.18 66.65 69.33 73.74 70 80 90

0 100 200 300 400 m/z 500 600 700

RT: 0.00 - 94.86 100 90 13.92 80 33.31 35.37 70
Relative Abundance

RT: 0.00 - 94.86
32.69 32.34 NL: 2.00E8 TIC MS LARC_CD36_IgG_ U937LiveCell_350m MNaCl_Zorbax_ST RANGE_Nov5_101 105143835

100 90 80 70

32.75

NL: 1.74E7 Base Peak MS LARC_CD36_IgG_U 937LiveCell_350mM NaCl_Zorbax_STRAN GE_Nov5_10110514 3835

Extracted from: \\Sun\labprojects\CD36\Larc_WorkingCopy\3_LARC_antiCD36_IgG\LARC_CD36_IgG_U937LiveCell_350mMNaCl_Zorbax_STRANGE_Nov5_101105143835.raw #1225 RT: 16.14 ITMS, CID, z=+2, Mono m/z=388.36426 Da, MH+=775.72124 Da, Match Tol.=0.5 Da 700 600
Intens ity [counts ]

b1+ 4 371.1358

35.44

500 400 379.0180 300 200

PIK3CB

60 50 40 30 20 5.10 6.67 10 15.72 0 0 10 20 30 40 50 Time (min) 60 70 80 90 31.61 37.75 40.57 41.89 44.41 36.44 36.99

Relative Abundance

60 32.28 50 40 30 43.78 20 13.92 41.10 10 6.43 13.50 0 0 10 25.14 31.46 20 30 40 50 Time (min) 60 70 52.00 53.32 62.43 47.15 53.96 59.23

313.2328 100
74.62 79.46 80.17 87.72 80 90 71.58 70.03

328.1381

53.32 53.88

y4 561.1990 516.2970 400 m/z 500 600 700

1+

74.62 63.87 69.41 75.16 80.17 83.93

0 100 200 300

RT: 0.00 - 100.03 100 90 60.09 80 13.22 70
Relative Abundance

RT: 0.00 - 100.03
60.39 NL: 1.25E8 TIC MS LARC_CD36_Ig G_U937LIVEcell _400mMNaCl_Z ORBAX_CHAR MED_Nov15

100 90 80 70

60.45

60.76

NL: 1.87E7 Base Peak MS LARC_CD36_IgG _U937LIVEcell_40 0mMNaCl_ZORB AX_CHARMED_N ov15

Extracted from: C:\data_CHARMED\CHARMED_NOVEMBER2010\LARC_CD36_IgG_U937LIVEcells_CHARMED\LARC_CD36_IgG_U937LIVEcell_400mMNaCl_ZORBAX_CHARMED_Nov15.RAW #3606 RT: 45.81 ITMS, CID, z=+2, Mono m/z=388.17538 Da, MH+=775.34349 Da, Match Tol.=0.5 Da 200 b1+ 4 371.2634 150
Intens ity [counts ]

59.46 63.14
Relative Abundance

63.14

PIK3CB

60 50 40 30 20 6.08 10 25.15 29.85 42.02 0 0 10 20 30 40 50 Time (min) 60 70 80 90 19.99 57.78 50.93 46.89

60 50 40 30 13.28 72.79 78.56 59.78

100

379.5129 y 1+ 4 516.3400 497.8835 605.3311

20.82

63.94 67.97 72.79 78.64 80.95 84.84

59.46

50

346.0414 312.1181

20 10 1.68 12.13 0
100

86.69 89.24 95.94

14.35 23.71 26.82 31.14 20 30 40

69.87 57.78 50.69 51.47 50 Time (min) 60 70 80

83.69 85.00 88.17 90 100

0 100 200 300 400 m/z 500 600 700

0

10

101

Phosphoinositide 3-kinase
TIC
RT: 0.00 - 86.57 100 90 54.01 80 70
Relative Abundance

Base Peak
RT: 0.00 - 86.57
54.19 NL: 1.91E8 TIC MS LARC2_oxLDL _50mMNaCl_Z ORBAX300A_ C18_5u_STRA NGE_May19

Spectrum
NL: 1.28E7 Base Peak MS LARC2_oxLDL_ 50mMNaCl_ZOR BAX300A_C18_ 5u_STRANGE_ May19

100 90 80 70

54.19

Extracted from: C:\data_STRANGE\STRANGE_MAY2010\LARC2_oxLDL STRANGE\LARC2_oxLDL_50mMNaCl_ZORBAX300A_C18_5u_STRANGE_May19.RAW #3400 RT: 42.31 ITMS, CID, z=+3, Mono m/z=438.60904 Da, MH+=1313.81256 Da, Match Tol.=0.8 Da

55.51 57.13

1600 1400
Intens ity [counts ]

53.83

54.60

64.80

428.9157

63.85 55.33 57.84 42.57 46.80 42.11 41.88 41.30 65.83
Relative Abundance

1200 1000 800 600 421.1603 400 200 0 200 300 400 500 m/z 600 700 800 y 1+ 3 316.7968 381.3074 517.5444 577.4659 527.6217 658.4852

PIK3CB

60 50 40 30 20 10 3.93 12.28 12.95 13.80 0 0 10 20 30 40 50 Time (min) 25.89 33.00 38.14

60 50 40

46.91 47.74

66.34 66.82 68.42 71.04

57.84 64.10 30 42.74 53.65 58.29 71.83 79.65 10 4.01 0 19.77 23.70 32.93 38.07 9.78 18.49 10 20 30 40 50 Time (min) 60 70 80 68.42 75.54 85.48

75.54 76.11 84.70

20

42.11

60

70

80

0

RT: 0.00 - 96.86 100 90 80 70
Relative Abundance

RT: 0.00 - 96.86
94.66 NL: 2.32E7 TIC MS LARC4_oxLDL_ 700mMNaCl_ZO RBAX5um_300 Acolumn_CHAR MED_Aug23

100 90 80 70

21.36 22.05 21.10 20.75 23.46 24.34 25.18 25.61 26.70 59.40 27.20 29.49 87.66 82.59 83.27 81.69 78.88 77.30 31.15 34.48 67.56 38.27 61.75 52.44

93.31

94.58 NL: 4.20E6 Base Peak MS LARC4_oxLDL_7 00mMNaCl_ZOR BAX5um_300Acol umn_CHARMED_ Aug23 93.38 88.36

Extracted from: C:\data_CHARMED\CHARMED_Aug2010\LARC4_oxLDL_CHARMED_optParameters\LARC4_oxLDL_700mMNaCl_ZORBAX5um_300Acolumn_CHARMED_Aug23.RAW #6362 RT: 81.16 ITMS, CID, z=+2, Mono m/z=388.08017 Da, MH+=775.15306 Da, Match Tol.=0.5 Da

500 378.4445 400
Intens ity [counts ]

PIK3CB

60 50 40 30 20 10 0 0

Relative Abundance

9.44 10.06 9.12 8.57 5.05 10.53 13.32

91.26

60 50 40 30 20 10 0 2.34 2.65 10.37 14.41 0 10 20 29.42 30 38.95 40 46.68 58.65 50 Time (min) 59.40 60

300

355.1155

83.35 82.67 82.14 81.61

200 y 1+ 1 175.0784 y 1+ 2 288.1683 b1+ 5 480.2361 486.2893 530.6599 445.2721

100

0
78.96 72.31 76.69 70 80 90

100

200

300

400 m/z

500

600

700

10

20

30

40

50 Time (min)

60

70

80

90

102

HMGCR
TIC
RT: 0.00 - 103.10 100 90 80 70
Relative Abundance

Base Peak
RT: 0.00 - 103.10
NL: 2.07E8 TIC MS LARC_oxLDL_2 00mMNaCl_NSI _150umMonMad eColumn_CHAR MED_Mar23

Spectrum
NL: 4.92E6 Base Peak MS LARC_oxLDL_20 0mMNaCl_NSI_15 0umMonMadeColu mn_CHARMED_ Mar23

61.73 60.86

100 90 80 70

40.36 40.59

Extracted from: C:\data_CHARMED\CHARMED_March2010\LARC_CHARMED\LARC_oxLDL_200mMNaCl_NSI_150umMonMadeColumn_CHARMED_Mar23.RAW #5144 RT: 68.88 ITMS, CID, z=+3, Mono m/z=488.58801 Da, MH+=1463.74948 Da, Match Tol.=0.8 Da

10000 473.1864 8000
Intens ity [counts ]

60.03 59.82

43.72 50.07 52.63 57.56 29.50 30.58 36.86

HMGCR

60 50 40 30 20 10 0 0 10 20 30 40 50 Time (min) 60 0.97 2.50 12.77

Relative Abundance

731.4428 6000 y 2+ 7 415.9546 366.0729

64.92 66.37 68.00 69.72 71.38

60 50 40 30 20 10 0

2.41 3.09 28.87 9.02 21.63 25.80

81.75

58.74

80.77

4000

238.2885

530.3674 644.4676

59.75 60.86 66.09 67.48 79.57 75.74 81.90 86.06

82.76 91.83 93.15 94.56

2000
99.53

0 200 300 400 500 m/z 600 700 800 900

28.48 29.58

40.59

50.41

70

80

90

100

0

10

20

30

40

50 Time (min)

60

70

80

90

100

RT: 0.00 - 92.20 100 90 80 70 60.42
Relative Abundance

RT: 0.00 - 92.20
56.66 NL: 3.25E8 TIC MS LARC2_oxLDL _TRPBEADS_ ZORBAX300A _C18_5u_STR ANGE_May26

100 90 80 70

56.26 58.19

NL: 2.07E7 Base Peak MS LARC2_oxLDL_ TRPBEADS_ZO RBAX300A_C18 _5u_STRANGE_ May26

Extracted from: C:\data_STRANGE\STRANGE_MAY2010\LARC2_oxLDL STRANGE\LARC2_oxLDL_TRPBEADS_ZORBAX300A_C18_5u_STRANGE_May26.RAW #6574 RT: 79.18 ITMS, CID, z=+3, Mono m/z=785.75891 Da, MH+=2355.26218 Da, Match Tol.=0.8 Da

50 767.4932 40
Intens ity [counts ]

52.77 49.88 44.92

61.18 67.68

HMGCR

60 52.65 50 52.14 40 30 20 10 0 0 6.22 11.66 15.76 20.84 31.38 34.94 44.92 45.09 67.68 71.18 44.40 44.17 43.62 71.91 61.93

Relative Abundance

60 50

30

71.18 40 62.12 30 20 44.35 87.37 77.03 81.68 43.81 1.93 4.44 0 10 15.53 18.34 20 33.20 35.24 42.89 30 40 50 Time (min) 60 70 80 90

2+ y 18 935.2922 892.4136

20

728.9482

1010.2070 1056.7831

10

460.5898

75.64

76.40 78.21 87.37

10 0

0 400 600 800 m/z 1000 1200 1400

10

20

30

40

50 Time (min)

60

70

80

90

RT: 0.00 - 97.00 100 90 80 70
Relative Abundance

RT: 0.00 - 97.00
83.74 82.92 79.60 74.87 74.65 72.66
Relative Abundance

87.61 88.48

NL: 1.52E8 TIC MS 89.20 LARC_oxLDL_1 90.94 50mMNaCl_NSI _150umMonMad 91.09 eColumn_CHAR MED_Mar22

100 90 80 70 60 50 63.71 40 30 20 10 0 19.01 30.10 30.84 37.14 40.43 11.44 15.78 58.54 63.18 87.17 84.79 63.96

88.55 88.92 89.20 75.58 73.57 75.99 89.72 67.41 76.34

87.61

NL: 5.60E6 Base Peak MS LARC_oxLDL_15 0mMNaCl_NSI_15 0umMonMadeColu mn_CHARMED_ Mar22

Extracted from: C:\data_CHARMED\CHARMED_March2010\LARC_CHARMED\LARC_oxLDL_150mMNaCl_NSI_150umMonMadeColumn_CHARMED_Mar22.RAW #3202 RT: 43.46 ITMS, CID, z=+3, Mono m/z=488.58707 Da, MH+=1463.74665 Da, Match Tol.=0.8 Da 300 250
Intens ity [counts ]

402.9889 479.0945 470.9541

200 150 100 50 0 200 300
2+ y6 358.8489

HMGCR

60 50 40 30 20 10 0.16 5.38 0 0 10 20 30 40 50 Time (min) 8.45 23.85 24.83 42.75

66.05 70.33 63.96 63.18 57.68 58.54 57.27 56.95 55.33 54.52 52.74 51.58 50.35

90.07 90.43 90.80

556.2071

653.9481

51.91 57.68 51.75

b1+ 7 734.4855 748.4766

400

500 m/z

600

700

800

900

60

70

80

90

0

10

20

30

40

50 Time (min)

60

70

80

90

103

Janus Kinases
TIC
RT: 0.00 - 90.93 100 90 80 70 29.00
Relative Abundance

Base Peak
RT: 0.00 - 90.93
NL: 1.12E8 TIC MS LARC_IgG_350 mMNaCl_150umI D5um300AMonM adeSP006_CHA RMED_Apr27

Spectrum
NL: 2.64E7 Base Peak MS LARC_IgG_350m MNaCl_150umID5 um300AMonMade SP006_CHARME D_Apr27

30.95 34.41 41.74 30.59 39.97 41.98
Relative Abundance

100 90 80 70

34.48

Extracted from: C:\data_CHARMED\CHARMED_April2010\LARC_IgG CHARMED\LARC_IgG_350mMNaCl_150umID5um300AMonMadeSP006_CHARMED_Apr27.RAW #3361 RT: 43.65 ITMS, CID, z=+3, Mono m/z=835.76233 Da, MH+=2505.27243 Da, Match Tol.=0.8 Da

30.95

500 817.3526 400 300 797.9178 200 100 0 400 600 800 729.3519 899.4298

2+ y 19 1073.6201

49.14

41.74 60 50 28.92 40 30 20 45.03 56.87

JAK1

60 50 28.70 40 30 20 58.08 62.68 68.19 10 6.22 6.72 0 0 10 20 30 40 50 Time (min) 60 21.90 22.57 50.83 51.25 56.87 49.31 49.81

Intens ity [counts ]

1000.7001

37.39 49.14

1177.4526

68.52 74.26 78.36 84.31 70 80 90

10 0 0

28.55 6.72 9.01 21.65 22.57 10 20 30 40 50.75 50 Time (min)

66.67

67.93 74.26 78.28 70 80 80.53 90

1000 m/z

1200

1400

1600

60

RT: 0.00 - 100.06 100 90 34.62 80 70
Relative Abundance

RT: 0.00 - 100.06
35.72 36.36 38.82 41.55 44.80 49.64 NL: 1.28E8 TIC MS LARC2_oxLDL_T RPBEADS_150u mID5um300AMon MadeSP006_CH ARMED_May27

100 90 80 70 34.68 32.91 36.42

41.55 44.80

NL: 2.47E7 Base Peak MS LARC2_oxLDL_TR PBEADS_150umID 5um300AMonMade SP006_CHARMED _May27

Extracted from: C:\data_CHARMED\CHARMED_MAY2010\LARC2_oxLDL_CHARMED\LARC2_oxLDL_TRPBEADS_150umID5um300AMonMadeSP006_CHARMED_May27.RAW #1702 RT: 21.67 ITMS, CID, z=+2, Mono m/z=365.23093 Da, MH+=729.45458 Da, Match Tol.=0.8 Da 3000 2500
Intens ity [counts ]

476.0985

33.99 60 50 32.91

Relative Abundance

JAK1

51.13 51.99 52.41 52.76 53.54

2000 1500 1000 500 b1+ 3 356.3138 467.0681 419.6266 400 m/z 500 511.5940 y 1+ 5 582.4271 615.5082 600 700

60 46.99 50 40 30 49.24

40 30 31.99 20 10 5.27 0 0 10 20 30 40 50 Time (min) 60 70 80 90 57.54 58.18 59.56 60.79 65.33 70.74 78.68

52.34

20 32.37
82.37 84.73

57.46 59.06 78.68 65.49 70.74 76.96 82.29 82.98 30 40 50 Time (min) 60 70 80 90

143.1769 0 100
96.66 100

242.1789

7.13 18.13 19.34 20.48

10
96.66

0
100

6.68 0 10

22.63 19.34 23.24 20

200

300

RT: 0.00 - 90.12 100 90 60.77 80 67.51 70
Relative Abundance

RT: 0.00 - 90.12
61.73 63.02 61.03 67.36 NL: 9.94E7 TIC MS LARC3_oxLDL _400mMNaCl_Z ORBAX300A_C 18_5u_STRAN GE_June18

100 90 80 70

59.40

67.28

NL: 9.91E6 Base Peak MS LARC3_oxLDL_4 00mMNaCl_ZOR BAX300A_C18_ 5u_STRANGE_J une18

Extracted from: C:\data_STRANGE\STRANNGE_JUNE2010\LARC3_oxLDL STRANGE\LARC3_oxLDL_400mMNaCl_ZORBAX300A_C18_5u_STRANGE_June18.RAW #5820 RT: 74.49 ITMS, CID, z=+3, Mono m/z=623.99829 Da, MH+=1869.98032 Da, Match Tol.=0.8 Da

400
Intens ity [counts ]

b 2+ 4 221.1156

59.40
Relative Abundance

b 2+ 5 294.9460 369.0319 606.0428

JAK1

60 50 40 30 8.44 20 4.51 10 24.23 28.50 0 0 10 20 30 40 50 Time (min) 60 44.45 41.57 18.94 20.00 22.66 54.51 54.30

68.75 69.46 69.94 71.51 72.65 73.25 76.42 52.93 51.08 50.22 49.39

60 50 63.09 40 30 55.76 54.73 84.76

300

200 b1+ 5 442.4719588.3815 685.8533

100

84.76

20 42.79 10 5.80 6.02 14.25 0
70 80 90

68.52 51.30 45.07 77.00 77.66

0 200 400 600 m/z 800 1000 1200

42.48 24.76 32.45 38.78 20 30

0

10

40 50 Time (min)

60

70

80

90

RT: 0.00 - 97.23 100 90 64.85 80 70
Relative Abundance

RT: 0.00 - 97.23
66.06 65.26 66.32 66.94 NL: 1.35E8 TIC MS LARC3_oxLDL _450mMNaCl_Z ORBAX300A_C 18_5u_STRAN GE_June18

100 90 80 70

63.69 69.58

NL: 1.84E7 Base Peak MS LARC3_oxLDL_4 50mMNaCl_ZOR BAX300A_C18_ 5u_STRANGE_J une18

Extracted from: C:\data_STRANGE\STRANNGE_JUNE2010\LARC3_oxLDL STRANGE\LARC3_oxLDL_450mMNaCl_ZORBAX300A_C18_5u_STRANGE_June18.RAW #5376 RT: 68.72 ITMS, CID, z=+3, Mono m/z=924.13733 Da, MH+=2770.39743 Da, Match Tol.=0.8 Da

350 300
Intens ity [counts ]

1219.4905

63.75
Relative Abundance

250 200 150 100 496.2539 610.3738 1332.6942 830.8795 974.4719 1124.2210 1051.1342 906.4980

JAK1

60 69.81 50 70.84 40 30 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 5.42 8.34 13.82 14.84 15.87 17.06 19.86 23.67 62.01 61.36 60.52 63.16 71.24 72.67 73.38 74.55 75.81 78.06

60 50 40 30 62.01 20 70.55 85.39 41.01 42.89 44.48 50 Time (min) 60 70 58.90 71.71 77.22 86.26 90

50 0 400 600

85.39 86.26 92.87

13.39 10 0.40 5.02 0 0 10 20 30 40 80 17.06 26.94 35.24

41.08 42.89

55.66

800

1000 m/z

1200

1400

1600

1800

RT: 0.00 - 82.35 100 90 80 61.48 70
Relative Abundance
Relative Abundance

RT: 0.00 - 82.35
61.28 NL: 1.44E8 TIC MS LARC3_oxLDL _600mMNaCl_Z ORBAX300A_C 18_5u_STRAN GE_June21

100 90 80 70

61.28

NL: 4.01E7 Base Peak MS LARC3_oxLDL_6 00mMNaCl_ZOR BAX300A_C18_ 5u_STRANGE_J une21

Extracted from: C:\data_STRANGE\STRANNGE_JUNE2010\LARC3_oxLDL STRANGE\LARC3_oxLDL_600mMNaCl_ZORBAX300A_C18_5u_STRANGE_June21.RAW #5056 RT: 63.56 ITMS, CID, z=+3, Mono m/z=926.48523 Da, MH+=2777.44114 Da, Match Tol.=0.8 Da

160 140
Intens ity [counts ]

1060.3682 907.7311

62.50

JAK1

60 50 40 30 20 49.97 10 0 0 10 20 30 40 Time (min) 50 7.42 8.66 9.04 3.79 10.73 14.97 16.57 42.65 43.94 33.78 37.54 32.96

61.14 55.52 57.49 55.33

63.23 63.68 64.28

120 100 80 60 40 20

63.68 60 50 40 30 60.72 57.21 20 54.15 65.27 68.99 10 0 3.87 8.12 12.69 16.11 0 10 20 33.78 35.65 43.94 24.61 31.44 30 40 Time (min) 51.85 50 60 70 76.28 77.06 80

1201.7959 1089.8466

64.65 54.01 50.64 68.91 70.15 76.28

64.28

0 400 600 800 1000 m/z 1200 1400 1600 1800

77.06

60

70

80

RT: 0.00 - 90.16 100 90 58.92 80 70
Relative Abundance

RT: 0.00 - 90.16
60.12 59.14 60.54 NL: 6.48E7 TIC MS LARC3_oxLD L_PBS_ZORB AX300A_C18 _5u_STRANG E_June23

100 90 80 70 35.79 51.01

60.69

80.99

60.69 58.10 51.01 50.58

NL: 3.37E6 Base Peak MS LARC3_oxLDL _PBS_ZORBA X300A_C18_5u _STRANGE_Ju ne23

Extracted from: C:\data_STRANGE\STRANNGE_JUNE2010\LARC3_oxLDL STRANGE\LARC3_oxLDL_PBS_ZORBAX300A_C18_5u_STRANGE_June23.RAW #5050 RT: 64.53 ITMS, CID, z=+3, Mono m/z=1028.85376 Da, MH+=3084.54673 Da, Match Tol.=0.8 Da

250 b 2+ 21 1205.9683 1241.9585
3+ b 24 936.91301010.0837

200
Intens ity [counts ]

JAK1

60 49.77 50 40 30 20 10 0 0 10 20 30 40 50 Time (min) 60 48.86 48.24 5.88 6.98 8.18 3.26 8.49 10.03 10.57 17.33 35.79 20.06 33.30 31.94 47.93 46.83 46.50 45.78

62.94 63.58 64.07 64.67 65.86 67.63 72.92 80.99

Relative Abundance

60 77.96 50 33.60 40 30 20 10 0 7.30 7.55 4.93 17.33 20.90 32.55 16.50 48.56 46.58 33.30 60.12 57.79 37.51 65.52 65.94 82.68 48.94 72.92

150

100

654.0437

50

83.30

0 400 600 800 1000 m/z 1200 1400 1600 1800 2000

70

80

90

0

10

20

30

40

50 Time (min)

60

70

80

90

104

Janus Kinases
TIC
RT: 0.00 - 90.53 100 90 80 70
Relative Abundance

Base Peak
RT: 0.00 - 90.53
NL: 3.93E7 TIC MS LARC2_oxLDL_8 00mMNaCl_150u mID5um300AMon MadeSP006_CH ARMED_May25

Spectrum
NL: 1.88E7 Base Peak MS LARC2_oxLDL_80 0mMNaCl_150umI D5um300AMonMad eSP006_CHARME D_May25

37.02

100 90 80 70

35.12 37.02

Extracted from: C:\data_CHARMED\CHARMED_MAY2010\LARC2_oxLDL_CHARMED\LARC2_oxLDL_800mMNaCl_150umID5um300AMonMadeSP006_CHARMED_May25.RAW #4230 RT: 53.64 ITMS, CID, z=+3, Mono m/z=727.05200 Da, MH+=2179.14145 Da, Match Tol.=0.8 Da 500 668.0717 714.6033 300 844.6476 973.7437 100 603.3984 944.4727

35.12

400
38.06 14.00 13.73 39.01 51.52 46.07
Relative Abundance

31.07 60 50 40 30 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 13.52 12.97 6.88 12.50 21.38 20.93 14.89 30.46 53.66 45.21

JAK1

60 50 34.18 40 30 31.07 42.25 20.93 14.00 21.61 22.21 22.82 51.52 53.66 45.21 54.38 59.68 38.93

Intens ity [counts ]

200

490.3371

70.42 59.68 62.17 70.73 85.02 89.75

20 10 4.97 0
90

13.52

70.34 73.95 70 80

0 200
85.02 90

400

600

800 m/z

1000

1200

1400

0

10

20

30

40

50 Time (min)

60

RT: 0.00 - 100.04 100 90 90.66 80 70
Relative Abundance
Relative Abundance

RT: 0.00 - 100.04
91.44 NL: 2.10E7 TIC MS LARC2_oxLDL _CHLOROFOR M_ZORBAX300 A_C18_5u_ST RANGE_May26

100 90 80 70

91.44

NL: 4.53E6 Base Peak MS LARC2_oxLDL_ CHLOROFORM_ ZORBAX300A_C 18_5u_STRANG E_May26

Extracted from: C:\data_STRANGE\STRANGE_MAY2010\LARC2_oxLDL STRANGE\LARC2_oxLDL_CHLOROFORM_ZORBAX300A_C18_5u_STRANGE_May26.RAW #5411 RT: 68.68 ITMS, CID, z=+3, Mono m/z=708.07214 Da, MH+=2122.20188 Da, Match Tol.=0.8 Da

120 100
Intens ity [counts ]

2+ b16 988.2989

JAK1

60 45.69 50 49.77 40 50.15 30 20 10 0 0 10 20 30 40 50 Time (min) 1.52 5.92 50.91 34.86 35.54 27.57 31.90 13.04 15.46 58.37

60.94 66.01 75.42 84.95 77.12 82.87 86.24

99.60 94.06

60 50 47.50 49.77 40 30 20 10 0 24.08 5.46 5.16 19.32 0 10 20 30.38 31.29 32.65 38.87 46.68 58.37 50.99 59.93 65.22 77.12 75.81 84.63 99.05 86.24 90.66

80 60 40 20 0 200 400 600

y 1+ 6 689.6669 796.8600 625.8707 782.4238 y 1+ 4 522.3052

2+ b15 931.6032

838.7579

800 m/z

1000

1200

1400

60

70

80

90

100

30

40

50 Time (min)

60

70

80

90

100

RT: 0.00 - 96.77 100 90 80 42.90 45.63 70
Relative Abundance

RT: 0.00 - 96.77
43.94 NL: 1.12E8 TIC MS LARC_IgG_150 mMNaCl_150umI D5um300AMonM adeSP006_STR ANGE_Apr26

100 90 80 70

43.94 54.90

NL: 1.11E7 Base Peak MS LARC_IgG_150m MNaCl_150umID5 um300AMonMade SP006_STRANGE _Apr26

Extracted from: C:\data_STRANGE\APRIL_2010_STRANGE\LARC_IgG_STRANGE\LARC_IgG_150mMNaCl_150umID5um300AMonMadeSP006_STRANGE_Apr26.RAW #4761 RT: 63.84 ITMS, CID, z=+3, Mono m/z=699.38281 Da, MH+=2096.13388 Da, Match Tol.=0.8 Da

200 680.4692
Intens ity [counts ]

42.75 46.15 50.01 58.18
Relative Abundance

150

JAK1

60 50

57.47

60 50 40 30 42.75 20 10 0 35.79 7.46 11.63 22.70 27.62 35.20 0 10 20 30 40 50 Time (min) 60 70 80 90 82.34 82.67 81.67 89.94 91.59 43.50 44.10 50.01

59.75 42.31 40 30 20 10 7.46 7.90 10.78 18.86 0 0 10 20 30 40 50 Time (min) 60 70 80 90 36.04 41.22 40.35 39.60 60.57 64.32 66.12 69.05 71.72 72.42 76.41 82.34 27.62 35.79

100

36.21 58.18 59.08

71.72

2+ b16 961.4529

50
39.93 60.57 64.58

612.2360 584.1983

781.7393

2+ y 14 891.4768 812.2283

83.09 92.00

0 200 400 600 800 m/z 1000 1200 1400

RT: 0.00 - 90.73 100 90 54.66 80 70
Relative Abundance

RT: 0.00 - 90.73
55.72 56.44 56.69 NL: 3.98E7 TIC MS LARC_IgG_Wa sh_150umID5u m300AMonMad eSP006_STRA NGE_Apr30 64.88 65.05 22.44 25.69 20.74 52.75
Relative Abundance

100 90 80 55.22 70

70.41

57.36 59.56

NL: 3.52E6 Base Peak MS LARC_IgG_Wash _150umID5um30 0AMonMadeSP0 06_STRANGE_A pr30

Extracted from: C:\data_STRANGE\APRIL_2010_STRANGE\LARC_IgG_STRANGE\LARC_IgG_Wash_150umID5um300AMonMadeSP006_STRANGE_Apr30.RAW #5385 RT: 74.26 ITMS, CID, z=+3, Mono m/z=955.16687 Da, MH+=2863.48606 Da, Match Tol.=0.8 Da

40

982.5320 932.9235 1061.6705 907.7352

21.39 22.04

54.26 54.09

1296.0963

Intens ity [counts ]

JAK2

60 50 40 20.32 30 20 10 4.11 8.28 19.90

30

70.41 81.43 80.49 75.20 81.69

60 50 40 30

57.86 80.49 81.43 59.73 81.69

20

822.0127 1639.4410

52.17 48.62 48.21 47.80 38.60 47.09

10
89.47 50.69 8.53 8.93 0.32 38.60 47.88 20.90 21.64 22.20 37.87 26.02 20 30 39.24 40.53 40 50 Time (min) 60 63.07 76.59 69.74

20 10 0

0 400
80 90

26.75 0 0 10 20 30

600

800

1000 m/z

1200

1400

1600

1800

40

50 Time (min)

60

70

80

90

0

10

70

RT: 0.00 - 91.19 100 90 80 70
Relative Abundance

RT: 0.00 - 91.19
34.63 38.06 39.00 41.25 43.44 47.07 34.28 33.87 48.50 48.76
Relative Abundance

NL: 1.20E8 TIC MS LARC2_oxLDL_1 00mMNaCl_150u mID5um300AMon MadeSP006_CH ARMED_May19

100 90 80 70 60 50 40 30 20 34.28 33.87

40.39 41.38 34.63 73.61

NL: 1.54E7 Base Peak MS LARC2_oxLDL_10 0mMNaCl_150umI D5um300AMonMad eSP006_CHARME D_May19

Extracted from: C:\data_CHARMED\CHARMED_MAY2010\LARC2_oxLDL_CHARMED\LARC2_oxLDL_100mMNaCl_150umID5um300AMonMadeSP006_CHARMED_May19.RAW #2489 RT: 31.26 ITMS, CID, z=+3, Mono m/z=383.85870 Da, MH+=1149.56156 Da, Match Tol.=0.8 Da

600 500 400 300 200 100 0 234.3275

y 2+ 5 327.3348 371.8148

y 2+ 8 468.2479

JAK2

60 33.34 50 40 23.26 30 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 6.48 50.30 50.61 51.47 56.05 56.35 57.50 59.69 63.71 11.76 19.76 24.55 74.42 74.98 80.61 73.61

Intens ity [counts ]

516.5565 377.6392
2+ b6 284.7930

47.07

b1+ 6 525.5291 568.2277

51.64 55.03 56.05

22.47
85.25

10 1.02 2.35 0 8.52 20.82 20

33.23 31.60 30 40 50 Time (min)

57.42 70.12 68.47 60 70 74.89 83.32 90

100

200

300

400 m/z

500

600

700

90

0

10

80

RT: 0.00 - 89.83 100 42.12 90 54.48 80 70
Relative Abundance

RT: 0.00 - 89.83
53.46 53.93 54.27 NL: 8.12E7 TIC MS LARC2_oxLDL _250mMNaCl_ ZORBAX300A_ C18_5u_STRA NGE_May20

100 90 80 70

48.20

37.70

NL: 9.57E6 Base Peak MS LARC2_oxLDL_ 250mMNaCl_ZO RBAX300A_C18 _5u_STRANGE_ May20

Extracted from: C:\data_STRANGE\STRANGE_MAY2010\LARC2_oxLDL STRANGE\LARC2_oxLDL_250mMNaCl_ZORBAX300A_C18_5u_STRANGE_May20.RAW #5802 RT: 68.32 ITMS, CID, z=+3, Mono m/z=918.78015 Da, MH+=2754.32590 Da, Match Tol.=0.8 Da

60 50
Intens ity [counts ]

901.3912 1007.5974

37.21
Relative Abundance

JAK2

60 50 40 14.01 30 7.73 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 28.26 21.73 75.49 80.91 13.22 32.24 60.55 61.04 61.47 65.40 66.20 14.48 55.84 56.14 36.43 34.32 56.90

60 50 40 37.21 30 20 10 4.02 0 0 10 20 30 9.32 21.65 22.19 35.85 31.33 28.11

42.68

40 30 854.4443 20 10

37.99 39.14 53.46

1118.2850

1+ 1265.0306y 12 1287.3876

74.62

54.07 71.33 61.71 70.77 79.21 40 50 Time (min) 60 70 80 87.05

74.62

0 400 600 800 1000 m/z 1200 1400 1600 1800

105

Janus Kinases
TIC
RT: 0.00 - 92.22 100 90 41.28 80 70
Relative Abundance

Base Peak
RT: 0.00 - 92.22
NL: 1.31E8 TIC MS LARC2_oxLDL _300mMNaCl_ ZORBAX300A_ C18_5u_STRA NGE_May20

Spectrum
NL: 1.27E7 Base Peak MS LARC2_oxLDL_ 300mMNaCl_ZO RBAX300A_C18 _5u_STRANGE_ May20

50.33

100 90 80 70

43.30

Extracted from: C:\data_STRANGE\STRANGE_MAY2010\LARC2_oxLDL STRANGE\LARC2_oxLDL_300mMNaCl_ZORBAX300A_C18_5u_STRANGE_May20.RAW #5142 RT: 62.19 ITMS, CID, z=+3, Mono m/z=918.77551 Da, MH+=2754.31198 Da, Match Tol.=0.8 Da

50.65

41.40

50.09

80 70
Intens ity [counts ]

899.7246

49.40 60 42.51 50 40 30 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 90 28.14 7.39 11.03 11.93 19.81 38.52 63.04 77.36 72.98 77.92 81.26 40.40 58.16 39.83 59.52 62.22 53.59 55.52
Relative Abundance

48.54 60 50 40 53.59 30 20 10 5.63 8.60 11.41 0 0 10 20 30 40 50 Time (min) 60 70 80 90 40.40 35.73 38.44 28.07 27.70 55.68 58.39 63.20 72.98 81.73 92.16 77.52 73.53

60 50 40 30 20 10 0 400 600 800 1000 m/z 1200 1400 1600 1800 1039.8931 553.7636
2+ y 16 823.4548

JAK2

1106.4368 1263.5676 1143.2156 1645.5458

29.45

RT: 0.00 - 88.30 100 90 47.81 80 70
Relative Abundance

RT: 0.00 - 88.30
47.33 NL: 1.81E8 TIC MS LARC2_oxLDL _350mMNaCl_ ZORBAX300A_ C18_5u_STRA NGE_May20

100 90 80 70

47.51

NL: 2.12E7 Base Peak MS LARC2_oxLDL_ 350mMNaCl_ZO RBAX300A_C18 _5u_STRANGE_ May20

Extracted from: C:\data_STRANGE\STRANGE_MAY2010\LARC2_oxLDL STRANGE\LARC2_oxLDL_350mMNaCl_ZORBAX300A_C18_5u_STRANGE_May20.RAW #5064 RT: 60.65 ITMS, CID, z=+3, Mono m/z=873.13965 Da, MH+=2617.40439 Da, Match Tol.=0.8 Da

100 854.4273
Intens ity [counts ]

80 60 40 20 645.4909 0 400 600 800 1000 m/z 1200 1400 1600 934.0539 1085.8042
2+ b 20 1235.7122

JAK2

60 53.14 50 40 33.98 30 33.50 20 32.16 10 3.08 0 0 10 20 30 40 50 Time (min) 60 70 80 10.30 10.83 23.80 30.46 36.13 36.43 53.48 44.18 39.29 53.89 56.86 57.39 58.27 59.08 62.45

Relative Abundance

48.11

60 50 35.97 40 30 40.72 20 33.98 10 0 0 0.48 3.39 10.30 16.05 24.41 10 20 30 40 50 Time (min) 31.51 69.91 53.89 56.27 73.86 69.11 76.08 77.75 60 70 80

38.09 46.17

51.67

787.6491

69.91 73.94 76.08 80.82

RT: 0.00 - 88.21 100 38.39 90 80 70
Relative Abundance

RT: 0.00 - 88.21
65.41 42.14 42.51 64.99 65.81 NL: 7.85E7 TIC MS LARC_oxLDL_5 00mMNaCl_NSI_ 150umMonMane Column_STRAN GE_March26

100 90 80 70

38.39 38.54

38.17

NL: 1.54E7 Base Peak MS LARC_oxLDL_500 mMNaCl_NSI_150 umMonManeColum n_STRANGE_Mar ch26

Extracted from: C:\data_STRANGE\STRANGE_MArch_2010\LARC_STRANGE\LARC_oxLDL_500mMNaCl_NSI_150umMonManeColumn_STRANGE_March26.RAW #5140 RT: 69.09 ITMS, CID, z=+3, Mono m/z=814.44019 Da, MH+=2441.30600 Da, Match Tol.=0.8 Da 160 140
Intens ity [counts ]

796.2641 977.1347

42.75

47.26 51.40 64.26 63.69
Relative Abundance

120 100 80 60 40 20
3+ b 20 765.2617

47.49 60 37.22 50 40 30 20 10 0 0 10 20 30 40 50 Time (min) 3.89 4.44 6.44 8.33 15.68 21.82 28.22 9.20 36.52 35.30 34.41 33.07 31.94

44.70 60 65.41 50 65.65 40 30 21.90 20 8.33 10 0 8.02 21.02 22.07 20.24 10.93 18.24 23.30 33.23 52.21 63.52 69.80 73.52 81.60 30 40 50 Time (min) 60 70 80 68.73 45.33 47.72 50.05 51.88

JAK2

68.33

73.52 74.59

74.99

1031.8672 933.4501

76.29 77.84 80.70 81.11

640.8063

0 400 600 800 m/z 1000 1200 1400 1600

60

70

80

0

10

20

RT: 0.00 - 106.17 100 90 44.56 80 43.10 70
Relative Abundance
Relative Abundance

RT: 0.00 - 106.17
48.26 45.33 NL: 2.80E8 TIC MS LARC_OXLDL_l Beads_NSI_150 umMonMadeCol umn_STRANGE _March17

100 90 80

54.04

50.77 54.04 54.45 56.61 58.44 60.91 61.97 72.75 73.30 74.70 71.52

49.93 70 45.08 54.45 60 50 40 30 44.36 59.19 39.74 61.05 61.66 62.13 62.53 69.38 10 0 21.42 28.13 8.09 16.80 0 10 20 30 34.20 58.89 71.52

NL: 1.86E7 Base Peak MS LARC_OXLDL_lB eads_NSI_150um MonMadeColumn _STRANGE_Marc h17

Extracted from: C:\data_STRANGE\STRANGE_MArch_2010\LARC\LARC_OXLDL_lBeads_NSI_150umMonMadeColumn_STRANGE_March17.RAW #5187 RT: 65.42 ITMS, CID, z=+3, Mono m/z=685.38190 Da, MH+=2054.13114 Da, Match Tol.=0.8 Da

900 800 700
Intens ity [counts ]

905.2217

42.34 60 41.48 50 40 30 37.87 20 10 0 0 10 20 30 40 3.30 14.53 16.56 37.09 35.25 19.57 40.91 39.74

600 500 400 300 200 100 0 554.3380
2+ y6 325.9930 439.0479

JAK3

726.9661 675.5363 776.7072 855.4514

926.2199

1127.5875

78.07 79.15 79.72 80.15

78.56 82.94 85.74

20
97.30

89.63 91.13

200

400

600

800 m/z

1000

1200

50 60 Time (min)

70

80

90

100

40

50 60 Time (min)

70

80

90

100

106

Phospholipase D
TIC
RT: 0.00 - 90.73 100 90 54.66 80 70
Relative Abundance

Base Peak
RT: 0.00 - 90.73
56.69 57.36 59.56 64.88 65.05
Relative Abundance

Spectrum
NL: 3.52E6 Base Peak MS LARC_IgG_Wash _150umID5um30 0AMonMadeSP0 06_STRANGE_A pr30

55.72 56.44

NL: 3.98E7 TIC MS LARC_IgG_Wa sh_150umID5u m300AMonMad eSP006_STRA NGE_Apr30

100 90 80 55.22 70

70.41

Extracted from: C:\data_STRANGE\APRIL_2010_STRANGE\LARC_IgG_STRANGE\LARC_IgG_Wash_150umID5um300AMonMadeSP006_STRANGE_Apr30.RAW #4865 RT: 66.76 ITMS, CID, z=+3, Mono m/z=589.96106 Da, MH+=1767.86863 Da, Match Tol.=0.8 Da

200 701.3445
Intens ity [counts ]

21.39 22.04

54.26 54.09

150

PLD1

60 50 20.74 40 20.32 30 20 10 4.11 8.28 19.90

22.44 25.69

52.75

70.41 81.43 80.49 75.20 81.69

60 50 40 30

57.86 80.49 81.43 59.73 81.69

100 570.9188 50
2+ b12 624.4881 579.9976

52.17 48.62 48.21 47.80 38.60 47.09

89.47 20 8.53 8.93 10 0.32 0
60 70 80 90

50.69 38.60 47.88 20.90 21.64 22.20 37.87 26.02 20 30 39.24 40.53 40 50 Time (min) 60 63.07 76.59 69.74

357.2839 0 200
80 90

497.3351

832.0992 799.9746

26.75 0 0 10 20 30

300

400

500

600

700 m/z

800

900

1000

1100

40

50 Time (min)

0

10

70

RT: 0.00 - 99.25 100 90 59.72 80 59.27 70
Relative Abundance

RT: 0.00 - 99.25
60.17 64.54 NL: 1.61E8 TIC MS LARC3_oxLDL _200mMNaCl_Z ORBAX300A_C 18_5u_STRAN GE_June17

100 90 80 70

60.17

65.27 65.91 66.11 66.76 67.68 67.95 68.43

NL: 2.26E7 Base Peak MS LARC3_oxLDL_2 00mMNaCl_ZOR BAX300A_C18_ 5u_STRANGE_J une17

Extracted from: C:\data_STRANGE\STRANNGE_JUNE2010\LARC3_oxLDL STRANGE\LARC3_oxLDL_200mMNaCl_ZORBAX300A_C18_5u_STRANGE_June17.RAW #5427 RT: 67.63 ITMS, CID, z=+3, Mono m/z=611.67395 Da, MH+=1833.00730 Da, Match Tol.=0.8 Da 40000
2+ b13 738.4608

30000
64.54
Intens ity [counts ]

PLD2

60 50 40 30 54.90 20 4.60 10.91 10 0 0 10 20 30 40 50 Time (min) 60 11.73 16.37 30.37 54.01 52.66 41.94 47.72 56.64

Relative Abundance

58.10

2+ b10 547.0433

60 50 40 58.16 30

68.91 56.13 55.17 69.41 69.71 71.08 72.71 75.16 76.70 85.69

20000 y 1+ 3 357.2755 244.1279 681.7499 627.2600

795.0112

59.27

10000
55.17 66.11 67.15 68.56 71.44 74.68 80

2+ y 14 809.6767

20 10 3.96 0 53.54 24.86 20 30 39.13 42.48 38.14 40 50 Time (min) 60

85.69 91.44 90

12.76

86.48 70 80 90

98.93

10.91 11.12 10

0 200 400 600 m/z 800 1000 1200

0

70

RT: 0.00 - 90.16 100 90 58.92 80 70
Relative Abundance

RT: 0.00 - 90.16
60.12 59.14 60.54 NL: 6.48E7 TIC MS LARC3_oxLD L_PBS_ZORB AX300A_C18 _5u_STRANG E_June23

100 90 80 70 35.79 51.01

60.69

80.99

60.69 58.10 51.01 50.58

NL: 3.37E6 Base Peak MS LARC3_oxLDL _PBS_ZORBA X300A_C18_5u _STRANGE_Ju ne23

Extracted from: C:\data_STRANGE\STRANNGE_JUNE2010\LARC3_oxLDL STRANGE\LARC3_oxLDL_PBS_ZORBAX300A_C18_5u_STRANGE_June23.RAW #5106 RT: 65.33 ITMS, CID, z=+3, Mono m/z=993.80933 Da, MH+=2979.41343 Da, Match Tol.=0.8 Da

100 975.2903
Intens ity [counts ]

80

PLD2

60 49.77 50 40 30 48.86 48.24 5.88 6.98 8.18 3.26 8.49 20 10.03 10 0 0 10 20 30 40 50 Time (min) 60 10.57 17.33 35.79 20.06 33.30 31.94 47.93 46.83 46.50 45.78

62.94 63.58 64.07 64.67 65.86 67.63 72.92 80.99

Relative Abundance

943.5393 1048.9041 1151.4110

60 77.96 50 33.60 40 30 20 10 0 7.30 7.55 17.33 20.90 32.55 16.50 48.56 46.58 33.30 60.12 57.79 37.51 65.52 65.94 82.68 48.94 72.92

60 40 20 0 400 600 800 1000

1387.2847 863.2433

4.93

83.30

1200 m/z

1400

1600

1800

2000

70

80

90

0

10

20

30

40

50 Time (min)

60

70

80

90

RT: 0.00 - 103.10 100 90 80 70
Relative Abundance

RT: 0.00 - 103.10
61.73 60.86 NL: 2.07E8 TIC MS LARC_oxLDL_2 00mMNaCl_NSI _150umMonMad eColumn_CHAR MED_Mar23

100 90 80 70

40.36 40.59

60.03 59.82

43.72 50.07 52.63 57.56 29.50 30.58 36.86 28.87

NL: 4.92E6 Base Peak MS LARC_oxLDL_20 0mMNaCl_NSI_15 0umMonMadeColu mn_CHARMED_ Mar23

Extracted from: C:\data_CHARMED\CHARMED_March2010\LARC_CHARMED\LARC_oxLDL_200mMNaCl_NSI_150umMonMadeColumn_CHARMED_Mar23.RAW #6879 RT: 91.52 ITMS, CID, z=+3, Mono m/z=853.76160 Da, MH+=2559.27024 Da, Match Tol.=0.8 Da 1000 1151.8879

800
Intens ity [counts ]

PLD2

60 50 40 30 20 10 0 0 10 20 30 40 50 Time (min) 60 0.97 2.50 12.77

Relative Abundance

64.92 66.37 68.00 69.72 71.38

60 50 40 30 20 10 0

2.41 3.09 9.02 21.63 25.80

600

768.4162

81.75

58.74

80.77

400 b 3+ 21 804.9166
2+ b10 715.3177 570.0322

59.75 60.86 66.09 67.48 79.57 75.74 81.90 86.06

82.76 91.83 93.15 94.56

200
99.53

961.7670 1024.6379

1257.5237 1200 1400 1600

0 400 600 800 1000 m/z

28.48 29.58

40.59

50.41

70

80

90

100

0

10

20

30

40

50 Time (min)

60

70

80

90

100

RT: 0.00 - 92.00 100 90 80 70
Relative Abundance

RT: 0.00 - 92.00
33.21 33.94 32.46 29.74 29.37 34.57 37.69 NL: 7.77E7 TIC MS LARC_oxLDL_3 50mMNaCl_NSI _150umMonMad eColumn_CHAR MED_Mar26

100 90 80 70

33.21

45.31 46.36 46.66 47.70 49.81 50.77 58.29 54.65 60.68 61.75 62.52 63.18 64.73 69.71 70.12 72.01 74.80 76.61

NL: 8.93E6 Base Peak MS LARC_oxLDL_35 0mMNaCl_NSI_15 0umMonMadeColu mn_CHARMED_ Mar26

Extracted from: C:\data_CHARMED\CHARMED_March2010\LARC_CHARMED\LARC_oxLDL_350mMNaCl_NSI_150umMonMadeColumn_CHARMED_Mar26.RAW #5386 RT: 72.54 ITMS, CID, z=+3, Mono m/z=804.33820 Da, MH+=2411.00003 Da, Match Tol.=0.8 Da 800 700 964.7447 600

43.79

Relative Abundance

32.08 60 50 26.42 40

33.94 34.33

Intens ity [counts ]

PLD3

60 50 40 30 20 10 0 0 10 20

28.53 27.64

500 400 300 200 b1+ 6 764.4534

26.59

34.88 30

46.04 46.43 45.71 46.66

61.01 60.68 58.29

1018.8364

87.88 86.72

62.26 20 3.99 10 6.44 0 20.41 10 24.27 48.03 50.93 66.30 68.89 71.69

100 0
75.30 80 89.55 90

723.5721

785.2015

1091.1744

1.15 3.99

8.24

24.27

77.92 30 40 50 Time (min) 60 70 80 90

400

600

800 m/z

1000

1200

1400

1600

0

20

30

40

50 Time (min)

60

70

RT: 0.00 - 84.46 100 90 80 70
Relative Abundance

RT: 0.00 - 84.46
28.87 32.88 28.63 NL: 6.42E7 TIC MS LARC_oxLDL_6 00mMNaCl_NSI _150umMonMad eColumn_CHAR MED_Mar31

100 90 80 70

28.87 28.63 29.26

NL: 2.01E7 Base Peak MS LARC_oxLDL_60 0mMNaCl_NSI_15 0umMonMadeColu mn_CHARMED_ Mar31

Extracted from: C:\data_CHARMED\CHARMED_March2010\LARC_CHARMED\LARC_oxLDL_600mMNaCl_NSI_150umMonMadeColumn_CHARMED_Mar31.RAW #3689 RT: 49.88 ITMS, CID, z=+3, Mono m/z=431.87579 Da, MH+=1293.61283 Da, Match Tol.=0.8 Da 700 600
Intens ity [counts ]

343.0273

33.12
Relative Abundance

PLD3

60 50 40 27.66 30 20 10 0 0 10 20 30 26.08 24.73 22.40 20.10 19.08

44.25 43.05 39.15

45.97

32.79 60 35.50 50 44.17 40 30 20 63.28 63.77 64.51 62.86 59.03 4.84 6.04 0 0 10 22.40 20 23.16 54.64 65.56 72.73 73.96 30 40 Time (min) 50 60 70 80 38.98 46.37

500 400 300 200 100 0 200 300 400 500 m/z 600 700 800 b 2+ 5 303.1835 375.5026 493.2788 554.8516
2+ y7 413.1810

46.53 47.02 47.75 49.04 50.83 59.03 63.53 64.11 64.51

425.5942 638.6306 604.0787

65.88 66.12

27.91
72.73 74.70

4.84

11.35

10

40 Time (min)

50

60

70

80

107

Phospholipase D
TIC
RT: 0.00 - 103.10 100 90 80 70
Relative Abundance

Base Peak
RT: 0.00 - 103.10
NL: 2.07E8 TIC MS LARC_oxLDL_2 00mMNaCl_NSI _150umMonMad eColumn_CHAR MED_Mar23

Spectrum
NL: 4.92E6 Base Peak MS LARC_oxLDL_20 0mMNaCl_NSI_15 0umMonMadeColu mn_CHARMED_ Mar23

61.73 60.86

100 90 80 70

40.36 40.59

Extracted from: C:\data_CHARMED\CHARMED_March2010\LARC_CHARMED\LARC_oxLDL_200mMNaCl_NSI_150umMonMadeColumn_CHARMED_Mar23.RAW #7029 RT: 93.59 ITMS, CID, z=+3, Mono m/z=712.01160 Da, MH+=2134.02024 Da, Match Tol.=0.8 Da 300 250
Intens ity [counts ]

60.03 59.82

43.72 50.07 52.63 57.56 29.50 30.58 36.86

702.0862

PLD6

60 50 40 30 20 10 0 0 10 20 30 40 50 Time (min) 60 0.97 2.50 12.77

Relative Abundance

200 150 100 50 653.7502 590.1993
2+ b18 943.3713 2+ b14

64.92 66.37 68.00 69.72 71.38

60 50 40 30 20 10 0

2.41 3.09 28.87 9.02 21.63 25.80

81.75

58.74

80.77

59.75 60.86 66.09 67.48 79.57 75.74 81.90 86.06

82.76 91.83 93.15 94.56

748.2845

887.0776
1+ 992.9101y10 1000.3620

99.53

0 200 400 600 800 m/z 1000 1200 1400

28.48 29.58

40.59

50.41

70

80

90

100

0

10

20

30

40

50 Time (min)

60

70

80

90

100

RT: 0.00 - 89.31 100 90 80 70
Relative Abundance

RT: 0.00 - 89.31
32.39 NL: 2.53E8 TIC MS LARC_IgG_PB S_150umID5um 300AMonMade SP006_CHAR MED_Apr30

100 90 80

35.40

33.00

32.39 38.33 49.27 60 43.04 50 40 30 31.88 20 19.60 10 18.85 6.59 0 0 10 17.18 20 21.21 22.12 23.47 30 40 50 Time (min) 51.45 56.38 58.41 72.32 60 70 78.77 81.78 80 66.85 73.68 77.83 55.72 70

NL: 1.64E7 Base Peak MS LARC_IgG_PBS _150umID5um30 0AMonMadeSP0 06_CHARMED_ Apr30

Extracted from: C:\data_CHARMED\CHARMED_April2010\LARC_IgG CHARMED\LARC_IgG_PBS_150umID5um300AMonMadeSP006_CHARMED_Apr30.RAW #4215 RT: 54.60 ITMS, CID, z=+3, Mono m/z=1072.94385 Da, MH+=3216.81699 Da, Match Tol.=0.8 Da 700 600
Intens ity [counts ]

1006.0330

PLD6

60 50 40 30 20 10 3.83 11.11 0 0 10 20 30 19.02 19.60 18.43 31.49 17.92 29.41

35.40 43.04 44.22 45.50 48.00 51.37 52.51 55.72 56.71 57.47 58.84 59.77 61.33 66.94 73.68 77.83 40 50 Time (min) 60 70 80

Relative Abundance

33.55 33.86

500 400 300 200 100 0 400 600 800 1000 1200 m/z 1400 1600 1800 2000 1196.9641 1050.8369 b13 1508.8219 1320.3868
1+

79.10

108

Phosphatidate Phosphatases
TIC
RT: 0.00 - 90.73 100 90 54.66 80 70
Relative Abundance

Base Peak
RT: 0.00 - 90.73
56.69 57.36 59.56 64.88 65.05
Relative Abundance

Spectrum
NL: 3.52E6 Base Peak MS LARC_IgG_Wash _150umID5um30 0AMonMadeSP0 06_STRANGE_A pr30

55.72 56.44

NL: 3.98E7 TIC MS LARC_IgG_Wa sh_150umID5u m300AMonMad eSP006_STRA NGE_Apr30

100 90 80 55.22 70

70.41

Extracted from: C:\data_STRANGE\APRIL_2010_STRANGE\LARC_IgG_STRANGE\LARC_IgG_Wash_150umID5um300AMonMadeSP006_STRANGE_Apr30.RAW #4083 RT: 55.66 ITMS, CID, z=+3, Mono m/z=766.73206 Da, MH+=2298.18161 Da, Match Tol.=0.8 Da 300 250
Intens ity [counts ]

21.39 22.04

54.26 54.09

754.8267
2+ y 18 1028.0817

200 150 100 50 0 200 400 600 800 m/z

Lipin1

60 50 20.74 40 20.32 30 20 10 4.11 8.28 19.90

22.44 25.69

52.75

70.41 81.43 80.49 75.20 81.69

60 50 40 30

57.86 80.49 81.43 59.73 81.69 89.47

52.17 48.62 48.21 47.80 38.60 47.09

2+ y 17 2+ y 15 963.1256 906.2291 850.1592

20 8.53 8.93 10 0.32 0
60 70 80 90

50.69 38.60 47.88 20.90 21.64 22.20 37.87 26.02 20 30 39.24 40.53 40 50 Time (min) 60 63.07 76.59 69.74

709.8116

1048.7982 1000 1200 1400

26.75 0 0 10 20 30

40

50 Time (min)

0

10

70

80

90

RT: 0.00 - 96.96 5.71 100 90 80 70
Relative Abundance

RT: 0.00 - 96.96
NL: 1.07E8 TIC MS LARC_oxLDL_5 50mMNaCl_NSI_ 150umMonMane Column_STRAN GE_March26

100 90 80 70

68.62

6.63 6.92

NL: 1.32E7 Base Peak MS LARC_oxLDL_550 mMNaCl_NSI_150 umMonManeColum n_STRANGE_Mar ch26

Extracted from: C:\data_STRANGE\STRANGE_MArch_2010\LARC_STRANGE\LARC_oxLDL_550mMNaCl_NSI_150umMonManeColumn_STRANGE_March26.RAW #3352 RT: 45.24 ITMS, CID, z=+3, Mono m/z=526.94019 Da, MH+=1578.80600 Da, Match Tol.=0.8 Da

200 509.0897
Intens ity [counts ]

Lipin1

60 50 40

7.16

Relative Abundance

150

60 50 6.63 40 5.18 30 20 10 0 65.63 56.10 59.31 55.76 73.25 73.65 74.63 80.49 70 80

68.53 68.95 7.73 65.88 54.44 50.65 49.75 47.39 23.25 27.00 43.16 37.79 63.32 72.84 73.57 75.03

100

3+ y6 270.7914

30 20 10 0 0

7.98 8.39 16.43 16.91

50
7.41 50.32 7.66 14.62 23.75 27.58 31.16 20 30 45.45 40 48.70

b1+ 3 243.0925

3+ b11 517.1703 469.0935

656.9117 679.0591 723.8046

79.36 81.25 87.61 96.77

0
82.55 96.85 90

200

300

400

500

600 m/z

700

800

900

1000

10

20

30

40

50 Time (min)

60

70

80

90

0

10

50 Time (min)

60

RT: 0.00 - 91.36 100 90 80 31.34 70
Relative Abundance
Relative Abundance

RT: 0.00 - 91.36
27.00 NL: 5.65E7 TIC MS LARC_oxLDL_7 00mMNaCl_NSI _150umMonMad eColumn_CHAR MED_Mar31

100 90 80 70

27.00

30.95

NL: 1.96E7 Base Peak MS LARC_oxLDL_70 0mMNaCl_NSI_15 0umMonMadeColu mn_CHARMED_ Mar31

Extracted from: C:\data_CHARMED\CHARMED_March2010\LARC_CHARMED\LARC_oxLDL_700mMNaCl_NSI_150umMonMadeColumn_CHARMED_Mar31.RAW #2470 RT: 33.43 ITMS, CID, z=+3, Mono m/z=559.65479 Da, MH+=1676.94980 Da, Match Tol.=0.8 Da 80 70 714.8623 60
Intens ity [counts ]

541.1925 550.0755

Lipin1

60 50 40 30 0.39 20 10 0 0 10 20 30 40 50 Time (min) 60 70 80 1.05 1.61 2.72 4.94 7.22 25.23 20.50 33.53 36.59 43.15 60.14 60.80 56.39 44.29 51.35 61.78 62.02 67.55 43.96

60 30.55 33.29 50 40 30 20 10 0 3.96 6.50 0 10 20.10 19.60 15.60 20 30 40 50 Time (min) 60

50 40 30 20 10 0
3+ y 13 516.6008

653.3803

767.0172

36.59 36.84 41.61 44.12 60.47 60.05 60.80 61.29

68.52 68.77 86.18 86.91 79.60 84.72 77.22 90

51.67 56.39

62.66 67.63 70.17 70

85.04 85.60 80 90

200

300

400

500

600 m/z

700

800

900

1000

1100

RT: 0.00 - 98.16 100 90 80 70
Relative Abundance

RT: 0.00 - 98.16
50.60 49.95 48.99 48.71 48.09 51.42 56.87 57.09 57.46 61.71 62.39 63.28 63.79 47.01 65.87 68.51 68.74 69.43 69.66 70.70 79.65
Relative Abundance

NL: 2.26E8 TIC MS LARC_OXLDL _PBS_NSI_150 umMonManeCo lumn_STRANG E_March18

100 90 80 48.71 70 60 50 40 30 54.39 54.73 18.78 18.37 10.32 17.90 10.83 5.65 17.02 19.37 26.54 29.81 31.03 39.73 34.36 43.56 57.02

79.49 79.73

NL: 6.11E6 Base Peak MS LARC_OXLDL_ PBS_NSI_150um MonManeColumn _STRANGE_Mar ch18

Extracted from: C:\data_STRANGE\STRANGE_MArch_2010\LARC\LARC_OXLDL_PBS_NSI_150umMonManeColumn_STRANGE_March18.RAW #3502 RT: 47.03 ITMS, CID, z=+3, Mono m/z=640.68628 Da, MH+=1920.04428 Da, Match Tol.=0.8 Da 4000
2+ b12 617.9836

3000
Intens ity [counts ]

Lipin1

60 50

68.51 63.64 72.12 74.66

2000

631.0549

46.29 40 30 20 10 0 0 10 20 30 40 50 Time (min) 60 15.68 16.39 24.93 44.34 43.71 42.68 41.58 8.69 10.74 39.56 37.87 35.33

81.82 86.19 90.33 91.89

1000 459.0441
97.06 96.46

705.3290 540.7620

904.5399

20 2.31 10 0

86.27

831.4936 888.4396 600 m/z 800 1000 1200

0 200 400

70

80

90

0

10

20

30

40

50 Time (min)

60

70

80

90

RT: 0.00 - 110.02 100 90 80 30.81 70
Relative Abundance

RT: 0.00 - 110.02
40.54 45.52 40.23 46.26 48.29 32.37 NL: 2.94E8 TIC MS LARC_OXLDL_50 mMNaClextract_N SI_150umMonMan eColumn_STRAN GE_March18

100 90 80 70

47.72

48.16

NL: 3.66E7 Base Peak MS LARC_OXLDL_50m MNaClextract_NSI_1 50umMonManeColu mn_STRANGE_Mar ch18

Extracted from: C:\data_STRANGE\STRANGE_MArch_2010\LARC\LARC_OXLDL_50mMNaClextract_NSI_150umMonManeColumn_STRANGE_March18.RAW #4172 RT: 51.45 ITMS, CID, z=+3, Mono m/z=823.08191 Da, MH+=2467.23117 Da, Match Tol.=0.8 Da 800 700
Intens ity [counts ]

49.01

804.3909 b 2+ 22 1132.2920 b 3+ 22 755.3398 b 1057.5879 1005.6931
1+ 10

600 500 400 300 200

PPAPDC

60 50 40 30

30.37

50.81 54.34 56.98 61.63 62.70 65.22 66.56 68.71 72.89 74.83 89.38 79.67 87.49 90.97

Relative Abundance

60 50 40 30 20 10 2.26 9.77 0 0 10 30.81 49.64 24.59 29.91 22.99 20 30 40 50 60 Time (min) 60.24 64.31 66.72 74.99 81.51 88.95 80 90 100 106.79 110 61.29 61.63

1176.1743

40.80

28.62 20 10 9.77 10.26 0 0 10 20 30 40 50 60 Time (min) 26.52 25.10 22.99

100 0 400 600 800 m/z 1000 1200 1400 1600

100.96 108.57 70 80 90 100 110

70

109

110

REFERENCES
Aderem, A. & Underhill, D.M. 1999, "Mechanisms of phagocytosis in macrophages", Annual Review of Immunology, vol. 17, pp. 593-623. Aiken, M., Ginsberg, M., Byers-Ward, V. & Plow, E. 1990, "Effects of OKM5, a monoclonal antibody to glycoprotein IV, on platelet aggregation and thrombospondin surface expression", Blood, vol. 76, no. 12, pp. 2501-2509. Akifusa, S., Kamio, N., Shimazaki, Y., Yamaguchi, N., Nonaka, K. & Yamashita, Y. 2010, "Involvement of the JAK-STAT pathway and SOCS3 in the regulation of adiponectingenerated reactive oxygen species in murine macrophage RAW 264 cells", Journal of cellular biochemistry, vol. 111, no. 3, pp. 597-606. Aviram, M. 1993, "Modified Forms of Low-Density-Lipoprotein and Atherosclerosis", Atherosclerosis, vol. 98, no. 1, pp. 1-9. Bamberger, M.E., Harris, M.E., McDonald, D.R., Husemann, J. & Landreth, G.E. 2003, "A Cell Surface Receptor Complex for Fibrillar -Amyloid Mediates Microglial Activation", The Journal of Neuroscience, vol. 23, no. 7, pp. 2665-2674. Bhatt, K.H., Pandey, R.K., Dahiya, Y. & Sodhi, A. 2010, "Protein kinase C and protein tyrosine kinase regulate peptidoglycan-induced nuclear factor-B activation and inducible nitric oxide synthase expression in mouse peritoneal macrophages in vitro", Molecular immunology, vol. 47, no. 4, pp. 861-870. Bobryshev, Y.V. 2006, "Monocyte recruitment and foam cell formation in atherosclerosis", Micron, vol. 37, no. 3, pp. 208-222. Boekhoudt, G.H., Frazier-Jessen, M.R. & Feldman, G.M. 2007, "Immune complexes suppress IFN-gamma signaling by activation of the Fc-gamma RI pathway", Journal of leukocyte biology, vol. 81, no. 4, pp. 1086-1092. Bull, H.A., Brickell, P.M. & Dowd, P.M. 1994, "src-related protein tyrosine kinases are physically associated with the surface antigen CD36 in human dermal microvascular endothelial cells", FEBS letters, vol. 351, no. 1, pp. 41-44. Calvo, D., Gomez-Coronado, D., Suarez, Y., Lasuncion, M.A. & Vega, M.A. 1998, "Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL", J.Lipid Res., vol. 39, no. 4, pp. 777-788. Cammer, M., Gevrey, J., Lorenz, M., Dovas, A., Condeelis, J. & Cox, D. 2009, "The Mechanism of CSF-1-induced Wiskott-Aldrich Syndrome Protein Activation in Vivo", Journal of Biological Chemistry, vol. 284, no. 35, pp. 23302-23311.
111

Chan, G., Bivins-Smith, E.R., Smith, M.S. & Yurochko, A.D. 2009, "NF-B and phosphatidylinositol 3-kinase activity mediates the HCMV-induced atypical M1/M2 polarization of monocytes", Virus research, vol. 144, no. 1-2, pp. 329-333. Chen, K., Febbraio, M., Li, W. & Silverstein, R.L. 2008, "A Specific CD36-Dependent Signaling Pathway Is Required for Platelet Activation by Oxidized Low-Density Lipoprotein", Circulation research, vol. 102, no. 12, pp. 1512-1519. Chiou, W., Don, M., Liao, J. & Wei, B. "Psoralidin inhibits LPS-induced iNOS expression via repressing Syk-mediated activation of PI3K-IKK-IB signaling pathways", European journal of pharmacology, vol. In Press, Uncorrected Proof. Cho, M., Moon, Y., Heo, Y., Woo, Y., Ju, J., Park, K., Kim, S., Park, S., Kim, H. & Min, J. 2009, "NF-B inhibition leads to increased synthesis and secretion of MIF in human CD4+ T cells", Immunology letters, vol. 123, no. 1, pp. 21-30. Chou, M., Fogelstrand, L., Hartvigsen, K., Hansen, L.F., Woelkers, D., Shaw, P.X., Choi, J., Perkmann, T., Bäckhed, F., Miller, Y.I., Hörkkö, S., Corr, M., Witztum, J.L. & Binder, C.J. 2009, "Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans", The Journal of clinical investigation, vol. 119, no. 5, pp. 1335-1349. Collins, R.F., Touret, N., Kuwata, H., Tandon, N.N., Grinstein, S. & Trimble, W.S. 2009, "Uptake of oxLDL by CD36 occurs by an actin-dependent pathway distinct from macropinocytosis", Journal of Biological Chemistry, . Collot-Teixeira, S., Martin, J., McDennott-Roe, C., Poston, R. & McGregor, J.L. 2007, "CD36 and macrophages in atherosclerosis", Cardiovascular research, vol. 75, no. 3, pp. 468-477. Coraci, I.S., Husemann, J., Berman, J.W., Hulette, C., Dufour, J.H., Campanella, G.K., Luster, A.D., Silverstein, S.C. & El Khoury, J.B. 2002, "CD36, a Class B Scavenger Receptor, Is Expressed on Microglia in Alzheimer's Disease Brains and Can Mediate Production of Reactive Oxygen Species in Response to -Amyloid Fibrils", The American Journal of Pathology, vol. 160, no. 1, pp. 101-112. Corrotte, M., Chasserot-Golaz, S., Huang, P., Du, G., Ktistakis, N.T., Frohman, M.A., Vitale, N., Bader, M. & Grant, N.J. 2006, "Dynamics and Function of Phospholipase D and Phosphatidic Acid During Phagocytosis", Traffic, vol. 7, no. 3, pp. 365-377. Cuschieri, J., Sakr, S., Bulger, E., Knoll, M., Arbabi, S. & Maier, R.V. 2009, "Oxidant Alterations in Cd16 Expression are Cytoskeletal Induced", Shock, vol. 32, no. 6, pp. 572577. Dalvai, M. & Bystricky, K. 2010, "Cell Cycle and Anti-Estrogen Effects Synergize to Regulate Cell Proliferation and ER Target Gene Expression", PLoS ONE, vol. 5, no. 6, pp. e11011.

112

Daoud, A.S., Jarmolych, J., Augustyn, J.M. & Fritz, K.E. 1981, "Sequential Morphologic Studies of Regression of Advanced Atherosclerosis", Archives of Pathology & Laboratory Medicine, vol. 105, no. 5, pp. 233-239. Daviet, L., Malvoisin, E., Wild, T.F. & McGregor, J.L. 1997, "Thrombospondin induces dimerization of membrane-bound, but not soluble CD36", Journal of Thrombosis and Haemostasis, vol. 78, no. 2, pp. 897-901. Davis, R.S. 2007, "Fc Receptor-Like Molecules", Annual Review of Immunology, vol. 25, no. 1, pp. 525-560. de Kruif, M.D., van Gorp, E.C.M., Keller, T.T., Ossewaarde, J.M. & ten Cate, H. 2005, "Chlamydia pneumoniae infections in mouse models: relevance for atherosclerosis research", Cardiovascular research, vol. 65, no. 2, pp. 317-327. Drage, M.G., Pecora, N.D., Hise, A.G., Febbraio, M., Silverstein, R.L., Golenbock, D.T., Boom, W.H. & Harding, C.V. 2009, "TLR2 and its co-receptors determine responses of macrophages and dendritic cells to lipoproteins of Mycobacterium tuberculosis", Cellular immunology, vol. 258, no. 1, pp. 29-37. Endemann, G., Stanton, L.W., Madden, K.S., Bryant, C.M., White, R.T. & Protter, A.A. 1993, "Cd36 is a Receptor for Oxidized Low-Density-Lipoprotein", Journal of Biological Chemistry, vol. 268, no. 16, pp. 11811-11816. Endo, A. 1979, "Monacolin K, a new hypocholesterolemic agent that specifically inhibits 3hydroxy-3-methylglutaryl coenzyme A reductase", The Journal of Antibiotics, vol. 33, no. 3, pp. 334-336. Engelmann, B. & Wiedmann, M.K.H. 2010, "Cellular phospholipid uptake: Flexible paths to coregulate the functions of intracellular lipids", Biochimica et Biophysica Acta (BBA) Molecular and Cell Biology of Lipids, vol. 1801, no. 6, pp. 609-616. Epstein, D., Rowlette, L. & Roberts, B. 1999, "Acto-myosin drug effects and aqueous outflow function", Investigative Ophthalmology Visual Science, vol. 40, no. 1, pp. 74-81. Etienne-Manneville, S. & Hall, A. 2002, "Rho GTPases in cell biology", Nature, vol. 420, no. 6916, pp. 629-635. Febbraio, M., Hajjar, D.P. & Silverstein, R.L. 2001, "CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism", Journal of Clinical Investigation, vol. 108, no. 6, pp. 785-791. Febbraio, M., Podrez, E.A., Smith, J.D., Hajjar, D.P., Hazen, S.L., Hoff, H.F., Sharma, K. & Silverstein, R.L. 2000, "Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice", Journal of Clinical Investigation, vol. 105, no. 8, pp. 1049-1056.
113

Feldman, G., Chuang, E. & Finbloom, D. 1995, "IgG immune complexes inhibit IFN-gammainduced transcription of the Fc gamma RI gene in human monocytes by preventing the tyrosine phosphorylation of the p91 (Stat1) transcription factor", The Journal of Immunology, vol. 154, no. 1, pp. 318-325. Fulton, D., Condro, M.C., Pearce, K. & Glanzman, D.L. 2008, "The Potential Role of Postsynaptic Phospholipase C Activity in Synaptic Facilitation and Behavioral Sensitization in Aplysia", Journal of neurophysiology, vol. 100, no. 1, pp. 108-116. Garcia, C.K., Wilund, K., Arca, M., Zuliani, G., Fellin, R., Maioli, M., Calandra, S., Bertolini, S., Cossu, F., Grishin, N., Barnes, R., Cohen, J.C. & Hobbs, H.H. 2001, "Autosomal Recessive Hypercholesterolemia Caused by Mutations in a Putative LDL Receptor Adaptor Protein", Science, vol. 292, no. 5520, pp. 1394-1398. Georgakopoulos, T., Moss, S.T. & Kanagasundaram, V. "Integrin CD11c contributes to monocyte adhesion with CD11b in a differential manner and requires Src family kinase activity", Molecular immunology, vol. 45, no. 13, pp. 3671-3681. Ghosh, S., Gepstein, S., Heikkila, J.J. & Dumbroff, E.B. 1988, "Use of a scanning densitometer or an ELISA plate reader for measurement of nanogram amounts of protein in crude extracts from biological tissues", Analytical Biochemistry, vol. 169, no. 2, pp. 227-233. Glass, C.K. & Witztum, J.L. 2001, "Atherosclerosis: The Road Ahead", Cell, vol. 104, no. 4, pp. 503-516. Gousset, K., Tsvetkova, N.M., Crowe, J.H. & Tablin, F. 2004, "Important role of raft aggregation in the signaling events of cold-induced platelet activation", Biochimica et Biophysica Acta (BBA) - Biomembranes, vol. 1660, no. 1-2, pp. 7-15. Gralczyk, K., Soszyska, K., Haus, O., Bielis, R. & Ro, D. 2009, The influence of lovastatin on thrombomodulin gene expression in vascular endothelial cells--in vitro study. Greenberg, S., Chang, P. & Silverstein, S.C. 1994, "Tyrosine phosphorylation of the gamma subunit of Fc gamma receptors, p72syk, and paxillin during Fc receptor-mediated phagocytosis in macrophages.", Journal of Biological Chemistry, vol. 269, no. 5, pp. 38973902. Greenberg, S., Chang, P. & Silverstein, S.C. 1993, "Tyrosine phosphorylation is required for Fc receptor-mediated phagocytosis in mouse macrophages.", The Journal of experimental medicine, vol. 177, no. 2, pp. 529-534. Grkovich, A., Armando, A., Quehenberger, O. & Dennis, E.A. 2009, "TLR-4 mediated group IVA phospholipase A2 activation is phosphatidic acid phosphohydrolase 1 and protein kinase C dependent", BBA - Molecular and Cell Biology of Lipids, vol. 1791, no. 10, pp. 975-982.

114

Groves, E., Dart, A., Covarelli, V. & Caron, E. 2008, Molecular mechanisms of phagocytic uptake in mammalian cells, Birkhäuser Basel. Ha, H., Lee, J., Kim, H., Kwak, H.B., Kim, H., Lee, S.E., Rhee, J.H., Kim, H. & Lee, Z.H. 2008, "Stimulation by TLR5 Modulates Osteoclast Differentiation through STAT1/IFN-{beta}", The Journal of Immunology, vol. 180, no. 3, pp. 1382-1389. Han, C., Fu, J., Liu, Z., Huang, H., Luo, L. & Yin, Z. 2010, Dipyrithione inhibits IFN--induced JAK/STAT1 signaling pathway activation and IP-10/CXCL10 expression in RAW264.7 cells, Birkhäuser Basel. Hatta, M., Matsuzaki, T., Morioka, Y., Yoshida, Y. & Noda, M. 2009, "Density- and serumdependent regulation of the Reck tumor suppressor in mouse embryo fibroblasts", Cellular signalling, vol. 21, no. 12, pp. 1885-1893. Hillyard, D.Z., Jardine, A.G., McDonald, K.J. & Cameron, A.J.M. 2004, "Fluvastatin inhibits raft dependent Fc gamma receptor signalling in human monocytes", Atherosclerosis, vol. 172, no. 2, pp. 219-228. Hirano, K., Kuwasako, T., Nakagawa-Toyama, Y., Janabi, M., Yamashita, S. & Matsuzawa, Y. 2003, "Pathophysiology of Human Genetic CD36 Deficiency", Trends in cardiovascular medicine, vol. 13, no. 4, pp. 136-141. Hoebe, K., Georgel, P., Rutschmann, S., Du, X., Mudd, S., Crozat, K., Sovath, S., Shamel, L., Hartung, T., Zahringer, U. & Beutler, B. 2005, "CD36 is a sensor of diacylglycerides", Nature, vol. 433, no. 7025, pp. 523-527. Hoosdally, S.J., Andress, E.J., Wooding, C., Martin, C.A. & Linton, K.J. 2009, "The Human Scavenger Receptor CD36", Journal of Biological Chemistry, vol. 284, no. 24, pp. 1627716288. Hu, X., Chen, J., Wang, L. & Ivashkiv, L.B. 2007, "Crosstalk among Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation", Journal of leukocyte biology, vol. 82, no. 2, pp. 237-243. Huang, M.M., Bolen, J.B., Barnwell, J.W., Shattil, S.J. & Brugge, J.S. 1991, "Membrane glycoprotein IV (CD36) is physically associated with the Fyn, Lyn, and Yes protein-tyrosine kinases in human platelets", Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 17, pp. 7844-7848. Huang, Y., Yan, M., Collins, R.F., DiCiccio, J.E., Grinstein, S. & Trimble, W.S. 2008, "Mammalian Septins Are Required for Phagosome Formation", Molecular biology of the cell, vol. 19, no. 4, pp. 1717-1726.

115

Imagawa, N., Nagasawa, K., Nagai, K., Kawakami-Honda, N. & Fujimoto, S. "Protein kinase Cindependent pathway for NADPH oxidase activation in guinea pig peritoneal polymorphonuclear leukocytes by cytochalasin D", Archives of Biochemistry and Biophysics, vol. 438, no. 2, pp. 119-124. Ishibashi, S., Brown, M.S., Goldstein, J.L., Gerard, R.D., Hammer, R.E. & Herz, J. 1993, "Hypercholesterolemia in Low-Density-Lipoprotein Receptor Knockout Mice and its Reversal by Adenovirus-Mediated Gene Delivery", Journal of Clinical Investigation, vol. 92, no. 2, pp. 883-893. Ivashkiv, L.B. 2009, "Cross-regulation of signaling by ITAM-associated receptors", Nature immunology, vol. 10, no. 4, pp. 340-347. Janabi, M., Yamashita, S., Hirano, K., Matsumoto, K., Sakai, N., Hiraoka, H., Kashiwagi, H., Tomiyama, Y., Nozaki, S. & Matsuzawa, Y. 2001, "Reduced Adhesion of MonocyteDerived Macrophages from CD36-Deficient Patients to Type I Collagen", Biochemical and biophysical research communications, vol. 283, no. 1, pp. 26-30. Janabi, M., Yamashita, S., Hirano, K., Sakai, N., Hiraoka, H., Matsumoto, K., Zhang, Z., Nozaki, S. & Matsuzawa, Y. 2000, "Oxidized LDL-Induced NF-{kappa}B Activation and Subsequent Expression of Proinflammatory Genes Are Defective in Monocyte-Derived Macrophages From CD36-Deficient Patients", Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 8, pp. 1953-1960. Jankowski, A., Zhu, P. & Marshall, J.G. 2008, "Capture of an activated receptor complex from the surface of live cells by affinity receptor chromatography", Analytical Biochemistry, vol. 380, no. 2, pp. 235-248. Jimenez, B., Volpert, O.V., Crawford, S.E., Febbraio, M., Silverstein, R.L. & Bouck, N. 2000, "Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1", Nature medicine, vol. 6, no. 1, pp. 41-48. Jing Chen-Roetling, Li, Z. & Regan, R.F. 2008, "Hemoglobin Neurotoxicity is Attenuated by Inhibitors of the Protein Kinase CK2 Independent of Heme Oxygenase Activity", Current Neurovascular Research, vol. 5, no. 3, pp. 193-198. Jones, M.L., Shawe-Taylor, A.J., Williams, C.M. & Poole, A.W. 2009, "Characterization of a novel focal adhesion kinase inhibitor in human platelets", Biochemical and biophysical research communications, vol. 389, no. 1, pp. 198-203. Jones, N.L., Reagan, J.W. & Willingham, M.C. 2000, "The Pathogenesis of Foam Cell Formation : Modified LDL Stimulates Uptake of Co-Incubated LDL Via Macropinocytosis", Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 3, pp. 773-781.

116

Jones, N.L. & Willingham, M.C. 1999, "Modified LDLs are internalized by macrophages in part via macropinocytosis", The Anatomical Record, vol. 255, no. 1, pp. 57-68. Kavanagh, I.C., Symes, C.E., Renaudin, P., Nova, E., Mesa, M.D., Boukouvalas, G., Leake, D.S. & Yaqoob, P. 2003, "Degree of oxidation of low density lipoprotein affects expression of CD36 and PPAR, but not cytokine production, by human monocyte-macrophages", Atherosclerosis, vol. 168, no. 2, pp. 271-282. Kazerounian, S., Duquette, M., Reyes, M.A., Lawler, J.T., Song, K., Perruzzi, C., Primo, L., Khosravi-Far, R., Bussolino, F., Rabinovitz, I. & Lawler, J. 2011, "Priming of the vascular endothelial growth factor signaling pathway by thrombospondin-1, CD36, and spleen tyrosine kinase", Blood, . Kim, D.-., Lee, S.C. & Lee, H.-. 2009, "CD137 ligand-mediated reverse signals increase cell viability and cytokine expression in murine myeloid cells: Involvement of mTOR/p70S6 kinase and Akt", European journal of immunology, vol. 39, no. 9, pp. 2617-2628. Koenigsknecht, J. & Landreth, G. 2004, "Microglial Phagocytosis of Fibrillar -Amyloid through a 1 Integrin-Dependent Mechanism", The Journal of Neuroscience, vol. 24, no. 44, pp. 9838-9846. Kruth, H.S., Jones, N.L., Huang, W., Zhao, B., Ishii, I., Chang, J., Combs, C.A., Malide, D. & Zhang, W. 2005, "Macropinocytosis Is the Endocytic Pathway That Mediates Macrophage Foam Cell Formation with Native Low Density Lipoprotein", Journal of Biological Chemistry, vol. 280, no. 3, pp. 2352-2360. Kuchibhotla, S., Vanegas, D., Kennedy, D.J., Guy, E., Nimako, G., Morton, R.E. & Febbraio, M. 2008, "Absence of CD36 protects against atherosclerosis in ApoE knock-out mice with no additional protection provided by absence of scavenger receptor A I/II", Cardiovascular research, vol. 78, no. 1, pp. 185-196. Kunjathoor, V.V., Febbraio, M., Podrez, E.A., Moore, K.J., Andersson, L., Koehn, S., Rhee, J.S., Silverstein, R., Hoff, H.F. & Freeman, M.W. 2002, "Scavenger Receptors Class A-I/II and CD36 Are the Principal Receptors Responsible for the Uptake of Modified Low Density Lipoprotein Leading to Lipid Loading in Macrophages", Journal of Biological Chemistry, vol. 277, no. 51, pp. 49982-49988. Kusner, D., Hall, C. & Schlesinger, L. 1996, "Activation of phospholipase D is tightly coupled to the phagocytosis of Mycobacterium tuberculosis or opsonized zymosan by human macrophages", The Journal of experimental medicine, vol. 184, no. 2, pp. 585-595. Lafrenaye, A.D. & Fuss, B. 2010, "Focal adhesion kinase can play unique and opposing roles in regulating the morphology of differentiating oligodendrocytes", Journal of Neurochemistry, vol. 115, no. 1, pp. 269-282.

117

Laitinen, L., Takala, E., Vuorela, H., Vuorela, P., Kaukonen, A.M. & Marvola, M. "Anthranoid laxatives influence the absorption of poorly permeable drugs in human intestinal cell culture model (Caco-2)", European Journal of Pharmaceutics and Biopharmaceutics, vol. 66, no. 1, pp. 135-145. Larsen, E.C., DiGennaro, J.A., Saito, N., Mehta, S., Loegering, D.J., Mazurkiewicz, J.E. & Lennartz, M.R. 2000, "Differential Requirement for Classic and Novel PKC Isoforms in Respiratory Burst and Phagocytosis in RAW 264.7 Cells", The Journal of Immunology, vol. 165, no. 5, pp. 2809-2817. Larsen, E.C., Ueyama, T., Brannock, P.M., Shirai, Y., Saito, N., Larsson, C., Loegering, D., Weber, P.B. & Lennartz, M.R. 2002, "A role for PKC- in FcR-mediated phagocytosis by RAW 264.7 cells", The Journal of cell biology, vol. 159, no. 6, pp. 939-944. Lee, K.J., Kim, H.A., Kim, P.H., Lee, H.S., Ma, K.R., Park, J.H., Kim, D.J. & Hahn, J.H. 2004, "Ox-LDL suppresses PMA-induced MMP-9 expression and activity through CD36mediated activation of PPAR-gamma", EXPERIMENTAL and MOLECULAR MEDICINE, vol. 36, no. 6, pp. 534-544. Lennartz, M.R. 1999, "Phospholipases and phagocytosis: the role of phospholipid-derived second messengers in phagocytosis", The international journal of biochemistry & cell biology, vol. 31, no. 3-4, pp. 415-430. Li, G., Xie, J., Lei, X. & Zhang, L. 2009, "Macrophage migration inhibitory factor regulates proliferation of gastric cancer cells via the PI3K/Akt pathway", World Journal of Gastroenterology, vol. 15, no. 44, pp. 5541-5548. Lipsky, R.H., Eckert, D.M., Tang, Y. & Ockenhouse, C.F. 1997, "The carboxyl-terminal cytoplasmic domain of CD36 is required for oxidized low-density lipoprotein modulation of NF-kappaB activity by tumor necrosis factor-alpha", RECEPTORS & SIGNAL TRANSDUCTION, vol. 7, no. 1, pp. 1-11. Llodrá, J., Angeli, V., Liu, J., Trogan, E., Fisher, E.A. & Randolph, G.J. 2004, "Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques", Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 32, pp. 11779-11784. Loike, J.D., Shabtai, D.Y., Neuhut, R., Malitzky, S., Lu, E., Husemann, J., Goldberg, I.J. & Silverstein, S.C. 2004, "Statin Inhibition of Fc Receptor-Mediated Phagocytosis by Macrophages Is Modulated by Cell Activation and Cholesterol", Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 11, pp. 2051-2056. Maa, M., Chang, M.Y., Chen, Y., Lin, C., Yu, C.J., Yang, Y.L., Li, J., Chen, P., Tang, C., Lei, H. & Leu, T. 2008, "Requirement of Inducible Nitric-oxide Synthase in Lipopolysaccharidemediated Src Induction and Macrophage Migration", Journal of Biological Chemistry, vol. 283, no. 46, pp. 31408-31416.
118

Mallants, R., Vlaeminck, V., Jorissen, M. & Augustijns, P. 2009, "An improved primary human nasal cell culture for the simultaneous determination of transepithelial transport and ciliary beat frequency", Journal of Pharmacy and Pharmacology, vol. 61, no. 7, pp. 883-890. Mandal, C.C., Ghosh-Choudhury, N., Yoneda, T., Choudhury, G.G. & Ghosh-Choudhury, N. "Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44", Journal of Biological Chemistry, . Marshall, J.G., Booth, J.W., Stambolic, V., Mak, T., Balla, T., Schreiber, A.D., Meyer, T. & Grinstein, S. 2001, "Restricted Accumulation of Phosphatidylinositol 3-Kinase Products in a Plasmalemmal Subdomain during Fc Receptor-Mediated Phagocytosis", The Journal of cell biology, vol. 153, no. 7, pp. 1369-1380. Mathers, C.D., Boerma, T. & Ma Fat, D. 2009, "Global and regional causes of death", British medical bulletin, vol. 92, no. 1, pp. 7-32. Maxeiner, H., Husemann, J., Thomas, C.A., Loike, J.D., Khoury, J.E. & Silverstein, S.C. 1998, "Complementary Roles for Scavenger Receptor A and CD36 of Human Monocyte­derived Macrophages in Adhesion to Surfaces Coated with Oxidized Low-Density Lipoproteins and in Secretion of H2O2", The Journal of experimental medicine, vol. 188, no. 12, pp. 22572265. Medeiros, L.A., Khan, T., El Khoury, J.B., Pham, C.L.L., Hatters, D.M., Howlett, G.J., Lopez, R., O'Brien, K.D. & Moore, K.J. 2004, "Fibrillar Amyloid Protein Present in Atheroma Activates CD36 Signal Transduction", Journal of Biological Chemistry, vol. 279, no. 11, pp. 10643-10648. Metzler, B., Hu, Y., Dietrich, H. & Xu, Q. 2000, "Increased Expression and Activation of StressActivated Protein Kinases/c-Jun NH2-Terminal Protein Kinases in Atherosclerotic Lesions Coincide with p53", American Journal of Pathology, vol. 156, no. 6, pp. 1875-1886. Miao, W., Vasile, E., Lane, W.S. & Lawler, J. 2001a, "CD36 associates with CD9 and integrins on human blood platelets", Blood, vol. 97, no. 6, pp. 1689-1696. Miki, S., Horikawa, K., Nishizumi, H., Suemura, M., Sato, B., Yamamoto, M., Takatsu, K., Yamamoto, T. & Miki, Y. 2001, "Reduction of atherosclerosis despite hypercholesterolemia in lyn-deficient mice fed a high-fat diet", Genes to Cells, vol. 6, no. 1, pp. 37-42. Miksa, M., Wu, R., Cui, X., Dong, W., Das, P., Simms, H.H., Ravikumar, T.S. & Wang, P. 2007, "Vasoactive Hormone Adrenomedullin and Its Binding Protein: Anti-Inflammatory Effects by Up-Regulating Peroxisome Proliferator-Activated Receptor-{gamma}", The Journal of Immunology, vol. 179, no. 9, pp. 6263-6272. Mogami, H., Mills, C.L. & Gallagher, D.V. 1997, "Phospholipase C inhibitor, U73122, releases intracellular Ca2+, potentiates Ins(1,4,5)P-3-mediated Ca2+ release and directly activates ion channels in mouse pancreatic acinar cells", Biochemical Journal, vol. 324, pp. 645-651.
119

Mohty, D., Pibarot, P., Despres, J., Cote, C., Arsenault, B., Cartier, A., Cosnay, P., Couture, C. & Mathieu, P. 2008, "Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis", Arteriosclerosis Thrombosis and Vascular Biology, vol. 28, no. 1, pp. 187-193. Munteanu, A., Taddei, M., Tamburini, I., Bergamini, E., Azzi, A. & Zingg, J. 2006, "Antagonistic Effects of Oxidized Low Density Lipoprotein and -Tocopherol on CD36 Scavenger Receptor Expression in Monocytes", Journal of Biological Chemistry, vol. 281, no. 10, pp. 6489-6497. Nakata, A., Nakagawa, Y., Nishida, M., Nozaki, S., Miyagawa, J., Nakagawa, T., Tamura, R., Matsumoto, K., Kameda-Takemura, K., Yamashita, S. & Matsuzawa, Y. 1999, "CD36, a Novel Receptor for Oxidized Low-Density Lipoproteins, Is Highly Expressed on LipidLaden Macrophages in Human Atherosclerotic Aorta", Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 5, pp. 1333-1339. Nikkhah, M., Strobl, J., Peddi, B. & Agah, M. 2009, "Cytoskeletal role in differential adhesion patterns of normal fibroblasts and breast cancer cells inside silicon microenvironments", Biomedical Microdevices, vol. 11, no. 3, pp. 585-595. Nozaki, S., Kashiwagi, H., Yamashita, S., Nakagawa, T., Kostner, B., Tomiyama, Y., Nakata, A., Ishigami, M., Miyagawa, J. & Kameda-Takemura, K. 1995, "Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects", The Journal of clinical investigation, vol. 96, no. 4, pp. 1859-1865. Olakowska, E. & Olakowski, M. 2006, "Propranolol--a place in the modern therapy", Wiadomoci Lekarskie, vol. 59, no. 5-6, pp. 388-391. O'Luanaigh, N., Pardo, R., Fensome, A., Allen-Baume, V., Jones, D., Holt, M.R. & Cockcroft, S. 2002, "Continual Production of Phosphatidic Acid by Phospholipase D Is Essential for Antigen-stimulated Membrane Ruffling in Cultured Mast Cells", Molecular biology of the cell, vol. 13, no. 10, pp. 3730-3746. Pan, X., Darby, C., Indik, Z.K. & Schreiber, A.D. 1999, "Activation of Three Classes of Nonreceptor Tyrosine Kinases Following Fc[gamma] Receptor Crosslinking in Human Monocytes,", Clinical Immunology, vol. 90, no. 1, pp. 55-64. Pang, Y., Zheng, B., Fan, L., Rhodes, P.G. & Cai, Z. "IGF1 protects oligodendrocyte progenitors against TNFinduced damage by activation of PI3K/Akt and interruption of the mitochondrial apoptotic pathway", Glia, vol. 55, no. 11, pp. 1099-1107. Park, Y.M., Febbraio, M. & Silverstein, R.L. 2009, CD36 modulates migration of mouse and human macrophages in response to oxidized LDL and may contribute to macrophage trapping in the arterial intima.(Research article)(Report).

120

Pentikainen, M.O., Oksjoki, R., Oorni, K. & Kovanen, P.T. 2002, "Lipoprotein Lipase in the Arterial Wall: Linking LDL to the Arterial Extracellular Matrix and Much More", Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 2, pp. 211-217. Podrez, E.A., Febbraio, M., Sheibani, N., Schmitt, D., Silverstein, R.L., Hajjar, D.P., Cohen, P.A., Frazier, W.A., Hoff, H.F. & Hazen, S.L. 2000, "Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species", The Journal of clinical investigation, vol. 105, no. 8, pp. 1095-1108. Podrez, E.A., Poliakov, E., Shen, Z., Zhang, R., Deng, Y., Sun, M., Finton, P.J., Shan, L., Febbraio, M., Hajjar, D.P., Silverstein, R.L., Hoff, H.F., Salomon, R.G. & Hazen, S.L. 2002, "A Novel Family of Atherogenic Oxidized Phospholipids Promotes Macrophage Foam Cell Formation via the Scavenger Receptor CD36 and Is Enriched in Atherosclerotic Lesions", Journal of Biological Chemistry, vol. 277, no. 41, pp. 38517-38523. Prieto, J., Eklund, A. & Patarroyo, M. 1994, "Regulated Expression of Integrins and Other Adhesion Molecules during Differentiation of Monocytes into Macrophages", Cellular immunology, vol. 156, no. 1, pp. 191-211. Qiao, J., Tripathi, J., Mishra, N., Cai, Y., Tripathi, S., Wang, X., Imes, S., Fishbein, M., Clinton, S., Libby, P., Lusis, A. & Rajavashisth, T. 1997, "Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice", American Journal of Pathology, vol. 150, no. 5, pp. 1687-1699. Rahaman, S.O., Lennon, D.J., Febbraio, M., Podrez, E.A., Hazen, S.L. & Silverstein, R. 2006, "A CD36-dependent signaling cascade is necessary for macrophage foam cell formation", Cell Metabolism, vol. 4, no. 3, pp. 211-221. Rahaman, S.O., Swat, W., Febbraio, M. & Silverstein, R.L. 2011, "Vav Family Rho Guanine Nucleotide Exchange Factors Regulate CD36-mediated Macrophage Foam Cell Formation", Journal of Biological Chemistry, vol. 286, no. 9, pp. 7010-7017. Ricci, R., Sumara, G., Sumara, I., Rozenberg, I., Kurrer, M., Akhmedov, A., Hersberger, M., Eriksson, U., Eberli, F.R., Becher, B., Boren, J., Chen, M., Cybulsky, M.I., Moore, K.J., Freeman, M.W., Wagner, E.F., Matter, C.M. & Luscher, T.F. 2004, "Requirement of JNK2 for Scavenger Receptor A-Mediated Foam Cell Formation in Atherogenesis", Science, vol. 306, no. 5701, pp. 1558-1561. Ross, R. 1999, "Atherosclerosis -- An Inflammatory Disease", New England Journal of Medicine, vol. 340, no. 2, pp. 115-126. Roy, B. & Rai, U. 2008, "Role of adrenoceptor-coupled second messenger system in sympathoadrenomedullary modulation of splenic macrophage functions in live fish Channa punctatus", General and comparative endocrinology, vol. 155, no. 2, pp. 298-306.

121

Ruiz-Velasco, N., Domínguez, A. & Vega, M.A. 2004, "Statins upregulate CD36 expression in human monocytes, an effect strengthened when combined with PPAR- ligands Putative contribution of Rho GTPases in statin-induced CD36 expression", Biochemical pharmacology, vol. 67, no. 2, pp. 303-313. Rusiñol, A.E., Yang, L., Thewke, D., Panini, S.R., Kramer, M.F. & Sinensky, M.S. 2000, Isolation of a Somatic Cell Mutant Resistant to the Induction of Apoptosis by Oxidized Low Density Lipoprotein. Sanderson, M.P., Gelling, S.J., Rippmann, J.F. & Schnapp, A. 2010, "Comparison of the antiallergic activity of Syk inhibitors with optimized Syk siRNAs in FcRI-activated RBL-2H3 basophilic cells", Cellular immunology, vol. 262, no. 1, pp. 28-34. Santy, L.C. & Casanova, J.E. 2001, "Activation of ARF6 by ARNO stimulates epithelial cell migration through downstream activation of both Rac1 and phospholipase D", The Journal of cell biology, vol. 154, no. 3, pp. 599-610. Scott, C.C., Dobson, W., Botelho, R.J., Coady-Osberg, N., Chavrier, P., Knecht, D.A., Heath, C., Stahl, P. & Grinstein, S. 2005, "Phosphatidylinositol-4,5-bisphosphate hydrolysis directs actin remodeling during phagocytosis", The Journal of cell biology, vol. 169, no. 1, pp. 139149. Segal, G., Lee, W., Arora, P., McKee, M., Downey, G. & McCulloch, C. 2001, "Involvement of actin filaments and integrins in the binding step in collagen phagocytosis by human fibroblasts", Journal of cell science, vol. 114, no. 1, pp. 119-129. Segrest, J.P., Jones, M.K., De Loof, H. & Dashti, N. 2001, "Structure of apolipoprotein B-100 in low density lipoproteins", Journal of lipid research, vol. 42, no. 9, pp. 1346-1367. Seizer, P.F., Schiemann, S.F., Merz, T.F., Daub, K.F., Bigalke, B.F., Stellos, K.F., Muller, I.F., Stockle, C.F., Muller, K.F., Gawaz M FAU - May, Andreas,E. & May, A.E. 2010, CD36 and macrophage scavenger receptor a modulate foam cell formation via inhibition of lipidladen platelet phagocytosis. Serghides, L., Smith, T.G., Patel, S.N. & Kain, K.C. 2003, "CD36 and malaria: friends or foes?", Trends in parasitology, vol. 19, no. 10, pp. 461-469. Shen, L., Zhou, L., Wang, B., Pu, J., Hu, L., Chai, D., Wang, L., Zeng, J. & He, B. 2008, "Oxidized low-density lipoprotein induces differentiation of RAW264.7 murine macrophage cell line into dendritic-like cells", Atherosclerosis, vol. 199, no. 2, pp. 257-264. Silverstein, R.L. & Febbraio, M. 2000, "CD36 and atherosclerosis", Current opinion in lipidology, vol. 11, no. 5, pp. 483-491.

122

Singh, U., Dasu, M.R., Yancey, P.G., Afify, A., Devaraj, S. & Jialal, I. 2008, "Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats", Journal of lipid research, vol. 49, no. 5, pp. 1015-1023. Slomiany, A., Nishikawa, H. & Slomiany, B.L. 2002, "Screening and modulation of extracellular signals by mucous barrier. Serum glycosylphosphatidylinositol phospholipase D (gpi-pld) releases protective mucous barrier from oral mucosa", Journal of Physiology and Pharmacology, vol. 53, no. 1, pp. 21-38. Smith, J.D., Trogan, E., Ginsberg, M., Grigaux, C., Tian, J. & Miyata, M. 1995, "Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E", Proceedings of the National Academy of Sciences, vol. 92, no. 18, pp. 8264-8268. Srivastava, R.A., Ito, H., Hess, M., Srivastava, N. & Schonfeld, G. 1995, "Regulation of low density lipoprotein receptor gene expression in HepG2 and Caco2 cells by palmitate, oleate, and 25-hydroxycholesterol.", Journal of lipid research, vol. 36, no. 7, pp. 1434-1446. Stadanlick, J.E., Kaileh, M., Karnell, F.G., Scholz, J.L., Miller, J.P., Quinn III, W.,J., Brezski, R.J., Treml, L.S., Jordan, K.A., Monroe, J.G., Sen, R. & Cancro, M.P. 2008, "Tonic B cell antigen receptor signals supply an NF-[kappa]B substrate for prosurvival BLyS signaling", Nature immunology, vol. 9, no. 12, pp. 1379-1387. Stewart, C.R., Stuart, L.M., Wilkinson, K., van Gils, J.,M., Deng, J., Halle, A., Rayner, K.J., Boyer, L., Zhong, R., Frazier, W.A., Lacy-Hulbert, A., Khoury, J.E., Golenbock, D.T. & Moore, K.J. 2010, "CD36 ligands promote sterile inflammation through assembly of a Tolllike receptor 4 and 6 heterodimer", Nature immunology, vol. 11, no. 2, pp. 155-161. Stuart, L.M., Bell, S.A., Stewart, C.R., Silver, J.M., Richard, J., Goss, J.L., Tseng, A.A., Zhang, A., Khoury, J.B.E. & Moore, K.J. 2007, "CD36 Signals to the Actin Cytoskeleton and Regulates Microglial Migration via a p130Cas Complex", Journal of Biological Chemistry, vol. 282, no. 37, pp. 27392-27401. Sulahian, T., Imrich, A., DeLoid, G., Winkler, A. & Kobzik, L. 2008, "Signaling pathways required for macrophage scavenger receptor-mediated phagocytosis: analysis by scanning cytometry", Respiratory Research, vol. 9, no. 1, pp. 59. Sun, X., He, X., Tzipori, S., Gerhard, R. & Feng, H. 2009, "Essential role of the glucosyltransferase activity in Clostridium difficile toxin-induced secretion of TNF- by macrophages", Microbial pathogenesis, vol. 46, no. 6, pp. 298-305.

123

Suzuki, H., Kurihara, Y., Takeya, M., Kamada, N., Kataoka, M., Jishage, K., Ueda, O., Sakaguchi, H., Higashi, T., Suzuki, T., Takashima, Y., Kawabe, Y., Cynshi, O., Wada, Y., Honda, M., Kurihara, H., Aburatani, H., Doi, T., Matsumoto, A., Azuma, S., Noda, T., Toyoda, Y., Itakura, H., Yazaki, Y., Horiuchi, S., Takahashi, K., Kruijt, J.K., van Berkel, Theo J. C., Steinbrecher, U.P., Ishibashi, S., Maeda, N., Gordon, S. & Kodama, T. 1997, "A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection", Nature, vol. 386, no. 6622, pp. 292-296. Swanson, J.A. & Hoppe, A.D. 2004, "The coordination of signaling during Fc receptor-mediated phagocytosis", Journal of leukocyte biology, vol. 76, no. 6, pp. 1093-1103. Tandon, N.N., Kralisz, U. & Jamieson, G.A. 1989, "Identification of glycoprotein IV (CD36) as a primary receptor for platelet-collagen adhesion.", Journal of Biological Chemistry, vol. 264, no. 13, pp. 7576-7583. Tandon, N., Lipsky, R., Burgess, W. & Jamieson, G. 1989, "Isolation and characterization of platelet glycoprotein IV (CD36)", Journal of Biological Chemistry, vol. 264, no. 13, pp. 7570-7575. Tao, N., Wagner, S.J. & Lublin, D.M. 1996, "CD36 Is Palmitoylated on Both N- and C-terminal Cytoplasmic Tails", Journal of Biological Chemistry, vol. 271, no. 37, pp. 22315-22320. Tatara, Y., Ohishi, M., Yamamoto, K., Shiota, A., Hayashi, N., Iwamoto, Y., Takeda, M., Takagi, T., Katsuya, T., Ogihara, T. & Rakugi, H. 2009, "Macrophage inflammatory protein-1 induced cell adhesion with increased intracellular reactive oxygen species", Journal of Molecular and Cellular Cardiology, vol. 47, no. 1, pp. 104-111. Thorne, R.F., Marshall, J.F., Shafren, D.R., Gibson, P.G., Hart, I.R. & Burns, G.F. 2000, "The Integrins 31 and 61 Physically and Functionally Associate with CD36 in Human Melanoma Cells", Journal of Biological Chemistry, vol. 275, no. 45, pp. 35264-35275. Thorne, R.F., Mhaidat, N.M., Ralston, K.J. & Burns, G.F. 2007, "Shed gangliosides provide detergent-independent evidence for Type-3 glycosynapses", Biochemical and biophysical research communications, vol. 356, no. 1, pp. 306-311. Tripathi, A. & Sodhi, A. 2008, "Prolactin-induced production of cytokines in macrophages in vitro involves JAK/STAT and JNK MAPK pathways", International immunology, vol. 20, no. 3, pp. 327-336. Tsimikas, S., Brilakis, E.S., Lennon, R.J., Miller, E.R., Witztum, J.L., McConnell, J.P., Kornman, K.S. & Berger, P.B. 2007, "Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events", Journal of lipid research, vol. 48, no. 2, pp. 425-433. Underhill, D.M. & Goodridge, H.S. 2007, "The many faces of ITAMs", Trends in immunology, vol. 28, no. 2, pp. 66-73.
124

van der Vusse, G.J., van Bilsen, M., Glatz, J.F.C., Hasselbaink, D.M. & Luiken, J.J.F.P. 2002, Critical steps in cellular fatty acid uptake and utilization, Springer Netherlands. Varret, M., Abifadel, M., Rabès, J. & Boileau, C. 2008, "Genetic heterogeneity of autosomal dominant hypercholesterolemia", Clinical genetics, vol. 73, no. 1, pp. 1-13. Wang, W., Wu, Y. & Wu, C. 2006, "Prevention of Platelet Glycoprotein IIb/IIIa Activation by 3,4-Methylenedioxy--Nitrostyrene, A Novel Tyrosine Kinase Inhibitor", Molecular pharmacology, vol. 70, no. 4, pp. 1380-1389. Wendt, M. & Schiemann, W. 2009, "Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis", Breast Cancer Research, vol. 11, no. 5, pp. R68. Wilkinson, B., Koenigsknecht-Talboo, J., Grommes, C., Lee, C.Y.D. & Landreth, G. 2006, "Fibrillar -Amyloid-stimulated Intracellular Signaling Cascades Require Vav for Induction of Respiratory Burst and Phagocytosis in Monocytes and Microglia", Journal of Biological Chemistry, vol. 281, no. 30, pp. 20842-20850. Xue, Q., Jenkins, S.A., Gu, C., Smeds, E., Liu, Q., Vasan, R., Russell, B.H. & Xu, Y. 2010, "Bacillus anthracis Spore Entry into Epithelial Cells Is an Actin-Dependent Process Requiring c-Src and PI3K", PLoS ONE, vol. 5, no. 7, pp. e11665. Yamada, Y., Doi, T., Hamakubo, T. & Kodama, T. 1998, "Scavenger receptor family proteins: roles for atherosclerosis, host defence and disorders of the central nervous system", Cellular and Molecular Life Sciences, vol. 54, no. 7, pp. 628-640. Yamamoto, N., Ikeda, H., Tandon, N., Herman, J., Tomiyama, Y., Mitani, T., Sekiguchi, S., Lipsky, R., Kralisz, U. & Jamieson, G. 1990, "A platelet membrane glycoprotein (GP) deficiency in healthy blood donors: Naka- platelets lack detectable GPIV (CD36)", Blood, vol. 76, no. 9, pp. 1698-1703. Yang, W.S., Seo, J.W., Han, N.J., Choi, J., Lee, K., Ahn, H., Lee, S.K. & Park, S. 2008, "High glucose-induced NF-{kappa}B activation occurs via tyrosine phosphorylation of I{kappa}B{alpha} in human glomerular endothelial cells: involvement of Syk tyrosine kinase", AJP - Renal Physiology, vol. 294, no. 5, pp. F1065-1075. Yu, Y., Huang, Z., Yang, P., Rui, Y. & Yang, P. 2003, "Proteomic Studies of Macrophagederived Foam Cell from Human U937 Cell Line Using Two-dimensional Gel Electrophoresis and Tandem Mass Spectrometry", Journal of cardiovascular pharmacology, vol. 42, no. 6, pp. 782-789. Zeng, Y., Tao, N., Chung, K., Heuser, J.E. & Lublin, D.M. 2003b, "Endocytosis of Oxidized Low Density Lipoprotein through Scavenger Receptor CD36 Utilizes a Lipid Raft Pathway That Does Not Require Caveolin-1", Journal of Biological Chemistry, vol. 278, no. 46, pp. 45931-45936.
125

Zheleznyak, A. & Brown, E.J. 1992, "Immunoglobulin-mediated phagocytosis by human monocytes requires protein kinase C activation. Evidence for protein kinase C translocation to phagosomes.", Journal of Biological Chemistry, vol. 267, no. 17, pp. 12042-12048. Zingg, J.M., Ricciarelli, R. & Azzi, A. 2000, "Scavenger receptors and modified lipoproteins: Fatal attractions?", IUBMB life, vol. 49, no. 5, pp. 397-403. Zu, L., Shen, Z., Wesley, J. & Cai, Z.P. "PTEN inhibitors cause a negative inotropic and chronotropic effect in mice", European journal of pharmacology, vol. In Press, Uncorrected Proof.

126

